Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f0032ef62ca343dfb4bf79577e2aa8d1-jamesst]; Kenny, Dermot [Kublin, James (b)(6); Li, Rose (b) (6) Menetski, Joseph (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (b)(6)(FYDIBOHF23SPDLT)/cn=Recipients/cn=5001af52dc4a427ea3d34f1e072f8cb7-menetskijp]; Qashu, Felicia (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=366447a553f44696b2c79484d90e41e5-qashufm]; Santos, Michael (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ab38cb6836de44e18ef4cc6952f65f80-santosmr]; Tuvesson, Nancy Wholley, David (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]; Elsaid, Olivia [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=userf0efa7bd] Subject: ACTIV Clinical Trial Capacity Working Group - reporting meeting Clinical Trial Capacity Working Group Meeting Agenda 07142020.pdf Attachments: Location: https://fnih.zoom. (b) (6) Start: 7/14/2020 1:00:00 PM End: 7/14/2020 2:00:00 PM Show Time As: Tentative Required Bascles, Lionel; Cohen, Myron; Corey, Larry; Davey, Victoria; Desrosiers, Betsy; Dickens, Jim (NIH/NCATS) [C]; Attendees: Doroshow, James (NIH/NCI) [E]; Garner, Carlos; Goff, David (NIH/NHLBI) [E]; Kurilla, Mike; Mensah, George; Nayak, Seema (NIH/NIAID) [E]; Payton, Manzine; Resnansky, Laura; Sizemore, Christine (NIH/FIC) [E]; Srinivasan, Badhri; Stein, Peter (FDA/CDER); Takas, Therese; Vincent, Mike; Weinmann, Gail; Stratton, Ben Optional Wachtel, Jonathan; Colvis, Christine (NIH/NCATS) [E]; Hughes, Eric; Jansen, Kathrin; Lowy, Douglas (NCI); Read, Sarah Attendees: (NIH/NIAID) [E]; Young, John; Ardiff, Bernadette; Criffield, Robin; Hamilton, Nancy; Melencio, Cheryl (FNIH) [T]; Minnich, Beth; Mueller-Reichenstein, Petra; Pico, Dianna; Quadros, Nora; Rebecca (NIH/NCATS) Katz [E] Zoe (NIH/NHLBI) Hill [C] (Adam, Stacey (FNIH) [T]; Anderson, Margaret; (b) (6) Ashley (NIH/OD) Parker [E] (Carluccio, Dana; Culp, Michelle (NIH/OD) [E]; Gadbois, Ellen (NIH/OD) [E]; Gonzalez, Nina; Heaton, Penny; James, Stephanie; Kenny, Dermot; Kublin, James; Li, Rose; Menetski, Joseph (FNIH) [T]; Qashu, Felicia; Santos, Michael (FNIH); Tuvesson, Nancy; Wholley, David (FNIH) [T]; Elsaid, Olivia Dear WG members; During this call we will share some exciting updates regarding the development of the playbooks'; and we will have an important discussion about updating the site survey for NCATS. Looking' forward to the call and hope you can make it! Karen Dear Clinical Trial Capacity Working group members - As the tiger teams continue to work closely with ACTIV protocol development and operations teams, and the 'playbook' development teams ramp up to quickly develop these resources, we will reduce the number of times the full WG meets in July to every other week (July 14th and 28th). Best, Karen Karen Tountas is inviting you to a scheduled Zoom meeting. Join Zoom Meeting https://fnih.zoom.us/j (b)(6)Meeting ID: (b) (6) Password: (b) (6) One tap mobile (b)(6)US (Chicago) US (New York) Dial by your location US (Chicago) (b) (6) US (New York) US (Germantown) US (Tacoma) US (Houston) US (San Jose) US (San Jose) Meeting ID: (b) (6) Password: (b) (6) Find your local number: https://fnih.zoom.us (b) (6)

From: Wholley, David (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=CD9E702FCF28414883D0B6996D677257-WHOLLEYD] Sent: 7/30/2020 11:33:41 AM To: Adam, Stacey (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dcd875f0679648859e1cf101c0943414-adamsj4]; Lane, Cliff (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2d7e368a3137473bbce161547a82f2de-clane]; Collins, Francis (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=410e1ca313f44ced9938e50d2ff0b6c2-collinsf]; Freire, Maria (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=8598d551d1d3455eaf14854c83f41d84-freiremc]; Austin, Christopher (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=17597cabc42247548e596778304f781f-austinc]; Tabak, Lawrence (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=02e22836b5ff4e9988e3770cfc7ee770-tabakl]; Anderson, James (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=73143d1860bc42458be254ca21573b23-andersonjm]; Parker, Ashley (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras] Subject: RE: [EXTERNAL] Materials for July 29 ACTIV Executive Committee Teleconference OK. From: Adam, Stacey (FNIH) [T] < (b) (6) Sent: Wednesday, July 29, 2020 11:05 PM To: Wholley, David (FNIH) [T] < (b) (6) Lane, Cliff (NIH/NIAID) [E] < (b) (6) Collins, Francis Austin, Christopher (NIH/NCATS) [E] (NIH/OD)[E] <Freire, Maria (FNIH) [T] < (b)(6)(b) (6) < (b) (6) Tabak, Lawrence (NIH/OD) [E] < Anderson, James (NIH/OD) [E] (b) (6) Parker, Ashley (NIH/OD) [E] < (b) (6) (b)(6)Subject: RE: [EXTERNAL] Materials for July 29 ACTIV Executive Committee Teleconference Hi Team, I just confirmed with the ACTIV-3 team they will be testing a subset of the patients from ACTIV-3, but it will be done under a separate protocol called INSIGHT 004 that is open at certain sites where the trial will be activated. Thanks, Stacev Stacey J. Adam, PhD Director, Cancer Research Partnerships Direct: (b) (6) Mobile: (b)(6)From: Wholley, David (FNIH) [T] (b)(6)Sent: Wednesday, July 29, 2020 9:53 PM To: Lane, Cliff (NIH/NIAID) [E] (b) (6) >; Collins, Francis (NIH/OD) [E] (b) (6) ; Freire, Maria (FNIH) [T] Austin, Christopher (NIH/NCATS) [E] < ; Tabak, Lawrence (NIH/OD) (b) (6) (b)(6)Anderson, James (NIH/OD) [E] ; Parker, Ashley (NIH/OD) [E] [E] (b) (6) (b) (6) (b) (6)

otacey salu tilele is collec	ction of samples for ger	netic characterization	in ACTIV-3. Copy	ring her for clar	ification.
From: Lane, Cliff (NIH/NI					
Sent: Wednesday, July 29					
To : Wholley, David (FNIH	(b) (6)	Collins, Francis (I	VIH/OD) [E]	(b) (6)	Freire, Maria
FNIH) [T] (b) (6)	; Austin, Christop	her (NIH/NCATS) [E]	(b) (6)	Tabak, l	awrence (NIH/OD
E] (b) (6)	; Anderson, Jame	s (NIH/OD) [E]	(b) (6)	>; Parker,	Ashley (NIH/OD) [I
(b) (6)					
Subject: Re: [EXTERNAL]	Materials for July 29 A	CTIV Executive Comm	ittee Teleconfere	nce	
		(b) (5)			
		() ()			
-1177					
Cliff					
rom: "Wholley, David	(FNIH) [T]" (b	o) (6)			
Date: Wednesday, July	29, 2020 at 5:58 PM				
o: "Collins, Francis (N			e, Maria (FNIH)	[T]" (b)	(6)
					,
Austin, Christopher (N			"Lane, Cliff (NIF		() (-)
(b) (6) >	, Lawrence Tabak <	(b) (6)	"Andersor	n, James (NIH,	/OD) [E]"
(b) (6)	"Parker, Ashle	ey (NIH/OD) [E]" <	(b) (6)		
Subject: RE: [EXTERNA	11 Materials for July 2	9 ACTIV Executive (•	
AND COL INC. LEVILLINIA	Lj Widteriais for July 2	S ACTIV EXECUTIVE C	ommittee relec	conference	
Justice HE. [EXTENNA	Ej Wateriais for July 2	JACTIV EXECUTIVE C	ommittee relec	conference	
	an in the second				ote to both of us)
Francis, I composed the f	following reply to Robe	rt for your considerat	ion. I'm happy to	send it (he wro	
Francis, I composed the f you can; feel free to edit	following reply to Robe of course in either case	rt for your considerat	ion. I'm happy to	send it (he wro	
Francis, I composed the f you can; feel free to edit	following reply to Robe of course in either case	rt for your considerat	ion. I'm happy to	send it (he wro	
Francis, I composed the f you can; feel free to edit mentioned this morning.	following reply to Robe of course in either case	rt for your considerat	ion. I'm happy to	send it (he wro	
Francis, I composed the f you can; feel free to edit mentioned this morning.	following reply to Robe of course in either case	rt for your considerat e. Cliff, please weigh	ion. I'm happy to	send it (he wro	
Francis, I composed the f you can; feel free to edit mentioned this morning.	following reply to Robe of course in either case	rt for your considerat	ion. I'm happy to	send it (he wro	
Francis, I composed the foucan; feel free to edit mentioned this morning.	following reply to Robe of course in either case	rt for your considerat e. Cliff, please weigh	ion. I'm happy to	send it (he wro	
Francis, I composed the foucan; feel free to edit mentioned this morning.	following reply to Robe of course in either case	rt for your considerat e. Cliff, please weigh	ion. I'm happy to	send it (he wro	
rancis, I composed the fou can; feel free to edit nentioned this morning.	following reply to Robe of course in either case	rt for your considerat e. Cliff, please weigh	ion. I'm happy to	send it (he wro	
rancis, I composed the fou can; feel free to edit mentioned this morning.	following reply to Robe of course in either case	rt for your considerat e. Cliff, please weigh	ion. I'm happy to	send it (he wro	
Francis, I composed the foucan; feel free to edit mentioned this morning.	following reply to Robe of course in either case	rt for your considerat e. Cliff, please weigh	ion. I'm happy to	send it (he wro	
Francis, I composed the f you can; feel free to edit mentioned this morning. Hi Robert:	following reply to Robe of course in either case	rt for your considerat e. Cliff, please weigh	ion. I'm happy to	send it (he wro	
Francis, I composed the f you can; feel free to edit mentioned this morning. Hi Robert:	following reply to Robe of course in either case	rt for your considerat e. Cliff, please weigh	ion. I'm happy to	send it (he wro	
Francis, I composed the foot of the foot o	following reply to Robe of course in either case	rt for your considerat e. Cliff, please weigh	ion. I'm happy to	send it (he wro	
Francis, I composed the force of the following can; feel free to edit mentioned this morning. Hi Robert:	following reply to Robe of course in either case	rt for your considerat e. Cliff, please weigh	ion. I'm happy to	send it (he wro	
Francis, I composed the food can; feel free to edit mentioned this morning. Hi Robert: Regards, David	following reply to Robe of course in either case . Thanks	rt for your considerat e. Cliff, please weigh (b) (5)	ion. I'm happy to	send it (he wro	
Francis, I composed the four can; feel free to edit mentioned this morning. Hi Robert: Regards, David From: Collins, Francis (NI	following reply to Rober of course in either case. Thanks	rt for your considerat e. Cliff, please weigh (b) (5)	ion. I'm happy to	send it (he wr	
Francis, I composed the food can; feel free to edit mentioned this morning. Hi Robert: Regards, David From: Collins, Francis (NI Sent: Wednesday, July 29	following reply to Rober of course in either case. Thanks IH/OD) [E] (b) (69, 2020 7:43 AM	rt for your considerat e. Cliff, please weigh (b) (5)	ion. I'm happy to	send it (he wro	he NIAID study yo
Francis, I composed the food can; feel free to edit mentioned this morning. Hi Robert: Regards, David From: Collins, Francis (NI Sent: Wednesday, July 29	following reply to Rober of course in either case. Thanks IH/OD) [E] (b) (69, 2020 7:43 AM	rt for your considerat e. Cliff, please weigh (b) (5)	ion. I'm happy to	send it (he wro	
Francis, I composed the four can; feel free to edit mentioned this morning. Hi Robert: Regards, David From: Collins, Francis (NI Sent: Wednesday, July 25	following reply to Rober of course in either case. Thanks IH/OD) [E] (b) (6) 9, 2020 7:43 AM [T] (b) (6)	rt for your considerat e. Cliff, please weigh (b) (5)	ion. I'm happy to	send it (he wro	he NIAID study yo
Francis, I composed the four can; feel free to edit mentioned this morning. Hi Robert: Regards, David From: Collins, Francis (NI Sent: Wednesday, July 25 To: Freire, Maria (FNIH) [NIH/NCATS) [E]	following reply to Rober of course in either case. Thanks IH/OD) [E] (b) (6) 9, 2020 7:43 AM [T] (b) (6) (b) (6) >; Lane,	rt for your considerate. Cliff, please weigh (b) (5)	ion. I'm happy to in on how I have o I) [T] (b) (6 (b) (6)	send it (he wro characterized the s) >; Aus ; Tabak, La	he NIAID study yo
Francis, I composed the four can; feel free to edit mentioned this morning. Hi Robert: Regards, David From: Collins, Francis (NI Sent: Wednesday, July 25 To: Freire, Maria (FNIH) [NIH/NCATS) [E]	following reply to Rober of course in either case. Thanks IH/OD) [E] (b) (6) 9, 2020 7:43 AM [T] (b) (6) (b) (6) >; Lane,	rt for your considerat e. Cliff, please weigh (b) (5) (b) (f) (b) (f)	ion. I'm happy to in on how I have o	send it (he wro characterized the s) >; Aus ; Tabak, La	tin, Christopher

Cc: Adam, Stacey (FNIH) [T] <

(b) (6)

From: Plenge, Robert (b) (6)
Sent: Wednesday, July 29, 2020 7:33 AM

To: Wholley, David (FNIH) [T] (b) (6) Collins, Francis (NIH/OD) [E] (b) (6)

Subject: Re: [EXTERNAL] Materials for July 29 ACTIV Executive Committee Teleconference

Given the recent genetic data (<u>here</u>, <u>here</u>, <u>here</u>, <u>here</u>), is it worth considering more routine genetic testing (e.g., GWAS, WES) in ACTIV trials to guide future repurposing?

From		yl (FNIH) [T]"	(b) (6)	> on beha	alf of "Wholley,	David (FNIH) [T]"
D	(b) (6)	2020 -+ 40 FF DNA					
	1	2020 at 10:55 PM			11D 1 Ct 1	"	
10: "/	F2: V5	r (NIH/NCATS) [E]			"Bancel, Steph		
		, "Ca			5) >, "		
r=311	(b) (6)	, "Cinia	ar, Tomas"	(b) (6) >,"		
[E]"	(b) (6)	"Corey, Larry					
<		"Disbrow, Gary					
<		"Erbelding					
<		"Fauci, Anthony					
	(b) (6) >, "(Gadbois, Ellen (NIH	/OD) [E]"	(b) (6)	>, "Gibb	ons, Gary (N	NIH/NHLBI) [E]"
<	(b) (6)	"Hudson, Thom	nas"	(b) (6)	, "Jar	nes, Stephar	nie (FNIH) [T]"
<	(b) (6) "Jo	hnson, Robert (O	S/ASPR/BARD/	۸)" <	(b) (6)	."Kram	er, Lvnn"
("Lane, Cliff (N	IIH/NIAID) [E]	1	(b) (6) , "L	epore, John	H)
b	(b) (6)	"Marks, Peter	(FDA/CBER)" <	((b) (6)	"Marston,	Hilary
(NIH/	NIAID) [E]"				RC) [E]"		,
"Mee	ker, David"	(b) (6)	>, "Menets	ki, Joseph (F	NIH) [T]"	(b) (6)	>,
"Mes	sonnier, Nancy (C	DC/DDID/NCIRD/C	DD)" (b) (6) >, "F	Pandya, Hitesh"		
<	(b) (6)	. "Par	ngalos, Mene"		(b) (6)	>, "	Pao, William"
	(b) (6)	, "Parker, Ashl	ey (NIH/OD) [I]"	(b) (6)	"Paul, Ste	ve"
<	(b) (6)	"Perlmutter, Rog	ger" <	(b) (6)	, "Pl	enge, Rober	t"
	(b) (6)	, "Plump, Andy"					
(b)	(6)	>, "Rasi, Guido"					
	(b) (6)	, "Reese, David"	< (b) ((6)	Rouse, Doris" <	(b) (6)	"Santos,
Mich	ael (FNIH) [T]"				(b) (6)		
(FDA)	/CDER)" <	(b) (6)					
[E]"	(b) (6)	>, "Talley,					
	(b) (6)	"Vessey, Rupe	ert"	(b) (6)	"Virgin, Ski	o" (b) ((6)
"Who	olley, David (FNIH)	[T]" (b) (6)					
		>, "Young					ne (NIH/NCATS)
[E]"	(b) (6)				(b) (6)		
	(b) (6)	, "Jansen, Ka		(b) (6)			el (NIH/NCATS)
[E]" <			ouglas (NCI)" «			rah (NIH/NI	
<		"Young, John"	(b)	.,,,,			consecution of the straight
	Bianchi, Diana (NII		(b) (6)		rnes, Noni (NIH	/CSR) [E]"	
<		, "Glass, Roger (N			"Hode	5 (F. 1970)	"[3] (AIN/HIN
<	(b) (6)	"Koob, George					etz, Walter
	/NINDS) [E]" <	(b) (6)			(NIH/NCCIH) [E		,
(/	, [=]	(0) (0)	Lange	,	()	,	

<	(b) (6)	,"No	orris, Andre	ea (NIH/CII	r) [E]" <	(b) (6)	"Perez-	Stable, El	iseo
(NIH)	NIMHD) [E]"	(1)	o) (6)	, "Ro	odgers, G	riffin (NIH/N	NIDDK) [E]"			
<	(b) (6)	13	"Schwetz,	Tara (NIH/	OD) [E]" <	(b)	(6)	. "Shar	pless, Nor	man
(NIH/	/NCI) [E]" <	(b) (6)	"Tucci, I	Debara (N	NIH/NIDCD)	[E]"	(b) (6)		,
"Tum	minia, Santa (I	NIH/NEI) [E]"		(b) (6)	>, "\	/olkow, Nor	a (NIH/NID	A) [E]"		
	(b) (6)	"Woy	chik, Rick (NIH/NIEHS	(a) [E]" <	(b) (6	j) .	"Adam,	Stacey (FN	√(T] (HII
<	(b) (6)	"Alvarez, Ro	sa" <	(b) (6))	. "Anderso	n, Margare	et"		
<	(b) (6)		"Chen, He	elen" < <u>gi</u>	(b)	(6)	"Elsaid, C	livia"		
	(b) (6)	, "Gonz	alez, Nina"	<	(b) (6)		"James, Ste	phanie (FNIH) [T]'	t:
	(b) (6)									
<	(b) (6)	"Stratton,	Ben"	(b) (6)	, "Tolmar	n, Brett" <		(b) (6)	
	ntas, Karen (FN								>, "Wh	olley,
David	(FNIH) [T]"	(b) (6)	>, "A	nderson, Ja	ames (NII	H/OD) [E]"		(b) (6)		
"Burk	low, John (NIF	H/OD) [E]"	(b) (6)	, "Castill	ejos, Carlos'	(1	b) (6)	, "Cu	lp,
	elle (NIH/OD) [, '	'Freire,
Maria	a (FNIH) [T]" <	(b) (6)	, "Ga	dbois, Eller	n (NIH/O[D) [E]"	(b) (6)		, "Woline	tz,
	e (NIH/OD) [E]'							(b) (6	5)	
"Gorı	man, Greta (FN	IIH) [T]" <	(b) (6)	."Ha	allett, Ad	rienne (NIH)	/OD) [E]"			
	(b) (6)	, "M	eltzer, Abb	ey (FNIH)	[T]"	(b) (6)	, "Myl	es, Rena	te (NIH/O	D) [E]"
<	(b) (6)	"Melen	cio, Cheryl	(FNIH) [T]	' <	(b) (6)				
Subje	ect: [EXTERNAL	.] Materials f	or July 29 A	ACTIV Exec	utive Con	nmittee Tele	econference	e		
Rese	nt-From:	(b) (6)								

[Use CAUTION when opening links/attachments]

Dear ACTIV EC members, Working Group Co-Chairs, and meeting participants:

Please see attached the PowerPoint slides, including the agenda, for our meeting (via Zoom) from 2:30 PM to 4:00 PM Eastern U.S. time tomorrow, Wednesday July 29. I have also attached notes from our July 1 Leadership Team meeting as well as our last ACTIV EC meeting on July 15.

The Zoom meeting information is:

```
Join Zoom Meeting

https://fnih.zoom.us/j (b) (6)

Meeting ID: (b) (6)

Password: (b) (6)

One tap mobile

(b) (6)

US (Germantown)

US (Chicago)
```

Dial by your location

```
(b) (6) US (Germantown)
US (Chicago)
US (New York)
US (San Jose)
US (San Jose)
US (Tacoma)
US (Houston)
Belgium
elgium
```

```
(b)(6)
           elgium
           elgium
           elgium
           Canada
           Canada
           Canada
           Canada
           Canada
           rance
           rance
           rance
           rance
           rance
           apan
           apan
           apan
            Italy
             Italy
            Italy
           Switzerland
           Switzerland
           Switzerland
           Switzerland
           Switzerland
            United Kingdom
            United Kingdom
            United Kingdom
            United Kingdom
            United Kingdom
            United Kingdom
  (b) (6)
     (b) (6)
```

Meeting ID: Password: (b) (6)

(b)(6)Find your local number: https://fnih.zoom.us

Please let Joe Menetski or Cheryl Melencio here at FNIH (copied) know if you are having any problems connecting. I look forward to a productive meeting.

Regards,

David

David Wholley Senior Vice-President, Research Partnerships Foundation for the National Institutes of Health (b) (6) fnih.org

11400 Rockville Pike Suite 600 North Bethesda, MD 20852

In 2019, the FNIH earned the highest rating from Charity Navigator for the fifth consecutive year and was recognized as an organization that exceeds industry standards.

APAR0000000950-2516957

This message (including any attachments) may contain confidential, proprietary, privileged and/or private information. The information is intended to be for the use of the individual or entity designated above. If you are not the intended recipient of this message, please notify the sender immediately, and delete the message and any attachments. Any disclosure, reproduction, distribution or other use of this message or any attachments by an individual or entity other than the intended recipient is prohibited.

From: Menetski, Joseph (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=5001AF52DC4A427EA3D34F1E072F8CB7-MENETSKIJP] Sent: 7/17/2020 6:47:58 PM To: Parker, Ashley (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras] CC: Alvarez, Rosa Maria [(b) (6) Subject: RE: ACTIV Preclinical full working group Sorry Ashley, I will follow up with Rosa to make sure you are always on the list (good list, not bad list 😂) Joe From: Parker, Ashley (NIH/OD) [E] < (b)(6)Sent: Friday, July 17, 2020 2:43 PM To: Menetski, Joseph (FNIH) [T] < Subject: RE: ACTIV Preclinical full working group Hi Joe, Following up to let you know I did not receive the calendar invites to the preclinical subgroup meetings. I hope to be included soon. Thank you, Ashley From: Menetski, Joseph (FNIH) [T] < (b)(6)Sent: Wednesday, July 8, 2020 2:51 PM To: Parker, Ashley (NIH/OD) [E] < (b) (6) Subject: RE: ACTIV Preclinical full working group Will do. I have sent a note to Rosa Alvarez to make sure you are added to the subgroups. Joe From: Parker, Ashley (NIH/OD) [E] < (b)(6)Sent: Wednesday, July 8, 2020 1:52 PM To: Menetski, Joseph (FNIH) [T] Subject: RE: ACTIV Preclinical full working group Thanks, Joe! Can you also please add me to the preclinical subgroup meetings? Ashley From: Menetski, Joseph (FNIH) [T] (b)(6)Sent: Wednesday, July 8, 2020 1:50 PM ; Hild, Sheri (NIH/OD) [E] To: (b)(6)(b)(6)(b) Baric, Ralph (b)(6)Ottinger, Elizabeth (NIH/NCATS [E] < Colvis, Christine (b)(6)(b)(6)(NIH/NCATS) [E] (b)(6)Hewitt, Judith (NIH/NIAID) [E] Deming, Damon (b)(6)

(FDA/	CDER)		(b) (6	j)			Park	er, Ashley (N	H/OD) [E]
		(b) (6)		Ad	ams, Pete	r (OS/ASPR/	BARDA)		
	(b) (6)	>; Rao, Srinivas	(b)	(6)	; Qashu	i, Felicia (NIF	1/OD) [E]		
	(b	Tomas Cihlar	(b) (6)		; Pitt, N	∕largaret L C	IV USARN	IY MEDCOM L	JSAMRIID
(USA)	(b) (d	5) >; Pu	inturieri, Anto	nello (NIH/	NHLBI) [E]		(b) (6)	>; Chai	rette, Marc
(NIH/N	NHLBI) [E]	(b) (6)	>; Fessel, Jos	sh (NIH/NHL	.BI) [E]	(b) (6)			
Cc: Dia	amond, Michael	(b) (6)	; Aust	in, Christop	her (NIH/I	NCATS) [E]	(b)) (6) >	Florence,
Clint (I	NIH/NIAID) [E]	(b) (6)	; Simon	, Dina (NIH/	'OD) [C] <	(b) (d	5)	: Wholley, Day	vid (FNIH)
[T]	(b) (6)	>; Melencio, Che	eryl (FNIH) [T]	(b)	(6)	>; Colvis, Ch	ristine (N	IIH/NCATS) [E]	
	(b) (6)	Desrosiers, I	Betsy	(b) (6)	Hug	hes, Eric		
	(b) (6)	Jansen, Ka	athrin	(b) (6)		Kurilla, M	ichael (NI	H/NCATS) [E]	
	(b) (6)	Lowy, Dougl	as (NCI) <	(b) (6)	Read, Sa	arah (NIH/NI	AID) [E]	(b) (6)	;
Tounta	as, Karen (FNIH)	[T] (b) (6)	Santo	os, Michael	(FNIH) [T]	(b) (d	5)	; Adam, Stace	y (FNIH) [T]
		mes, Stephanie (F				ez, Rosa Mar			
Kim, E	lizabeth <	(b) (6) T	olman, Brett <	< (1	b) (6)	Wacht	el, Jonath	an	
	(b) (6)	>; Prabhavathi I	Fernandes		(b) (6)		Rose Li		
	(b) (6)		arluccio		b) (6)			Enrique (NIH/I	NCATS) [E]
<	(b) (6)	Jonson, Sama	intha (NIH/NC	ATS) [E]	(b)	(6)	<u>∨</u> >; Gor	nzalez, Nina	
	(b) (6)	: Burrus-Sh	aw, Cyndi (NI	H/OD) [E]		(b) (6)	>; F	Rodriguez, Rob	oin D
	(b) (6)	Dave Frankows	ski	(b) (6))	<u>m</u> >; l	Baric, Ton	ii C	
	(b) (6)		y, Douglas (NI					łaigwood	
	(b) (6)	Stratton, Benja	min	(b) (6)	(Gadbois, Elle	n (NIH/O	D) [E]	
	(b) (6)	Anderson, Jan	nes (NIH/OD)	[E] <	(b) (6)				

Subject: ACTIV Preclinical full working group

Dear Preclinical Working group and attendees,

I apologize for not providing the minutes from last week's meeting. Here they are for your review.

Sincerely, Joe

Joseph P. Menetski Ph.D.

Associate Vice President, Research Partnerships

Foundation for the National Institutes of Health

(b) (6) fnih.org

11400 Rockville Pike, Suite 600, North Bethesda, MD 20852



Donate to the FNIH's Pandemic Response Fund to combat COVID-19: fnih.org/pandemic



From:		l (FNIH) [T] [/O=EXCHAI DLT)/CN=RECIPIENTS/C				
Sent:	1/12/2021 9:59:	03 PM				
То:		l (FNIH) [T] [/o=Exchang DLT)/cn=Recipients/cn=				ra
	(b) (6)) (6) ; C		
	(b) (6)	Collins, Fra	ncis (NIH/OD) [E] [/d	=ExchangeLabs/ou=l	Exchange Administrati	ve Group
	(FYDIBOHF23SPI	DLT)/cn=Recipients/cn=	410e1ca313f44ced	9938e50d2ff0b6c2-cd	ollinsf]; Corey, Larry	
	(b) (6)	Culp, Michelle	(NIH/OD) [E] [miche	elle.cu (b) (6) V	ictoria Davey	
	(b) (6)				Dolsten, Mikael	
	(b) (Erbelding	g, Emily (NIH/NIAID)	[E] [(b) (6)	Erck, Stan	
	(b) (6)	Fauci, Anthony	NIH/NIAID) [E] [(b) (6) G	adbois, Ellen (NIH/OD)) [E]
	(b) (6)	Gibbons, Gary	(NIH/NHLBI) [E] [ga	(b) (6)	Hudson, Thomas	
	(b)	Fauci, Anthony (Gibbons, Gary (6) James,	Stephanie (FNIH) [T	(b) (6) ;	Johnson, Robert (OS/A	ASPR/BARDA)
	(b) (6	Kramer, Ly	nn [(b) (6)	Lane, Cliff	(NIH/NIAID) [E]	
	(b) (6)	Lepore, John [jo	hn.j. (b) (6)	Marks, Peter (FDA	(b)	(6)
	Mascola, John (N	NIH/VRC) [E] [(1	b) (6)]; Me	eker, David [(b) (6) Me	netski, Joseph
		(b) (6) ; Messo				
) (6)]; Pac				E]
	(b) (6)	Perlmutter, R	oger (l	o) (6) Ple	enge, Robert	_
	(b) (6)	Plump, Andy [; Santos, Michael	(b) (6)	Reese, Day	vid (b) (6)	Rouse,
	(b) (6) ; Stein, P	eter (FDA/CDER)	(b) (6)	Stoffels, Paul	
	(b) (6)	Tabak, Lawrenc	e (NIH/OD) [E] [(b) (6)	j; Talley, Michael	1. 10
	(b) (d	Tsai, John	(b) (6)	Vessey, Ruper	(b) (6)	J; Virgin,
	Skip (b) (6)) Wholley, David (I	-NIH)[1] (b)	(6) Young, Joi	nn ((b) (6)	
		(NIH/NCATS) [E]	(b) (6)	; Desrosiers, Betsy [(b) (6)	I (NIIII (NICATO)
	Eric Hughes [Kurilla, Michae	(NITI/NCATS)
	[E] (b)	Adam, Stacey ((6)]; Read, Sarah		
		Adam, Statey (Fyor (b) (6) ; Chen, Hel	on! (b) (c)];
	Connelly Sarah	(6) Appell, (b) (6)	Gonzalez Nina	(h) (6	Hawk Harriso	J,
	(b) (6)]; Mendelson, Jes	co (b) (4	(b) (c)	na (b) (6)	Sorosa,
	$\Delta \log 1$ (b)) (6) Stratton,	Reniamin	(b) (6) : hto	lman (b) (6)	301034,
	Wachtel Ionath	an [(b) (6)	l: Anderson, lar	nes (NIH/OD) [F] [(b) (6)	1: Burklow
	John (NIH/OD) [I	E) (b) (6)	Carluccio, Dana	(b) (c	6) Cas	tilleios. Carlos
	(b) (6)	FNIH Central Ac	count [(b	(6) Halle	tt, Adrienne (NIH/OD)	[E]
	(b) (6)		oanne (NIH/NCATS)			ate (NIH/OD)
	[E] [(b) (rrie (NIH/OD) [E] [c]; Meltzer, Abbey (F	
	(b) (6)	Embry, Alan (NIH)		. , . ,	kayya, Rajeev	3.3.6
	(b)	(6) Rutter	Joni (NIH/NCATS) [; Cwalina, Alex	
	(b) (6)		a (FNIH) [T] [(b) (6) Brodd, L	auren (NIH/OD) [E]	
	(b) (6)	Bancel, Steph	ane [(b) (6)	Pangalos, Mene	
	(b) (6) ; Pa	ul, Steve (b)) (6) ; Rachel	Ramoni (b) (6)
	Reed, John [(b) (6) W	oodcock, Janet (FDA	A/OC) [/o=ExchangeLa	abs/ou=Exchange Adm	inistrative
	Group (FYDIBOH	IF23SPDLT)/cn=Recipie	nts/cn=9bc3fc3ebfc	f48879f92169bd7644	e29-Janet.Woodc]	
CC:	Austin, Sarah (N	IH/NIAID) [E] (b) (6) ; Bara	asch, Kimberly (NIH/N		
	(b) (d	The second control of	aw, Cyndi (NIH/OD)	* * * * * * * * * * * * * * * * * * * *		rea (NIH) [C]
	[trea. (b) (6		` ' ' '	Coan, Amano	• • • • • • • • • • • • • • • • • • • •];
	Conrad, Patricia		(b) (6)	Dimishkov, Roxanne		
	(b) (d	•		Fuhrer, Nicol	- ' ' ' '	
	Giorgi, Sara	(b) (6)	; Hoban, Michelle	` ' \ '	Hoffstetter, Rena	ta (FNIH) [T]
	(b) (6)	Iberdemaj, Vai	`	/ \ /	s, Christine S.	
		(6) Lever,		· / · /	Magbie-Robinson, Kim	(NIH/OD) [C]
		\ /	n, Melisa [(b)	` '	Ayanna (NIH/OD) [E]	
	(b) (d		- '	Dynamic Control of the Control of th	` ' ` '	
	Protasiewicz, An	n (b) (6)	Riggin, N	Mary [(b) (6)	Ripley, Nade	ge

(b) (6)	Schuster,	Donna	(b) (6)	Sepulveda, Do	orina (FNIH) [T]
(b) (6)	Simon, Dina (NIH/O	D) [C] [(b) (6)	Suha	na, Tina (NIH/VRC)	[E]
(b) (6)]; Thomas, Ashley (F	DA/CDER) [(b) (6)]; Wood, Gre	tchen (NIH/OD) [E]
(b) (6)	Togashi, Mieko (NIH)	/NCI) [E] [(b) (6))	.gov]; Underwood,	Nancy
(b) (6)	Zottoli, Je	essica [Jessica	(b)	(6)	Hughes, Karen (NI	H/OD) [E]
(b) (6)	Regan, Donna M [(b)	(6)	Plenge	e, Robert [(b) (6)
Vessey, Rupert [(b) (6)	Burke, Leslie	lesl	(b) (6)	Moghiminia	, Mahtab
(NIH/NCATS) [E] [(b) (6)	Lowy, Do	ouglas (NIF	I/NCI) [E] [(b) (6)]; Bell, Julie
(b) (6)	Riccobene, Ki	m [(b)	(6)			

Subject: ACTIV Leadership Team Call #16

Location: https://fnih.zoom.us/ (b) (6)

Start: 5/28/2021 1:00:00 PM **End**: 5/28/2021 2:30:00 PM

Show Time As: Busy

Required Attendees:

Melencio, Cheryl (FNIH) [T]; Bancel, Stephane; Carter, Kara; Cavaleri, Marco; Cihlar, Tomas; Collins, Francis (NIH/OD) [E]; Corey, Larry; Culp, Michelle (NIH/OD) [E]; Davey, Victoria; Disbrow, Gary (OS/ASPR/BARDA); Dolsten, Mikael; Erbelding, Emily (NIH/NIAID) [E]; Erck, Stan; Fauci, Anthony (NIH/NIAID) [E]; Gadbois, Ellen (NIH/OD) [E]; Gibbons, Gary (NIH/NHLBI) [E]; Hudson, Thomas; James, Stephanie (FNIH) [T]; Johnson, Robert (OS/ASPR/BARDA); Kramer, Lynn; Lane, Cliff (NIH/NIAID) [E]; Lepore, John; Marks, Peter (FDA/CBER); Mascola, John; Meeker, David; Menetski, Joseph (FNIH) [T]; Messonnier, Nancy (CDC/DDID/NCIRD/OD); Pandya, Hitesh; Pangalos, Mene; Pao, William; Parker, Ashley (NIH/OD) [E]; Paul, Steve; Perlmutter, Roger; Plenge, Robert; Plump, Andy; Ramoni, Rachel; Reed, John; Reese, David; Rouse, Doris; Santos, Michael (FNIH) [T]; Skovronsky, Daniel; Stein, Peter (FDA/CDER); Stoffels, Paul; Tabak, Lawrence (NIH/OD) [E]; Talley, Michael; Tsai, John; Vessey, Rupert; Virgin, Skip; Wholley, David (FNIH) [T]; Woodcock, Janet (FDA/OC); Young, John; Colvis, Christine (NIH/NCATS) [E]; Desrosiers, Betsy; Hughes, Eric; Jansen, Kathrin; Kurilla, Michael (NIH/NCATS) [E]; Lowy, Douglas (NCI); Read, Sarah (NIH/NIAID) [E]; Adam, Stacey (FNIH) [T]; Anderson, Margaret; Appell, Evan; Chen, Helen; Connelly, Sarah; Gonzalez, Nina; Hawk, Harrison; Mendelson, Jesse; Nasr, Hana; Sorosa, Alex; Stratton, Ben; Tolman, Brett; Wachtel, Jonathan; Anderson, James (NIH/OD) [E]; Burklow, John (NIH/OD) [E]; Carluccio, Dana; Castillejos, Carlos; FNIH Central Account; Hallett, Adrienne (NIH/OD) [E]; Lumsden, Joanne (NIH/NCATS) [C]; Myles, Renate (NIH/OD) [E]; Wolinetz, Carrie (NIH/OD) [E]; Meltzer, Abbey (FNIH) [T]; Embry, Alan (NIH/NIAID) [E]; Venkayya, Rajeev; Rutter, Joni (NIH/NCATS) [E]; Cwalina, Alex; Brodd, Lauren (NIH/OD) [E]

Optional Attendees:

Austin, Sarah (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [E]; Bell, Julie; Burrus-Shaw, Cyndi (NIH/OD) [E]; Carver, Trea (NIH) [C]; Caulfied, Anita; Coan, Amanda; Conrad, Patricia (NIH/NIAID) [E]; Dimishkov, Roxanne (NIH/NHLBI) [C]; Edl, Susan; Fuhrer, Nicole; Giorgi, Sara; Hoban, Michelle; Hoffstetter, Renata (FNIH) [T]; Iberdemaj, Vaide; Jenkins, Christine S.; Krack, Kimberly; Lever, Susan; Magbie-Robinson, Kim (NIH/OD) [C]; Martin, Melisa; McManus, Ayanna (NIH/OD) [E]; Minnich, Beth; Perala, Mie; Protasiewicz, Ann; Riccobene, Kim; Riggin, Mary; Ripley, Nadege; Schuster, Donna; Sepulveda, Dorina (FNIH) [T]; Simon, Dina (NIH/OD) [C]; Suhana, Tina (NIH/VRC) [E]; Thomas, Ashley (FDA/CDER); Wood, Gretchen (NIH/OD) [E]; Togashi, Mieko (NIH/NCI) [E]; Underwood, Nancy; Zottoli, Jessica; Hughes, Karen (NIH/OD) [E]; Regan, Donna M; Plenge, Robert; Vessey, Rupert; Burke, Leslie; Moghiminia, Mahtab (NIH/NCATS) [E]; Lowy, Douglas (NIH/NCI) [E]

Joseph Menetski is inviting you to a scheduled Zoom meeting.

```
Join Zoom Meeting https://fnih.zoom. (b) (6)

Meeting ID: (b) (6)

Passcode: (b)
One tap mobile (b) (6)

Dial by vour location (b) (6)

US (Washington D.C)
US (Chicago)
US (New York)
```

```
(b)(6)
                                 US (San Jose)
                                 US (San Jose)
US (Tacoma)
                                 US (Houston)
                                 lgium
elgium
                                 elgium
                                 elgium
                                 elgium
                                 elgium
                                 Canada
                                 Canada
                                 Canada
                                 Canada
                                 Canada
                                 Canada
                                 France
                                 France
                                 France
                                 France
                                 France
                                 Japan
                                 Japan
                                 Japan
                     (b)(6)
                                  Italy
                                     Italy
                                  Italy
                     (b)(6)
                                   Switzerland
                                   Switzerland
                                   Switzerland
                                   Switzerland
                                   Switzerland
                                   Switzerland
                                  United Kingdom
United Kingdom
United Kingdom
United Kingdom
                     (b)(6)
                     (b) (6)
(b) (6)
(b) (6)
                     (b) (6)
                                   United Kingdom
                     (b) (6)
(b) (6)
(b) (6)
                                   United Kingdom
                                   United Kingdom
Meeting ID: (b) (6)
Passcode: (b) (6)
Find your local number: https://fnih.zoom.u
                                                                 (b)(6)
```

Adam, Stacey (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=DCD875F0679648859E1CF101C0943414-ADAMSJ4] 6/20/2020 3:51:18 PM Bozzette, Sam (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=85f05a3619cf47c7ae39d7bcf0aac88d-bozzettesaa]; Butterton, Joan [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=219ecac4faae4ebab8a45ce8ee2490c3-joan_butter]; De Claro, R. Angelo (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c495c3ee25ca461ba6a829b124062448-DECLAROR.fd]; Draghia-Akli, Ruxandra [Eisner, Mark [(b) (6) (b) (6) Gottesdiener, Keith (b) (6) Hughes, Eric [**Judy Currier** (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=890082c7c1e34902b0f535320cd16650-jscurrier.m]; Kim, Elizabeth LaVange, Lisa [Levy, Elliot [Mellors, John W (b) (6) (b) (6) (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user257cb364]; Menon, Sandeep [Parker, Ashley (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange (b) (6) Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras]; Patel, Naimish [naimish.patel@sanofi.com]; Peppercorn, Amanda [Poole, Mike (b) (6) Proschan, Michael (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=7b45059209b4468bb4ba02b0dfbbb3e4-proscham]; Read, Sarah (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=527b160038004a199ae6e0bac2226099-readsa]; Santos, Michael (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ab38cb6836de44e18ef4cc6952f65f80-santosmr]; Shen, Yuan Li (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ae30a02e983e4e8a979dfec7257a1802-shenyu.fda]; Stein, Peter (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b4a14118481b4b39ba7e62a8d6425f79-Peter.Stein]; Wholley, David (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]; Buchman, Tim (OS/ASPR/BARDA) (CTR) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=00f8a853d8d740f8a8cdd55cbf8eb9da-Tim.Buchman]; Collins, Sylva (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f6b8f588067140fe988f0832c2387725-Sylva.Colli]; Amanda Peppercorn Garner, Carl : Higgs, Elizabeth (NIH/NIAID) [E] (b) (6) (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0601ca55a82841aba16353b96cff8ca9-ehiggs]; Koroshetz, Walter (NIH/NINDS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e8338dd7cdcd432e986961f1548c5ec6-koroshetzw]; Timothy Burgess [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=52e5e03dcbc847709eaab64457efa57e-TimothyBurg]; Reineck, Lora (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a62d88ba0c3b44e3bb922236c61304b3-reineckla]; Aggarwal, Neil (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d4c9de6615504ff9889f3b0c44a63526-aggarwalnr]; Rosenberg, Yves (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a5cb3e9a3a2747c38c42f68f5c8e40cf-rosenbey]; Goff, David (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=036113c7be0f42f897d1294cfbb99c10-goffdc]; Brown, Jeremy (NIH/NINDS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ce971eefec944a68a94addd3b24835f5-brownj7]; Gadbois, Ellen (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0243d1d6e6f248268d2edec566c26c2a-gadboisel]; Culp, Michelle (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4e38fa37e0424217aa0a283cba9e5098-mculp]; Jacqueline Kirchner (b) (6)

From:

Sent:

To:

CC:		H/NCATS) [E] [/o=Exch				(29-7)
	(FYDIBOHF23SPDLT)	/cn=Recipients/cn=4b	7e84cce0984578	96b2df19fa17	'2c87-ccolvis]; Desrosier	FOR STATE OF THE S
	(b) (d	5) Janse	n, Kathrin [(b) (6)	Kurilla, Michae	el (NIH/NCATS) [E]
		ou=Exchange Administ				
	(FYDIBOHF23SPDLT)	/cn=Recipients/cn=dc	4e85061e3943b9	b8ad3f42672	7861f-mkurilla]; Lowy, D	Oouglas (NCI)
	[/o=ExchangeLabs/d	ou=Exchange Administ	rative Group			
	(FYDIBOHF23SPDLT)	/cn=Recipients/cn=54	fa75fe6e304e34l	a567c66b832	baa0-drl.helix.n]; Young	, John
	(b) (6)	Biggs, Mary	(b) (6)	Butc	her, Tina [(b)	(6)
	Demarcus [(b) (6) Ma	acone, Erin [(b) (6)	Melencio, Cheryl (FN	IH) [T]
	[/o=ExchangeLabs/d	u=Exchange Administ	rative Group			
	(FYDIBOHF23SPDLT)	/cn=Recipients/cn=27	9e14fa7428415b	b86087d08b6	28e6f-melencioc]; Salati	hin, Carla
	(b) (6)	Tountas, K	aren (FNIH) [T] [/	o=ExchangeLa	bs/ou=Exchange Admin	istrative Group
	(FYDIBOHF23SPDLT)	/cn=Recipients/cn=40	c04fef6f1e46f5b	750753cd5a14	f93-tountaskh]; Menets	ski, Joseph (FNIH) [T
	[/o=ExchangeLabs/d	u=Exchange Administ	rative Group			
	(FYDIBOHF23SPDLT)	/cn=Recipients/cn=50	01af52dc4a427e	a3d34f1e072f	8cb7-menetskijp]; James	s, Stephanie (FNIH)
	[T] [/o=ExchangeLab	s/ou=Exchange Admir	nistrative Group			
	(FYDIBOHF23SPDLT)	/cn=Recipients/cn=f0	032ef62ca343dfb	4bf79577e2aa	a8d1-jamesst]; Wachtel,	Jonathan
	(b) (6)	Tolman, Brett [(b) (6)	Alvare	z, Rosa [(b) (6)
		ExchangeLabs/ou=Excl		tive Group	ayayaa araanaana ah	
		/cn=Recipients/cn=us			(b) (6)	Rose
	Li Central Account [(b) (6)		, Margaret [(b) (6)	Lucas
	Smalldon [(b) (6)		, Benjamin [(b) (6)	
	(b) (6)	Mollica, Lin		(b) (6)	Qashu, Felicia (NIF	H/OD) [E]
	\ / \ /	u=Exchange Administ	70 5	(-) (-)		
				b2c79484d90	e41e5-qashufm]; Patter:	son, Amy
		ExchangeLabs/ou=Exc				304 F (1) C (1) (1) (1) (1) (1)
					b70f-pattersa]; Rubin, [Daniel B.
	- The First Control of the State of the Stat	hangeLabs/ou=Exchar				
		1911 - T. 1912 - 1912 - 1913 - 1913 - 1913 - 1913			42aad-RUBIND.fda]; Mai	rston, Hilary
		ExchangeLabs/ou=Exc				•
					L16f3-marstonhd]; Chen	, Helen Q.
	(b) (6)	Wung, Peter /U			loots, W. Keith (NIH/NH	
		u=Exchange Administ				
				9262c6c2eca5	9d4c-hootswk]; Groesch	h, Mary (NIH/NHLBI)
		s/ou=Exchange Admir				
		[1] [1] [1] [1] [1] [1] [1] [1] [1] [1]		83186b9d987	0344e-groeschm]; Shipp	, Allan (NIH/NHLBI)
		s/ou=Exchange Admir			,, ,,	,
				aef107bd0ce2	27715-shippa]; Kindzelsk	ci, Andrei
		ExchangeLabs/ou=Exc				YO
		/cn=Recipients/cn=8b	1977		2db5c-kindzelskia1	
Subject:	- 37	orking Group Meeting				
Attachments:				/ TX-Clinical \	Norking Group Meeting	
	Guide_20200618.pd		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			

Dear ACTIV TX-Clinical Working Group,

Thank you all again for a great meeting this week. In follow-up, please find attached the formal summary for our meeting on June 18, 2020.

In addition, in response to the question on the agents for the ACTIV-4 trial, the NHBLI team has provided the following information:

Currently we consider the following:

For pre-hospital trial:

• Adaptive design study of placebo control, anti-platelets (for example dipyridamole), direct anti-coagulant (for example apixaban). Arms may be dropped for futility and/or adaptively combined along the study.

In-hospital trial:

• Adaptive design of UF and LMW heparin in low prophylaxis dose and high therapeutic dose with and without anti-platelets (for example dipyridamole).

Post-hospitalization trial:

 Adaptive design study to investigate continuation of LMWH, anti-platelets (dipyridamole), direct anti-coagulant (for example rivaroxaban) after 3 weeks of post-hospital discharge with LMWH treatment. Arms may be dropped for futility and/or adaptively combined along the study.

Also, for those, interested in getting access to the CTC WG Dashboard for network and sites please email me and I can send you the details on the information that you will need to send to our team to get access.

Thanks, Stacey

Stacey J. Adam, PhD

Director, Cancer

Research Partnerships

Foundation for the National Institutes of Health

Direct: (b) (6) | Mobile: (b) (6)

fnih.org

11400 Rockville Pike, Suite 600, North Bethesda, MD 20852



Donate to the FNIH's Pandemic Response Fund to combat COVID-19: fnih.org/pandemic



From: Menetski, Joseph (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=5001AF52DC4A427EA3D34F1E072F8CB7-MENETSKIJP] Sent: 6/15/2020 5:04:44 PM To: (b) (6) Hild, Sheri (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange (b) (6) Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=edd7f1939fb94be3bf063f925ac15f02-hildsa]; (b) (6) (b) (6) (b) (6) Baric, Ralph [/o=ExchangeLabs/ou=Exchange Administrative Group (b) (6) (FYDIBOHF23SPDLT)/cn=Recipients/cn=48e35ab1d3044465a7790ee4ded5bc32-rbaric.emai]; Ottinger, Elizabeth (NIH/NCATS [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ad34123055944f97bedbef038d375cd7-ottingerea]; Colvis, Christine (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4b7e84cce098457896b2df19fa172c87-ccolvis]; Hewitt, Judith (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2d0a7dadfcbd42cbb4014d9b26af30cc-ihewitt]; Deming, Damon (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=8a5ace9923ae415aa3d85ac09cb76f85-DEMINGD.fda]; (b) (6) Parker, Ashley (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras]; ken.duncan@gatesfoundation.org; Adams, Peter (OS/ASPR/BARDA) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f6e22f801f9146ef90116c4311c6f3ee-Peter.Adams]; Rao, Srinivas Qashu, Felicia (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=366447a553f44696b2c79484d90e41e5-gashufm]; Tomas Cihlar Pitt, Margaret L CIV USARMY MEDCOM USAMRIID (USA) [(b) (6) Punturieri, Antonello (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ca7f3106e5f24b5cb5e933c6ee7a6bc7-punturieria]; Charette, Marc (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a7fa2baf951848b5bf1f76a049a0eca6-charettemf]; Fessel, Josh (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=294e2bb481d94b83a1917f15338dfe19-fesseljp] CC: Diamond, Michael [(b) (6) Gonzalez, Nina [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user3c2f486d]; Florence, Clint (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5e032d0bc8554e8787e844a7773295fe-florencewc]; Simon, Dina (NIH/OD) [C] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e02345fa5d1d4d7eaf4e0f3da58bc1ac-simondm]; Wholley, David (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]; Austin, Christopher (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=17597cabc42247548e596778304f781f-austinc]; Melencio, Cheryl (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=279e14fa7428415bb86087d08b628e6f-melencioc]; Colvis, Christine (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4b7e84cce098457896b2df19fa172c87-ccolvis]; Desrosiers, Betsy Hughes, Eric [Jansen, Kathrin (b)(6)(b) (6) Kurilla, Michael (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (b) (6) (FYDIBOHF23SPDLT)/cn=Recipients/cn=dc4e85061e3943b9b8ad3f426727861f-mkurilla]; Lowy, Douglas (NCI) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=54fa75fe6e304e34ba567c66b832baa0-drl.helix.n]; Read, Sarah (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=527b160038004a199ae6e0bac2226099-readsa]; Tountas, Karen (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=40c04fef6f1e46f5b750753cd5a14f93-tountaskh]; Santos, Michael (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ab38cb6836de44e18ef4cc6952f65f80-santosmr]; Adam, Stacey (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=dcd875f0679648859e1cf101c0943414-adamsj4]; James, Stephanie (FNIH) [T]

	[/o=Exchan	geLabs/ou=	Exchange A	dministrative	Group				
	(FYDIBOHF:	23SPDLT)/c	n=Recipients	s/cn=f0032ef	62ca343dfb4bf	79577e2a	a8d1-james	st]; Alvarez, Rosa M	aria
	((b) (6)	Kim, El	izabeth [(b) (6)	Tolmar	n, Brett [(b) (6)	Wachtel,
	Jonathan [(b)	(6)	Prabhavathi	Fernandes [(b) (6)	Rose Li	
	[(b) (6)	Dai	na Carluccio [(b) (6)		Lagos, Enrique (N	IIH/NCATS)
	[E] [/o=Excl	nangeLabs/	ou=Exchang	e Administrat	ive Group				
	(FYDIBOHF:	23SPDLT)/c	n=Recipients	s/cn=ae9041a	b27204d83b0	6752f67a4	4b0d1-lago	ses]; Jonson, Saman	tha
					e Administrativ				
							d69a7-jons	onsg]; Burrus-Shaw,	Cyndi
		[전투기 (FINE NO. 100 NO.		그, 아이스 아이들이 되었다.	dministrative G				
							c31f6-shaw	cy]; Rodriguez, Robi	n D
	[(b)	(6)	Dave Fran	_		(6)		Baric, Toni C	
	[(b) (6)						u=Exchange Adminis	
						78bb17840	c56902718	a-lowyd]; Nancy Hai	igwood
				dministrative				u a cal como da e se disposações de la proporti do esta esta esta esta esta esta esta esta	
								woon.oh]; Stratton,	
		(b) (6)						ange Administrative	Group
2000					d6e6f248268d2	2edec566c	26c2a-gadb	ooisel]	
Subject:			all working g						
Attachments:	2020-06-10	_Precilnica	i_wG_Sumn	nary_F2.docx					
Dear Preclinio	al working	group mer	mbers and a	attendees,					
					N 11 - 1790 - 17			2004	
Please find th	e minutes f	rom last w	reeks meeti	ing attached	. Feel free to	contact n	ne if you h	ave any questions.	
Best regards,									
oe									
Original A	ppointmen	t							
Subject: ACTI	• • • • • • • • • • • • • • • • • • • •		ing group						
170				1.00 AM (II	TC-05:00) Eas	tern Time	1115 & Ca	nada)	
Where: https		The second secon	10.00 /1101 1		(b) (6)	icenti inne	, (OS & Ca	naud).	
where. nttps	.// 111111.2001	ii.us,			(0) (0)				
honging tim	o for prodir	sical WC							
Changing time	e for preciir	lical WG							
		- 2							
oseph Mene	tski is invitii	ng you to a	scheduled	Zoom meet	ting.				
- Marin Table - Marines	31 (242) 5								
oin Zoom Me									
https://fnih.z	oom.us			(b) (6)					
Meeting ID:	(b) (6)								
Password: (b	(6)								
One tap mobi	le								
	(b) (6))	U	S (Germant	own)				
				S (Chicago)	,				
				- (8-/					
Dial by your lo	ocation								
(b) ((Carmont	o						
(0) ((Germante	own)						
		(Chicago)							
	US	(New York	c)						
	US	(San Jose)							
		(San Jose)							
		(Tacoma)							
		(Houston)							
	03	(

Meeting ID: (b) (6)
Password: (b) (6)

Find your local number: https://fnih.zoom.us (b) (6)

From:	(FYDIBOHF23SPDLT)/	CN=RECIPIENTS/CN=D	BS/OU=EXCHANGE ADN DCD875F0679648859E1		
Sent:	5/22/2020 2:30:56 AM				.70
То:	Ruxandra Draghia-Aki	(FYDIBOHF23SPDLT)/ li [(b) (6) .c		o160038004a199ae6 /o=ExchangeLabs/ou	eObac2226099-readsa]; =Exchange Administrative (b) (6) Colvis,
	(FYDIBOHF23SPDLT)/(b) (6)	cn=Recipients/cn=4b7 Stein, Peter (이 없었다면 되었다. 기계에 걸린이 아랫동안 때문이 아니다면 하다.	f19fa172c87-ccolvis]; igeLabs/ou=Exchange	Young, John Administrative Group
	(b) (6)	Buchm	14118481b4b39ba7e6 nan, Tim (OS/ASPR/BAR	DA) (CTR) [/o=Exchar	ngeLabs/ou=Exchange
					55cbf8eb9da-Tim.Buchman];
	Vincent, Michael [[(b) (6)	(b) (6) Wung, Peter /US [Keith Gottesdien (b) (6)	er [(b) (Koroshetz, Walter	
	(FYDIBOHF23SPDLT)/		38dd7cdcd432e98696		etzw]; Higgs, Elizabeth
	(FYDIBOHF23SPDLT)/	cn=Recipients/cn=060	ange Administrative Gr 91ca55a82841aba16353	3b96cff8ca9-ehiggs];	
	(b) (6) (FYDIBOHF23SPDLT)/	cn=Recipients/cn=036	5113c7be0f42f897d129	4cfbb99c10-goffdc]	nge Administrative Group
CC:	Elizabeth Kim [N (37) N	=Exchange Administrative
					nenetskijp]; Alvarez, Rosa
	Maria (b) (-	· · · · · · · · · · · · · · · · · · ·	(b) (6) (b) (6)
			abs/ou=Exchange Admi 5b2244466140faa95aaa		s]; Wholley, David (FNIH) [T]
		=Exchange Administra		aroocaa, o parnera	sj,
	50% (C. C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C			996d677257-wholley	d]; Melencio, Cheryl (FNIH)
	7.00.00	/ou=Exchange Admini		74006620066 malana	is al. Lucas Cosalldan
	(b) (e14fa7428415bb86087 alker, Paula (NIH/NIND		375
		/			O3bcfd32930-walkerp1];
		[PROPERTY] [HONOR TO THE PROPERTY OF THE PRO	Labs/ou=Exchange Adr 4c7d13389454f89fe34		n]; Rose Li Central Account
	(b) (6)	Chen, Helen	Q. [(b) (6)		
Subject:	ACTIVITY-Clinical Age	nt Prioritization Subgr	oun Meeting #13		
Location:	https://fnih.zoom.u	THE THOTHE ZUCION SUBS	(b) (6)		
Start:	5/28/2020 4:00:00 PM	М	(-) (-)		
End:	5/28/2020 5:00:00 PM	M			
Show Time As:	Tentative				
Required	Eric Hughes; Read, Sa	rah (NIH/NIAID) [E]; R	uxandra Draghia-Akli; J	ohn Mellors; Naimish	n Patel; Colvis, Christine
Attendees:			(FDA/CDER); Poole, Mik t Levy; Wung, Peter /U:		S/ASPR/BARDA) (CTR); (NIH/NINDS) [E]; Higgs,
			Goff, David (NIH/NHLB		
Optional Attendees:	Parker, Ashley (NIH/C	하는 것이 없는 것이다.		Cheryl (FNIH) [T]; Luc	b) (6) (b) (6) as Smalldon; Walker, Paula ount; Chen, Helen Q.
Stacey Adam	is inviting you to	a scheduled Zoom	meeting.		
T 1 77 -					
Join Zoom N	_		(b) (6)		
https://fnih.z	OOIII.		(b) (6)		,

Meeting ID: (b) (6)
Password: (b) (6)
One tap mobile
(b) (6)
US (Chicago)
US (New York)

Dial by your location

(b) (6) US (Chicago)
US (New York)
US (Germantown)
US (San Jose)
US (Tacoma)
US (Houston)
US (San Jose)

Meeting ID: (b) (6)
Password: (b) (6)

Find your local number: https://fnih.zoom.us (b) (6)

From: Melencio, Cheryl (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=279E14FA7428415BB86087D08B628E6F-MELENCIOC] 9/25/2020 4:57:20 PM Melencio, Cheryl (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=279e14fa7428415bb86087d08b628e6f-melencioc]; Collins, Francis (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=410e1ca313f44ced9938e50d2ff0b6c2-collinsf]; Disbrow, Gary (OS/ASPR/BARDA) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=62a151e39ab942d88a813b449f9f6ccb-Gary.Disbro]; Dolsten, Mikael Fauci, Anthony (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=df38103d75134f658ae2d356f0396b94-afauci]; Gibbons, Gary (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b71b953b50a5495ca0f2869ab13bc407-gibbonsgh]; Marks, Peter (FDA/CBER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b2e527dbda2b4a86b8d72f06b813d471-MarksP.fda]; Pao, William Stoffels, Paul [Plump, Andrew [(b) (6) (b) (6) (b) (6) Woodcock, Janet (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9bc3fc3ebfcf48879f92169bd7644e29-Janet.Woodc]; Colvis, Christine (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4b7e84cce098457896b2df19fa172c87-ccolvis]; Desrosiers, Betsy Eric Hughes [/o=ExchangeLabs/ou=Exchange Administrative Group (b)(6)(FYDIBOHF23SPDLT)/cn=Recipients/cn=f97951a53cd54153b5daa9d99ad4ec90-EricHughes]; Jansen, Kathrin Kurilla, Michael (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dc4e85061e3943b9b8ad3f426727861f-mkurilla]; Lowy, Douglas (NCI) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=54fa75fe6e304e34ba567c66b832baa0-drl.helix.n]; Read, Sarah (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=527b160038004a199ae6e0bac2226099-readsa]; Young, John Adam, Stacey (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dcd875f0679648859e1cf101c0943414-adamsj4]; Alvarez, Rosa Maria [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user706e5647]; Margaret Anderson [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ab9a138f1e284c689fedfb10b8cc5295-marganderso]; Appell, Evan [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user7ee69e83]; Chen, Helen Q. [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user34aa917e]; Gonzalez, Nina [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user3c2f486d]; Hawk, Harrison [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user280c84f8]; Menetski, Joseph (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Mendelson, Jesse (b)(6)Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5001af52dc4a427ea3d34f1e072f8cb7-menetskijp]; Santos, Michael (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ab38cb6836de44e18ef4cc6952f65f80-santosmr]; Stratton, Benjamin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=usere3ed7188]; btolman [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user7b137a1e]; Tountas, Karen (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=40c04fef6f1e46f5b750753cd5a14f93-tountaskh]; Wachtel, Jonathan Wholley, David (FNIH) [T] [/o=ExchangeLabs/ou=Exchange (b) (6) Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]; Barasch, Kimberly (NIH/NIAID) [C] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ea5fad4c52f64f80b7daee4982ae495f-baraschk]; Conrad, Patricia (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=7ea3e3ea7daa432887495d6825c9e588-conradpa]; Dimishkov, Roxanne (NIH/NHLBI) [C] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d8415061971c493881c08c8c6cd75fb8-dimishkovrd]; McManus, Ayanna (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=bcf06de08ba845249b9b36ad216e237e-amcmanus]; Perala, Mie

Sent:

To:

CC:

COLL0000010161-2516964

[(b) (6)	Protasiewicz, Ann [(b)	(6)	Riccobene, Kim	
[(b) (6)	Thomas, Ashley (FDA/CD	ER) [/o=Excha	ngeLabs/ou=E	xchange Administrative Group	
(FYDIBOHF23SPDLT)/c	n=Recipients/cn=1bcd5d3	f7c1e4309a25	1d013e1cc89k	00-Ashley.Thom]; Wood, Gretchen	
(NIH/OD) [E] [/o=Exch	angeLabs/ou=Exchange Ad	dministrative (iroup		
(FYDIBOHF23SPDLT)/c	n=Recipients/cn=549f390	b39d044a8b5d	11e0e1a8f76c1	Lf-woodgs]; Anderson, James (NIH/OD)
[E] [/o=ExchangeLabs/	ou=Exchange Administrat	ive Group			
					23-andersonjm]; Austin, Christopher	
	점 입자 : (18. 18. 18. 18. 18. 18. 18. 18. 18. 18.	xchangeLabs/ou=Exchang				
				96778304f78	1f-austinc]; Burklow, John (NIH/OD) [E]
- 5	경기 경기 등에 시간하면 하는 것이 하게 하지만 하는 것이 없었다.	Exchange Administrative				
(ca-burklowj]; Carluccio, Dana	
l	(b) (6	,	os, Carlos	(b) (6)	Culp, Michelle (NIH/OD) [E]	
		Exchange Administrative		202 0 50	20 1.3 58111.0 1.14	
(98-mculp]; FNIH Central Account	
l	(b) (6)				Exchange Administrative Group	
				485468314108	34-freiremc]; Gadbois, Ellen (NIH/OD)	ĮĖ,
	[20] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2]	Exchange Administrative		odosECCs2Cs	2a gadhaicell Hellett Adrianne	
		n=Recipients/cn=0243010 angeLabs/ou=Exchange Ad			2a-gadboisel]; Hallett, Adrienne	
					b-hallettaa]; Lane, Cliff (NIH/NIAID) [E	1
		=Exchange Administrative		103803173331	b-Hallettaaj, Lalle, Cilli (MIT/MAID) [L	1
- 5				161547a82f2	de-clane]; Myles, Renate (NIH/OD) [E]	
		=Exchange Administrative		210154760212	de-danej, Myles, Kenate (Min, OD) [E]	
				92a1823c1b5	22-mylesr]; Parker, Ashley (NIH/OD) [E	Εì
		Exchange Administrative			,,,,,	-,
				aaaafe06ebd7	70-parkeras]; Tabak, Lawrence (NIH/OI	D)
		ou=Exchange Administrat			•	
				3770cfc7ee77	0-tabakl]; Wolinetz, Carrie (NIH/OD) [E	Ξ]
		Exchange Administrative				
(FYDIBOHF23SPDLT)/c	n=Recipients/cn=1c65504	0d47346c7b04	4d7bc11a403e	cb-wolinetzcd]; Burrus-Shaw, Cyndi	
(NIH/OD) [E] [/o=Exch	angeLabs/ou=Exchange Ad	dministrative (iroup		
(FYDIBOHF23SPDLT)/c	n=Recipients/cn=5bbac95	b1f6e4514a29	9b318030c31	f6-shawcy]; Carver, Trea (NIH) [C]	
		Exchange Administrative				
2	그 그 아이들은 사이들은 보다 되어 아니는 사람이 되었다고 있다면 하는데 하다.			2b8663cd448c	d3-carverkr]; Hughes, Karen (NIH/OD)	[E]
-	[[[[[[[] [] [] [] [] [] [] [] [] [] [] [Exchange Administrative				
					1a-hugheskp]; Lagos, Enrique	
		xchangeLabs/ou=Exchange				
- 70				6/52f6/a44b0	d1-lagoses]; Sepulveda, Dorina (FNIH)	
		ou=Exchange Administrat			Security and all Cinesas Dine (NULL/OD)	
- 0		n=Recipients/cn=6/5erco ou=Exchange Administrat		ерзсзеаттая	-sepulvedade]; Simon, Dina (NIH/OD)	
_				o0f2da59bc1a	c-simondm]; Tajalli, Ada (NIH/OD) [E]	
		Exchange Administrative		eorsuasoucta	c-simonum, rajam, Ada (Mm/OD) [L]	
-	엄마 없는 어린 아이 아이를 하는 것이 하는 것이 아이를 하는 것이 없는 것이 없다.			c241h285625	47-tajallian]; Gorman, Greta (FNIH) [T]	1
		Exchange Administrative		702410203023	47-tajamanj, Gorman, Greta (FWH) [1]	1
- 7				841696e460f0	62-gormanmj]; Meltzer, Abbey (FNIH)	
- 8		ou=Exchange Administrat		. 120000 10010	oz gormannyj) merezery nozey (r min,	
-				f852e698e538	2-meltzerak]; Togashi, Mieko (NIH/NC	(1)
		ou=Exchange Administrat				7
-	8.5. (Tr)			467e738767f8	3e-togashim]; Underwood, Nancy	
[(b) (6)	Zottoli, Jessic		0) (6)	•	
-						
A	CTIV EC & Working G	roup Co-Chair Meeting				
h	ttps://fnih.zoom.	(b) (6)			
		,				

Subject:

Location:

11/4/2020 3:00:00 PM Start: 11/4/2020 4:00:00 PM End:

Show Time As: Busy

Required Attendees: Collins, Francis (NIH/OD) [E]; Disbrow, Gary (OS/ASPR/BARDA); Dolsten, Mikael; Fauci, Anthony (NIH/NIAID) [E]; Gibbons, Gary (NIH/NHLBI) [E]; Marks, Peter (FDA/CBER); Pao, William; Plump, Andrew; Stoffels, Paul; Woodcock, Janet (FDA/CDER); Colvis, Christine (NIH/NCATS) [E]; Desrosiers, Betsy; Hughes, Eric; Jansen, Kathrin; Kurilla, Michael (NIH/NCATS) [E]; Lowy, Douglas (NCI); Read, Sarah (NIH/NIAID) [E]; Young, John

Optional Attendees: Adam, Stacey (FNIH) [T]; Alvarez, Rosa; Anderson, Margaret; Appell, Evan; Chen, Helen; Gonzalez, Nina; Hawk, Harrison; Mendelson, Jesse; Menetski, Joseph (FNIH) [T]; Santos, Michael (FNIH) [T]; Stratton, Ben; Tolman, Brett; Tountas, Karen (FNIH) [T]; Wachtel, Jonathan; Wholley, David (FNIH) [T]; Barasch, Kimberly (NIH/NIAID) [C]; Conrad, Patricia (NIH/NIAID) [E]; Dimishkov, Roxanne (NIH/NHLBI) [C]; McManus, Ayanna (NIH/OD) [E]; Perala, Mie; Protasiewicz, Ann; Riccobene, Kim; Thomas, Ashley (FDA/CDER); Wood, Gretchen (NIH/OD) [E]; Anderson, James (NIH/OD) [E]; Austin, Christopher (NIH/NCATS) [E]; Burklow, John (NIH/OD) [E]; Carluccio, Dana; Castillejos, Carlos; Culp, Michelle (NIH/OD) [E]; FNIH Central Account; Freire, Maria (FNIH) [T]; Gadbois, Ellen (NIH/OD) [E]; Hallett, Adrienne (NIH/OD) [E]; Lane, Cliff (NIH/NIAID) [E]; Myles, Renate (NIH/OD) [E]; Parker, Ashley (NIH/OD) [E]; Tabak, Lawrence (NIH/OD) [E]; Wolinetz, Carrie (NIH/OD) [E]; Burrus-Shaw, Cyndi (NIH/OD) [E]; Carver, Trea (NIH) [C]; Hughes, Karen (NIH/OD) [E]; Lagos, Enrique (NIH/NCATS) [E]; Sepulveda, Dorina (FNIH) [T]; Simon, Dina (NIH/OD) [C]; Tajalli, Ada (NIH/OD) [E]; Gorman, Greta (FNIH) [T]; Meltzer, Abbey (FNIH) [T]; Togashi, Mieko (NIH/NCI) [E]; Underwood, Nancy; Zottoli, Jessica

Joseph Menetski is inviting you to a scheduled Zoom meeting.

```
Join Zoom Meeting
https://fnih.zoom.
                                            (b) (6)
Meeting ID:
                (b) (6)
Passcode: (b)
One tap mobile
                                              US (Germantown)
                   (b) (6)
                                              US (Chicago)
Dial by your location
                         US (Germantown)
                         US (Chicago)
                         US
                             (New York)
                         US (San Jose)
                         US (San Jose)
                         US (Tacoma)
                         US (Houston)
                         lgium
                         elgium
                         elgium
                         elgium
                         elgium
                         elgium
                         Canada
                         Canada
                         Canada
                         Canada
                         Canada
                         Canada
                         France
                         France
                         France
                         France
                         France
                         Japan
                         Japan
                         Japan
                          Italy
                             Italy
                           Italy
                           Switzerland
                           Switzerland
                           Switzerland
                           Switzerland
                           Switzerland
                           Switzerland
                          United Kingdom
                           United Kingdom
```

```
(b) (6)

United Kingdom
```

From:		(b) (6)		(b) (6)				
Sent: To: Subject:			s (NIH/OD) [E] PDLT)/cn=Red				nistrative Group 0d2ff0b6c2-collins	f]
All good Let's co (b) (6	nsider	to catch up 1,	/1 in a coupl	le of weeks or w	hen yo	ou find it help	ful on the many t	topics
Sent fro	om my i	Phone						
	On Ma	ir 2, 2021, at	14:36, Collin	s, Francis (NIH/	OD) [E]	(b) ((6) wrote	:
	Yes, w	e also deligi	nted to pus	h forward on t	he pro	otease inhibi	tors!	
							e need for boos people, get va	sts. I'm just hoping ccinated!
	Best, I	Francis						
	From:	(b) (6)	-L 2 2024 0	(b) (6)				
	To : Co	Tuesday, Mar Ilins, Francis (t: Re: [EXTER	NIH/OD) [E]	(b) (6)				
	Francis	5						
	was t		r that ACTIV	approved our	V and	ORAL proteas	e inhibitor (PI) po	ending phase 1 data
				handful of indiv data we need t				nd are progressing
	Let's s	tay in touch						
			· And they was produced the second control	next steps w Co s third boost an				IH and Pfizer are
	(b)	(6)						
	Sent fr	om my iPhon	е					
		On Feb 15,	2021, at 19:	09, Collins, Fran	cis (NII	H/OD) [E]	(b) (6)	wrote:
		Hi (b) (6)						

Very interesting presentation, and a great opportunity to work together on the next steps. Let's do this!

Best, Francis

Dear Francis

Thanks for organizing that we all could come together today on a holiday to swiftly discuss the protease inhibitor program

We are very excited to progress the discussed partnership Best (b) (6)

Sent from my iPhone

On Feb 13, 2021, at 11:49, Collins, Francis (NIH/OD) [E] (b) (6) wrote:

Though it's a federal holiday, Monday might also be a possibility – I'd be fine with that.

Francis

 From: Collins, Francis (NIH/OD) [E]

 Sent: Saturday, February 13, 2021 11:17 AM

 To:
 (b) (6)

 Cc: Fauci, Anthony (NIH/NIAID) [E]
 (b) (6)
 Lane, Cliff

 (NIH/NIAID) [E]
 (b) (6)
 Wholley, David (FNIH) [T]

 (b) (6)
 Wood, Gretchen (NIH/OD) [E]

 (b) (6)
 ; Barasch, Kimberly (NIH/NIAID) [E]

 (b) (6)
 ; Conrad, Patricia (NIH/NIAID) [E]

Subject: RE: [EXTERNAL] a few follow ups

Hi (b) (6)

I've discussed with Tony, and we are very interested in meeting with you and your team. I'd like Tony, Cliff Lane, David Wholley, and me to join, and you can decide which of the Pfizer team would be most essential.

I'm looping in Gretchen Wood who can work with your Pfizer team to find a good time for this. Tuesday may be a challenge, but all of us will seek to move calendars around if necessary.

Best, Francis

From: (b) (6)

Sent: Friday, February 12, 2021 2:32 PM

To: Collins, Francis (NIH/OD) [E] (b) (6)

Subject: Re: [EXTERNAL] a few follow ups

Francis

If you prefer a smaller group , I am pleased also to present the protease drug highlights myself and john together w our CEO Albert Bourla from Pfizer to meet the three of you

Best

(b)(6)

Sent from my iPhone

On Feb 12, 2021, at 14:16, (b) (6) wrote:

Dear Francis

I and our Pfizer CEO Albert Bourla just reviewed the clinical plans from our protease inhibitor team . We also assessed manufacturing needs (for EUA) to possibly plan for success with time lines for potential EUA already in 2021 or early 2022 (pending good data of course).

We would enjoy as you suggested below meeting you, Tony and David as soon as possible - maybe Tuesday next week (Monday is holiday) to discuss how we can work together on our IV and ORAL pan-Corona virus protease inhibitor (Pi) drugs.

In this time of SARSCov2 viral evolution, they seems like a drug class w great promise.

We have submitted the IV PI drug to ACTIV w positive reception . We are planning to submit the oral PI drug to ACTIV on Wednesday next week .

Albert will join me in the meeting w you. If you want to have some more detailed background science on the drugs, I was thinking to bring in our two key scientist leaders in this area eg Liesa Anderson and Charlotte

Allerton . Liesa participated in ACTIV since the start within therapeutics related work streams .

Look forward to your response

Best (b) (6)

Sent from my iPhone

On Feb 11, 2021, at 05:26, Collins, Francis (NIH/OD) [E]

(b) (6) > wrote:

Hi (b) (6)

Thanks for quick response to my message - and wow, the progress on the oral anti-protease is fantastic! In the face of rising concerns about viral variants in the spike protein, the efficacy against all coronaviruses is extremely encouraging - will this even cure the common cold? (3) I am sure the ACTIV team would be ready to move quickly to slot this into ACTIV-2/3, pending the results of your phase 1 SAD-MAD studies. Considering possible combination therapies could also be a very appealing next step.

Let me know when you are ready to discuss – I'd like to bring Tony Fauci and David Wholley into that conversation soon.

Best, Francis

From: (b) (6)

Sent: Wednesday, February 10, 2021 8:36 AM

To: Collins, Francis (NIH/OD) [E]

(b) (6)

Subject: Re: [EXTERNAL] a few follow


ups


Hi Francis

Good that you try to correct NYT article but TIME paper was great

The exciting piece w the antiviral protease inhibitor (PI) drugs is that they are pan-corona virus active w potential as a drug for any new pandemic coronavirus. They also will inhibit all presently known SARSCov2 mutant variants that mainly affect SPIKE

Confidential update





Sent from my iPhone

On Feb 10, 2021, at 06:33, Collins, Francis (NIH/OD) [E]

(b) (6) wrote:

Hi (b) (6)

Just checking in. First, thanks for your kind words that were quoted in the TIME magazine profile – very much appreciated!

Second, I have been distressed by the uninformed characterization of the ACTIV efforts on therapeutics in the New York Times article ten days ago by Carl Zimmer, and a more recent OpEd from Zeke Emanuel et al. The TIME article gave a much more accurate depiction, and I hope

that was noticed. My staff and I are working in other ways to correct the record on this including an upcoming New Yorker article and 60 Minutes segment that will be much more positive!

Third, I am glad to see positive momentum in moving forward with the Pfizer anti-protease therapeutic through ACTIV. I hear good things about PF-07304814, and the potential for entering this into the ACTIV-3 trial in the near future. Of course I'm also intensely curious about your progress with an oral antiprotease, since that could be a true gamechanger for this pandemic - and an advance desperately needed at a time where new SARS-CoV-2 viral variants are causing a concern. Anything you can tell me about progress there?

All the best, Francis

From: Heatherington, Anne [(b) (6)

Sent: 7/1/2020 12:54:44 AM

To: Plump, Andrew [(b) (6)

CC: Wholley, David (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]; Collins, Francis (NIH/OD)

[E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=410e1ca313f44ced9938e50d2ff0b6c2-collinsf]; Culp, Michelle (NIH/OD) [E]

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=4e38fa37e0424217aa0a283cba9e5098-mculp]

Subject: Re: Data Sharing Slide for ACTIV LT Meeting

Flag: Follow up

Thanks David. One additional point to note is that we now have clearly assigned points of contact between COVID R&D (Sandeep Menon, Pfizer) and NIH (Michelle Culp) to ensure a smooth relationship.

Anne

On Jun 30, 2020, at 7:34 PM, Plump, Andrew <

(b) (6)

wrote:

Hi David - Yes, I will be at tomorrow's meeting and can speak to these points together with Francis.

Cheers,

Andy

Sent from my iPad

On Jun 30, 2020, at 7:33 PM, Wholley, David (FNIH) [T] <

(b) (6)

Be advised that this email came from outside Takeda / お知らせ:社外から送信されたメールです

Hi Andy-

Just a heads up that on tomorrow's Leadership Team call (which I see you have accepted on your calendar) we will be addressing as an action item the follow up on data sharing discussions. We've prepared the following reasonably high level slide that you and Francis could talk to. Thanks, David

<Update on Data Sharing_Slide for ACTIV LT Meeting.pptx>

The content of this email and of any files transmitted may contain confidential, proprietary or legally privileged information and is intended solely for the use of the person/s or entity/ies to whom it is addressed. If you have received this email in error you have no permission whatsoever to use, copy, disclose or forward all or any of its contents. Please immediately notify the sender and thereafter delete this email and any attachments.

From: Collins, Francis (NIH/OD) [E] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP

(FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=410E1CA313F44CED9938E50D2FF0B6C2-COLLINSF]

Sent: 5/2/2020 2:29:00 PM

To: Wholley, David (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]

CC: Tabak, Lawrence (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=02e22836b5ff4e9988e3770cfc7ee770-tabakl]

Subject: RE: Update on other COVID "master protocol" efforts

This is indeed a cause for serious concern. See my note about a conversation I had with Gary Gibbons yesterday, and the need to bring NHLBI back into the tent.

Do I need to have the same conversation with Walter Koroshetz?

FC

From: Wholley, David (FNIH) [T] < (b) (6)

Sent: Friday, May 1, 2020 7:12 PM

To: Collins, Francis (NIH/OD) [E] < (b) (6)

Cc: Tabak, Lawrence (NIH/OD) [E] < (b) (6)

Subject: Update on other COVID "master protocol" efforts

Hi Francis,

I sat in on several of the Working Group calls today and had my daily update with my team and one with Deloitte. I learned:

- The VA is working on a master protocol for COVID; Margaret Anderson thinks Mike Milken is behind this. Karen
 Tountas has arranged for our VA rep on the Clinical Trial Capacity Group, Victoria Davey, to set up a call with the
 VA MP folks and the ACTIV MP design Sub Group Stacey Adam is leading.
- From a presentation that Mike Poole of Gates Foundation gave us, their Tx Accelerator is arranging reasonably robust testing of many of the compounds we are looking to prioritize for ACTIV, including to our surprise mAbs. We still see daylight, but differentiation will be that much more challenging.
- NHLBI is actively designing an MP in their PETAL network for anticoagulants. Thanks to Cliff Lane, we are trying
 to get Amy Patterson to speak to Sarah Read and Stacey so we have some chance to decently align approaches.
- NINDS is both collaborating with NHLBI and running their own protocol using their SIREN network.

We cannot control what Milken and Gates do, but it is distressing to see efforts announced within NIH that more or less completely overlap and potentially compete for the same kinds of protocols and patients that ACTIV is attempting to address. It makes the partnership overall look disorganized. In fact one of our WG co-chairs used the chat feature on Zoom to comment on the side to one of my folks during a description of one of the other side NIH institute efforts that "this is like a circus—how do these people not talk to each other?"

This is not good. While you have my commitment that we will always do what we can to make sure we communicate to others in NIH the ACTIV plans, we are going to lose control of the public narrative overall if this continues. I think there is still time to address this; I would suggest a way be found to bring these other efforts together under the ACTIV banner and brand as soon as possible.

Regards, David David Wholley Senior Vice-President, Research Partnerships Foundation for the National Institutes of Health (b) (6)

inih.org

11400 Rockville Pike Suite 600 North Bethesda, MD 20852

In 2019, the FNIH earned the highest rating from Charity Navigator for the fifth consecutive year and was recognized as an organization that exceeds industry standards.

From:		NIH) [T] [/O=EXCHANGELABS/)/CN=RECIPIENTS/CN=279E14			
Sent:	1/12/2021 9:59:03	PM			
То:		NIH) [T] [/o=ExchangeLabs/ou)/cn=Recipients/cn=279e14fa			ioc]; Carter, Kara
	(b) (6)	Cavaleri, Marco	(b) (6)	; Cihlar, T	omas
	(b) (6)	Collins, Francis (NIH/			ge Administrative Group
)/cn=Recipients/cn=410e1ca3	13f44ced9938e5	0d2ff0b6c2-collinsf];	Corey, Larry
	(b) (6)	Culp, Michelle (NIH/OD)	[E] (b) ((6) Victoria	Davey
	(b) (6)]; Disbrow, Gary (OS/ASPR	R/BARDA) [(b) (6) D	olsten, Mikael
		Erbelding, Emily (N			
		Fauci, Anthony (NIH/NIAID			
	(b) (6)	Gibbons, Gary (NIH/NHL	BI) [E] (b) (6) Hudso	on, Thomas
	(b) (6)	James, Stephanie	(FNIH) [T]	(b) (6) ; Johnso	n, Robert (OS/ASPR/BARDA)
	(b) (6)	Kramer, Lynn [(b) (6)	Lane, Cliff (NIH/N	IAID) [E]
	(b) (6)	Lepore, John (b)	(6) Mar	rks, Peter (FDA/CBER	(b) (6)
	Mascola, John (NIH,	/VRC) [E] (b) (6)]; Meeker, Da	avid [(b) (6) Menetski, Joseph
	(FNIH) [T] (b) (6) ; Messonnier, Nan	icy (CDC/DDID/N	CIRD/OD) (b) (b)	6) Pandya, Hitesh
)]; Pao, William			
	(b) (6)	Perlmutter, Roger [(b) (6)	Plenge, Ro	obert
	(b) (6)	Plump, Andy [; Santos, Michael (FNIH) [T]	(b) (6)	Reese, David [(b) (6) Rouse,
	Doris (b) (6)	; Santos, Michael (FNIH) [T]	(b) (6)	Skovronsky, Dan	iel
	(b) (6)	; Stein, Peter (FDA)	CDER) [(b) (6) Sto	ffels, Paul
	(b) (6)	; Stein, Peter (FDA/ Tabak, Lawrence (NIH/OD) [E] (b)) (6)]; Talle	y, Michael
	(b) (6)	Tsai, John [(b) (6)	Vessey, Rupert [(b) (6)]; Virgin,
	Skip (b) (6)	Wholley, David (FNIH) [T] [dwhol	Young, John [(b) (6)
		H/NCATS) [E] (b) (6)	; Desro	siers, Betsy [(b) (6)
	Eric Hughes [Kurilla, Michael (NIH/NCATS)
	[E] [michael.	Lowy, Douglas (NCI	(b) (6)]; Read, Sarah (NIH/N	NIAID) [E]
		Adam, Stacey (FNIH) [T] [(b) (6)	Margaret Anderson	า
	(b) (6)		(b) (6)	; Chen, Helen	(b) (6)];
		(b) (6) Gonza	lez, Nina	(b) (6)	Hawk, Harrison
	(b) (6)		(b) (6)	Nasr, Hana [(b) (6) Sorosa,
	Alex (b) (6)) Stratton, Benjamin	(b) (6)	; btolman [(b) (6)
	Wachtel, Jonathan	(b) (6)]; And	erson, James (NII	H/OD) [E] [(b) (6)]; Burklow,
	John (NIH/OD) [E] [(b) (6) Carluce	cio, Dana [(b) (6)	Castillejos, Carlos
	(b) (6)	FNIH Central Account [(b) (6)	Hallett, Adri	enne (NIH/OD) [E]
	(b) (6)]; Lumsden, Joanne (NI		(b) (6)	Myles, Renate (NIH/OD)
	[E] [(b) (6)	Wolinetz, Carrie (NIH/	OD) [E]	(b) (6)]; Me	eltzer, Abbey (FNIH) [T]
	(b) (6)	Embry, Alan (NIH/NIAID) [E]	(b) (6)	Venkayya, F	Rajeev
	(b) (6)			` / ` /	alina, Alex
	(b) (6)	Milan, Marina (FNIH) [7	[(b) (6)	Brodd, Lauren (
	(b) (6)	Bancel, Stephane [(b) (6)		os, Mene
	(b) (d	•	(b) (6)	; Rachel Ramon	
	Reed, John [1154	1,000	Exchange Administrative
		SSPDLT)/cn=Recipients/cn=9bo			
CC:	Austin, Sarah (NIH/			mberly (NIH/NIAID) [
	(b) (6)	Burrus-Shaw, Cyndi		(b) (6)]; Carver, Trea (NIH) [C]
	[trea. (b) (6)		(b) (6)	Coan, Amanda [(b) (6)];
	Conrad, Patricia (NI			kov, Roxanne (NIH/N	
	(b) (6)]; Edl, Susan	(b) (6)	Fuhrer, Nicole [(b) (6)
	Giorgi, Sara		, Michelle [\ / \ /	offstetter, Renata (FNIH) [T]
	(b) (6)	Iberdemaj, Vaide [vaide.	(b) (6)	Jenkins, Chris	
	(b) (6)				-Robinson, Kim (NIH/OD) [C]
	(b) (6)		` ' ` '	McManus, Ayanna	
	(b) (6)	Minnich, Beth [(b) (6)	Perala, Mie [m	
	Protasiewicz, Ann [(b) (6)	Riggin, Mary [(b) (6)	Ripley, Nadege

	(b) (6)	Schuster,	Donna [donn	ia.		Sepulveda, D	orina (FNIH) [T]
ì	(b) (6)	Simon, Dina (NIH/O	시스(1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	(b) (6)	Suha	na, Tina (NIH/VRC	
ì	(b) (6)]; Thomas, Ashley (F) (6)		etchen (NIH/OD) [E]
[(b) (6)	Togashi, Mieko (NIH,	/NCI) [E] [(b) (6)		gov]; Underwood,	Nancy
[(b) (6)	Zottoli, Je	essica [Jessica	(b)	(6)	Hughes, Karen (N	IH/OD) [E]
[(b) (6)	Regan, Donna M [(b)	(6)	Plenge	e, Robert [(b) (6)
Vesse	y, Rupert [(b) (6)	Burke, Leslie	[lesl	(b) (6)	Moghiminia	a, Mahtab
(NIH/I	NCATS) [E] [(b) (6)	Lowy, D	ouglas (NIH	I/NCI) [E] [(b) (6)]; Bell, Julie
	(b) (6)	Riccobene, Ki	m [(b)	(6)			

Subject: ACTIV Leadership Team Call #16

Location: https://fnih.zoom.us (b) (6)

Start: 5/28/2021 1:00:00 PM **End**: 5/28/2021 2:30:00 PM

Show Time As: Busy

Required Attendees:

Melencio, Cheryl (FNIH) [T]; Bancel, Stephane; Carter, Kara; Cavaleri, Marco; Cihlar, Tomas; Collins, Francis (NIH/OD) [E]; Corey, Larry; Culp, Michelle (NIH/OD) [E]; Davey, Victoria; Disbrow, Gary (OS/ASPR/BARDA); Dolsten, Mikael; Erbelding, Emily (NIH/NIAID) [E]; Erck, Stan; Fauci, Anthony (NIH/NIAID) [E]; Gadbois, Ellen (NIH/OD) [E]; Gibbons, Gary (NIH/NHLBI) [E]; Hudson, Thomas; James, Stephanie (FNIH) [T]; Johnson, Robert (OS/ASPR/BARDA); Kramer, Lynn; Lane, Cliff (NIH/NIAID) [E]; Lepore, John; Marks, Peter (FDA/CBER); Mascola, John; Meeker, David; Menetski, Joseph (FNIH) [T]; Messonnier, Nancy (CDC/DDID/NCIRD/OD); Pandya, Hitesh; Pangalos, Mene; Pao, William; Parker, Ashley (NIH/OD) [E]; Paul, Steve; Perlmutter, Roger; Plenge, Robert; Plump, Andy; Ramoni, Rachel; Reed, John; Reese, David; Rouse, Doris; Santos, Michael (FNIH) [T]; Skovronsky, Daniel; Stein, Peter (FDA/CDER); Stoffels, Paul; Tabak, Lawrence (NIH/OD) [E]; Talley, Michael; Tsai, John; Vessey, Rupert; Virgin, Skip; Wholley, David (FNIH) [T]; Woodcock, Janet (FDA/OC); Young, John; Colvis, Christine (NIH/NCATS) [E]; Desrosiers, Betsy; Hughes, Eric; Jansen, Kathrin; Kurilla, Michael (NIH/NCATS) [E]; Lowy, Douglas (NCI); Read, Sarah (NIH/NIAID) [E]; Adam, Stacey (FNIH) [T]; Anderson, Margaret; Appell, Evan; Chen, Helen; Connelly, Sarah; Gonzalez, Nina; Hawk, Harrison; Mendelson, Jesse; Nasr, Hana; Sorosa, Alex; Stratton, Ben; Tolman, Brett; Wachtel, Jonathan; Anderson, James (NIH/OD) [E]; Burklow, John (NIH/OD) [E]; Carluccio, Dana; Castillejos, Carlos; FNIH Central Account; Hallett, Adrienne (NIH/OD) [E]; Lumsden, Joanne (NIH/NCATS) [C]; Myles, Renate (NIH/OD) [E]; Wolinetz, Carrie (NIH/OD) [E]; Meltzer, Abbey (FNIH) [T]; Embry, Alan (NIH/NIAID) [E]; Venkayya, Rajeev; Rutter, Joni (NIH/NCATS) [E]; Cwalina, Alex; Brodd, Lauren (NIH/OD) [E]

Optional Attendees:

Austin, Sarah (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [E]; Bell, Julie; Burrus-Shaw, Cyndi (NIH/OD) [E]; Carver, Trea (NIH) [C]; Caulfied, Anita; Coan, Amanda; Conrad, Patricia (NIH/NIAID) [E]; Dimishkov, Roxanne (NIH/NHLBI) [C]; Edl, Susan; Fuhrer, Nicole; Giorgi, Sara; Hoban, Michelle; Hoffstetter, Renata (FNIH) [T]; Iberdemaj, Vaide; Jenkins, Christine S.; Krack, Kimberly; Lever, Susan; Magbie-Robinson, Kim (NIH/OD) [C]; Martin, Melisa; McManus, Ayanna (NIH/OD) [E]; Minnich, Beth; Perala, Mie; Protasiewicz, Ann; Riccobene, Kim; Riggin, Mary; Ripley, Nadege; Schuster, Donna; Sepulveda, Dorina (FNIH) [T]; Simon, Dina (NIH/OD) [C]; Suhana, Tina (NIH/VRC) [E]; Thomas, Ashley (FDA/CDER); Wood, Gretchen (NIH/OD) [E]; Togashi, Mieko (NIH/NCI) [E]; Underwood, Nancy; Zottoli, Jessica; Hughes, Karen (NIH/OD) [E]; Regan, Donna M; Plenge, Robert; Vessey, Rupert; Burke, Leslie; Moghiminia, Mahtab (NIH/NCATS) [E]; Lowy, Douglas (NIH/NCI) [E]

Joseph Menetski is inviting you to a scheduled Zoom meeting.

```
Join Zoom Meeting
https://fnih.zoom.us/

Meeting ID: (b) (6)
Passcode: (b)
One tan mobile
(b) (6)

Dial by your location
(b) (6)

US (Washington D.C)
US (Chicago)
US (Washington D.C)
US (Chicago)
US (New York)
```

```
(b)(6)
                               US (San Jose)
                              US (San Jose)
US (Tacoma)
                               US (Houston)
                              lgium
elgium
                               elgium
                               elgium
                               elgium
                               elgium
                               Canada
                               Canada
                               Canada
                               Canada
                               Canada
                               Canada
                               France
                               France
                               France
                               France
                               France
                               Japan
                               Japan
                               Japan
                               Italy
                                  Italy
                                Italy
                                Switzerland
                                Switzerland
                                Switzerland
                                Switzerland
                                Switzerland
                                Switzerland
                                United Kingdom
                               United Kingdom
United Kingdom
United Kingdom
                                United Kingdom
                                United Kingdom
                   (b) (6)
(b) (6)
                                United Kingdom
Meeting ID: (b) (6)
Passcode: (b) (6)
Find your local number: https://fnih.zoom.
                                                            (b) (6)
```

From: Anderson, James (NIH/OD) [E] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP

(FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=73143D1860BC42458BE254CA21573B23-ANDERSONJM]

Sent: 5/13/2020 11:23:17 AM

To: Tabak, Lawrence (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=02e22836b5ff4e9988e3770cfc7ee770-tabakl]; Colvis, Christine (NIH/NCATS)

[E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=4b7e84cce098457896b2df19fa172c87-ccolvis]; Wholley, David (FNIH) [T]

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]; Menetski, Joseph (FNIH)

[T] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=5001af52dc4a427ea3d34f1e072f8cb7-menetskijp]

Subject: FW: Agenda for ACTIV EC meeting tomorrow morning at 8:00 AM Eastern US Time

Attachments: Need for NHP planning coordination process 5-12-2020.docx

Larry,

My responsibilities start earlier today that I thought. Attach is a summary of where we are with planning for NHP use for COVID research. Feel free to paraphrase at today's Exec Comm meeting and tomorrow's ICD meeting.

We plan to make the admin supplements to the NPRCs (\$30M from Hugh) require that the NPRCs develop a coordinating center to interact with ACTIV. Interaction with the NIAID resources still requires coordination.

Thanks for your help.

Jim

From: W	holley, David (F	FNIH) [T] <	(b) (6)					
Sent: Tue	esday, May 12,	2020 9:57 PM						
To: Collin	ns, Francis (NIH	/OD) [E] <	(b) (6)	Dolsten, Mik	ael <	(b) (6)		Fauci, Anthony
(NIH/NIA	ND) [E] <	(b) (6)	Gibbons, Gary	y (NIH/NHLBI)	[E] <	(b) (6)	Pao,	William
<	(b) (6)	Stoffels, Pa	ul [JJCUS] <	(b) (6)	Woo	dcock, Janet (FDA/CDE	₹)
<	(b) (6)	Colvi	s, Christine (NII	H/NCATS) [E] <	((b) (6)	Desros	iers, Betsy
<	(b) (6)	H	ughes, Eric <	(b) (6))	Jansen, Kat	hrin	
<	(b) (6)		Michael (NIH/N			(6) L	owy, Dou	glas (NIH/NCI) [[
<	(b) (6)	Read, Sarah (N	IH/NIAID) [E] <	(b) (6)	Y	oung, John		
<	(b) (6)	Menets	ki, Joseph (FNII	H) [T] <	(b) (6)	Adam, St	acey (FNI	H) [T]
< (t	b) (6) Tou	untas, Karen (FN	IIH) [T] <	(b) (6)	Santos, M	ichael (FNIH)	[⊺] <	(b) (6)
	laria (FNIH) [T]	< (b) (6)	Tabak, La	wrence (NIH/C)D) [E] <	(b) (6))	Lane, Cliff
(NIH/NIA	AID) [E] <	(b) (6)	Parker, Ashley	(NIH/OD) [E] <	((b) (6)	Anderso	on, James
(NIH/OD)) [E] <	(b) (6)	Austin, Chi	ristopher (NIH)	NCATS) [E	[] < (b)	(6)	Wolf-Rodda,
Julie (FNI	IH) [T] <	(b) (6)	Gonzalez, Nin	AND DESCRIPTION OF THE PROPERTY OF THE PROPERT	(b) (6)			
Cc: Mele	ncio, Cheryl (FI	> [T] (HIV	(b) (6)	Wood, Gretch	nen (NIH/C	DD) [E] <	(b) (6)	
Subject:	Agenda for AC	TIV FC meeting	tomorrow more	ning at 8:00 AN	1 Factorn	IIS Time		

Subject: Agenda for ACTIV EC meeting tomorrow morning at 8:00 AM Eastern US Time

Importance: High

Dear ACTIV EC members, Working Group Co-Chairs, and meeting participants:

Please see attached the agenda for our meeting tomorrow morning (via Zoom) and a copy of the letter from the Therapeutics- Clinical Working Group you received earlier today, for our discussion.

Please let Joe Menetski or Cheryl Melencio know if you are having any problems connecting. I look forward to a productive meeting.

Regards,

David

David Wholley Senior Vice-President, Research Partnerships Foundation for the National Institutes of Health

(b)(6)

fnih.org

11400 Rockville Pike Suite 600 North Bethesda, MD 20852

In 2019, the FNIH earned the highest rating from Charity Navigator for the fifth consecutive year and was recognized as an organization that exceeds industry standards.

From: Amanda Peppercorn [(b) (6)

Sent: 5/14/2020 3:59:41 PM

To: Collins, Francis (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=410e1ca313f44ced9938e50d2ff0b6c2-collinsf] Myles, Renate (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=7d317f5626934585b3692a1823c1b522-mylesr]; Meltzer, Abbey (FNIH) [T]

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=c341d86cf7404a78ac8f852e698e5382-meltzerak]; Wholley, David (FNIH) [T]

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]

Subject: RE: Time sensitive: Making your ACTIV Participation Public

Yes, you may use my name.

Best,

CC:

Amanda

Amanda Peppercorn, M.D. GSK Research & Development

mobile

(b) (6)

email

(b) (6)

From: Collins, Francis (NIH/OD) [E] < (b) (6)

Sent: Thursday, May 14, 2020 11:00 AM

To: Collins, Francis (NIH/OD) [E] < (b) (6)

Cc: Myles, Renate (NIH/OD) [E] < (b) (6) Meltzer, Abbey (FNIH) [T] < (b) (6) Wholley, David

(FNIH)[T] < (b)(6)

Subject: Time sensitive: Making your ACTIV Participation Public

EXTERNAL

Dear ACTIV Colleagues:

Yes, this message is for you, though your address was in the bcc line!

NIH would like to launch an ACTIV webpage to provide stakeholders with a central resource for information about our efforts, including announcements, scientific papers, and new developments. Currently, the content is based on publicly available information, but we would like add the ACTIV leadership and working group members. Your representation on ACTIV demonstrates the breadth and depth of expertise and experience from all sectors committed to this effort. Please send your responses to me, cc'ing Renate Myles, Abbey Meltzer, and David Wholley by 12:00 p.m. ET tomorrow, Friday, May 15, if you agree to be listed on the web site as part of the ACTIV team.

Thanks, Francis

Francis S. Collins, MD, PhD NIH Director GSK monitors email communications sent to and from GSK in order to protect GSK, our employees, customers, suppliers and business partners, from cyber threats and loss of GSK Information. GSK monitoring is conducted with appropriate confidentiality controls and in accordance with local laws and after appropriate consultation.

Menetski, Joseph (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=5001AF52DC4A427EA3D34F1E072F8CB7-MENETSKIJP] 12/22/2020 4:45:56 PM Menetski, Joseph (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5001af52dc4a427ea3d34f1e072f8cb7-menetskijp]; Hild, Sheri (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=edd7f1939fb94be3bf063f925ac15f02-hildsa]; (b) (6) m; (b) (6) (b)(6)Baric, Ralph [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=48e35ab1d3044465a7790ee4ded5bc32-rbaric.email; Ottinger, Elizabeth (NIH/NCATS [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ad34123055944f97bedbef038d375cd7-ottingerea]; Colvis, Christine (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4b7e84cce098457896b2df19fa172c87-ccolvis]; Hewitt, Judith (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2d0a7dadfcbd42cbb4014d9b26af30cc-ihewitt]; Deming, Damon (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=8a5ace9923ae415aa3d85ac09cb76f85-DEMINGD.fda]; Parker, Ashley (NIH/OD) [E] (b) (6) (b) (6) (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras]; Collins, Francis (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=410e1ca313f44ced9938e50d2ff0b6c2-collinsf]; ; Adams, Peter (OS/ASPR/BARDA) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f6e22f801f9146ef90116c4311c6f3ee-Peter.Adams]; Rao, Srinivas Qashu, Felicia (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=366447a553f44696b2c79484d90e41e5-qashufm]; Tomas Cihlar Pitt, Margaret L CIV USARMY MEDCOM USAMRIID (USA) [(b) (6) (b) (6) Punturieri, Antonello (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ca7f3106e5f24b5cb5e933c6ee7a6bc7-punturieria]; Charette, Marc (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a7fa2baf951848b5bf1f76a049a0eca6-charettemf]; Fessel, Josh (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=294e2bb481d94b83a1917f15338dfe19-fesseljp]; I (b)(6)Wholley, David (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]; Austin, Christopher (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=17597cabc42247548e596778304f781f-austinc]; Melencio, Cheryl (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=279e14fa7428415bb86087d08b628e6f-melencioc]; Desrosiers, Betsy (b)(6)Eric Hughes [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f97951a53cd54153b5daa9d99ad4ec90-EricHughes]; Jansen, Kathrin Kurilla, Michael (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dc4e85061e3943b9b8ad3f426727861f-mkurilla]; Lowy, Douglas (NCI) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=54fa75fe6e304e34ba567c66b832baa0-drl.helix.n]; Read, Sarah (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=527b160038004a199ae6e0bac2226099-readsa]; Tountas, Karen (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=40c04fef6f1e46f5b750753cd5a14f93-tountaskh]; Santos, Michael (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ab38cb6836de44e18ef4cc6952f65f80-santosmr]; Adam, Stacey (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dcd875f0679648859e1cf101c0943414-adamsj4]; James, Stephanie (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f0032ef62ca343dfb4bf79577e2aa8d1-jamesst]; Alvarez, Rosa Maria

From:

Sent:

To:

CC:

	[/o=ExchangeLabs/ou=	Exchange Administrative	Group (FYDIBOHF23SPDL	T)/cn=Recipients/cn=us	er706e5647]; Kim,				
	Elizabeth (b) ((6) btolman [/o=E	xchangeLabs/ou=Exchange	e Administrative Group					
	(FYDIBOHF23SPDLT)/c	n=Recipients/cn=user7b3	37a1e]; Wachtel, Jonatha	n (b) (6)	Prabhavathi				
	Fernandes [(b) (6)	Diamond, Michael [(b) (6) Rose L	i				
	(b) (6)	Dana Carluccio	(b) (6)		ique (NIH/NCATS)				
		ou=Exchange Administra							
	(FYDIBOHF23SPDLT)/cn=Recipients/cn=ae9041ab27204d83b06752f67a44b0d1-lagoses]; Jonson, Samantha								
		xchangeLabs/ou=Exchang							
			69d654bef89b0d39b145d	169a7-ionsonsgl: Gonzal	ez. Nina				
	[/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user3c2f486d]; Simon, Dina (NIH/OD) [C] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e02345fa5d1d4d7eaf4e0f3da58bc1ac-simondm]; Burrus-Shaw, Cyndi (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group								
			5b1f6e4514a299b318030d	31f6-shawcyl- Rodrigue	z Robin D				
	(b) (6)	Dave Frankowski [(b) (6)	antoinette_b					
			Group (FYDIBOHF23SPDL	_					
					erbobo44ci]; Lowy,				
			change Administrative Gro		Clima (NULL (NULL ID)				
			e4739478bb17840c56902	/18a-lowyd]; Florence,	Clint (NIH/NIAID)				
		ou=Exchange Administra		2055 5 2 2 2					
			0bc8554e8787e844a7773	295fe-florencewcj; Nanc	cy Haigwood				
		Exchange Administrative							
	60	55	f440d84691ac0a530e4ba6	177	0				
			Group (FYDIBOHF23SPDL		ere3ed7188];				
			ou=Exchange Administrati						
			d6e6f248268d2edec566c2	26c2a-gadboisel]; Anders	son, James				
		angeLabs/ou=Exchange A		10000-100 II II II II II II II	DK 3000 300				
	아이 주었다. 그 아이는 이렇게 되었다고 있었다면 아이를 하다 하다 아이들을 하는 것만 하나 이 것을 통해 하나 아	하다. 맛이 아내가 있는데 아내 프라이트 아이에 아이를 살아 가겠었다. 아이를 맞는다. 나일 때문에 아이지 않는데 아니다	1860bc42458be254ca215	the control of the co					
		=Exchange Administrative	Group (FYDIBOHF23SPDL						
	Mason, Stephen [(b) (6)	(b) (6)		y, Sarah				
	[/o=ExchangeLabs/ou=	Exchange Administrative	Group (FYDIBOHF23SPDL	T)/cn=Recipients/cn=us	er3ed93bab];				
	(b) (6) Lu	ımsden, Joanne (NIH/NCA	TS) [C] [/o=ExchangeLabs,	ou=Exchange Administr	ative Group				
	(FYDIBOHF23SPDLT)/c	n=Recipients/cn=1be900	c2388d41f48e3f2cbcb2fed	1349-lumsdenjm]; K C Ke	ent Lloyd				
	(b) (6)	(b) (6)							
Subject:	ACTIV Preclinical full w	vorking group							
Attachments:	Untitled Attachment								
Location:	https://fnih.zoom.		(b) (6)						
Start:	4/22/2020 2:00:00 PM	1							
End:	4/22/2020 3:00:00 PM	1							
Show Time As:	Tentative								
Recurrence:	Weekly								
	every Wednesday from	n 10:00 AM to 11:00 AM							
Required	Hild, Sheri (NIH/OD) [E		(b) (6)	(b) (e	5)				
Attendees:	(b) (6)	(b) (6)	(b) (6)	(b) (6)					
	(b) (6)	(b) (6)	` ' ' ' '						
	(b) (6)	(b) (6)		(b) (6)	Parker,				
		collins, Francis (NIH/OD) [Adams, Pet					
	보다. () [17] [17] [17] [17] [17] [17] [17] [17]	- 10 10 10 10 10 10 10 10 10 10 10 10 10	(NIH/OD) [E]; Tomas Cihla						
	이 주었다. 하시 하다 이번 나이가 먹어지자 아이지를 하다 하지 않는데 취득하다 하나 있다.		(LBI) [E]; Charette, Marc (N						
		(b) (6)		,, [2], 1 23201, 30	,, [6],				
Optional	Wholley, David (FNIH)		NIH/NCATS) [E]; Melencio,	Cheryl (FNIH) [T]: Colvie	s. Christine				
Attendees:			; Jansen, Kathrin; Kurilla,						
Attenuees.			en (FNIH) [T]; Santos, Mic						
		107 STATE OF	a; Kim, Elizabeth; Tolman,		1,1,750				
	ocepitation (114)	, L. II , mean and mode width	-,, Lucascui, Tomidii,	co, it wontedly romating	,				

Fernandes; Diamond, Michael; Rose Li; Dana Carluccio; Lagos, Enrique (NIH/NCATS) [E]; Jonson, Samantha

(NIH/NCATS) [E]; Gonzalez, Nina; Simon, Dina (NIH/OD) [C]; Burrus-Shaw, Cyndi (NIH/OD) [E]; Rodriguez, Robin D; Dave Frankowski; Baric, Toni C; Lowy, Douglas (NIH/NCI) [E]; Florence, Clint (NIH/NIAID) [E]; Nancy Haigwood; Stratton, Benjamin; Gadbois, Ellen (NIH/OD) [E]; Anderson, James (NIH/OD) [E]; Hawk, Harrison; Mason, Stephen; Connelly, Sarah; (b) (6) .com; Lumsden, Joanne (NIH/NCATS) [C]; K C (b) (6) Kent Lloyd; (b) (6) Changing time for preclinical WG Joseph Menetski is inviting you to a scheduled Zoom meeting. Join Zoom Meeting https://fnih.zoom.us (b)(6)Meeting ID: (b)(6)Passcode: (b) (6) One tap mobile (b)(6)US (Germantown) US (Chicago) Dial by your location (b) (6) US (Germantown) US (Chicago) US (New York) US (San Jose) US (San Jose) US (Tacoma)

US (Houston)

(b) (6)

(b) (6)

Find your local number: https://fnih.

Meeting ID:

Passcode: (b) (6)

From: Wholley, David (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP

(FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=CD9E702FCF28414883D0B6996D677257-WHOLLEYD]

Sent: 4/30/2020 2:18:13 PM

To: Collins, Francis (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=410e1ca313f44ced9938e50d2ff0b6c2-collinsf]; Lane, Cliff (NIH/NIAID) [E]

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=2d7e368a3137473bbce161547a82f2de-clane]

Subject: FW: ACTIV TX-Clinical Master Protocol Subgroup Meeting #7

Flag: Follow up

FYI, something to think about.

From: Bozzette, Sam (N	NIH/NCATS) [E] <	(b) (6)						
Sent: Thursday, April 30, 2020 9:19 AM								
To: Adam, Stacey (FNIH	H) [T] < (b) (6) Butterton,	Joan <	(b) (6)	Collins, Sylva			
(FDA/CDER) <	(b) (6)	Judy Currier <	(b) (6)	De Claro,	R. Angelo (FDA/CDER)			
< (b) (6)	Mark Eis	ner < (b)	(6) Ke	eith Gottesdiener				
< (b) (6)	Eric H	ughes <	(b) (6)	LaVange, Lisa M <	(b) (6)			
Elliott Levy < (b)) (6) Sand	eep Menon <	(b) (6)	Amand	la Peppercorn			
< (b) (6)	Pros	chan, Michael (NII	I/NIAID) [E] <	(b) (6)	Read, Sarah			
(NIH/NIAID) [E] <	(b) (6)	Amanda Pepperco	orn <	(b) (6)	Price, Dionne			
(FDA/CDER) <	(b) (6)	Rubin, Daniel B.	(FDA/CDER) <	(b) (6)	Shen, Yuan Li			
(FDA/CDER) <	(b) (6)	Farley, John (FD	A/CDER) <	(b) (6)	Goff, David (NIH/NHLBI)			
[E] < (b) (6)	Vincent, Mich	ael < (t) (6)					
Cc: Mary Biggs <	(b) (6)	Demarcus <	(b) (6)	Macone, Erir	(b) (6)			
Tountas, Karen (FNIH) [[T] (b) (6)	Wachtel, J	onathan <	(b) (6)	Elizabeth Kim			
< (b) (6)	Parker, Ashley (N	NIH/OD) [E] <	(b) (6)	Butcher, Tina				
(b) (6)	Wholley, D	avid (FNIH) [T] <	(b) (6)	Melencio, Chery	I (FNIH) [T]			
< (b) (6)	Wung, Peter /US	(b) (6)	Qash	nu, Felicia (NIH/OD) [E]			
< (b) (6)	Stratton, Benja	min < (b) (6)					
Subject: Re: ACTIV TX-Clinical Master Protocol Subgroup Meeting #7								

Good morning all:

It would seem that our active control arm had been identified. Should we get in the queue with Gilead sooner rather than later - or have we already reached out to them?

S

From: "Adam, Stacey (FN Date: Thursday, April 23,		b) (6)			
To: "Bozzette, Sam (NIH/		(b) (6)	, "Butterto	on, Joan"	(b) (6) >,
"Collins, Sylva (FDA/CDEI	R)" < (b)		>, "Judy Currier"	(b) (6)	>, "De Claro,
Angelo (FDA/CDER)" <	(b) (6)	"N	Mark Eisner"	(b) (6)	>, "Keith Gottesdiene
(b) (6)	"Eric Hu	ıghes"	(b) (6)	, "LaVange, I	Lisa M"
(b) (6)	"Elliott Levy"	(b) (6)	>, "Sandeep	Menon"	(b) (6)
"Amanda Peppercorn" <	(b) (6)	"Proschan, M	chael (NIH/NIAID)	(E)"
(b) (6)	"Read, Sarah	(NIH/NIAID) [[E]" < (b) (6) "Amar	nda Peppercorn"
(b) (6)	"Price	e, Dionne (FD/	A/CDER)" <	(b) (6)	>, "Rubin, Daniel B.
(FDA/CDER)"	(b) (6)	"Shen, Yuan	Li (FDA/CDER)"	(b) (6)	>, "Farley, John

(FDA)	/CDER)"	(b) (6)	'Goff, David (NI	H/NHLBI) [E]"	(b) (6) >, "Vincent, Michael"
	(b) (6)					
Cc: "N	Mary Biggs" <	(b) (6)	"Demarcus"	(b) ((6)	, "Macone, Erin"
	(b) (6)	>, "Tountas, Karen (F	NIH) [T]"	(b) (6)	"Wachtel,	Jonathan"
	(b) (6)	, "Elizabeth Kim'	(b) (6)	, "Par	ker, Ashley (NIH/OD) [E]"
<	(b) (6)	"Butcher, Tina"	< (b)	(6)	"Wholley, D	avid (FNIH) [T]"
	(b) (6)	, "Melencio, Cheryl (FNIH) [T]"	(b) (6)	>, "Wung,	Peter /US"
	(b) (6)	, "Qashu, Felic	ia (NIH/OD) [E]'	(b) ((6)	"Stratton, Benjamin"
	(b) (6)					

Subject: RE: ACTIV TX-Clinical Master Protocol Subgroup Meeting #7

Dear TX-Clinical Master Protocol Subgroup,

Please find attached the materials for tomorrow's meeting.

- 2. Slides for discussion updated with the decisions from today
- 3. A useful resource about current standard clinical treatment guidelines from the front lines for COVID. This may be a useful resource in selecting how to do minimal data collection and trying to understand SOC.

Please let me know if you have questions or other things you think would be helpful for the group to review.

```
Thanks,
Stacey
Stacey J. Adam, PhD
Director, Cancer
Research Partnerships
Direct: (b) (6) | Mobile:
                                   (b) (6)
Join Zoom Meeting
https://fnih.zoom.
                                              (b)(6)
Meeting ID:
               (b) (6)
Password: (b) (6)
One tap mobile
                  (b) (6)
                                         US (Chicago)
                                         US (New York)
Dial by your location
         (b)(6)
                    US (Chicago)
                    US (New York)
                    US (San Jose)
                    US (San Jose)
                    US
                    US
                    US (Houston)
Meeting ID:
                (b) (6)
Password: (b) (6)
Find your local number: https://fnih.zoom.
```

(b) (6)

From: Collins, Francis (NIH/OD) [E] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP

(FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=410E1CA313F44CED9938E50D2FF0B6C2-COLLINSF]

Sent: 7/3/2020 3:46:25 PM

To: Fauci, Anthony (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=df38103d75134f658ae2d356f0396b94-afauci]; Lane, Cliff (NIH/NIAID) [E]

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=2d7e368a3137473bbce161547a82f2de-clane]; Lowy, Douglas (NIH/NCI) [E]

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=f1b7b8fe4739478bb17840c56902718a-lowyd]; Mascola, John (NIH/VRC) [E]

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=7f78b40a596b4ca4a2850a429d1ae3f2-jmascola]

CC: Wholley, David (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]

Subject: RE: Gallo and OPV

Attachments: OPV

Hi Tony, Cliff, Doug, and John (and looping in David)

Bob Gallo is back with a complaint that no one has followed up on the OPV idea. See attached. Was this discussed in the ACTIV Vaccines WG or in any other venue?

Tx, Francis

From: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)

Sent: Sunday, May 3, 2020 1:45 PM

 To: Lane, Cliff (NIH/NIAID) [E]
 (b) (6)
 Collins, Francis (NIH/OD) [E]
 (b) (6)

 Cc: Lowy, Douglas (NIH/NCI) [E]
 (b) (6)
 Mascola, John (NIH/VRC) [E]
 (b) (6)

Subject: RE: Gallo and OPV

Totally agree with Cliff's advice.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)

Phone: (b) (6) FAX: (301) (b) (6) E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lane, Cliff (NIH/NIAID) [E] < (b) (6)

Sent: Sunday, May 3, 2020 1:22 PM

To: Collins, Francis (NIH/OD) [E] < (b) (6)

Cc: Lowy, Douglas (NIH/NCI) [E] < (b) (6) : Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Mascola, John (NIH/VRC) [E] (b) (6)

Subject: Re: Gallo and OPV

Francis,

I am not sure you need any sort of detailed response. I would just send a thank-you and indicate you will be sure those working on this at NIH are aware.

Cliff

On May 3, 2020, at 12:55 PM, Collins, Francis (NIH/OD) [E] (wrote:

Hi all,

I'm a bit at a loss to know how to respond to Bob Gallo. The aggressive manner in which he is promoting OPV causes me to worry he has lost objectivity about its promise. But is there any chance he has something here that could work?

Francis

From: Gallo, Robert (b) (6) **Sent:** Sunday, May 3, 2020 12:07 PM

To: Collins, Francis (NIH/OD) [E] (b) (6)

Subject: RE: Your query to Dr. Kadlec

Dear Francis,

It was a pleasure to hear from you, and yes, it has been a long time since we met or even spoke. Moons ago I was set to write to you after reading your wonderful book, but I ended up instead speaking with others about it. I should add at this point that I did not quickly respond to your email of a few days ago because I simply missed it.

It is true that I strongly suggest that OPV be quickly (already it is not quickly) brought forward for induction of a strong innate immune response to prevent or markedly reduce SARS-CoV-2 infection and/or severity until the field obtains a proven safe and efficacious vaccine producing a long lasting, adaptive immunity. OPV is very safe (notably for OPV 1 and 3 as bOPV which we will use and completely safe in a vaccinated population), simple, cheap, rather obvious, yet unique among the massive number of vaccines many (maybe most) of which are the same or at least if not exactly the same aiming at the same mechanism (targeting the spike and searching for the putative correlate of neutralizing Abs.).

OPV should work for a few months and possibly longer. Also it should be working multiple times so I think could cover more than a few months, giving us time for a proven vaccine of adaptive immunity, which might be very long lasting as is hoped.

In the main the WHO comments are correct. Of course we sought and have letters of support from them as well as from many others. Though they are again supportive in their notes to you, there is one item that surprises me. They add that there was no clinical efficacy results

as yet. They know or certainly should know that there is plenty of clinical data for this concept with BCG, OPV, and live Measles vaccine. Needless to say this is what turned me on during our regular Global Virus Network (GVN)conference calls. (Incidentally GVN is an organization I have thought of bringing to your attention. I think you would find it impressive and useful). I would be happy to share with you the clinical observations with OPV if you wish.

I would like to take a small diversion, but I suspect you are aware of these things. My colleagues and I respect the WHO because of its representation and because we have colleagues/friends there as well. However, sometimes bureaucracy of a massive degree leads to inaction or even much worse-- political expediency. I won't bother you with details of these unless you ask, but I had such experiences with HTLV-1 which we discovered in 1980 as the 1st human retrovirus and which cause not only the highest incidence of cancer (% of infections) of any virus and other fatal diseases as well but mainly in less developed countries (plus Japan) and again with HIV in 1984. Behavior was not beneficial. Perhaps it will be of relevance in the future because a few at WHO took a position to remove OPV (Sabin) in favor of IPV (Salk) in their polio eradication scheme. It was a huge failure. As my FDA collaborator, Konstantin Chumakov, says "Blessed be Bill Gates" because he saved OPV and saved the day and in so doing has produced a still better OPV.

There is indeed data also for BCG as well as live Measles though I know less of the latter. BCG is less available, requires injection, harder to make, not as safe, and we think unlikely to be as effective as OPV. Nonetheless, we favor its use too. The mechanisms will be similar.

You asked whether monkey trials are planned. For several reasons definitely not —though we are planning some monkey experiments, but not large enough for "clinical" conclusions. The main reasons are: 1) cost; 2) that billions not thousands or millions have received OPV safely and in our collective view (and we know the studies pretty well) protection has been clinically shown; 3) In a pandemic we wished to move quickly (so far we must say that has not been achieved). A typical monkey vaccine study will take time, but 4) in this case it would be a huge amount of lost time as monkeys require great doses of polio for infection and monkeys have to be trained to drink their orange juice. It would be hard to imagine that such studies would even give us useful information.

On a final digression Francis I have had 36 years of on/off experiences with glycosylated spike proteins—their analyses immunologically and especially regarding use in vaccines and developing neutralizing Abs. I believe it will be a mistake to put most eggs in that basket. The risks: shortened antibody half life; 2) protection NOT correlating with neutralizing Abs; 3) sometimes hazards from them. Admittedly, they might work, but I trust and hope that not everything is going in this bag. If you wish to discuss this again I will be available.

Finally, I hd no idea you were into vaccines or SARS-2 nor any part of CoVID-19 disease, but I am very happy to learn this.

Thanks.

Bob Gallo

From: Collins, Francis (NIH/OD) [E] (b) (6)

Sent: Thursday, April 30, 2020 5:00 PM

To: Gallo, Robert < (b)(6)Cc: Disbrow, Gary (OS/ASPR/BARDA) (b) (6) ; Kadlec, Robert (OS/ASPR/IO) >; Tabak, Lawrence (NIH/OD) [E] v>; Shuy, Bryan (b) (6) (b) (6) >; Johnson, Robert (OS/ASPR/BARDA) (OS/ASPR/IO) < (b) (6) (b)(6)Mascola, John (NIH/VRC) [E] Lane, Cliff (NIH/NIAID) [E] (b) (6) (b)(6)Subject: Your query to Dr. Kadlec

CAUTION: This message originated from a non UMB, UMSOM, FPI, or UMMS email system. Whether the sender is known or not known, hover over any links before clicking and use caution opening attachments.

Dear Bob,

It's been quite a while since we've chatted. Bob Kadlec asked me to respond to your query about the possible use of OPV to activate innate immunity and provide COVID-19 protection. Has this been tested in a non-human primate model? I note the recommendation below that says a clinical trial is planned – can you tell me more about that?

As you can imagine, we are all flat out on the vaccine development pathway!

Francis

The use of oral polio vaccine (OPV) to prevent SARS-CoV2 (Polio Eradication Campaign)

There is no evidence that oral poliovirus vaccine (OPV) protects people against infection with COVID-19 virus.

A clinical trial addressing this question is planned in the USA, and WHO will evaluate the evidence when it is available.

In the absence of evidence, WHO does not recommend OPV vaccination for the prevention of COVID-19. WHO continues to recommend OPV as part of essential immunization services to prevent poliomyelitis and as part of global polio eradication efforts.

There are experimental signals from various studies over the years that OPV has non-specific effects on the immune system. These effects have not been well characterized and their clinical relevance is unknown. Such non-specific effects may not be limited to OPV, as other live vaccines have also been associated with non-specific protective effects (such as BCG vaccine against tuberculosis). Nonlive vaccines in contrast do not seem to have the same effects.

The exact mechanism of non-specific protection induced by live vaccines needs to be elucidated further. Clinical studies could begin immediately because the vaccines in question are licensed and have an excellent safety record. Clinical trials involving off-label use of various drugs licensed for other indications are currently underway. The existing scientific rationale suggests that the same should be done for OPV and other live vaccines. A study is currently being discussed with various partners and vaccine manufacturers, including the US FDA, the outcomes of which will be carefully assessed to determine potential use in the context of the spread of SARS-CoV2 until the time when specific vaccines and antiviral therapies are ready.

From: Kadlec, Robert (OS/ASPR/IO) (b) (6) >

Sent: Thursday, April 30, 2020 10:28 AM

To: Gallo, Robert (b) (6) >; Collins, Francis (NIH/OD) [E] (b) (6)

Tabak, Lawrence (NIH/OD) [E] (b) (6) ; Shuy, Bryan (OS/ASPR/IO) (b) (6)

Subject: Re: Respone

Dr Gallo thank you for your note and I appreciate you reaching out to me. I have copied Dr Collins and Dr Tabak to consider the ACTIV forum they have created to bring industry academia and government to consider scientific base approaches That you have described. Dr Collins has organized a vaccine group and I assess could be the best and fastest place to discuss your concept. I am sure they will connect with you soonest

Best

Bob Kadlec.

Sent from my iPhone

On Apr 30, 2020, at 10:02 AM, Gallo, Robert (b) (6) > wrote:

Dear Dr. Kaldec,

I have not heard from you in over a week. You mentioned getting back to me in a day or two. Time is passing. I am asking you to look at OPV 1 plus 3 serotypes as a bivalent, completely safe vaccine with powerful stimulation of innate immunity lasting several weeks, which can be given a second or third time, and with a historical track record of preventing other infections from entirely different RNA viruses (such as protecting against influenza). Therefore, it should be really helpful for some months, and I think get us past a second wave of SARS-CoV-2, and help people return to work safely. I don't understand delays or apparent lack of interest. Who can possibly be against this? If you hear of hypothetical problems we can show you that these are false. Just ask the questions, and we can give you the evidence.

However, no answer from you suggests no interest and must quickly make alternative pathways. I am though quite surprised and fear you are receiving "fake news" if you will pardon the expression. Some have been against this who defend their old and failed position on polio eradication with their promotion of the use of the inactivated polio virus vaccine. Please note that in the US between 1962 and 1985 we received (safely) the oral polio (OPV). Moreover, if vaccinated already there has not been a single case of a complication and BILLIONS have received it. No it will not last long as innate immunity is short lived, but we strongly believe that we can break the back of the SARS-CoVID-2 spread. Also note that this is what Bill Gates is doing now in India and much of the Eastern hemisphere.

There are countries outside the US wanting to move fast on this. We are waiting for your reply.

Robert Gallo Director, Institute of Human Virology, Professor of Medicine and Professor of Microbiology, UMB, School of Medicine, Baltimore,

And

Co-founder and International Science Advisor of the Global Virus Network (GVN)

From: Melencio, Cheryl (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=279E14FA7428415BB86087D08B628E6F-MELENCIOC] Sent: 7/21/2020 7:19:34 PM To: Melencio, Cheryl (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=279e14fa7428415bb86087d08b628e6f-melencioc]; Austin, Christopher (NIH/NCATS) [E] ; Bancel, Stephane [(b) (6) Carter, Kara (b) (6) Cavaleri, Marco [Cihlar, Tomas (b)(6)(b)(6)Collins, Francis (NIH/OD) [E] [coll ; Corey, Larry [(b) (6) (b) (6) (b)(6)Disbrow, Gary (OS/ASPR/BARDA) [Culp, Michelle (NIH/OD) [E] (b) (6) (b)(6)Dolsten, Mikael [Erbelding, Emily (NIH/NIAID) [E] [Erck, Stan (b) (6) (b)(6)Fauci, Anthony (NIH/NIAID) [E] [Gadbois, Ellen (NIH/OD) [E] (b) (6) (b)(6)Gibbons, Gary (NIH/NHLBI) [E] [ga Hudson, Thomas (b)(6)(b) (6) James, Stephanie (FNIH) [T] [Johnson, Robert (OS/ASPR/BARDA) (b) (6) (b) (6) Lane, Cliff (NIH/NIAID) [E] 1: Kramer, Lynn [(b) (6) (b)(6)(b) (6) Lepore, John [(b)(6)Marks, Peter (FDA/CBER) [(b)(6)Marston, Hilary (NIH/NIAID) [E] [hila (b) (6) Mascola, John (NIH/VRC) [E] (b) (6) 1; Meeker, David [Menetski, Joseph (FNIH) [T] [(b)(6)Messonnier, Nancy (b) (6) (CDC/DDID/NCIRD/OD) [Pandya, Hitesh ; Pao, William (b) (6) (b) (6) Parker, Ashley (NIH/OD) [E] [Perlmutter, Roger (b) (6) (b) (6) Plenge, Robert [Plump, Andy (b) (6) (b)(6)(b) (6) Rachel Ramoni [rachel. (b)(6)Rasi, Guido (b)(6)Reed, John ; Reese, David []; Rouse, Doris [(b)(6)(b) (6) Santos, (b) (6) Michael (FNIH) [T] [Skovronsky, Daniel [Stein, Peter (FDA/CDER) (b) (6) (b) (6)]; Stoffels, Paul [Tabak, Lawrence (NIH/OD) [E] (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=02e22836b5ff4e9988e3770cfc7ee770-tabakl]; Talley, Michael (b)(6)Tsai, John [(b)(6)Vessey, Rupert [(b)(6)]; Virgin, Skip ; Wholley, David (FNIH) [T] [dwhol Woodcock, Janet (FDA/CDER) (b) (6) (b)(6)Young, John [Colvis, Christine (NIH/NCATS) [E] (b)(6)(b) (6) [christine.colvis@nih.gov]; Desrosiers, Betsy [el Eric Hughes (b)(6)(b)(6)Jansen, Kathrin [Kurilla, Michael (NIH/NCATS) [E] (b) (6) Lowy, Douglas (NCI) ; Read, Sarah (NIH/NIAID) [E] (b) (6) (b) (6) Villafana, Tonya Brian Rosen [(b) (6) (b)(6)(b) (6) Pangalos, Mene [Paul, Steve [(b)(6)(b)(6)CC: Adam, Stacey (FNIH) [T] [Alvarez, Rosa [Anderson, Margaret (b) (6) (b) (6) (b)(6)Chen, Helen [(b)(6)Elsaid, Olivia (b) (6) Gonzalez, Nina [Stratton, Benjamin | (b) (6) (b) (6) Tolman, Brett Tountas, Karen (FNIH) [T] [ktount (b) (6) Wachtel, Jonathan (b)(6)]; Anderson, James (NIH/OD) [E] [Burklow, John (NIH/OD) [E] (b) (6) (b)(6).gov]; Castillejos, Carlos [.com]; FNIH Central Account [(b)(6)(b)(6)(b)(6)Hallett, Adrienne (NIH/OD) [E] [(b)(6)Myles, Renate (NIH/OD) [E] (b) (6) Wolinetz, Carrie (NIH/OD) [E] []; Burrus-Shaw, Cyndi (NIH/OD) [E] (b) (6) (b)(6); Carver, Trea (NIH) [C] [trea. (b)(6)Hardesty, Rebecca (NIH/OD) [E] Lagos, Enrique (NIH/NCATS) [E] ; Sepulveda, Dorina (FNIH) [T] (b)(6)(b) (6) Gorman, Greta (FNIH) [T] Simon, Dina (NIH/OD) [C] [d (b)(6)(b)(6)Meltzer, Abbey (FNIH) [T] [Togashi, Mieko (NIH/NCI) [E] (b)(6)(b)(6)Underwood, Nancy [Zottoli, Jessica (b)(6)(b) (6) Austin, Sarah (NIH/NIAID) [E] [austinsj@niaid.nih.gov]; Barasch, Kimberly (NIH/NIAID) [Jessica.Zottol (b)(6)[C][(b)(6)Conrad, Patricia (NIH/NIAID) [E] [conradpa@niaid.nih.gov]; Dimishkov, Roxanne (NIH/NHLBI) [C] [Edl, Susan [Giorgi, Sara (b)(6)Hoban, Michelle [Hoffstetter, Renata (FNIH) [T] sara. (b)(6)(b)(6)Iberdemaj, Vaide [va Lever, Susan (b)(6)(b)(6)McManus, Ayanna (NIH/OD) [E] [1; Minnich, Beth (b) (6) (b)(6)Protasiewicz, Ann Perala, Mie (b) (6) (b) (6) (b)(6)Riccobene, Kim [Riggin, Mary [(b)(6)(b) (6) Suhana, Tina (NIH/VRC) [E] [Ripley, Nadege [(b) (6) (b)(6)Thomas, Ashley (FDA/CDER) [(b)(6)Wood, Gretchen (NIH/OD) [E] [David

(b) (6)

Meeker [(b) (6)	Dana Carluccio [(b) (6)	Hawk, Harrison
(b) (6)	Lucas Smalldon	(b) (6)		Hamilton, Nancy
(b)	(6) Lowy, D	ouglas (NIH/NCI) [E] [(b) (6)]; Vessey, Rupert
(b) (6	0 1			

Subject: ACTIV Leadership Team Call #7

Location: https://fnih.zoom. (b) (6)

Start: 8/26/2020 7:00:00 PM **End**: 8/26/2020 8:00:00 PM

Show Time As: Busy

Required Attendees:

Austin, Christopher (NIH/NCATS) [E]; Bancel, Stephane; Carter, Kara; Cavaleri, Marco; Cihlar, Tomas; Collins, Francis (NIH/OD) [E]; Corey, Larry; Culp, Michelle (NIH/OD) [E]; Disbrow, Gary (OS/ASPR/BARDA); Dolsten, Mikael; Erbelding, Emily (NIH/NIAID) [E]; Erck, Stan; Fauci, Anthony (NIH/NIAID) [E]; Gadbois, Ellen (NIH/OD) [E]; Gibbons, Gary (NIH/NHLBI) [E]; Hudson, Thomas; James, Stephanie (FNIH) [T]; Johnson, Robert (OS/ASPR/BARDA); Kramer, Lynn; Lane, Cliff (NIH/NIAID) [E]; Lepore, John; Marks, Peter (FDA/CBER); Marston, Hilary (NIH/NIAID) [E]; Mascola, John; Meeker, David; Menetski, Joseph (FNIH) [T]; Messonnier, Nancy (CDC/DDID/NCIRD/OD); Pandya, Hitesh; Pangalos, Mene; Pao, William; Parker, Ashley (NIH/OD) [E]; Paul, Steve; Perlmutter, Roger; Plenge, Robert; Plump, Andy; Ramoni, Rachel; Rasi, Guido; Reed, John; Reese, David; Rouse, Doris; Santos, Michael (FNIH) [T]; Skovronsky, Daniel; Stein, Peter (FDA/CDER); Stoffels, Paul; Tabak, Lawrence (NIH/OD) [E]; Talley, Michael; Tsai, John; Vessey, Rupert; Virgin, Skip; Wholley, David (FNIH) [T]; Woodcock, Janet (FDA/CDER); Young, John; Colvis, Christine (NIH/NCATS) [E]; Desrosiers, Betsy; Hughes, Eric; Jansen, Kathrin; Kurilla, Michael (NIH/NCATS) [E]; Lowy, Douglas (NCI); Read, Sarah (NIH/NIAID) [E]; Villafana, Tonya; Brian Rosen

Optional Attendees:

Adam, Stacey (FNIH) [T]; Alvarez, Rosa; Anderson, Margaret; Chen, Helen; Elsaid, Olivia; Gonzalez, Nina; Stratton, Ben; Tolman, Brett; Tountas, Karen (FNIH) [T]; Wachtel, Jonathan; Anderson, James (NIH/OD) [E]; Burklow, John (NIH/OD) [E]; Castillejos, Carlos; FNIH Central Account; Hallett, Adrienne (NIH/OD) [E]; Myles, Renate (NIH/OD) [E]; Wolinetz, Carrie (NIH/OD) [E]; Burrus-Shaw, Cyndi (NIH/OD) [E]; Carver, Trea (NIH) [C]; Hardesty, Rebecca (NIH/OD) [E]; Lagos, Enrique (NIH/NCATS) [E]; Sepulveda, Dorina (FNIH) [T]; Simon, Dina (NIH/OD) [C]; Gorman, Greta (FNIH) [T]; Meltzer, Abbey (FNIH) [T]; Togashi, Mieko (NIH/NCI) [E]; Underwood, Nancy; Zottoli, Jessica; Austin, Sarah (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]; Conrad, Patricia (NIH/NIAID) [E]; Dimishkov, Roxanne (NIH/NHLBI) [C]; EdI, Susan; Giorgi, Sara; Hoban, Michelle; Hoffstetter, Renata (FNIH) [T]; Iberdemaj, Vaide; Lever, Susan; McManus, Ayanna (NIH/OD) [E]; Minnich, Beth; Perala, Mie; Protasiewicz, Ann; Riccobene, Kim; Riggin, Mary; Ripley, Nadege; Suhana, Tina (NIH/VRC) [E]; Thomas, Ashley (FDA/CDER); Wood, Gretchen (NIH/OD) [E]; David Meeker; Dana Carluccio; Hawk, Harrison; Vessey, Rupert; Lucas Smalldon; Hamilton, Nancy; Lowy, Douglas (NIH/NCI) [E]

Shortening calls to one hour in length

Joseph Menetski is inviting you to a scheduled Zoom meeting.

```
Join Zoom Meeting
https://fnih.zoom.us/j/
                                              (b) (6)
Meeting ID:
                (b) (6)
Passcode: (b)
One tan mobile
                   (b) (6)
                                             US (Germantown)
                                             US (Chicago)
Dial by your location
             (b)(6)
                         US (Germantown)
                         US (Chicago)
                         US (New York)
                         US
                            (San Jose)
                         US
                            (San Jose)
                         US (Tacoma)
                         US (Houston)
                        elgium
                        Belgium
                        Belgium
                        Belgium
```

```
(b)(6)
                                       elgium
                                       elgium
Canada
                                       Canada
                                       Canada
                                       Canada
                                       Canada
                                       Canada
                                       -rance
                                       France
                                      France
                                       -rance
                                      France
                                       Japan
                                       Japan
                                       Japan
                                        Italy
                                           Italy
                                        Italy
                                        Switzerland
                                        Switzerland
                                        Switzerland
                                        Switzerland
                                        Switzerland
                                        Switzerland
                                       United Kingdom
Meeting ID: (b) (6)
Passcode: (b) (6)
Find your local number: https://fnih.zoom.u (b) (6)
```

From: Adam, Stacey (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=DCD875F0679648859E1CF101C0943414-ADAMSJ4] Sent: 4/19/2020 8:39:51 PM To: Bozzette, Sam (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=85f05a3619cf47c7ae39d7bcf0aac88d-bozzettesaa]; Butterton, Joan [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=219ecac4faae4ebab8a45ce8ee2490c3-joan_butter]; De Claro, R. Angelo (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c495c3ee25ca461ba6a829b124062448-DECLAROR.fd]; Draghia-Akli, Ruxandra | Eisner, Mark [Gottesdiener, Keith (b) (6) (b) (6) (b)(6)Hughes, Eric [**Judy Currier** (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=890082c7c1e34902b0f535320cd16650-jscurrier.m]; Kim, Elizabeth LaVange, Lisa [Levy, Elliot [Mellors, John W (b) (6) (b) (6) (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user257cb364]; Menon, Sandeep [(b) (6) Parker, Ashley (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras]; Patel, Naimish]; Peppercorn, Amanda [Poole, Mike (b) (6) (b) (6) Proschan, Michael (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=7b45059209b4468bb4ba02b0dfbbb3e4-proscham]; Read, Sarah (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=527b160038004a199ae6e0bac2226099-readsa]; Santos, Michael (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ab38cb6836de44e18ef4cc6952f65f80-santosmr]; Shen, Yuan Li (FDA/CDER) I/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ae30a02e983e4e8a979dfec7257a1802-shenyu.fda]; Stein, Peter (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b4a14118481b4b39ba7e62a8d6425f79-Peter.Stein]; Wholley, David (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]; Buchman, Tim (OS/ASPR/BARDA) (CTR) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=00f8a853d8d740f8a8cdd55cbf8eb9da-Tim.Buchman]; Collins, Sylva (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f6b8f588067140fe988f0832c2387725-Sylva.Colli]; Amanda Peppercorn (b) (6) CC: Meltzer, Abbey (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c341d86cf7404a78ac8f852e698e5382-meltzerak]; Menetski, Joseph (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5001af52dc4a427ea3d34f1e072f8cb7-menetskijp) Subject: Time Sensitive Request for Response from ACTIV Therapeutics-Clinical Working Group Dear ACTIV Therapeutics-Clinical Working Group Members, I hope this message finds you well. I am writing to seek your approval to publicly list your name in association with this ACTIV working group. A reporter has reached out to the FNIH asking for the names of the working group members, and we would like to point them to a listing of these names on the FNIH website, once you have provided clearance for this. The FNIH's Vice President of Communications and Events, Abbey Meltzer, will be tracking these approvals, so please send your approval to her at (b) (6) . If you have any questions, please do not hesitate to reach out to Abbey.

Stacey J. Adam, PhD

Best, Stacey Director, Cancer

Research Partnerships

Foundation for the National Institutes of Health

Direct: (b) (6) | Mobile: (b) (6)

fnih.org

11400 Rockville Pike, Suite 600, North Bethesda, MD 20852

f in v s

Stay at the forefront of FNIH news: fnih.org/newsletter

From: Allen-Gifford, Patrice (NIH/OD) [E] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP

(FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=67262490D6D441B48EFEC1AFF0700250-ALLENGIFFOR]

Sent: 8/26/2020 11:27:57 AM

To: Parker, Ashley (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras]

Subject: RE: Note to ICDs: Materials for August 26 ACTIV Partnership Leadership Team Teleconference

Thanks Ashley. I have it ready to go and had made the same adjustments. One question: rather than conference call, should it reference the COVID-19 call so ICDs who didn't participate in that won't think they missed an ICD meeting?

From: Parker, Ashley (NIH/OD) [E] < (b) (6)

Sent: Wednesday, August 26, 2020 7:25 AM

To: Collins, Francis (NIH/OD) [E] < (b) (6) Allen-Gifford, Patrice (NIH/OD) [E] (b) (6)

Cc: Wholley, David (FNIH) [T] < (b) (6) Melencio, Cheryl (FNIH) [T] < (b) (6) Gladman, Jordan

(NIH/OD)[E] < (b)(6)

Subject: RE: Note to ICDs: Materials for August 26 ACTIV Partnership Leadership Team Teleconference

Thank you, Francis.

Good morning Patrice,

I've made a few adjustments to the email below to go out to the ICD ONLY list this morning and reattached the materials.

Thanks, Ashley

To: ICD-ONLY-L@LIST.NIH.GOV

Cc: Wholley, David (FNIH) [T] (b) (6) >; Melencio, Cheryl (FNIH) [T] (b) (6)

Bcc: Parker, Ashley (NIH/OD) [E] (b) (6)

Dear Colleagues,

As discussed during our conference call yesterday, ICDs (principals only please; no surrogates or additional staff) are invited to join the virtual ACTIV leadership team meeting today August 26, 3:00-4:00pm. Please see the attached materials and link below. If you are able to join please ensure David Wholley and Cheryl Melencio know you are available to attend and please remain in "listen-only" mode during the meeting.

Thank you, Francis

From: Collins, Francis (NIH/OD) [E] (b) (6)

Sent: Wednesday, August 26, 2020 5:57 AM

To: Parker, Ashley (NIH/OD) [E] (b) (6)

(NIH/OD) [E] (b) (6) Allen-Gifford, Patrice (NIH/OD) [E] (b) (6)

Subject: RE: Note to ICDs: Materials for August 26 ACTIV Partnership Leadership Team Teleconference

Be sure to change the text of the e-mail from "tomorrow" to "today".

From: Collins, Francis (NIH/OD) [E] Sent: Wednesday, August 26, 2020 5:56 AM To: Parker, Ashley (NIH/OD) [E] (b)(6)Cc: Wholley, David (FNIH) [T] (b)(6)>; Melencio, Cheryl (FNIH) [T] (b) (6) ; Gladman, Jordan Allen-Gifford, Patrice (NIH/OD) [E] (NIH/OD) [E] (b)(6)(b)(6)Subject: RE: Note to ICDs: Materials for August 26 ACTIV Partnership Leadership Team Teleconference Yes, this note would be great. Looping in Exec Sec to ask that it be sent first thing this morning. Francis From: Parker, Ashley (NIH/OD) [E] < (b)(6)Sent: Tuesday, August 25, 2020 10:52 PM To: Collins, Francis (NIH/OD) [E] (b)(6)Cc: Wholley, David (FNIH) [T] ; Melencio, Cheryl (FNIH) [T] Gladman, Jordan (b) (6) (b)(6)(NIH/OD)[E] <Subject: Note to ICDs: Materials for August 26 ACTIV Partnership Leadership Team Teleconference Importance: High Hi Francis, To ensure the ICDs receive the information for the ACTIV LT meeting tomorrow – would you like to forward the following to the ICD only list. Below is a draft note for consideration. To: ICD-ONLY-L@LIST.NIH.GOV Cc: Wholley, David (FNIH) [T] (b)(6)Melencio, Cheryl (FNIH) [T] (b) (6) Dear Colleagues, As discussed during our conference call this afternoon, ICDs (principals only please; no surrogates or additional staff) are invited to join the virtual ACTIV leadership team meeting tomorrow August 26, 3:00-4:00pm. Please see the attached materials and link below. If you are able to join please ensure David Wholley and Cheryl Melencio know you are available to attend and please remain in "listen-only" mode during the meeting. Thank you, Francis

From: Melencio, Cheryl (FNIH) [T] < On Behalf Of Wholley, David (FNIH) [T] (b)(6)Sent: Tuesday, August 25, 2020 9:47 PM To: Austin, Christopher (NIH/NCATS) [E] < Bancel, Stephane (b) (6) Carter, Kara Cavaleri, Marco < (b)(6)(b) (6) Cihlar, Tomas Collins, Francis (NIH/OD) [E] (b)(6)(b) (6) >; Culp, Michelle (NIH/OD) [E] (b)(6)Corey, Larry (b)(6)(b)(6)Disbrow, Gary (OS/ASPR/BARDA) < (b)(6)Dolsten, Mikael ; Erbelding, (b) (6) Emily (NIH/NIAID) [E] < Erck, Stan Fauci, Anthony (NIH/NIAID) [E] (b) (6) (b) (6) (b) (6) Freire, Maria (FNIH) [T] ; Gadbois, Ellen (NIH/OD) [E] (b)(6); Gibbons, Gary (NIH/NHLBI) [E] >; Hudson, Thomas (b) (6) James, Stephanie (FNIH) [T] < Johnson, Robert (OS/ASPR/BARDA) (b)(6)(b) (6) (b)(6)Kramer, Lynn (b)(6): Lane, Cliff (NIH/NIAID) [E] < (b)(6)Marks, Peter (FDA/CBER) Lepore, John < (b)(6)(b) (6) Marston, Hilary

(NIH	/NIAID) [E] <	(b) (6)	Mascola, Joh	in (NIH/VRC) [E] <	(b) (6) N	leeker, David
	(b) (6)	: Menetski, Jo					
(CD	C/DDID/NCIRD/OF	(b) (6)	; Pandya, Hite	sh	(b) (6)	; Pang	alos, Mene
<	(b) (6)	; Pac	, William	(b) (6)	; Par	ker, Ashley (NIH/O	iD) [E] ; ni >; Reese, David
<	(b) (6)	Paul, Steve	(b) (6)	>; Perlr	mutter, Roger	(b) (6)	;
Plen	ge, Robert <	(b) (6)	Plump, Andy	(b) (6)	; Rachel Ramor	ni
	(b) (6)	Rasi, Guido <	(b) (6)) [2	>; Reed, John	(b) (6)	>; Reese, David
	(b) (6)	Rouse, Doris <	(b) (6) S	antos, iviich	aei (FNIH) [1]	(b) (6)	Skovronsky,
Dan	iel (b)	(6) >; St	ein, Peter (FDA	(CDER)	(b) (6)	Stoffels,	Paul
	(b) (6)	Tabak, Lawrence	(NIH/OD) [E]	(b)	(6)	; Talley, Michael	
	(b) (6)	Tsai, John	(b) (6)	.>;	Vessey, Ruper	t < (b) (6)	Virgin, Skip
	(b) (6) Wh	olley, David (FNIH)	[T] < (b)	(6) ; \	Woodcock, Jan	et (FDA/CDER)	
	(b) (6)	; Young, Desrosiers, B	John	(b) (6)	; Colv	is, Christine (NIH/N	ICATS) [E]
	(b) (6)	Desrosiers, B	etsy <	(b) (6)		Eric Hughes	
	(b) (6)	Jansen, Ka	hrin	(b) (6)	Kurill	a, Michael (NIH/NO	CATS) [E]
		Lowy, Dougla		b) (6) R	lead, Sarah (NI	H/NIAID) [E]	(b) (6)
You	ng, John	(b) (6)	>				
Cc: /	Adam, Stacey (FNI	H) $[T] < (b) (6)$: Alvarez,	Rosa <	(b) (6)	Anderson	, Margaret
	(b) (6)	Chen, H (b) (6) Santos, Michael (I	elen	(b) (6)	Elsaid, O	livia (b) (6)) >;
Gon	zalez, Nina	(b) (6)	Hawk, Har	rison	(b) (6)	>; Menetski, Jos	eph (FNIH) [T]
	(b) (6)	Santos, Michael (I	NIH) [T] <	(b) (6)	Stratton, I	Benjamin <	(b) (6)
btol	man (b)	(6) >; I oun	tas, Karen (FNII	H) [1]	(b) (6)	: Wachtel, Jonath	an
		Wholley, Davi					
		>; Austin, Chr					, John (NIH/OD) [E]
<	(b) (6)	Castillejos, Carlo	(b) (c	6) ; (Culp, Michelle	(NIH/OD) [E]	121
	(b) (6)	FNIH Central A	ccount <	(b) (6)	Fre	ire, Maria (FNIH) [7]
	(b) (6)	Gadbois, Ellen (NIH/	OD) [E] (; Hallett,	Adrienne (NIH/OD)) [E]
	(b) (6)		IIH/NIAID) [E]	(b) (6) ; My	les, Renate (NIH/C	DD) [E]
<		Parker, Ashley (N					
	(b) (6)					Burklow, John	
		>; Gorman, Greta					
<	(b) (6)	; Meltzer, Ab	pey (FNIH) [T]	(b) (6) Myle	es, Renate (NIH/OD)) [E]
	(b) (6)	; Wolinetz, Carrie	(NIH/OD) [E] <	(b)) (6) ;	Lucas Smalldon	-
	(b) (d	5) ;	Villafana, Tony	/a <	(b) (6)	>; Brian	Rosen
<	(b) (6)						

Subject: Materials for August 26 ACTIV Partnership Leadership Team Teleconference

Importance: High

Dear Colleagues:

Please see attached the PowerPoint slides, including the agenda, for our meeting (via Zoom) from 3:00 – 4:00 PM Eastern U.S. time tomorrow, Wednesday August 26. (As a reminder, this meeting and future LT meetings are 60 minutes in length.) I have also attached notes from our July 29 Leadership Team meeting as well as our last ACTIV EC meeting on August 14.

The Zoom meeting information is:

Join Zoom Meeting

https://fnih.zoom. (b) (6)

Meeting ID: (b) (6)
Passcode: (b) (6)
One tap mobile

```
(b)(6)
                                            US (Germantown)
                                            US (Chicago)
Dial by your location
          (b) (6)
                      S (Germantown)
                      S (Chicago)
                      S (New York)
                      S (San Jose)
                      S (San Jose)
                      S (Tacoma)
                      S (Houston)
                      gium
                      gium
                      gium
                      gium
                      gium
                      gium
                      anada
                     anada
                      anada
                     anada
                     anada
                      anada
                      ance
                      ance
                      ance
                      ance
                      ance
                      ıpan
                     ıpan
                     ıpan
                      taly
                       Italy
                      Italy
                      witzerland
                      witzerland
                      witzerland
                      witzerland
                      witzerland
                      witzerland
                      United Kingdom
                     United Kingdom
                     United Kingdom
                     United Kingdom
                     United Kingdom
                     United Kingdom
                      United Kingdom
```

Meeting ID: (b) (6)
Passcode: (b) (6)

Find your local number: https://fnih.zoom. (b) (6)

Please let Joe Menetski or Cheryl Melencio here at FNIH (copied) know if you are having any problems connecting. I look forward to a productive meeting.

Regards,

David

David Wholley Senior Vice-President, Research Partnerships Foundation for the National Institutes of Health (b) (6)

fnih.org

11400 Rockville Pike Suite 600 North Bethesda, MD 20852

In 2019, the FNIH earned the highest rating from Charity Navigator for the fifth consecutive year and was recognized as an organization that exceeds industry standards.

From: Tountas, Karen (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP

(FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=40C04FEF6F1E46F5B750753CD5A14F93-TOUNTASKH]

Sent:

7/10/2020 5:58:52 PM

To:

Culp, Michelle (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=4e38fa37e0424217aa0a283cba9e5098-mculp]; Gadbois, Ellen (NIH/OD) [E]

(b)(6)

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=0243d1d6e6f248268d2edec566c26c2a-gadboisel]

RE: ACTIV Clinical Trial Capacity survey dashboard Subject:

Hi Michelle,

You're probably not spending a lot of time using the ACTIV dashboard, but I was wondering whether you have taken a look lately and what you think? Have you heard comments from anyone - positive is always welcome, and constructive criticism will help improve the user experience.

Many thanks!

Karen

From: Culp, Michelle (NIH/OD) [E] < (b)(6)

Sent: Friday, May 22, 2020 11:38 AM

To: Wachtel, Jonathan < Gadbois, Ellen (NIH/OD) [E] < (b)(6)

Cc: Tountas, Karen (FNIH) [T] < (b)(6)

Subject: RE: ACTIV Clinical Trial Capacity survey dashboard

Thanks. I got in!

From: Wachtel, Jonathan (b)(6)

Sent: Friday, May 22, 2020 10:28 AM

To: Culp, Michelle (NIH/OD) [E]

Gadbois, Ellen (NIH/OD) [E] < (b)(6)(b) (6)

Cc: Tountas, Karen (FNIH) [T] < (b)(6)

Subject: FW: ACTIV Clinical Trial Capacity survey dashboard

Importance: High

Michelle/Ellen

Access granted. Please find the link below.


Best,

Jonathan Wachtel

Deloitte Consulting LLP Tel/Direct: (b) (6) www.deloitte.com

From: Tountas, Karen (FNIH) [T]

(b)(6)Sent: Wednesday, May 20, 2020 4:13 PM To: Bascles, Lionel >; Cohen, Myron >; Corey, Larry (b) (6) (b)(6)(b) (6) Victoria Davey Desrosiers, Betsy (b) (6) Dickens, Jim (NIH/NCATS) [C] (b)(6)(b)(6)>; Doroshow, James (NIH/NCI) [E] Goff, David (NIH/NHLBI) [E] ; Garner, Carlos (b) (6) (b) (6) (b)(6)Kurilla, Michael (NIH/NCATS) [E] < (b)(6)Mensah, George (NIH/NHLBI) [E] Nayak, Seema (NIH/NIAID) [E] < Payton, Manizhe (NIH/NIAID) [E] (b)(6)(b)(6)>; Resnansky, Laura >; Sizemore, Christine (NIH/FIC) [E] (b) (6) (b) (6)



Subject: [EXT] ACTIV Clinical Trial Capacity survey dashboard

Importance: High

Dear Colleagues,

BLUF*: The ACTIV Clinical Trial Capacity survey dashboard is ready for use Caveat – Now for those with NIH credential, and in a few days for those external to the NIH system

After several unforeseen technical issues with both the data and the infrastructure, the clinical network and site the dashboard is ready for use. A big thank you to Jonathan and Kevin and the team at Deloitte for putting this dashboard together. We're not letting them off the hook that easily – they already are working on incorporating the CRO-SMO survey data.

For those of you with NIH credentials, you will be able to access the dashboard through this link: https://analyticsqa.niaid.nih.gov/#/site/ACTIV/views/ACTIVCTCWGSurveyDashboard/Network-SiteMap?:iid=1. You will find four tabs at the top of the page: 1) Network-Site Map, a dashboard with the map (sites and COVID-19 data, by USA with county-level data or world-wide, country-level views) and the network and site filters; 2) Network Detail Dashboard, a one-page summary of the network based on the survey responses; 3) Glossary, a few definitions that we have been using; and, 4) Resources that might be of interest. I have poked around the dashboard a bit – use is fairly intuitive, but if you have questions please feel free to reach out to Kevin, Ethan, or Alyssa (copied on this email). However, please note that the dashboard is "hot off the press" so if you notice any issues with the dashboard, or would like to pass along thoughts that might improve the user experience, please bring them to the attention of Kevin, Ethan, or Alyssa.

The team is working on getting everyone else on the WG access, targeting the end of this week. Apparently, this has proved a bit more challenging for the NIH group that hosts this platform than anticipated.

As you all know, Karen

Karen H. Tountas, PhD Scientific Program Manager

Foundation for the National Institutes of Health

(b) (6) fnih.org

11400 Rockville Pike, Suite 600, North Bethesda, MD 20852



Donate to the FNIH's Pandemic Response Fund to combat COVID-19: fnih.org/pandemic



Confidentiality Notice: Information contained in this e-mail and attachments may be legally privileged and confidential. If you are not an intended recipient, you are hereby notified that dissemination, distribution or copying this e-mail and attachments is strictly prohibited; please delete the e-mail and attachments immediately.

*BLUF = bottom line up front

This message (including any attachments) contains confidential information intended for a specific individual and purpose, and is protected by law. If you are not the intended recipient, you should delete this message and any disclosure, copying, or distribution of this message, or the taking of any action based on it, by you is strictly prohibited.

Deloitte refers to a Deloitte member firm, one of its related entities, or Deloitte Touche Tohmatsu Limited ("DTTL"). Each Deloitte member firm is a separate legal entity and a member of DTTL. DTTL does not provide services to clients. Please see www.deloitte.com/about to learn more.

v.E.1

From: Collins, Francis (NIH/OD) [E] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=410E1CA313F44CED9938E50D2FF0B6C2-COLLINSF] Sent: 5/12/2020 4:49:13 PM To: Woodcock, Janet [(b)(6)RE: Letter to the ACTIV Executive Committee from the Therapeutics-Clinical Working Group Subject: Flag: Follow up Yes, I would like that. Can you do 3:30? From: Woodcock, Janet < (b) (6) Sent: Tuesday, May 12, 2020 11:28 AM To: Collins, Francis (NIH/OD) [E] < (b)(6)Subject: FW: Letter to the ACTIV Executive Committee from the Therapeutics-Clinical Working Group Can we discuss before tomorrow? jw From: Wholley, David (FNIH) [T] (b)(6)Sent: Tuesday, May 12, 2020 10:46 AM To: Collins, Francis S (NIH) ; Stoffels, Paul [JJCUS] Fauci, Anthony S (NIH) (b)(6)(b) (6) (b)(6); Gibbons, Gary H (NIH) (b)(6)>; Woodcock, Janet ; Pao, William Dolsten, Mikael (b)(6)(b) (6) </ (b)(6)Cc: Colvis, Christine M (NIH) < Desrosiers, Betsy Hughes, (b) (6) (b)(6)(b) (6) Eric < Read, Sarah W (NIH) Jansen, Kathrin (b)(6)Kurilla, Michael G (NIH) ; Lowy, Douglas R (NIH) (b Young, John Freire, Maria C (NIH) ; Tabak, (b)(6)(b)(6)(b)(6)Lawrence A (NIH) v>; Lane, Henry C (NIH) Parker, Ashley S (NIH) (b) (6) (b)(6)>; Anderson, James M (NIH) >; Austin, Christopher P (NIH) (b)(6)(b)(6)Wolinetz, Carrie D (NIH) < (b)(6)(b)(6)Subject: FW: Letter to the ACTIV Executive Committee from the Therapeutics-Clinical Working Group Dear ACTIV Executive Committee Members: Please see the attached letter from the ACTIV Therapeutics-Clinical Working Group received this morning, for consideration on tomorrow morning's Executive Committee teleconference. While we expect the proposals contained herein will be one major topic of discussion, the purpose of the meeting is to hear from all of the Working Group cochairs (copied on this note) regarding what is working and where they may be facing challenges in ACTIV, and jointly discuss strategy moving forward. David

From: Adam, Stacey (FNIH) [T] (b)(6)Sent: Tuesday, May 12, 2020 9:52 AM To: Wholley, David (FNIH) [T] < (b) (6) Cc: Read, Sarah (NIH/NIAID) [E] >; Eric Hughes 1>; Carlos O Garner (b)(6)(b)(6)**Judy Currier** >; Keith Gottesdiener (b)(6)(b) (6) Amanda Peppercorn < Stein, Peter (FDA/CDER) (b)(6)(b)(6)Higgs, Elizabeth (NIH/NIAID) [E] (b)(6)(b)(6)Subject: Letter to the ACTIV Executive Committee from the Therapeutics-Clinical Working Group

Hi David,

Please find attached a letter from the Therapeutics-Clinical Working Group to the ACTIV Executive Committee for their consideration. Overall, the letter is meant to relate some broad challenges and issues that the Therapeutics-Clinical group thinks the ACTIV PPP is facing, as well as some very specific requests for assistance from the ACTIV EC for our team.

Please relay this to the ACTIV EC for their review. Our group would welcome any feedback they have.

Thanks, Stacey

Stacey J. Adam, PhD

Director, Cancer

Research Partnerships

Foundation for the National Institutes of Health

Direct: (b) (6

(b) (6) Mobile: (b) (6)

fnih.org

11400 Rockville Pike, Suite 600, North Bethesda, MD 20852



Donate to the FNIH's Pandemic Response Fund to combat COVID-19: fnih.org/pandemic



Menetski, Joseph (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=5001AF52DC4A427EA3D34F1E072F8CB7-MENETSKIJP] 4/14/2020 5:23:50 PM (b)(6)(b) (6) (b) (6) (b)(6)(b)(6)(b) (6) (b) (6) (b) (6) Baric, Ralph [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=48e35ab1d3044465a7790ee4ded5bc32-rbaric.emai]; Ottinger, Elizabeth (NIH/NCATS [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ad34123055944f97bedbef038d375cd7-ottingerea]; Colvis, Christine (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4b7e84cce098457896b2df19fa172c87-ccolvis]; Hewitt, Judith (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2d0a7dadfcbd42cbb4014d9b26af30cc-jhewitt]; Deming, Damon (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=8a5ace9923ae415aa3d85ac09cb76f85-DEMINGD.fda]; (b) (6) (b) (6) Parker, Ashley (NIH/OD) [E] (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras]; Collins, Francis (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=410e1ca313f44ced9938e50d2ff0b6c2-collinsf]; (b) (6) Adams, Peter (OS/ASPR/BARDA) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f6e22f801f9146ef90116c4311c6f3ee-Peter.Adams] Wholley, David (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]; Austin, Christopher (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=17597cabc42247548e596778304f781f-austinc]; Melencio, Cheryl (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=279e14fa7428415bb86087d08b628e6f-melencioc]; Colvis, Christine (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4b7e84cce098457896b2df19fa172c87-ccolvis]; Desrosiers, Betsy Hughes, Eric [Jansen, Kathrin (b) (6) (b) (6) Kurilla, Michael (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (b)(6)(FYDIBOHF23SPDLT)/cn=Recipients/cn=dc4e85061e3943b9b8ad3f426727861f-mkurilla]; Lowy, Douglas (NCI) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=54fa75fe6e304e34ba567c66b832baa0-drl.helix.n]; Read, Sarah (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=527b160038004a199ae6e0bac2226099-readsa]; Tountas, Karen (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=40c04fef6f1e46f5b750753cd5a14f93-tountaskh]; Santos, Michael (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ab38cb6836de44e18ef4cc6952f65f80-santosmr]; Adam, Stacey (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dcd875f0679648859e1cf101c0943414-adamsj4]; James, Stephanie (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f0032ef62ca343dfb4bf79577e2aa8d1-jamesst]; Alvarez, Rosa Maria (b) (6) Kim, Elizabeth [(b) (6) Tolman, Brett [(b) (6) Wachtel, Jonathan [Prabhavathi Fernandes [Diamond, Michael (b)(6)(b)(6)Dana Carluccio Rose Li (b) (6) (b) (6) Lagos, Enrique (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ae9041ab27204d83b06752f67a44b0d1-lagoses]; Jonson, Samantha (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ce2f69369d654bef89b0d39b145d69a7-jonsonsg]; Gonzalez, Nina [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user3c2f486d]; Simon, Dina (NIH/OD) [C] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e02345fa5d1d4d7eaf4e0f3da58bc1ac-simondm]; Burrus-Shaw, Cyndi

(NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group

From:

Sent:

To:

CC:

COLL0000022497-2516980

(FYDIBOHF23SPDLT)/cn=Recipients/cn=5bbac95b1f6e4514a299b318030c31f6-shawcy]; Rodriguez, Robin D (b)(6)Subject: COVID Preclinical working group (meeting # 1) Attachments: PRECLINICAL Agenda, Questions and Bios for Therapeutics- Preclinical Working Group FNIH_0414_vF5.pdf; PRECLINICAL - Agenda and questions for first working group meeting 4 14 2020_VF.docx Location: https://zoom. (b)(6)4/14/2020 6:00:00 PM Start: 4/14/2020 7:30:00 PM End: Show Time As: Tentative (b)(6)Required Attendees: Parker, Ashley (NIH/OD) [E]; Collins, Francis (NIH/OD) [E]; (b) (6) Adams, Peter (OS/ASPR/BARDA) Optional Wholley, David (FNIH) [T]; Austin, Christopher (NIH/NCATS) [E]; Melencio, Cheryl (FNIH) [T]; Colvis, Christine Attendees: (NIH/NCATS) [E]; Desrosiers, Betsy; Hughes, Eric; Jansen, Kathrin; Kurilla, Michael (NIH/NCATS) [E]; Lowy, Douglas (NCI); Read, Sarah (NIH/NIAID) [E]; Tountas, Karen (FNIH) [T]; Santos, Michael (FNIH) [T]; Adam, Stacey (FNIH) [T]; James, Stephanie (FNIH) [T]; Alvarez, Rosa Maria; Kim, Elizabeth; Tolman, Brett; Wachtel, Jonathan; Prabhavathi Fernandes; Diamond, Michael; Rose Li; Dana Carluccio; Lagos, Enrique (NIH/NCATS) [E]; Jonson, Samantha (NIH/NCATS) [E]; Gonzalez, Nina; Simon, Dina (NIH/OD) [C]; Burrus-Shaw, Cyndi (NIH/OD) [E]; Rodriguez, Robin D Update: 4/14/2020 1:14; Added meeting materials Dear preclinical working group members, Thank you for agreeing to participate in this working group to help guide the COVID partnership effort. We are looking forward to working with you. We understand that time is of the essence and that many of you are occupied with other activities that address the COVID-19 pandemic. However, we ask for your flexibility and patience as we begin to schedule these meetings. We will do out best to ensure that all can attend and participate. We will be sending additional materials in the next day or so for you to prepare for this meeting. This will let us get to the important discussions and decisions that we need to make to move the process forward rapidly. Thank you again for your willingness to participate. Sincerely, Joe Menetski, for COVID preclinical working group Joseph Menetski is inviting you to a scheduled Zoom meeting. Join Zoom Meeting https://zoom.us/ (b) (6) Meeting ID: (b) (6) Password: (b) (6)

US (Chicago)

One tap mobile

(b)(6)

(b) (6) US (New York)

Dial by your location
(b) (6) US (Chicago)
US (New York)
US
US (Houston)
US (San Jose)
US (San Jose)
US (San Jose)
US

Meeting ID: (b) (6)

Password: (b) (6)

Find your local number: https://zoom.us/s

From: Collins, Francis (NIH/OD) [E] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP

(FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=410E1CA313F44CED9938E50D2FF0B6C2-COLLINSF)

Sent: 5/29/2020 10:44:43 PM

To: Freire, Maria (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=8598d551d1d3455eaf14854c83f41d84-freiremc]

Subject: Re: Key messages re: immunomodulators for slides for Moncef meeting tomorrow 5/30

Yes, she is waiting to see the draft ppts and will advise on the strategy then.

Sent from my iPhone

On May 29, 2020, at 6:06 PM, Freire, Maria (FNIH) [T] < (b) (6) wrote:

Francis - have you had a chance to chat with Janet to coordinate messages? She is critical - in her low-key way, she is able to carry a huge part of the load. Moncef knows she has a rock-solid reputation with industry folks. And, of course, she was the one who asked for the money. M.

On May 29, 2020, at 5:59 PM, Collins, Francis (NIH/OD) [E] < (b) (6) wrote:

Hi all,

I have received information from Amy Patterson about the anticoagulant trial, and I'd like to have that incorporated into the slide set that Deloitte is currently working on. Attached is the document from Amy. I have highlighted the main points that I would want to have included in the slides, trying if possible to mirror the same features that are going to be included in the description of the immunomodulator study.

See what you think. I stand ready to look at ppts anytime this evening.

One question about the immunomodulator trial that I noticed in Moncef's note – has FDA agreed with the plan to move straight into phase 3 from a safety and efficacy standpoint?

Thanks, Francis

From: Wholley, David (FNIH) [T] < (b) (6)

Sent: Friday, May 29, 2020 1:59 PM

To: Collins, Francis (NIH/OD) [E] < (b) (6)

Cc: Adam, Stacey (FNIH) [T] < (b) (6) Freire, Maria (FNIH) [T] < (b) (6) Gonzalez,

Nina < (b) (6) Parker, Ashley (NIH/OD) [E] < (b) (6)

Subject: Key messages re: immunomodulators for slides for Moncef meeting tomorrow 5/30

Francis:

Here is the outline of the slides I am asking Deloitte to work to put together with key messages. I don't know if you or Ashley have a good version of slide #1; it is more of an OWS slide than an ACTIV one. I also don't know what input NHLBI wants to provide; I took the liberty of naming the anticoag MP as "ACTIV-4" in the interest of teaming up on a commonly branded strategy, hope that is OK. I am providing this to Deloitte now so they can get going on starting the slides, but please feel free to

highlight maybe in red any wording you want changed or additions you would add in the meantime, and copy all on the reply.

- Maybe a diagram slide just reminding Moncef that OWS/Therapeutics and ACTIV are working together
- OWS/ACTIV Therapeutics has been taking a *portfolio* approach to addressing the dramatic health and economic challenges posed by the pandemic, with harmonized efforts that address both disease etiology and symptomology.
 - o ACTIV Baricitinib (ACTT2, sponsored by NIAID) in progress
 - ACTIV hiVIG (sponsored by NIAID) in progress
 - ACTIV-1 Inpatient Master Protocol of 3 host-targeted immune modulators (using CRO) – (Phase III) – ready to launch late June
 - ACTIV-2*- Neutralizing Monoclonal Antibodies Outpatient Master Protocol (using NIAID ACTG Network + CRO) - (Phase II/III) - projected launch June
 - ACTIV-3* Neutralizing Monoclonal Antibodies Inpatient Master Protocol (NIAID INSIGHT Network + NHLBI PETAL Network + CRO) – (Phase II/III) – projected launch July
 - ACTIV-4 Inpatient Master Protocols of 3+ Anticoagulant Therapies, and eventually, Anticoagulant+Immune Modulator Combinations (NHLBI-NINDS "Master" Network) – (Phase II/III) – projected launch late June
 - ACTIV-5 De Novo Master Protocol Structure to test promising agents not effectively evaluated elsewhere (e.g., antivirals) similar design to the mAb protocols, networks/sites/agents in discussions now projected launch August (if needed; i.e. if agents are not incorporated into mAb protocols)
 * current priority
 - [for this slide I think you can use the Agent Prioritization Snapshot slide (#12) from May 20 ACTIV EC call as a base
 - Prioritization Process (v 2.0) for ACTIV: (slide 14 from May 20 EC deck)
 - Results of First Agent Prioritization Reviews (slide 13 from May 20 deck)
 [Key Criteria for Scoring (slide 15 from 5/20) can go to backup
 - Prioritization and Protocol Design: Who is Involved two-box slide containing names and affiliations of those involved in the Proritization and MP Subgroups (quality folks!)
 - ACTIV-1 Protocol for immunomodulators
 - Agent prioritization included input from COVID R&D Leadership Consortium planned testing of 8-9 repurposed agents funded by industry (2 highest priority agents switched to ACTIV-1)
 - 3 agents chosen are well-established anti-inflammatories with solid rationale for MOA in COVID-19, not already being adequately tested elsewhere
 - All 3 either have initial Phase II data or are currently running companysponsored Phase II trials = high POS
 - Phase III master protocol design for ACTIV-1 includes aggressive efficacy and futility assessments to allow for early stopping at 25%, 50%, and 75% accrual, in order to quickly drop agents not showing efficacy (like a Phase II/III progression design, but design was faster for quicker launch)
 - Companies have agreed to share data + common control arm+ common endpoints + DSMB = efficiency and ability to compare results across arms (this does not happen if companies test separately)
 - Protocol is 80% complete
 - Substantial input from 25+ industry, academic, and government experts, including FDA clinical and stats
 - Statisticians include some of the best in the world for master protocol design: Lisa LaVange (UNC), Karen Price (Lilly), Michael Proschan (NIAID), Sandeep Menon (Pfizer)

- All three companies have written their sections of the protocols, which are being merged into the master design
- Working with OWS/BARDA on choice of CRO to run the trial; (b) (5)
- "ACTIV-4" Protocol for anticoagulants
 - Need bullets from NHBLI on this. Should emphasize similar themes (robust choice of agents through ACTIV process, powered by NHLBI/NINDS "network of networks" with rapid contracting and startup practices, protocol being drafted in parallel (ACTIV WG review), inclusion of vital natural history disease/treatment data, cost and justification, etc.)
- Maybe a final slide summarizing the budget asks? Should it include preclinical or just the clinical stuff? And perhaps NIH (Ashley) should draft that one given the sensitivity around the numbers?

David Wholley Senior Vice-President, Research Partnerships Foundation for the National Institutes of Health (b) (6)

fnih.org

11400 Rockville Pike Suite 600 North Bethesda, MD 20852

In 2019, the FNIH earned the highest rating from Charity Navigator for the fifth consecutive year and was recognized as an organization that exceeds industry standards.

<Responses to Qs re AC Clinical Trial Strategy 052920 final fsc.docx>

From: Melencio, Cheryl (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=279E14FA7428415BB86087D08B628E6F-MELENCIOC] Sent: 9/25/2020 5:00:39 PM To: Melencio, Cheryl (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=279e14fa7428415bb86087d08b628e6f-melencioc]; Austin, Christopher (NIH/NCATS) [E] ; Carter, Kara [(b)(6)Cavaleri, Marco (b) (6) Cihlar, Tomas []; Collins, Francis (NIH/OD) [E] (b) (6) (b)(6)Culp, Michelle (NIH/OD) [E] [Corey, Larry (b) (6) (b)(6)Disbrow, Gary (OS/ASPR/BARDA) [Dolsten, Mikael [Erbelding, (b)(6)(b) (6) Emily (NIH/NIAID) [E] [1; Erck, Stan [Gadbois, Ellen (NIH/OD) [E] (b) (6) (b)(6)Hudson, Thomas Gibbons, Gary (NIH/NHLBI) [E] [(b)(6)(b)(6)James, Stephanie (FNIH) [T] [Johnson, Robert (OS/ASPR/BARDA) (b) (6) (b)(6)Lane, Cliff (NIH/NIAID) [E] Kramer, Lynn [(b) (6) (b)(6)]; Marks, Peter (FDA/CBER) [Lepore, John (b)(6)(b)(6)(b)(6)Marston, Hilary (NIH/NIAID) [E] [(b)(6)Mascola, John (NIH/VRC) [E] (b) (6)]; Meeker, David [Menetski, Joseph (FNIH) [T] [(b)(6)Messonnier, Nancy (b)(6)(CDC/DDID/NCIRD/OD) [Pao, William Pandya, Hitesh [(b) (6) (b)(6)Parker, Ashley (NIH/OD) [E] [Perlmutter, Roger (b)(6)(b) (6) Plenge, Robert (b)(6); Plump, Andy (b) (6) Rachel Ramoni [Reese, David [(b)(6)(b) (6) (b) (6) Rouse. Doris [(b) (6) Santos, Michael (FNIH) [T] [(b)(6)Skovronsky, Daniel Stein, Peter (FDA/CDER) [Stoffels, Paul (b)(6)(b)(6)]; Tabak, Lawrence (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (b)(6)(FYDIBOHF23SPDLT)/cn=Recipients/cn=02e22836b5ff4e9988e3770cfc7ee770-tabakl]; Talley, Michael Tsai, John [(b)(6)(b) (6) Vessey, Rupert [(b)(6)1: Virgin. Skip [(b)(6)Wholley, David (FNIH) [T] [(b)(6)Woodcock, Janet (FDA/CDER) (b)(6)Young, John [Colvis, Christine (NIH/NCATS) [E] (b)(6)]; Eric Hughes [Jansen, Kathrin [(b) (6) (b)(6)(b)(6)Kurilla, Michael (NIH/NCATS) [E] [Lowy, Douglas (NCI) [Read, Sarah (b)(6)(b)(6)(NIH/NIAID) [E] [Victoria Davey [(b)(6)(b) (6) (b) (6) Bancel, Stephane [(b)(6)Fauci, Anthony (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=df38103d75134f658ae2d356f0396b94-afauci]; Pangalos, Mene Paul, Steve [Rasi, Guido [(b)(6)(b)(6)Desrosiers, Betsy [Reed, John [(b) (6) (b)(6)CC: Adam, Stacey (FNIH) [T] [Alvarez, Rosa Maria I (b) (6) Margaret Anderson (b) (6) Chen, Helen Q. [(b)(6)Appell, Evan [(b)(6)(b)(6)Gonzalez, Nina [Hawk, Harrison [Mendelson, Jesse (b) (6) (b)(6)Stratton, Benjamin [(b)(6)btolman [(b) (6) Tountas, Karen (FNIH) [T] ; Austin, Sarah (NIH/NIAID) [E] []; Barasch, (b)(6)(b)(6)Burrus-Shaw, Cyndi Kimberly (NIH/NIAID) [C] [Bell, Julie [(b)(6)(b) (6) (NIH/OD) [E] [Carver, Trea (NIH) [C] [Caulfied, Anita (b) (6) (b)(6)Coan, Amanda | (b)(6)Conrad, Patricia (NIH/NIAID) [E] (b)(6)Dimishkov, Roxanne (NIH/NHLBI) [C] [Edl, Susan (b) (6) (b)(6)Fuhrer, Nicole [Giorgi, Sara [(b) (6) (b)(6)(b) (6) Hoban, Michelle [Hoffstetter, Renata (FNIH) [T] [Iberdemaj, Vaide (b) (6) (b)(6)Jenkins, Christine S. [Lagos, Enrique (NIH/NCATS) [E] (b)(6)McManus, Ayanna (NIH/OD) [E]]; Lever, Susan [(b) (6) (b) (6) (b) (6) Minnich, Beth [(b)(6)Perala, Mie [(b) (6) Riccobene, Kim [Protasiewicz, Ann [(b)(6)(b) (6) Riggin, Mary Ripley, Nadege [Schuster, Donna (b)(6)(b)(6)]; Sepulveda, Dorina (FNIH) [T] [Simon, Dina (NIH/OD) [C] (b)(6)Suhana, Tina (NIH/VRC) [E] []; Thomas, Ashley (FDA/CDER) (b) (6) (b) (6) (b)(6)]; Wood, Gretchen (NIH/OD) [E] [Anderson, James (NIH/OD) [E] (b)(6)]; Burklow, John (NIH/OD) [E] [Carluccio, Dana (b) (6) (b) (6) Castillejos, Carlos [.com]; FNIH Central Account (b) (6) (b)(6)Hallett, Adrienne (NIH/OD) [E] [(b) (6)]; Myles, Renate (NIH/OD) [E] (b) (6)

[(b) (6)	Wolinetz, Carrie (NIH/OD) [E]	(b) (6)	Togashi, Miek	o (NIH/NCI) [E]
[(b) (6)]; Underwood, Nan	icy [(b) (6)	Zottoli, .	Jessica
[(b) (6)	Plenge, Robert [(b) (6)	\	/essey, Rupert [(b) (6)
Rega	in, Donna M	(b) (6) So	rosa, Alex [(b) (6	Connelly,	Sarah
[(b) (6)	Lowy, Douglas (NIH/N	ICI) [E] [(b) (6)]; John Lepore	
[(b) (6)	Grant, Sarah [(b) (6	5)	Qashu, Felicia (NIH	/OD) [E]
[(b) (6)]; Wachtel, Jonathan	(b) (6)	Han	nilton, Nancy	
[(b) (6)					

Subject: ACTIV Leadership Call #10

Location: https://fnih.zoom.us/ (b) (6)

Start: 11/19/2020 5:00:00 PM **End**: 11/19/2020 6:00:00 PM

Show Time As: Busy

Required Attendees: Austin, Christopher (NIH/NCATS) [E]; Bancel, Stephane; Carter, Kara; Cavaleri, Marco; Cihlar, Tomas; Collins, Francis (NIH/OD) [E]; Corey, Larry; Culp, Michelle (NIH/OD) [E]; Disbrow, Gary (OS/ASPR/BARDA); Dolsten, Mikael; Erbelding, Emily (NIH/NIAID) [E]; Erck, Stan; Fauci, Anthony (NIH/NIAID) [E]; Gadbois, Ellen (NIH/OD) [E]; Gibbons, Gary (NIH/NHLBI) [E]; Hudson, Thomas; James, Stephanie (FNIH) [T]; Johnson, Robert (OS/ASPR/BARDA); Kramer, Lynn; Lane, Cliff (NIH/NIAID) [E]; Lepore, John; Marks, Peter (FDA/CBER); Marston, Hilary (NIH/NIAID) [E]; Mascola, John; Meeker, David; Menetski, Joseph (FNIH) [T]; Messonnier, Nancy (CDC/DDID/NCIRD/OD); Pandya, Hitesh; Pangalos, Mene; Pao, William; Parker, Ashley (NIH/OD) [E]; Paul, Steve; Perlmutter, Roger; Plenge, Robert; Plump, Andy; Ramoni, Rachel; Rasi, Guido; Reed, John; Reese, David; Rouse, Doris; Santos, Michael (FNIH) [T]; Skovronsky, Daniel; Stein, Peter (FDA/CDER); Stoffels, Paul; Tabak, Lawrence (NIH/OD) [E]; Talley, Michael; Tsai, John; Vessey, Rupert; Virgin, Skip; Wholley, David (FNIH) [T]; Woodcock, Janet (FDA/CDER); Young, John; Colvis, Christine (NIH/NCATS) [E]; Desrosiers, Betsy; Hughes, Eric; Jansen, Kathrin; Kurilla, Michael (NIH/NCATS) [E]; Lowy, Douglas (NCI); Read, Sarah (NIH/NIAID) [E]; (b) (6) Davey, Victoria

Optional Attendees: Adam, Stacey (FNIH) [T]; Alvarez, Rosa; Anderson, Margaret; Appell, Evan; Chen, Helen; Gonzalez, Nina; Hawk, Harrison; Mendelson, Jesse; Stratton, Ben; Tolman, Brett; Tountas, Karen (FNIH) [T]; Wachtel, Jonathan; Austin, Sarah (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]; Bell, Julie; Burrus-Shaw, Cyndi (NIH/OD) [E]; Carver, Trea (NIH) [C]; Caulfied, Anita; Coan, Amanda; Conrad, Patricia (NIH/NIAID) [E]; Dimishkov, Roxanne (NIH/NHLBI) [C]; Edl, Susan; Fuhrer, Nicole; Giorgi, Sara; Hoban, Michelle; Hoffstetter, Renata (FNIH) [T]; Iberdemaj, Vaide; Jenkins, Christine S.; Krack, Kimberly; Lagos, Enrique (NIH/NCATS) [E]; Lever, Susan; McManus, Ayanna (NIH/OD) [E]; Minnich, Beth; Perala, Mie; Protasiewicz, Ann; Riccobene, Kim; Riggin, Mary; Ripley, Nadege; Schuster, Donna; Sepulveda, Dorina (FNIH) [T]; Simon, Dina (NIH/OD) [C]; Suhana, Tina (NIH/VRC) [E]; Thomas, Ashley (FDA/CDER); Wood, Gretchen (NIH/OD) [E]; Anderson, James (NIH/OD) [E]; Burklow, John (NIH/OD) [E]; Carluccio, Dana; Castillejos, Carlos; FNIH Central Account; Hallett, Adrienne (NIH/OD) [E]; Myles, Renate (NIH/OD) [E]; Wolinetz, Carrie (NIH/OD) [E]; Togashi, Mieko (NIH/NCI) [E]; Underwood, Nancy; Zottoli, Jessica; Plenge, Robert; Hamilton, Nancy; Vessey, Rupert; Regan, Donna M; Sorosa, Alex; Connelly, Sarah; Lowy, Douglas (NIH/NCI) [E]; John Lepore; Grant, Sarah; Qashu, Felicia (NIH/OD) [E]

Joseph Menetski is inviting you to a scheduled Zoom meeting.

```
Join Zoom Meeting
https://fnih.zoom.us,
                                             (b)(6)
Meeting ID:
                (b) (6)
Passcode: (b)
One tap mobile
                   (b) (6)
                                              US (Germantown)
                                              US (Chicago)
Dial by your location
                         US (Germantown)
                            (Chicago)
                         US
                            (New York)
                         US
                            (San Jose)
                         US
                            (San Jose)
                         US (Tacoma)
```

```
(b)(6)
                                      US (Houston)
lgium
elgium
                                       elgium
elgium
elgium
                                       elgium
                                       Canada
                                       Canada
                                       Canada
                                       Canada
                                       Canada
                                       Canada
                                       France
                                       France
                                       France
                                       France
                                       France
                                       Japan
                                       Japan
                                       Japan
                                        Italy
                                            Italy
                                        Italy
Switzerland
                                        Switzerland
Switzerland
                                         Switzerland
                                         Switzerland
                                         Switzerland
                                        United Kingdom
                         (b) (6)
(b) (6)
Meeting ID:
Passcode: (b) (6)
Find your local number: https://fnih.zoom.u
                                                                            (b) (6)
```

From: Adam, Stacey (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=DCD875F0679648859E1CF101C0943414-ADAMSJ4] Sent: 5/30/2020 12:33:03 AM To: Collins, Francis (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=410e1ca313f44ced9938e50d2ff0b6c2-collinsf]; Wholley, David (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd] CC: Freire, Maria (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=8598d551d1d3455eaf14854c83f41d84-freiremc]; Gonzalez, Nina [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user3c2f486d]; Parker, Ashley (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras] Subject: RE: Key messages re: immunomodulators for slides for Moncef meeting tomorrow 5/30 Hi Francis, Back to you in moments. Stacey Stacev J. Adam. PhD Director, Cancer Research Partnerships Direct: (b) (6) Mobile: (b) (6) From: Collins, Francis (NIH/OD) [E] < (b) (6) Sent: Friday, May 29, 2020 8:32 PM To: Wholley, David (FNIH) [T] < (b) (6) Cc: Adam, Stacey (FNIH) [T] < Freire, Maria (FNIH) [T] < (b) (6) Gonzalez, Nina (b) (6) Parker, Ashley (NIH/OD) [E] < (b) (6) (b) (6) Subject: RE: Key messages re: immunomodulators for slides for Moncef meeting tomorrow 5/30 Hoping these are coming to me soon, as I may want to do some editing -- and then I wanted to run them past Janet tonight. FC From: Wholley, David (FNIH) [T] (b)(6)Sent: Friday, May 29, 2020 7:41 PM To: Collins, Francis (NIH/OD) [E] < (b)(6)Cc: Adam, Stacey (FNIH) [T] (b) ; Freire, Maria (FNIH) [T] ; Gonzalez, Nina (b) (6) (b) (6) >; Parker, Ashley (NIH/OD) [E] Freire, Maria (FNIH) [T] (b) (6) Subject: RE: Key messages re: immunomodulators for slides for Moncef meeting tomorrow 5/30

Have seen and offered a few changes to the complete slide deck. They should be coming back to you as soon as Deloitte makes the changes.

From: Collins, Francis (NIH/OD) [E] < (b) (6)

Sent: Friday, May 29, 2020 5:59 PM

To: Wholley, David (FNIH) [T] (b) (6)

Cc: Adam, Stacey (FNIH) [T] (b) (6) Freire, Maria (FNIH) [T] (b) (6) >; Gonzalez, Nina (b) (6) ; Parker, Ashley (NIH/OD) [E] < (b) (6)

Subject: RE: Key messages re: immunomodulators for slides for Moncef meeting tomorrow 5/30

Hi all,

I have received information from Amy Patterson about the anticoagulant trial, and I'd like to have that incorporated into the slide set that Deloitte is currently working on. Attached is the document from Amy. I have highlighted the main points that I would want to have included in the slides, trying if possible to mirror the same features that are going to be included in the description of the immunomodulator study.

See what you think. I stand ready to look at ppts anytime this evening.

One question about the immunomodulator trial that I noticed in Moncef's note – has FDA agreed with the plan to move straight into phase 3 from a safety and efficacy standpoint?

Thanks, Francis

```
From: Wholley, David (FNIH) [T] (b) (6)

Sent: Friday, May 29, 2020 1:59 PM

To: Collins, Francis (NIH/OD) [E] < (b) (6)

Cc: Adam, Stacey (FNIH) [T] (b) (6) Freire, Maria (FNIH) [T] < (b) (6) ; Gonzalez, Nina (b) (6) ; Parker, Ashley (NIH/OD) [E] (b) (6)

Subject: Key messages re: immunomodulators for slides for Moncef meeting tomorrow 5/30
```

Francis:

Here is the outline of the slides I am asking Deloitte to work to put together with key messages. I don't know if you or Ashley have a good version of slide #1; it is more of an OWS slide than an ACTIV one. I also don't know what input NHLBI wants to provide; I took the liberty of naming the anticoag MP as "ACTIV-4" in the interest of teaming up on a commonly branded strategy, hope that is OK. I am providing this to Deloitte now so they can get going on starting the slides, but please feel free to highlight maybe in red any wording you want changed or additions you would add in the meantime, and copy all on the reply.

- Maybe a diagram slide just reminding Moncef that OWS/Therapeutics and ACTIV are working together
- OWS/ACTIV Therapeutics has been taking a portfolio approach to addressing the dramatic health and economic challenges posed by the pandemic, with harmonized efforts that address both disease etiology and symptomology.
 - ACTIV Baricitinib (ACTT2, sponsored by NIAID) in progress
 - ACTIV hiVIG (sponsored by NIAID) in progress
 - ACTIV-1 Inpatient Master Protocol of 3 host-targeted immune modulators (using CRO) (Phase III) ready to launch late June
 - ACTIV-2*- Neutralizing Monoclonal Antibodies Outpatient Master Protocol (using NIAID ACTG Network + CRO) - (Phase II/III) - projected launch June
 - ACTIV-3* Neutralizing Monoclonal Antibodies Inpatient Master Protocol (NIAID INSIGHT Network + NHLBI PETAL Network + CRO) – (Phase II/III) – projected launch July
 - ACTIV-4 Inpatient Master Protocols of 3+ Anticoagulant Therapies, and eventually,
 Anticoagulant+Immune Modulator Combinations (NHLBI-NINDS "Master" Network) (Phase II/III) –
 projected launch late June

- ACTIV-5 De Novo Master Protocol Structure to test promising agents not effectively evaluated elsewhere (e.g., antivirals) similar design to the mAb protocols, networks/sites/agents in discussions now projected launch August (if needed; i.e. if agents are not incorporated into mAb protocols)
 * current priority
 - [for this slide I think you can use the Agent Prioritization Snapshot slide (#12) from May 20 ACTIV EC call as a base
- Prioritization Process (v 2.0) for ACTIV : (slide 14 from May 20 EC deck)
- Results of First Agent Prioritization Reviews (slide 13 from May 20 deck)
 [Key Criteria for Scoring (slide 15 from 5/20) can go to backup
- Prioritization and Protocol Design: Who is Involved two-box slide containing names and affiliations of those involved in the Proritization and MP Subgroups (quality folks!)
- ACTIV-1 Protocol for immunomodulators
 - Agent prioritization included input from COVID R&D Leadership Consortium planned testing of 8-9 repurposed agents funded by industry (2 highest priority agents switched to ACTIV-1)
 - 3 agents chosen are well-established anti-inflammatories with solid rationale for MOA in COVID-19, not already being adequately tested elsewhere
 - All 3 either have initial Phase II data or are currently running company-sponsored Phase II trials
 = high POS
 - Phase III master protocol design for ACTIV-1 includes aggressive efficacy and futility assessments to allow for early stopping at 25%, 50%, and 75% accrual, in order to quickly drop agents not showing efficacy (like a Phase II/III progression design, but design was faster for quicker launch)
 - Companies have agreed to share data + common control arm+ common endpoints + DSMB = efficiency and ability to compare results across arms (this does not happen if companies test separately)
 - o Protocol is 80% complete
 - Substantial input from 25+ industry, academic, and government experts, including FDA clinical and stats
 - Statisticians include some of the best in the world for master protocol design: Lisa LaVange (UNC), Karen Price (Lilly), Michael Proschan (NIAID), Sandeep Menon (Pfizer)
 - All three companies have written their sections of the protocols, which are being merged into the master design
 - Working with OWS/BARDA on choice of CRO to run the trial;

(b) (5)

- "ACTIV-4" Protocol for anticoagulants
 - Need bullets from NHBLI on this. Should emphasize similar themes (robust choice of agents through ACTIV process, powered by NHLBI/NINDS "network of networks" with rapid contracting and startup practices, protocol being drafted in parallel (ACTIV WG review), inclusion of vital natural history disease/treatment data, cost and justification, etc.)
- Maybe a final slide summarizing the budget asks? Should it include preclinical or just the clinical stuff? And perhaps NIH (Ashley) should draft that one given the sensitivity around the numbers?

David Wholley Senior Vice-President, Research Partnerships Foundation for the National Institutes of Health

(b)(6)

fnih.org

11400 Rockville Pike Suite 600 North Bethesda, MD 20852

In 2019, the FNIH earned the highest rating from Charity Navigator for the fifth consecutive year and was recognized as an organization that exceeds industry standards.

	" 19. [1] [1] [1] [1] [1] [1] [1] [1] [1] [1]		EXCHANGELABS								
Sent:	5/27/2020 12	:00:04 AM									
To:	Eric Hughes [(b) (6) Rea	ad, Sarah (NIH/I n=Recipients/cr							
	Ruxandra Dra		(b) (6)				u=Exchange A				
		7	n=Recipients/cr				(b) (6)	Colvis,			
			=ExchangeLabs				(-) (-)	1 × 7 × 7 × 1 × 1 × 1 × 1			
			pients/cn=4b7e				l; Young, John				
) (6)		DA/CDER) [/o=8				ive Group			
		, , ,	pients/cn=b4a1					10 7 10 10 10 10 10 10 10 10 10 10 10 10 10			
	ĺ	(b) (6)		n, Tim (OS/ASP							
	Administrative					2. 22	15.5	-Tim.Buchman];			
	Vincent, Mich		(b) (6)	Keith Gotte			(6)	Elliott Levy			
	(b) (6) Wung	, Peter /US [(b) (6)	Koro	· · ·	r (NIH/NINDS)	[E]			
	[/o=Exchange	Labs/ou=Exchai	nge Administrat								
	(FYDIBOHF23SPDLT)/cn=Recipients/cn=e8338dd7cdcd432e986961f1548c5ec6-koroshetzw]; Higgs, Elizabeth										
	(NIH/NIAID) [E	E] [/o=Exchange	Labs/ou=Excha	nge Administra	tive Group						
	(FYDIBOHF23	SPDLT)/cn=Reci	pients/cn=0601	ca55a82841aba	16353b96cff	8ca9-ehiggs	; Carlos O Gari	ner			
	(b)) (6)	Goff, David (NII	H/NHLBI) [E] [/d	=ExchangeLa	bs/ou=Excha	ange Administr	ative Group			
	(FYDIBOHF23	SPDLT)/cn=Reci	pients/cn=0361	13c7be0f42f89	7d1294cfbb9	9c10-goffdc]					
CC:	Elizabeth Kim	(b) (6)	Menets	ki, Joseph (FNII	H) [T] [/o=Exc	nangeLabs/c	u=Exchange A	dministrative			
	Group (FYDIB	OHF23SPDLT)/c	n=Recipients/cr	=5001af52dc4	a427ea3d34f	Le072f8cb7-	menetskijp]; A	lvarez, Rosa			
	Maria [(b) (6)	Salathin, C	arla [(b) (6)		(b) (6)	(b) (6)			
	Parker, Ashley	(NIH/OD) [E] [o=ExchangeLab	s/ou=Exchange	Administrati	ve Group					
	(FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras]; Wholley, David (FNIH) [T]										
	[/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]; Melencio, Cheryl (FNIH)										
					3d0b6996d67	7257-wholle	eyd]; Melencio	, Cheryl (FNIH)			
		•	change Adminis								
	(FYDIBOHF23	SPDLT)/cn=Reci	pients/cn=279e				370				
		(b) (6)	Wa	ker, Paula (NIH	/NINDS) [E] [/	o=Exchange	Labs/ou=Exch	ange			
	7										
		이 [일반에게 하라면 되었는 걸게 살기었다.	OHF23SPDLT)/c	이 그 사이 전에 가게 된 것이 되었다면 하나 하다.			d03bcfd32930	-walkerp1];			
	Ward, Jackie (NIH/NINDS) [E]	[/o=ExchangeL	abs/ou=Exchan	ge Administra	tive Group					
	Ward, Jackie ((FYDIBOHF23	NIH/NINDS) [E] SPDLT)/cn=Reci	[/o=ExchangeL pients/cn=4114	abs/ou=Exchan c7d13389454f8	ge Administra 9fe3411cb3a	tive Group					
	Ward, Jackie ((FYDIBOHF23: [(b	NIH/NINDS) [E] SPDLT)/cn=Reci () (6)	[/o=ExchangeL	abs/ou=Exchan c7d13389454f8 . [(b) (ge Administra 9fe3411cb3a (6)	itive Group 834f-wardja					

Dear ACTIV Agent Prioritization Subgroup,

It has become apparent that our mAb Prioritizaiton Subteam will need to have a second meeting this week.

Since we are still working on getting back the data requested for this larger team, I was hoping this group would allow us to cancel this larger meeting and use the time to have just a meeting of our mAb Prioritizaiton Subteam.

This group will get an overall update on the progress of the TX-Clinical WG at our large WG meeting with both the Agent Prioritization and Master Protocol teams, and we will work to get individual meetings for the other Agent Prioritization Subteams on the books for next week if the data has been fully assembled.

Please let me know if you have any opposition to canceling the meeting to allow for the smaller group meeting. If a majority would prefer to keep the meeting, we will find another time for the small group.

Thanks, Stacey

Stacey J. Adam, PhD Director, Cancer

Research Partnerships

Direct: (b) (6) | Mobile: (b) (6)

Stacey Adam is inviting you to a scheduled Zoom meeting.

Join Zoom Meeting

https://fnih.zoom.us/ (b) (6)

Meeting ID: (b) (6)

Password: (b) (6)
One tap mobile

(b) (6) US (Chicago) US (New York)

Dial by your location

(b) (6) US (Chicago)
US (New York)
(b) (6) US (Germantown)
US (San Jose)
(b) (6) US (Tacoma)
(b) (6) US (Houston)

Meeting ID: (b) (6)

Password: (b) (6)

Find your local number: https://fnih.zoom.us/ (b) (6)

US (San Jose)

From: Adam, Stacey (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=DCD875F0679648859E1CF101C0943414-ADAMSJ4] Sent: 6/6/2020 5:00:32 PM To: Menetski, Joseph (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5001af52dc4a427ea3d34f1e072f8cb7-menetskijp]; Collins, Francis (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=410e1ca313f44ced9938e50d2ff0b6c2-collinsf]; Wholley, David (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]; Melencio, Cheryl (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=279e14fa7428415bb86087d08b628e6f-melencioc]; Wood, Gretchen (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=549f390b39d044a8b5d1e0e1a8f76c1f-woodgs] Subject: RE: Experts for ACTIV discussion on choosing neutralizing antibodies and mixtures Attachments: iTPP COVID-19 mAb PREP PEP Exec Summ.docx; iTPP COVID-19 mAb Treatment Exec Summ.docx Flag: Follow up Hi Joe and Francis, Did not receive anything ahead of time. This was planned on such short notice. We did not have time to get something from her, but I can give both these mAb criteria that they shared with our WG. Thanks, Stacey Stacey J. Adam, PhD Director, Cancer Research Partnerships Direct: (b) (6) | Mobile: (b)(6)From: Menetski, Joseph (FNIH) [T] < (b)(6)Sent: Saturday, June 6, 2020 12:55 PM To: Collins, Francis (NIH/OD) [E] < (b) (6) Wholley, David (FNIH) [T] < (b)(6)Adam, Stacey (FNIH) [T] < Melencio, Cheryl (FNIH) [T] < Wood, Gretchen (NIH/OD) [E] (b) (6) (b)(6)< (b) (6) Cc: Adam, Stacey (FNIH) [T] < (b)(6)Subject: RE: Experts for ACTIV discussion on choosing neutralizing antibodies and mixtures Not that I can see. Did anyone else get any, David? Joe From: Collins, Francis (NIH/OD) [E] (b)(6)Sent: Saturday, June 6, 2020 12:53 PM To: Menetski, Joseph (FNIH) [T] ; Wholley, David (FNIH) [T] < (b)(6)Adam, Stacey (b)(6): Melencio, Cheryl (FNIH) [T] (FNIH) [T] >; Wood, Gretchen (NIH/OD) [E] (b) (6) (b) (6) (b)(6)Cc: Adam, Stacey (FNIH) [T] (b) (6) Subject: RE: Experts for ACTIV discussion on choosing neutralizing antibodies and mixtures

OK. Did we get any read-ahead ma	aterial from .	Jacqueline?			
From: Menetski, Joseph (FNIH) [T] (b) Sent: Saturday, June 6, 2020 12:53 PM					
To: Collins, Francis (NIH/OD) [E]	(b) (6)	>; Wholley, [avid (FNIH) [T]	< (b) (6)	Adam, Stacey
(FNIH) [T] < (b) (6) >; Melend	cio, Cheryl (FN	IIH) [T]	(b) (6)	Wood, Gretch	en (NIH/OD) [E]
< (b) (6)					
Cc: Adam, Stacey (FNIH) [T] (b)					
Subject: RE: Experts for ACTIV discuss	ion on choosi	ng neutralizing	antibodies and	mixtures	
Dear Francis,					
The meeting has these invites.					
Wholley, David (FNIH) [T] Adam, Stacey (FNIH) [T]					
Menetski, Joseph (FNIH) [T]					
Jacqueline Kirchner					
Woodcock, Janet (FDA/CDER)					
Collins, Francis (NIH/OD) [E]					
joe					
From: Collins, Francis (NIH/OD) [E] Sent: Saturday, June 6, 2020 12:50 PM	(b) (6)				
To: Wholley, David (FNIH) [T] (b) (6) >	; Menetski, Jos	eph (FNIH) [T]	(b) (6)	>; Adam, Stacey
(FNIH) [T] (b) (6) >; Melend	cio, Cheryl (FN	IIH) [T]	(b) (6)	Wood, Gretch	en (NIH/OD) [E]
< (b) (6)					
Cc: Menetski, Joseph (FNIH) [T]	(b) (6)		ey (FNIH) [T]	(b) (6)	
Subject: RE: Experts for ACTIV discuss	ion on choosi	ng neutralizing	antibodies and	mixtures	
Sincere apologies, I just saw this me in?	essage. I do	n't know who	has been invi	ted to join this	s call, can someone fill
From: Wholley, David (FNIH) [T]	(b) (6)				
Sent: Saturday, June 6, 2020 7:21 AM		6 II: F	: /81111/05/1	(F) (A)	(0) A.I. (1)
To: Menetski, Joseph (FNIH) [T]	(b) (6)		ncis (NIH/OD) [
	cio, Cheryl (FN	IIH)[I]<	(b) (6)	Wood, Gretch	en (NIH/OD) [E]
(b) (6)	(1) (6)	A dam Cha	(ENUL) (E1	(1) (c)	i.
Cc: Menetski, Joseph (FNIH) [T] < im	(b) (6)	200 CO.	ey (FNIH) [T]	(b) (6)	>
Subject: Re: Experts for ACTIV discuss	ion on choosi	ng neutralizing	antibodies and	mixtures	
I noticed a label on today's call "data	shared in con	fidence". Does	this give us pau	ise in terms of i	nviting additional
experts?					
Get <u>Outlook for iOS</u>					
From: Menetski, Joseph (FNIH) [T] <	(b) (6)				
Sent: Friday, June 5, 2020 6:43:53 PM					
To: Collins, Francis (NIH/OD) [E]	(b) (6)				
	b) (6)	Menetski, Jos	eph (FNIH) [T] <	(b) (6)	Adam, Stacey

Subject: Experts for ACTIV discussion on choosing neutralizing antibodies and mixtures

(FNIH) [T] < sadam@fnih.org>

COLL0000017549-2516985

Dear Francis,

Stacey and I have polled our working groups, asking for suggestions and volunteers that could provide expert opinion on monoclonal antibody testing during conversations with Skip Virgin and Jacqueline Kirchner. The groups are very enthusiastic about this topic and we received almost 30 names of experts in the field. Given the time frame that we are asking for people to join these calls, I have picked 4 people that are already involved in ACTIV to invite to the Jacqueline Kirchner call tomorrow and 6 to invite to the call with Skip on Monday.

As I said, there were many more, but I think we would want to talk to them first, before bringing them into a discussion like this.

I am happy to invite these folks tonight, if it would be easier and agreeable to you (I would cc you). Or I have drafted a short email for you to send them below (as always, feel free to modify).

Best regards,

Joe

Memo: ACTIV discussion on choosing neutralizing antibodies and mixtures

Dear xx,

The NIH Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership is setting up protocols to assess monoclonal neutralizing antibodies as therapies against COVID-19. During discussions with the ACTIV Leadership Team and in collaboration with the upcoming Monoclonal Antibody Round Table, we have a meeting to gather additional expert opinion on the appropriate preclinical testing approaches, particularly for choosing mixtures or cocktails of neutralizing Abs. I would like to have your input in the important topic during a meeting [tomorrow at 1pm ET; or Monday at 2:45pm ET]. I realize this is short notice, but the ACTIV program is moving very fast and our rapid response is essential. I hope you can join me in this important discussion.

Sincerely, Francis Collins

Names and emails below.

Saturday call with J Kirchner: Peter Adams, (OS/ASPR/BARDA); (b)(6)Michael Diamond at Washington University at St Louis; (b)(6)Kara Carter at EvoTec; (b)(6)John W Mellors at University of Pittsburgh; (b) (6) Monday call with Skip Virgin: Peter Adams, (OS/ASPR/BARDA); (b)(6)Michael Diamond at Washington University at St Louis; (b) (6) Kara Carter at EvoTec; (b) (6) John W Mellors at University of Pittsburgh; (b)(6)Randall Tressler, (NIH/NIAID); (b) (6) Sebastian Breuer, Roche; (b) (6)

Joseph P. Menetski Ph.D.

Associate Vice President, Research Partnerships Foundation for the National Institutes of Health

Donate to the FNIH's Pandemic Response Fund to combat COVID-19: fnih.org/pandemic



From: (b) (6) Sent: 10/10/2020 6:30:56 PM

To: Santos, Michael (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=ab38cb6836de44e18ef4cc6952f65f80-santosmr]

CC: Lane, Cliff (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=2d7e368a3137473bbce161547a82f2de-clane]; Wholley, David (FNIH) [T]

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]; Freire, Maria (FNIH) [T]

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=8598d551d1d3455eaf14854c83f41d84-freiremc]

Subject: Re: Roster of ACTIV Vaccines WG

Can you do me a favor and just pull out the names and institutions of the people who are not on the Vaccines WG?

Sent from my iPhone

On Oct 10, 2020, at 2:21 PM, Santos, Michael (FNIH) [T] < (b) (6) wrote:

Hi Francis,

We don't maintain as nice of a version of the Sub-Group rosters, but here is the Clinical Trials Sub-Group list of names and organizations (some of which overlap with the main WG). We also commonly have additional guests depending on the topic, so if there's an organization or expertise that you're looking for that is not represented, we can invite them to a meeting ad hoc.

Thanks, Mike

Name	Organization
Paula Annunziato (co-chair)	Merck
Larry Corey (co-chair)	Fred Hutch
Ann Arvin	Stanford
Beth Bell	UW
Marco Cavaleri	EMA
Myron Cohen	UNC
Elizabeth Desrosiers	Merck
Macaya Douoguih	181
Peter Dull	Gates
Emilio Emini	Gates
Emily Erbelding	NIAID/NIH
Gregory M. Glenn	Novavax
Peter Gilbert	SCHARP/UW
Paul Gillard	GSK
Bill Gruber	Pfizer
Marion Gruber	CBER/FDA
Sanjay Gurunathan	Sanofi

Holli Hamilton	BARDA
Ian Hirsch	AZ
Peter Hotez	Baylor and Texas Children's
Laurent Humeau	Inovio
Kathrin Jansen	Pfizer
Cheryl Keech	Novavax
Kenneth Koury	Pfizer
Michael Kurilla	NCATS/NIH
Julie Ledgerwood	NIAID/NIH
Maarten Leyssen	1&1
Doug Lowy	NCI/NIH
Peter Marks	CBER/FDA
Mary Marovich	NIAID/NIH
Hilary Marston	NIAID/NIH
Stacey Martin	CDC
John Mascola	VRC/NIH
Nelson Michael	WRAIR
Jacqueline Miller	Moderna
Kayvon Modjarrad	WRAIR
Kathleen Neuzil	Maryland
Paul Offit	Penn/CHOP
Ashley Parker	NIH
Merlin Robb	Henry Jackson Foundation
François Roman	GSK
Jerald Sadoff	J&J
Stephanie Schrag	CDC
Sheri Schully	NIH
Sandra Sitar	VRC/NIH
Saranya Sridhar	Sanofi
Jennifer Verani	CDC
Michael Watson	Moderna
Tal Zaks	Moderna

Michael Santos, PhD

Associate Vice President, Science | Foundation for the National Institutes of Health

From: Collins, Francis (NIH/OD) [E] < (b) (6)

Sent: Saturday, October 10, 2020 12:47 PM **To:** Santos, Michael (FNIH) [T] < (b) (6)

Cc: Lane, Cliff (NIH/NIAID) [E] < (b) (6) Wholley, David (FNIH) [T] < (b) (6)

Freire, Maria (FNIH) [T] (b) (6) **Subject:** RE: Roster of ACTIV Vaccines WG

Thanks, this is helpful. Have you got a roster of the Clinical Trials Sub-Group?

From: Santos, Michael (FNIH) [T] < (b) (6)

Sent: Saturday, October 10, 2020 11:47 AM

To: Collins, Francis (NIH/OD) [E] (b) (6)

Cc: Lane, Cliff (NIH/NIAID) [E] (b) (6) >; Wholley, David (FNIH) [T] (b) (6) ;

Freire, Maria (FNIH) [T] (b) (6)

Subject: RE: Roster of ACTIV Vaccines WG

Hi Francis,

Sure, I'd be happy to convene a meeting of the WG.

The WG membership is attached. We also have a wider group of people that have been part of the subgroups, so depending on the topic and the ask we could invite them as well (e.g., for a clinical trials question we could convene the WG plus the Clinical Trials Sub-Group).

For next steps, if we can know a little more about the topic and the desired timing, I'm happy to connect with Kathrin and Doug and schedule a meeting with the appropriate set of people.

Best regards, Mike

Michael Santos, PhD

Associate Vice President, Science | Foundation for the National Institutes of Health

From: Collins, Francis (NIH/OD) [E] < collinsf@od.nih.gov>

Sent: Saturday, October 10, 2020 11:33 AM

To: Santos, Michael (FNIH) [T] < (b) (6)

Cc: Lane, Cliff (NIH/NIAID) [E] < (b) (6) Wholley, David (FNIH) [T] < dwhol (b) (6)

Freire, Maria (FNIH) [T] < (b) (6) **Subject:** Roster of ACTIV Vaccines WG

Hi Mike,

We might need to reconvene the ACTIV Vaccines WG for some advice about management of next steps for the trials. Can you send me the roster?

Francis

From: Wholley, David (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP

(FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=CD9E702FCF28414883D0B6996D677257-WHOLLEYD]

Sent: 10/18/2020 10:54:09 PM

To: Collins, Francis (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=410e1ca313f44ced9938e50d2ff0b6c2-collinsf]; Freire, Maria (FNIH) [T]

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=8598d551d1d3455eaf14854c83f41d84-freiremc]; Tabak, Lawrence (NIH/OD)

[E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=02e22836b5ff4e9988e3770cfc7ee770-tabakl]; Lane, Cliff (NIH/NIAID) [E]

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=2d7e368a3137473bbce161547a82f2de-clane]; Austin, Christopher

(NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=17597cabc42247548e596778304f781f-austinc]; Parker, Ashley (NIH/OD) [E]

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras]; Anderson, James (NIH/OD)

[E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=73143d1860bc42458be254ca21573b23-andersonjm]

Subject: RE: Need advice about presentation at a NASEM meeting

Flag: Follow up

Hi Francis:

Lisa LaVange is currently with UNC, but formerly a statistician with FDA, has done lots of work in cancer supporting Rick Pazdur and Janet Woodcock including on LungMAP—Ellen Sigal is a big fan by the way. From an ACTIV perspective Lisa has been an integral member of the overall Tx-Clinical Working Group, of the Master Protocol subgroup, and of the MP Statistics subgroup as these various entities have been assembled since April. Lisa has been absolutely integral to informing the statistical design of the ACTIV-1,-2, and -3 protocols, and has reviewed the other two protocols, in collaboration with Mike Proschan of NIAID, Sylvia Collins of FDA, and others. I have heard her on many calls I have attended, and in my experience Lisa navigates among the frequentist and Bayesian approaches nimbly and without taking a dogmatic approach. She is articulate and always pleasant and collegial to deal with.

If that sounds like a five-star review, I guess it is.

I defer to Cliff and others on the comparison to RECOVERY, but have asked Stacey Adam for a few bullets.

I leave the question regarding the antiviral summit to Jim and others.

Thanks, David

From: Collins, Francis (NIH/OD) [E] < (b)(6)Sent: Sunday, October 18, 2020 4:57 PM To: Wholley, David (FNIH) [T] < (b) (6) Freire, Maria (FNIH) [T] < (b) (6) Tabak, Lawrence Lane, Cliff (NIH/NIAID) [E] < (NIH/OD)[E] <(b)(6)Austin, Christopher (b) (6) Parker, Ashley (NIH/OD) [E] < (NIH/NCATS) [E] < (b)(6)(b)(6)Anderson, James

(NIH/OD)[E] < (b)(6)

Subject: Need advice about presentation at a NASEM meeting

Hi there War Roomies,

As you can see from the attached, the NASEM Forum on Drug Discovery, Development, and Translation is putting on a two day virtual meeting. Part of the first day is to hear about ACTIV, and compare and contrast that with RECOVERY. I could use your advice about what to include in my 15 minutes. Your assessment of the pros and cons of the RECOVERY trial design and implementation would be welcome. And can you remind me what role Lisa LaVange has played in ACTIV?

Vould this be a good opportunity to highlight the coming workshop on antivirals? Or would that be premature?	
rancis	

From: Wholley, David (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP

(FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=CD9E702FCF28414883D0B6996D677257-WHOLLEYD]

Sent: 1/28/2021 2:22:27 PM

To: Collins, Francis (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=410e1ca313f44ced9938e50d2ff0b6c2-collinsf]

CC: Freire, Maria (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=8598d551d1d3455eaf14854c83f41d84-freiremc]; Menetski, Joseph (FNIH)

[T] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=5001af52dc4a427ea3d34f1e072f8cb7-menetskijp]; Tabak, Lawrence

(NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=02e22836b5ff4e9988e3770cfc7ee770-tabakl]

Subject: FW: ACTIV - Emerging Viral Sequence Data Surveillance, Testing and Reporting

Flag: Follow up

Hi Francis, not sure where things stand with the effort to nail down PROTECT, but in the event it does not work out please see the additional suggestion forwarded to Joe Menetski by Felicia Qasha. Felicia is actually the Contract Officer on our OTA agreement for ACTIV, but she also attends some of the meetings. Thanks, David

From: Qashu, Felicia (NIH/OD) [E]

(b) (6)

Sent: Wednesday, January 27, 2021 4:15 PM

To: Connelly, Sarah < Menetski, Joseph (FNIH) [T] (b) (6) (b) (6)

Subject: RE: ACTIV - Emerging Viral Sequence Data Surveillance, Testing and Reporting

A candidate name to consider for the emerging variant effort:

ACTIV Data to Determine Variant Impact on COVID19 treatment and vaccine Efficacy

ADDVICE

From: Connel	lly, Sarah	(b) (6)	ļ.							
Sent: Wedne	sday, Januar	y 27, 2021 1:40	PM							
To: Baric, Ral	ph <	(b) (6)	(b) (6)	(b)	(6)	Hewitt,	Judith (NII	H/NIAID) [I	Ξ]
(b) (6	5) >;	Eakin, Ann (NIH	/NIAID) [E]	(b) (6)	>; Flore	nce, Cl	int (NIH/NI	AID) [E]	
(b)	(6)	Erlandson, Karl	(OS/ASPR/	BARDA)	(b)	(6)	>	; Colvis, Ch	ristine (NI	H/NCATS)
[E] ((b) (6)	>; Graham, B	arney (NIH,	/VRC) [E]	(b) (6)		; Stenzel,	Timothy (F	DA/CDRH)
	(b) (6)	Anderso	n, James (N	NIH/OD) [E]		(b) (d	5)	Jerr	nigan, Dan	iel B.
CDC/DDID/N	ICIRD/ID) <	(b) (6)	Wentwort	h, David E.	(CDC/DD	ID/NCIR	D/ID) <	(gl) (b) (6) : Bentl	ey, Lisa
Marie (OS/AS	SPR/SIIM)	(b) (6)		: Sullivan, N	Nancy (N	IH/VRC)	[E]	(b) (6)	; F	lall,
Matthew (NII	H/NCATS) [E]	(b) (6)	; S	herry, Steve	(NIH/NL	M/NCB	I) [E]	(b)	(6)	>; Pruit
Kim (NIH/NLN	M/NCBI) [E]	(b) (6))		(b)	(6)			(b) (6)	
(b) (6)	jay	(b) (6)	(b) (6)		(b) (6)	;	
	(b) (6)			(b) (6)		H	awk, H	arrison	(b) (6)	>;
Menetski, Jos	seph (FNIH) [(b) (6) : N	Λ acCannell,	Duncan	(CDC/DI	DID/NC	EZID/OD) <	(b) ((6)
NIH		(b) (6)		្រ; St	apleton,	Jack		(b) (6)	1	Phillips, L
Revell CIV DT	RA RD (USA)	(b) (6	j)	Qashu, Feli	cia (NIH/	OD) [E]	<	(b) (6)	: Na	ancy
Haigwood	(b) (6)	Dorm	tzer, Philip	Ralph <		(b) (6)		Janser	n, Kathrin	
			(b) (6)						Loo, Yueh-	Ming
	(b) (6)	Abra	ım, Michae		(b) (6	5)		>; Streich	er, Katie	
			(b) (6)) (6)			(b)	(6)		
(b) (6)) Loi	rraine Horgan <	((b) (6)	1>;	Li Yan			(Qing Zh	nu
		(b) (6)				And	drew C	harles Adaı	ms	
(b) ((6)	b) (6) Esse	er, Mark		(b) (6)		Dav	vid Margoli	S	
			(b) (6							nan, Richard
(NIH/NCATS)	[E]	(b) (6)	>; Wan, I	Kanny (NIH/	NCATS) [[C]	(b)	(6)	; Brimacor	mbe, Kyle

(NIH/NC	ATS) [E]	(b) (6)	; Bryant, Paula (NIH,	/NIAID) [E] <	(b) (6)
Cc:		(b)	(6)		antoinette_baric
	(b) (6)	>; Michelon	i, Gianni <	(b) (6)	Soren, Daniel (NIH/NLM/NCBI)
[C]	(b) (6)				
Subject:		ging Viral Sequence	Data Surveillance, To	esting and Reporting	
Dear Sub	group Members,				
Thombus	all far attanding	· ····· Francis a Visa	I Camuanaa subanaun	maating on Tuesda	Diagrams and attached for the
	and the same and t		you all have any add		y. Please see attached for the ts.
Best Reg	ards,				
Sarah					
Sarah Co	nnelly, PhD				
Deloitte C Tel/Direct	onsultina. LLP (b) (6)				
www.delo					
Origi	nal Appointment-				
(-1)	onnelly, Sarah				
	5.0	per 23, 2020 11:12	AM		
		b) (6)			
			(b) (6)		
	(b) (6)	Hawk Ha	rrison; Menetski, Jos	enh (FNIH) [T]: MacC	Cannell Duncan
(CDC/DD	ID/NCEZID/OD); F			이 10 전에 11일 이번 이번 경기를 가장하고 하네 이번 경기 때문	vell CIV DTRA RD (USA); Qashu,
	55%		tzer, Philip Ralph; Jar	33 67 50 19	(b) (6)
rol	(b) (6)		ling; Abram, Michael		(b) (6)
,	(b) ((6)	Lorraine Horg	an; Li Yan; Qing Zhu;	
(b) ((6) ; Andrew (Charles Adams; Ess	er, Mark; David Marg	golis;	(b) (6)
	(b) (6)		rd (NIH/NCATS) [E]; \	Wan, Kanny (NIH/NC	ATS) [C]; Brimacombe, Kyle
(NIH/NC	ATS) [E]; (1	b) (6)			
(:-1 / 5 11 1 / 5 11 5 4 / 51	CDI/ [C]			; Baric, Toni C; Micheloni, Gianni;
	aniel (NIH/NLM/N	4.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1	ta Surveillance, Testir	ng and Reporting	
			0:00 AM (UTC-05:00)		Canada)
	nttps://deloitte.zo		(b) (6)	Lustern mile (es a	carrada).
) (140 - 150 - 1 50 - 150 - 1			(-) (-)		•
Extendin	g these meetings	into the new year.			
Jo	in Meetin	g			
***************************************	sword:	olegida.	(b) (6)		
Pho	ne one-tap:				

Join by Telephone)			
Dial:				
		(b) (6)) (6	(b) (6)	(b) (6)
Meeting ID:				
Password:				
International numbers				

Zoom technology includes options for recording a meeting. If a meeting is being recorded, an audio and/or visual warning will be provided when you join a recorded meeting. A warning will also be provided if recording commences after you have joined the meeting. If you continue to participate in the meeting following these warnings, your participation will serve as your express consent to such recording.

This message (including any attachments) contains confidential information intended for a specific individual and purpose, and is protected by law. If you are not the intended recipient, you should delete this message and any disclosure, copying, or distribution of this message, or the taking of any action based on it, by you is strictly prohibited.

Deloitte refers to a Deloitte member firm, one of its related entities, or Deloitte Touche Tohmatsu Limited ("DTTL"). Each Deloitte member firm is a separate legal entity and a member of DTTL. DTTL does not provide services to clients. Please see www.deloitte.com/about to learn more.

v.E.1

From: Melencio, Cheryl (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=279E14FA7428415BB86087D08B628E6F-MELENCIOC] Sent: 7/15/2020 5:38:22 PM To: Collins, Francis (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=410e1ca313f44ced9938e50d2ff0b6c2-collinsf]; Wood, Gretchen (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=549f390b39d044a8b5d1e0e1a8f76c1f-woodgs] Subject: FW: ACTIV Vaccines Working Group meeting Location: Webex: https://nih.webex.com/ (b)(6)Start: 7/29/2020 2:00:00 PM End: 7/29/2020 3:00:00 PM Show Time As: Tentative ----Original Appointment----From: Santos, Michael (FNIH) [T] < (b) (6) Sent: Tuesday, June 30, 2020 3:18 PM To: Santos, Michael (FNIH) [T]; Lowy, Douglas (NIH/NCI) [E]; Arvin, Ann; Beth Bell (b)(6)(b)(6)(b)(6)Cavaleri Marco; (b) (6) (b) (6) Greg Glenn; Haynes, Barton; (b)(6)(b)(6)(b) (6) (b) (6) Marks, Peter (FDA/CBER); Mascola, John (NIH/VRC) [E]; Messonnier, Nancy (CDC/DDID/NCIRD/OD); Nelson Michael; Offit, Paul; Seals, Jonathan (OS/ASPR/BARDA); (b)(6)Tal Zaks: (b) (6) (b) (6) (b)(6)Cc: Tolman, Brett; Hopps, Markay; Kozlowski, Mary (NIH/NCI) [C]; Johnson, Maureen (b) (6) (NIH/NCI) [E]; Jeneffer Haynes; (b)(6)(b) (6) (b)(6)Austin, Sarah (NIH/NIAID) [E]; Isabel Ramsey; Parker, Ashley (b)(6)(NIH/OD) [E]; Marston, Hilary (NIH/NIAID) [E]; Qashu, Felicia (NIH/OD) [E]; Culp, Michelle (NIH/OD) [E]; Gadbois, Ellen (NIH/OD) [E]; Wholley, David (FNIH) [T]; Melencio, Cheryl (FNIH) [T]; Menetski, Joseph (FNIH) [T]; Adam, Stacey (FNIH) [T]; Tountas, Karen (FNIH) [T]; James, Stephanie (FNIH) [T]; Colvis, Christine (NIH/NCATS) [E]; Desrosiers, Betsy; Hughes, Eric; Kurilla, Michael (NIH/NCATS) [E]; Read, Sarah (NIH/NIAID) [E]; Paul Gillard; Hamilton, Holli (OS/ASPR/BARDA); Modjarrad, Kayvon CIV USARMY MEDCOM WRAIR (USA); Kathleen Neuzil; Schrag, Stephanie (CDC/DDID/NCIRD/DBD); Verani, Jennifer R. (CDC/DDID/NCIRD/DBD); Thornburg, Natalie (CDC/DDID/NCIRD/DVD); Gonzalez, Nina; 'Wachtel, Jonathan'; Stratton, Benjamin; Anderson, Margaret; (b) (6) (b)(6)Bethany Stokes; Kathleen Callahan; Arvin, Ann; Young, John Subject: ACTIV Vaccines Working Group meeting When: Wednesday, July 29, 2020 10:00 AM-11:00 AM (UTC-05:00) Eastern Time (US & Canada). Where: Webex: https://nih.webex. (b) (6) -- Do not delete or change any of the following text. --Join Webex meeting Meeting number (access code): (b) (6) Meeting password: (b)(6)Join from a video system or application Dial (b)(6)@nih.webex.com You can also dial (b) (6) and enter your meeting number.

ap to join from	n a mobile devi	ce (attendees only)
(b) (6)		Call-in toll number (US/Canada)
loin by phone		
(b) (6)	Call-in toll	number (US/Canada)
Richal call-in	numbers	

Join using Microsoft Lync or Microsoft Skype for Business

Dial (b) (6) @lync.webex.com

Can't join the meeting?

If you are a host, click here to view host information. IMPORTANT NOTICE Please note that this Weber service allows audio and other information sent during the session to be recorded, which may be discoverable in a legal matter. By joining this session, you automatically consent to such recordings. If you do not consent to being recorded, discuss your concerns with the host or do not join the session.

From: Wholley, David (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP

(FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=CD9E702FCF28414883D0B6996D677257-WHOLLEYD]

Sent: 3/21/2021 3:54:35 PM

To: Tabak, Lawrence (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=02e22836b5ff4e9988e3770cfc7ee770-tabakl]

CC: Melencio, Cheryl (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=279e14fa7428415bb86087d08b628e6f-melencioc]

Subject: RE: ACTIV Leadership Team Call #14

Flag: Follow up

Yes, sorry, I was aware but just missed this one.

From: Tabak, Lawrence (NIH/OD) [E] < (b) (6)

From: Wholley David (ENIH) [T] < (b) (6)

Sent: Sunday, March 21, 2021 11:53 AM

To: Wholley, David (FNIH) [T] < (b) (6)

Subject: Re: ACTIV Leadership Team Call #14

David;

Going forward, please swap Joni Rutter for Chris. Chris is recused from all ACTIV effort.

Thanks Larry

		rid (FNIH) [1] <	, , , ,			
Date: S	unday, Marc	h 21, 2021 at 11:51	AM			
To: Me	lencio, Cher	/l (FNIH) [T] <	(b) (6)	Austin, Christon	pher (NIH/NCAT	S) [E]
(b) ((6)	, Carter, Kara (Cava	aleri, Marco	
	(b) (6)	>, Cila	lar, Tomas <	(b) (6)	Collins,	Francis (NIH/OD) [E]
	(b) (6)	, Corey, Larry <	(b) (6)	Culp, Mic	chelle (NIH/OD)	[E]
	(b) (6)	, Victoria Dave	ey (b) (6)	, Dis	brow, Gary (OS,	/ASPR/BARDA)
	(b) (6)	Dolsten, Mi	kael <	(b) (6)	Erbelding, E	mily (NIH/NIAID) [E]
	(b) (6)	Erck, Stan	(b) (6)	Gadboi	s, Ellen (NIH/OD) [E]
<	(b) (6)	Gibbons, Gar	y (NIH/NHLBI) [I	E] < (b)	(6) Huc	dson, Thomas
	(b) (6)	James	, Stephanie (FN	$IH)\left[T\right] < \qquad (b$) (6) John	son, Robert
(OS/AS	PR/BARDA) ·	(b) (6)	Krame	r, Lynn	(b) (6)	Lane, Cliff
(NIH/N	IAID) [E] <	(b) (6)	Mascola, John	(NIH/VRC) [E] <	(b) (6)	Meeker, David
	(b) (6)	>, Menetski,				onnier, Nancy
(CDC/D	DID/NCIRD/	OD) < (b) (6)	Pandya, Hit	tesh	(b) (6)	Pao, William
(b)(6))(iley (NIH/OD) [E) Per	lmutter, Roger
	(b) (6)	>, Pleng	ge, Robert	(b) (6)	>, Plump, And	dy
	(b) (6)	, Reese,	David <	(b) (6)	Rouse, Doris <	(b) (6) Santos,
Michae	(FNIH) [T]		Skovronsky, D		(b) (6)	
(FDA/C	DER)	(b) (6)	>, Stoffels, Paul	(b) (6)	. Tabak,	Lawrence (NIH/OD) [E]
	(b) (6)	6) Talley, Mic	chae	(b) (6)	>, Tsai, John	
<	(b) (6)	Vessey, Rup	pert < (l	o) (6) V	irgin, Skip <	(b) (6) Woodcock,
Janet (f	DA/OC)	(b) (6)	>, Youn	ig, John	(b) (6)	Anderson, James
(NIH/O	D) [E]	(b) (6)	Burklow, Jo	hn (NIH/OD) [E]	(b) (6)	, Carluccio,
Dana <		(b) (6)	>, Castillej	os, Carlos	(b) (6)	FNIH Central Account
	(b) (6)	, Hallett, A	Adrienne (NIH/C	D) [E] <		Lumsden, Joanne
(NIH/N	CATS) [C]	(b) (6)	Myles, R	enate (NIH/OD)	[E] (b) (6)	Wolinetz,

Carrie (NI	H/OD) [E] <	(b) (6	j)	Colvis, Cl	nristine (N	IIH/NCAT	S) [E]	(b)	(6)	
Desrosier	s, Betsy	(b)	(6)	. E	ric Hughe	S	(b) (6	j)	Jan	sen,
Kathrin		b) (6)								
	NCI) <	(b) (6) Rea	ad, Sarah (N	IIH/NIAID) [E]	(b) (6)	Meltzer	Abbey	(FNIH)
	(b) (6)	Adam, Sta	cey (FNIH)	(T)	(b) (6)	. Mars	garet And	lerson		3
17 COM 2	(b) (6)	An	pell, Evan <		(b) (6)	Che	en. Helen			
((-) (-)		y, Sarah							
b	(b) (6)		, Harrison							
<	(b) (6)									>,
Stratton	Benjamin <		>	Tolman	Brett <(b)	(6)	, liex	> Wach	tel lor	
<	(b) (6)	Embry A	lan (NIH/N	ΙΔΙΩ) [F] <		(b) (6)	Ve	nkavva R	ieev	atriari
	(0) (0)		dan (ivii iy ivi							
	(b) (6)		, Fauci, An							
		Marks, P	eter (EDA/C	RERIZ	niyiviAloj A) (6) [-]	(U) (U) D-	ngalos M	ene	, 301111
`	(b) (6)	Iviai K5, F	Paul, Ste	DEN/	(b) (6))) (U) 	Pachel Ra	moni	CHC	
(b)	(0) (0)		hn		(0) (0)		lacifei Na	IIIOIII		
(b)	Sarah /NIIL	/ Need, 30 1/NIAID) [E] <			Parace	h Kimbo	rly/NIILI/N	MIVID/ [E]		
		Burru							Canva	Tron
									Carve	, rrea
		6) >, Ca							chlov	Davanna
		Conrac								Koxanne
(NIH/NHL			1 C						icole	
		Gio								
<		Hoffstette								
<	(b) (6)	Jer	ikins, Christ	ine S.	•	(b) (6)		>, Lagos, E	nrique	
(NIH/NCA	(15) [E]	(b) (6)	, Lev	er, Susan		(b) (6)	41.70	IVIag	gbie-Ro	binson,
	(OD) [C] <		(6)							/anna
(NIH/OD)			Mir							
	(b) (6)		ewicz, Ann <					obene, Kin	า	
		Riggin, Ma								
<	(b) (6)		Schuster, D							
[T]	(b) (6)		Dina (NIH/0					na, Tina (N		
		>, Thomas,				(b) (6)		Wood,		
(NIH/OD)		(b) (6)	, Hughes, K	2550			(b) (6)	, To	gashi,	Mieko
(NIH/NCI)	[E] <	(b) (6)	, L	Inderwoo	d, Nancy	<nancy< td=""><td></td><td>(b) (6)</td><td></td><td>Zottoli,</td></nancy<>		(b) (6)		Zottoli,
Jessica	(b)) (6)	Regan, Do	onna M <		(b) (6)		Vessey, R	upert	
	(b) (6)	Burke,	Leslie	(b)	(6)	Joh	n Lepore			
	(b) (6)	>, Lo	owy, Dougla	s (NIH/N	CI) [E]	(b) (6)	Grant, S	arah	
	(b) (6)	>, Pruitt	, Kim (NIH/	NLM/NCE	3I) [E] <	(b) (6)	Sher	ry, Ste	ve
(NIH/NLN	1/NCBI) [E]	(b) (6)	, Bell, Ju	lie (b) (6)				

Subject: RE: ACTIV Leadership Team Call #14

Dear ACTIV Leadership Team members and meeting attendees:

Please find attached the notes from our meeting this past Thursday, March 18, 2021. Please let me know if you have any questions or additional comments, and thank you for your participation in the call. Regards,

David

Adam, Stacey (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=DCD875F0679648859E1CF101C0943414-ADAMSJ4] 9/4/2020 12:10:16 AM Bozzette, Sam (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=85f05a3619cf47c7ae39d7bcf0aac88d-bozzettesaa]; Butterton, Joan [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=219ecac4faae4ebab8a45ce8ee2490c3-joan_butter]; De Claro, R. Angelo (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c495c3ee25ca461ba6a829b124062448-DECLAROR.fd]; Draghia-Akli, Ruxandra [(b) (6) Eisner, Mark [(b) (6) Gottesdiener, Keith (b)(6)Eric Hughes [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f97951a53cd54153b5daa9d99ad4ec90-EricHughes]; Judy Currier [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=890082c7c1e34902b0f535320cd16650-jscurrier.m]; Kim, Elizabeth LaVange, Lisa [(b) (6) Levy, Elliot [(b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user257cb364]; Parker, Ashley (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Menon, Sandeep [(b) (6) Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras]; Patel, Naimish [naimish. Peppercorn, Amanda [(b) (6) (b) (6) Proschan, Michael (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange (b) (6) Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=7b45059209b4468bb4ba02b0dfbbb3e4-proscham]; Read, Sarah (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=527b160038004a199ae6e0bac2226099-readsa]; Santos, Michael (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ab38cb6836de44e18ef4cc6952f65f80-santosmr]; Shen, Yuan Li (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ae30a02e983e4e8a979dfec7257a1802-shenyu.fda]; Stein, Peter (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b4a14118481b4b39ba7e62a8d6425f79-Peter.Stein]; Wholley, David (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]; Buchman, Tim (OS/ASPR/BARDA) (CTR) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=00f8a853d8d740f8a8cdd55cbf8eb9da-Tim.Buchman]; Collins, Sylva (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f6b8f588067140fe988f0832c2387725-Sylva.Colli]; Amanda Peppercorn : Higgs, Elizabeth (NIH/NIAID) [E] Garner, Carl [garner (b) (6) (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0601ca55a82841aba16353b96cff8ca9-ehiggs]; Koroshetz, Walter (NIH/NINDS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e8338dd7cdcd432e986961f1548c5ec6-koroshetzw]; Timothy Burgess [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=52e5e03dcbc847709eaab64457efa57e-TimothyBurg]; Reineck, Lora (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a62d88ba0c3b44e3bb922236c61304b3-reineckla]; Aggarwal, Neil (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d4c9de6615504ff9889f3b0c44a63526-aggarwalnr]; Rosenberg, Yves (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a5cb3e9a3a2747c38c42f68f5c8e40cf-rosenbey]; Goff, David (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=036113c7be0f42f897d1294cfbb99c10-goffdc]; Brown, Jeremy (NIH/NINDS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ce971eefec944a68a94addd3b24835f5-brownj7]; Gadbois, Ellen (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0243d1d6e6f248268d2edec566c26c2a-gadboisel]; Culp, Michelle (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4e38fa37e0424217aa0a283cba9e5098-mculp]; Jacqueline Kirchner Beigel, John (NIH) [E] [/o=ExchangeLabs/ou=Exchange Administrative (b) (6)

From:

Sent:

To:

	Group (FYDIBOHF2:	3SPDLT)/cn=Rec	ipients/cn=492	2ae062f7d74e	3cbd894e30160	869f0-jbeigel]; Ph	nillips, L Revell CIV	
	DTRA RD (USA) [(b) (6)	Petrovio	ck, Martha - 04	149 - MITLL [(b) (6)		
	(b) (6)	Sizemor	e, Christine (N	IH/FIC) [E] [/o	=ExchangeLabs/	ou=Exchange Adr	ministrative Group	
	(FYDIBOHF23SPDLT)/cn=Recipients	/cn=05494833	e0fc47a9acac	194cd338b201-c	sizemore]		
CC:	Colvis, Christine (NI	H/NCATS) [E] [/	o=ExchangeLab	os/ou=Exchan	ge Administrativ	e Group		
	(FYDIBOHF23SPDLT)/cn=Recipients	/cn=4b7e84cc	e098457896b	2df19fa172c87-c	colvis]; Desrosier	rs, Betsy	
	(b) (6)	Jansen, Kathi	rin [(b) (6)	Kurilla, Michae	el (NIH/NCATS) [E]	
	[/o=ExchangeLabs/		dministrative G	iroup				
	(FYDIBOHF23SPDLT				d3f426727861f-i	mkurilla]; Lowy, [Douglas (NCI)	
	[/o=ExchangeLabs/	ou=Exchange A	dministrative G	iroup				
	(FYDIBOHF23SPDLT	지어가는 보고 하는 이번 사람들이 보고 있는 사람들이 되고 있었다.			7c66b832baa0-c	Irl.helix.n]; Young	g, John	
	(b) (6)		s, Mary [(b) (6)	Butcher, Tir			
	Demarcus [(b) (6)	Macone, E			encio, Cheryl (FN	* /	
	[/o=ExchangeLabs/	` ' ' '					, , ,	
	(FYDIBOHF23SPDLT				087d08b628e6f-	melenciocl: Salat	hin, Carla	
	(b) (6)					Exchange Admin		
	\ / \ /						ski, Joseph (FNIH) [T	
	[/o=ExchangeLabs/					20. 20. 20. 20. 20. 20. 20. 20. 20. 20.		
					34f1e072f8cb7-m	nenetskiipl: Jame	s, Stephanie (FNIH)	
	[T] [/o=ExchangeLa					3,517	,	
	(FYDIBOHF23SPDLT				9577e2aa8d1-ia	messtl: Wachtel	. Jonathan	
	(b) (6)				ange Administrat			
	(FYDIBOHF23SPDLT				(T)		u=Exchange	
	Administrative Gro	550	20	170	3.00	277		
							ser3c2f486d]; Dana	
	Carluccio [(b) (6)		Rose Li Centra		(b) (6)	Anderson,	
	Margaret [(b) (6)		malldon [(b) (Stratton,	
	Benjamin [/o=Excha	` ' ' '		9.90 (1) 10 (1) (1) (1) (3) (3) (3) (4)		0)	Structory	
	(FYDIBOHF23SPDLT				(b) (6)	Mollica, Li	inda /US	
	(b) (6)					Exchange Admin		
	(FYDIBOHF23SPDLT							
	5.0	20				quantum, raccer	3011,71111,	
	(NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=afad1ca74b3e449d8b4f3191d65bb70f-pattersa]; Rubin, Daniel B. (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=35c2891059134111a3ed28f929042aad-RUBIND.fda]; Marston, Hilary (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group							
	(FYDIBOHF23SPDLT)/cn=Recipients/cn=ab30660917b942ffba9ae95d631116f3-marstonhd]; Chen, Helen Q.							
	[/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user34aa917e];							
	Wung, Peter /US [(b) (6) Hoots, W. Keith (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Ex							
	Administrative Gro					-		
	Groesch, Mary (NIF			100				
							, Allan (NIH/NHLBI)	
	[E] [/o=ExchangeLa	선택 보기를 잃었다 그리고 보이 전환 시간 사람이 없는 사람이 되었다.				8	,	
	(FYDIBOHF23SPDLT	nd har grant and all a franchist and a fine of the contract of		[1](***[1][4](****[1][4](***[1][4](***********************************	07bd0ce27715-	shippal: Kindzelsl	ki. Andrei	
	- ^					,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,	
	(NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=8bda5194bdca4d2594626f6313d2db5c-kindzelskia]; Hone, David M (Dave)							
	CIV DTRA J9 (USA) [5.			ODD JPEO CBRI		
	[ronald. (b)		· /	75		kchange Adminis	50	
	(FYDIBOHF23SPDLT	\ /	35		11.77			
	[/o=ExchangeLabs/	NO						
	Walker, Paula (NIH)			Managari Tak Managarata				
	(FYDIBOHF23SPDLT					The Property of the Control of the C		
Subject:	Slides from the ACT							
Attachments:	ACTIV_TX-Clinical_\					ORT overview fo	r ACTIV Clin Tx WG	

Dear ACTIV TX-Clinical WG Members,

090220 FINAL.pdf

As promised earlier today, please find attached the slides from our presentations today.

Thanks,

Stacey

Stacey J. Adam, PhD

Director, Cancer

Research Partnerships

Foundation for the National Institutes of Health

Direct:

(b) (6) Mobile:

(b) (6)

fnih.org

11400 Rockville Pike, Suite 600, North Bethesda, MD 20852









Donate to the FNIH's Pandemic Response Fund to combat COVID-19: fnih.org/pandemic



Wholley, David (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=CD9E702FCF28414883D0B6996D677257-WHOLLEYD] 1/17/2021 5:18:46 PM Melencio, Cheryl (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=279e14fa7428415bb86087d08b628e6f-melencioc]; Austin, Christopher (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=17597cabc42247548e596778304f781f-austinc]; Carter, Kara Cavaleri, Marco ; Cihlar, Tomas (b) (6) (b) (6) ; Collins, Francis (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (b) (6) (FYDIBOHF23SPDLT)/cn=Recipients/cn=410e1ca313f44ced9938e50d2ff0b6c2-collinsf]; Corey, Larry Culp, Michelle (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4e38fa37e0424217aa0a283cba9e5098-mculp]; Victoria Davey [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2c8291f38ec342f895243c0617e115ec-victoria.da]; Disbrow, Gary (OS/ASPR/BARDA) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=62a151e39ab942d88a813b449f9f6ccb-Gary.Disbro]; Dolsten, Mikael Erbelding, Emily (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e976ebf7b14142fbb3c5c294efb334fe-erbeldingej]; Erck, Stan Gadbois, Ellen (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0243d1d6e6f248268d2edec566c26c2a-gadboisel]; Gibbons, Gary (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b71b953b50a5495ca0f2869ab13bc407-gibbonsgh]; Hudson, Thomas James, Stephanie (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (b) (6) (FYDIBOHF23SPDLT)/cn=Recipients/cn=f0032ef62ca343dfb4bf79577e2aa8d1-jamesst]; Johnson, Robert (OS/ASPR/BARDA) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=feb0b05457404e2f8b88af78e9ac4dd9-Robert.John]; Kramer, Lynn Lane, Cliff (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (b) (6) (FYDIBOHF23SPDLT)/cn=Recipients/cn=2d7e368a3137473bbce161547a82f2de-clane]; Marks, Peter (FDA/CBER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b2e527dbda2b4a86b8d72f06b813d471-MarksP.fda]; Marston, Hilary (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ab30660917b942ffba9ae95d631116f3-marstonhd]; Mascola, John (NIH/VRC) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=7f78b40a596b4ca4a2850a429d1ae3f2-jmascola]; Meeker, David]; Menetski, Joseph (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5001af52dc4a427ea3d34f1e072f8cb7-menetskijp); Messonnier, Nancy (CDC/DDID/NCIRD/OD) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=441f65db836c4a89a42aecb9a0d9b96c-NAR5]; Pandya, Hitesh Pao, William [Parker, Ashley (NIH/OD) [E] (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras]; Perlmutter, Roger Plenge, Robert [Plump, Andy (b) (6) (b) (6) Rouse, Doris [(b)(6)Santos, Michael (FNIH) [T] (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ab38cb6836de44e18ef4cc6952f65f80-santosmr]; Skovronsky, Daniel Stein, Peter (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (b) (6) (FYDIBOHF23SPDLT)/cn=Recipients/cn=b4a14118481b4b39ba7e62a8d6425f79-Peter.Stein]; Tabak, Lawrence (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=02e22836b5ff4e9988e3770cfc7ee770-tabakl]; Talley, Michael Tsai, John [Vessey, Rupert [Virgin, (b) (6) (b) (6) Woodcock, Janet (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group Skip [(FYDIBOHF23SPDLT)/cn=Recipients/cn=9bc3fc3ebfcf48879f92169bd7644e29-Janet.Woodc]; Young, John Colvis, Christine (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4b7e84cce098457896b2df19fa172c87-ccolvis]; Eric Hughes [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f97951a53cd54153b5daa9d99ad4ec90-EricHughes]; Jansen, Kathrin Kurilla, Michael (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (b) (6)

From:

Sent:

To:

```
(FYDIBOHF23SPDLT)/cn=Recipients/cn=dc4e85061e3943b9b8ad3f426727861f-mkurilla]; Lowy, Douglas (NCI)
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=54fa75fe6e304e34ba567c66b832baa0-drl.helix.n]; Read, Sarah (NIH/NIAID)
[E] [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=527b160038004a199ae6e0bac2226099-readsa]; Adam, Stacey (FNIH) [T]
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=dcd875f0679648859e1cf101c0943414-adamsj4]; Margaret Anderson
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=ab9a138f1e284c689fedfb10b8cc5295-marganderso]; Appell, Evan
[/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user7ee69e83]; Chen,
Helen [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=8801b022ef974bf7bda8fd06f67002cf-qingchen.de]; Connelly, Sarah
[/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user3ed93bab];
Gonzalez, Nina [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=user3c2f486d]; Hawk, Harrison [/o=ExchangeLabs/ou=Exchange
Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user280c84f8]; Mendelson, Jesse
                          Nasr, Hana [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=userfe0939a1]; Sorosa, Alex [/o=ExchangeLabs/ou=Exchange Administrative
Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a221a6336336466793cff9145b09d91b-Contact_f12]; Stratton,
Benjamin [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=usere3ed7188]; btolman [/o=ExchangeLabs/ou=Exchange Administrative
Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user7b137a1e]; Tountas, Karen (FNIH) [T]
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=40c04fef6f1e46f5b750753cd5a14f93-tountaskh]; Wachtel, Jonathan
                       Anderson, James (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=73143d1860bc42458be254ca21573b23-andersonjm]; Burklow, John
(NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=2e57f267323b43c08be856acb5b964ca-burklowj]; Carluccio, Dana
                                    Castillejos, Carlos [
                                                                         FNIH Central Account
               (b)(6)
                                                            (b) (6)
                          Hallett, Adrienne (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
          (b)(6)
(FYDIBOHF23SPDLT)/cn=Recipients/cn=f1705e2e7c254b84a77f058dbf75b31b-hallettaa]; Myles, Renate (NIH/OD) [E]
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=7d317f5626934585b3692a1823c1b522-mylesr]; Wolinetz, Carrie (NIH/OD)
[E] [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=1c655040d47346c7b04d7bc11a403ecb-wolinetzcd]; Meltzer, Abbey (FNIH)
[T] [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=c341d86cf7404a78ac8f852e698e5382-meltzerak]; Esser, Mark
                             Bancel, Stephane [
                                                                                Fauci, Anthony (NIH/NIAID)
                                                            (b) (6)
[E] [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=df38103d75134f658ae2d356f0396b94-afauci]; Lepore, John
                       Pangalos, Mene [
                                                                        Paul, Steve [
                                                    (b) (6)
                                                                                          (b) (6)
Rachel Ramoni [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=d3f6cb5237a44b75887b8a1ca1f9bb91-Rachel.Ramo]; Reed, John
                       Reese, David [
                                           (b) (6)
                                                        Stoffels, Paul [
                                                                             (b) (6)
                                                                                          Desrosiers, Betsy
        (b) (6)
             (b) (6)
Austin, Sarah (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=292fcb760f9f4f199ebe343e08ef1781-austinsj]; Barasch, Kimberly
(NIH/NIAID) [C] [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=ea5fad4c52f64f80b7daee4982ae495f-baraschk]; Burrus-Shaw, Cyndi
(NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=5bbac95b1f6e4514a299b318030c31f6-shawcy]; Carver, Trea (NIH) [C]
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=ac05f976df484ed69022b8663cd448d3-carverkr]; Caulfied, Anita
                                                                 Conrad, Patricia (NIH/NIAID) [E]
                          Coan, Amanda
          (b) (6)
                                                 (b) (6)
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=7ea3e3ea7daa432887495d6825c9e588-conradpa]; Dimishkov, Roxanne
(NIH/NHLBI) [C] [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=d8415061971c493881c08c8c6cd75fb8-dimishkovrd]; Edl, Susan
```

CC:

	(b) (6)	Fuhrer, Nicole [(b) (6)	Giorgi, Sara [(b) (6)				
	Hoffstetter, Renata (Fl	NIH) [T] [/o=ExchangeLabs/	ou=Exchange Adr	ministrative Group					
	(FYDIBOHF23SPDLT)/c	n=Recipients/cn=c3e97585	70bf4ca08552ea	377170ec2a-hoffst	tetter]; Iberdemaj, Vaide				
	(b) (6)	Jenkins, Christine	S. [b) (6)	Lagos, Enrique (NIH/NCATS) [E]				
	[/o=ExchangeLabs/ou:	Exchange Administrative G	iroup						
	(FYDIBOHF23SPDLT)/cn=Recipients/cn=ae9041ab27204d83b06752f67a44b0d1-lagoses]; Lever, Susan								
	(b) (6)	Martin, Melisa [(-) (-)	McManus, Ayan	na (NIH/OD) [E]				
	/o=ExchangeLabs/ou=Exchange Administrative Group								
	(FYDIBOHF23SPDLT)/c	YDIBOHF23SPDLT)/cn=Recipients/cn=bcf06de08ba845249b9b36ad216e237e-amcmanus]; Minnich, Beth							
	(b) (6)	Perala, Mie [(b) (6)	Protasiewicz, Ann					
	(b) (6)	Riccobene, Kim [(b) (6)	Riggin, Mary					
	Ripley, Nadege [(b) (6)	Schuster, Donna	- \ / /	5) Sepulveda,				
	Dorina (FNIH) [T] [/o=l								
	(FYDIBOHF23SPDLT)/cn=Recipients/cn=675efcc8cf7b4f6986d1eb3c3ed1fd96-sepulvedade]; Simon, Dina (NIH [C] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e02345fa5d1d4d7eaf4e0f3da58bc1ac-simondm]; Suhana, Tina (NIH/N								
		Exchange Administrative G							
	^^^ [] [] [] [] [[] [] [] [] [] [] [] [] []	n=Recipients/cn=07e062bf			ana]; Thomas, Ashley				
		ingeLabs/ou=Exchange Adn							
	(FYDIBOHF23SPDLT)/cn=Recipients/cn=1bcd5d3f7c1e4309a251d013e1cc89b0-Ashley.Thom]; Wood, Gretchen (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=549f390b39d044a8b5d1e0e1a8f76c1f-woodgs]; Togashi, Mieko (NIH/NC								
	[E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=136a73bd42274938aa467e738767f83e-togashim]; Underwood, Nancy								
	(b) (6)	Zottoli, Jessica		5) Hugh	es, Karen (NIH/OD) [E]				
	[/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0e11e04daa2b44dea1a06ce7ab21cb1a-hugheskp]; Tajalli, Ada (NIH/OD) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4fd4747b0d954e27855c241b28562547-tajallian]; Regan, Donna M [(b) (6) Magbie-Robinson, Kim (NIH/OD) [C] [/o=ExchangeLabs/ou=Exchange Administrative								
	(b) (6)								
	30 - 50				7-magbierobin]; Vessey, Rupert				
	(b) (6)		R0.7.1071.70	071 15	ange Administrative Group				
	그림 [20] 14 [20] 15 [20] 15 [3] 15	n=Recipients/cn=f1b7b8fe4		[[12] [[12]	aj; Lumsden, Joanne				
	(NIH/NCATS) [C] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1be900c2388d41f48e3f2cbcb2fed349-lumsdenjm]; Ellis, Carol								
	The state of the s								
	(b) (6)]; Bell, Julie [(b) (6) Hoban, Michelle [Melencio, Cheryl (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group								
	nciosi								
Subject:		[FYDIBOHF23SPDLT]/cn=Recipients/cn=279e14fa7428415bb86087d08b628e6f-melencioc] RE: ACTIV Leadership/EC Call #12							
Attachments:	1500	adership_Team_and_Execu	itiva Committae	Mosting Summa	ry vEndf				
Actacimients.	ZOZI-OI-14_ACTIV_LE	adership_reall_alld_exect	uve_commutee	_iviceting_builifilat	y_vi.pui				

Dear ACTIV Executive Committee and Leadership Team members, and meeting attendees:

Attached please see the minutes from our meeting this past Thursday, January 14, 2021. As always please let me know if you have any additional comments or questions.

Regards, David Wholley Melencio, Cheryl (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=279E14FA7428415BB86087D08B628E6F-MELENCIOC] 11/12/2020 5:10:25 PM Melencio, Cheryl (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=279e14fa7428415bb86087d08b628e6f-melencioc]; Austin, Christopher (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=17597cabc42247548e596778304f781f-austinc]; Bancel, Stephane Carter, Kara | Cavaleri, Marco (b) (6) (b) (6) Cihlar, Tomas [Collins, Francis (NIH/OD) [E] (b) (6) (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=410e1ca313f44ced9938e50d2ff0b6c2-collinsf]; Corey, Larry Culp, Michelle (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4e38fa37e0424217aa0a283cba9e5098-mculp]; Disbrow, Gary (OS/ASPR/BARDA) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=62a151e39ab942d88a813b449f9f6ccb-Gary.Disbro]; Dolsten, Mikael Erbelding, Emily (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e976ebf7b14142fbb3c5c294efb334fe-erbeldingej]; Erck, Stan Fauci, Anthony (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=df38103d75134f658ae2d356f0396b94-afauci]; Gadbois, Ellen (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0243d1d6e6f248268d2edec566c26c2a-gadboisel]; Gibbons, Gary (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b71b953b50a5495ca0f2869ab13bc407-gibbonsgh]; Hudson, Thomas James, Stephanie (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f0032ef62ca343dfb4bf79577e2aa8d1-jamesst]; Johnson, Robert (OS/ASPR/BARDA) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=feb0b05457404e2f8b88af78e9ac4dd9-Robert.John]; Kramer, Lynn Lane, Cliff (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2d7e368a3137473bbce161547a82f2de-clane]; Lepore, John Marks, Peter (FDA/CBER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b2e527dbda2b4a86b8d72f06b813d471-MarksP.fda]; Marston, Hilary (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ab30660917b942ffba9ae95d631116f3-marstonhd]; Mascola, John (NIH/VRC) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=7f78b40a596b4ca4a2850a429d1ae3f2-jmascola]; Meeker, David Menetski, Joseph (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5001af52dc4a427ea3d34f1e072f8cb7-menetskijp]; Messonnier, Nancy (CDC/DDID/NCIRD/OD) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=441f65db836c4a89a42aecb9a0d9b96c-NAR5]; Pandya, Hitesh Pangalos, Mene [Pao, William (b) (6) (b) (6) (b) (6) Parker, Ashley (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras]; Paul, Steve Perlmutter, Roger [(b) (6) Plenge, Robert [(b) (6) Plump, Andy [Rachel Ramoni [/o=ExchangeLabs/ou=Exchange Administrative Group (b)(6)(FYDIBOHF23SPDLT)/cn=Recipients/cn=d3f6cb5237a44b75887b8a1ca1f9bb91-Rachel.Ramo]; Rasi, Guido (b) (6) Reed, John (b) (6) Reese, David [(b) (6) Rouse, Doris Santos, Michael (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ab38cb6836de44e18ef4cc6952f65f80-santosmr]; Skovronsky, Daniel (b)(6)Stein, Peter (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b4a14118481b4b39ba7e62a8d6425f79-Peter.Stein]; Stoffels, Paul Tabak, Lawrence (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (b)(6)(FYDIBOHF23SPDLT)/cn=Recipients/cn=02e22836b5ff4e9988e3770cfc7ee770-tabakl]; Talley, Michael Tsai, John [john. Vessey, Rupert [Wholley, (b) (6) (b) (6) David (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]; Woodcock, Janet (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9bc3fc3ebfcf48879f92169bd7644e29-Janet.Woodc]; Young, John

From:

Sent:

To:

```
Colvis, Christine (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative
                         (b) (6)
              Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4b7e84cce098457896b2df19fa172c87-ccolvis]; Desrosiers, Betsy
                                                Eric Hughes [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=f97951a53cd54153b5daa9d99ad4ec90-EricHughes]; Jansen, Kathrin
                                         Kurilla, Michael (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=dc4e85061e3943b9b8ad3f426727861f-mkurilla]; Lowy, Douglas (NCI)
              [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=54fa75fe6e304e34ba567c66b832baa0-drl.helix.n]; Read, Sarah (NIH/NIAID)
              [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=527b160038004a199ae6e0bac2226099-readsa]
CC:
              Anderson, James (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=73143d1860bc42458be254ca21573b23-andersonjm]; Burklow, John
              (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=2e57f267323b43c08be856acb5b964ca-burklowi]; Carluccio, Dana
              [dana.carluccio@roseliassociates.com]; Castillejos, Carlos [
                                                                                        FNIH Central Account
                                                                          (b) (6)
                                         Hallett, Adrienne (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=f1705e2e7c254b84a77f058dbf75b31b-hallettaa]; Myles, Renate (NIH/OD) [E]
              [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=7d317f5626934585b3692a1823c1b522-mylesr]; Wolinetz, Carrie (NIH/OD)
              [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=1c655040d47346c7b04d7bc11a403ecb-wolinetzcd]; Adam, Stacey (FNIH) [T]
              [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=dcd875f0679648859e1cf101c0943414-adamsj4]; Margaret Anderson
              [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=ab9a138f1e284c689fedfb10b8cc5295-marganderso]; Appell, Evan
              [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user7ee69e83]; Chen,
              Helen Q. [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=user34aa917e]; Connelly, Sarah [/o=ExchangeLabs/ou=Exchange
              Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user3ed93bab]; Gonzalez, Nina
              [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user3c2f486d]; Hawk,
              Harrison [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=user280c84f8]; Mendelson, Jesse
                                                                                                            asorosa
              [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=userffc6da86];
              Stratton, Benjamin [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=usere3ed7188]; btolman [/o=ExchangeLabs/ou=Exchange Administrative
              Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user7b137a1e]; Tountas, Karen (FNIH) [T]
              [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=40c04fef6f1e46f5b750753cd5a14f93-tountaskh]; Wachtel, Jonathan
                                      Gorman, Greta (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=280703da933d491586841696e460f062-gormanmj]; Meltzer, Abbey (FNIH)
              [T] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=c341d86cf7404a78ac8f852e698e5382-meltzerak]; Austin, Sarah (NIH/NIAID)
              [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=292fcb760f9f4f199ebe343e08ef1781-austinsj]; Barasch, Kimberly
              (NIH/NIAID) [C] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=ea5fad4c52f64f80b7daee4982ae495f-baraschk]; Bell, Julie
              [julie.bell@astrazeneca.com]; Burrus-Shaw, Cyndi (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative
              Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5bbac95b1f6e4514a299b318030c31f6-shawcy]; Carver, Trea (NIH) [C]
              [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=ac05f976df484ed69022b8663cd448d3-carverkr]; Caulfied, Anita
                                                                               Conrad, Patricia (NIH/NIAID) [E]
                                        Coan, Amanda [
                                                                (b) (6)
              [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=7ea3e3ea7daa432887495d6825c9e588-conradpa]; Dimishkov, Roxanne
              (NIH/NHLBI) [C] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=d8415061971c493881c08c8c6cd75fb8-dimishkovrd]; Edl, Susan
                                     Fuhrer, Nicole [
                                                                               Giorgi, Sara
                      (b) (6)
                                                              (b) (6)
                                                    Hoffstetter, Renata (FNIH) [T] [/o=ExchangeLabs/ou=Exchange
              Hoban, Michelle
                                      (b) (6)
```

Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c3e9758570bf4ca08552ea377170ec2a-hoffstetter];

Iberdemaj, Vaide [(b) (6)	Jenkins	, Christine S.	(b) (6)	Krack,		
Kimberly [kimberly];	(b) (6)		바람	[] [/o=ExchangeLabs			
Administrative Group (
Lever, Susan [(b) (6)				geLabs/ou=Exchange		
Administrative Group (d216e237e-amcmanus];		
Minnich, Beth [(b) (6)	Perala, Mie [(b) (d		ewicz, Ann		
(b) (6)		ene, Kim [(b) (6)	Riggin, Mary [(b) (6)		
Ripley, Nadege [(b) (6)	Schust	er, Donna [(b) (6)	Sepulveda,		
Dorina (FNIH) [T] [/o=E		u=Exchange Admir	nistrative Gro				
(FYDIBOHF23SPDLT)/cn=Recipients/cn=675efcc8cf7b4f6986d1eb3c3ed1fd96-sepulvedade]; Simon, Dina (NIH/OD)							
	[C] [/o=ExchangeLabs/ou=Exchange Administrative Group						
(FYDIBOHF23SPDLT)/cn=Recipients/cn=e02345fa5d1d4d7eaf4e0f3da58bc1ac-simondm]; Suhana, Tina (NIH/VRC) [E]							
[/o=ExchangeLabs/ou=Exchange Administrative Group							
(FYDIBOHF23SPDLT)/cn=Recipients/cn=07e062bf05a14748ba3d9fbb3e468057-esuhana]; Thomas, Ashley							
(FDA/CDER) [/o=Excha	(FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group						
(FYDIBOHF23SPDLT)/cn=Recipients/cn=1bcd5d3f7c1e4309a251d013e1cc89b0-Ashley.Thom]; Wood, Gretchen							
(NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group							
(FYDIBOHF23SPDLT)/cn=Recipients/cn=549f390b39d044a8b5d1e0e1a8f76c1f-woodgs]; Hughes, Karen (NIH/OD) [E]							
[/o=ExchangeLabs/ou=Exchange Administrative Group							
(FYDIBOHF23SPDLT)/cn=Recipients/cn=0e11e04daa2b44dea1a06ce7ab21cb1a-hugheskp]; Tajalli, Ada (NIH/OD) [E]							
[/o=ExchangeLabs/ou=Exchange Administrative Group							
(FYDIBOHF23SPDLT)/cn=Recipients/cn=4fd4747b0d954e27855c241b28562547-tajallian]; Togashi, Mieko (NIH/NCI)							
[E] [/o=ExchangeLabs/ou=Exchange Administrative Group							
(FYDIBOHF23SPDLT)/cr	n=Recipients/cn	=136a73bd42274	938aa467e73	8767f83e-togashim]	; Underwood, Nancy		
(b) (6)	Zott	toli, Jessica	(b) (6)				
ACTIV Leadership Tean	n Meeting #11						

Subject:

Location: https://fnih.zoom.us/ (b)(6)

12/16/2020 3:00:00 PM Start: End: 12/16/2020 4:00:00 PM

Show Time As: Busy

Required Attendees:

Austin, Christopher (NIH/NCATS) [E]; Bancel, Stephane; Carter, Kara; Cavaleri, Marco; Cihlar, Tomas; Collins, Francis (NIH/OD) [E]; Corey, Larry; Culp, Michelle (NIH/OD) [E]; Disbrow, Gary (OS/ASPR/BARDA); Dolsten, Mikael; Erbelding, Emily (NIH/NIAID) [E]; Erck, Stan; Fauci, Anthony (NIH/NIAID) [E]; Gadbois, Ellen (NIH/OD) [E]; Gibbons, Gary (NIH/NHLBI) [E]; Hudson, Thomas; James, Stephanie (FNIH) [T]; Johnson, Robert (OS/ASPR/BARDA); Kramer, Lynn; Lane, Cliff (NIH/NIAID) [E]; Lepore, John; Marks, Peter (FDA/CBER); Marston, Hilary (NIH/NIAID) [E]; Mascola, John; Meeker, David; Menetski, Joseph (FNIH) [T]; Messonnier, Nancy (CDC/DDID/NCIRD/OD); Pandya, Hitesh; Pangalos, Mene; Pao, William; Parker, Ashley (NIH/OD) [E]; Paul, Steve; Perlmutter, Roger; Plenge, Robert; Plump, Andy; Ramoni, Rachel; Rasi, Guido; Reed, John; Reese, David; Rouse, Doris; Santos, Michael (FNIH) [T]; Skovronsky, Daniel; Stein, Peter (FDA/CDER); Stoffels, Paul; Tabak, Lawrence (NIH/OD) [E]; Talley, Michael; Tsai, John; Vessey, Rupert; Wholley, David (FNIH) [T]; Woodcock, Janet (FDA/CDER); Young, John; Colvis, Christine (NIH/NCATS) [E]; Desrosiers, Betsy; Hughes, Eric; Jansen, Kathrin; Kurilla, Michael (NIH/NCATS) [E]; Lowy, Douglas (NCI); Read, Sarah (NIH/NIAID) [E]

Optional Attendees:

Anderson, James (NIH/OD) [E]; Burklow, John (NIH/OD) [E]; Carluccio, Dana; Castillejos, Carlos; FNIH Central Account; Hallett, Adrienne (NIH/OD) [E]; Myles, Renate (NIH/OD) [E]; Wolinetz, Carrie (NIH/OD) [E]; Adam, Stacey (FNIH) [T]; Anderson, Margaret; Appell, Evan; Chen, Helen; Connelly, Sarah; Gonzalez, Nina; Hawk, Harrison; Mendelson, Jesse; Sorosa, Alex; Stratton, Ben; Tolman, Brett; Tountas, Karen (FNIH) [T]; Wachtel, Jonathan; Gorman, Greta (FNIH) [T]; Meltzer, Abbey (FNIH) [T]; Austin, Sarah (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]; Bell, Julie; Burrus-Shaw, Cyndi (NIH/OD) [E]; Carver, Trea (NIH) [C]; Caulfied, Anita; Coan, Amanda; Conrad, Patricia (NIH/NIAID) [E]; Dimishkov, Roxanne (NIH/NHLBI) [C]; EdI, Susan; Fuhrer, Nicole; Giorgi, Sara; Hoban, Michelle; Hoffstetter, Renata (FNIH) [T]; Iberdemaj, Vaide; Jenkins, Christine S.; Krack, Kimberly; Lagos, Enrique (NIH/NCATS) [E]; Lever, Susan; McManus, Ayanna (NIH/OD) [E]; Minnich, Beth; Perala, Mie; Protasiewicz, Ann; Riccobene, Kim; Riggin, Mary; Ripley, Nadege; Schuster, Donna; Sepulveda, Dorina (FNIH) [T]; Simon, Dina (NIH/OD) [C]; Suhana, Tina

(NIH/VRC) [E]; Thomas, Ashley (FDA/CDER); Wood, Gretchen (NIH/OD) [E]; Hughes, Karen (NIH/OD) [E]; Tajalli, Ada (NIH/OD) [E]; Togashi, Mieko (NIH/NCI) [E]; Underwood, Nancy; Zottoli, Jessica

Joseph Menetski is inviting you to a scheduled Zoom meeting.

```
Join Zoom Meeting
https://fnih.zoom.us
                                                (b)(6)
Meeting ID:
                 (b) (6)
Passcode: (b)
One tan mohile
                     (b) (6)
                                                 US (Washington D.C)
                                                 US (Chicago)
Dial by vour location (b)(6)
                           JS (Washington D.C)
                           JS (Chicago)
                           JS (New York)
                           JS (San Jose)
                           JS (San Jose)
                           JS (Tacoma)
                           JS (Houston)
                           lgium
                           elgium
                           elgium
                           elgium
                           elgium
                           elgium
                           Canada
                           Canada
                           Canada
                           Canada
                           Canada
                           Canada
                           France
                           France
                           France
                           France
                           France
                           Japan
                           Japan
                           Japan
                            Italy
                              Italy
                            Italy
                            Switzerland
                            Switzerland
                            Switzerland
                            Switzerland
                            Switzerland
                            Switzerland
                            United Kingdom
                            United Kingdom
United Kingdom
                            United Kingdom
                            United Kingdom
                            United Kingdom
                            United Kingdom
Meeting ID: (b) (6)
Passcode: (b) (6)
Find your local number: https://fnih.zoom.u
                                                     (b) (6)
```

From: Tountas, Karen (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=40C04FEF6F1E46F5B750753CD5A14F93-TOUNTASKH] Sent: 4/18/2020 8:48:03 PM To: Bascles, Lionel [Cohen, Myron [/o=ExchangeLabs/ou=Exchange Administrative Group (b) (6) (FYDIBOHF23SPDLT)/cn=Recipients/cn=2141b9e28c1a421fb3c1c4f75dd4c457-myron_cohen]; Corey, Larry Desrosiers, Betsy [Dickens, Jim (NIH/NCATS) [C] (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=12591c90404e46caba73079cf4a5e2ea-dickensj]; Doroshow, James (NIH/NCI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a1d0fb9f055940c39b387cae2485faa6-doroshoi]; Goff, David (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=036113c7be0f42f897d1294cfbb99c10-goffdc]; Kurilla, Michael (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dc4e85061e3943b9b8ad3f426727861f-mkurilla]; Nayak, Seema (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=51d5ee6848004578b5bf9c808eca8f6f-nayaksu]; Parker, Ashley (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras]; Payton, Manizhe (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=81d1c1824bfa438a94da81520a8bca90-paytonma]; Resnansky, Laura Srinivasan, Badhri (b) (6) Stein, Peter (FDA/CDER) (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b4a14118481b4b39ba7e62a8d6425f79-Peter.Stein]; Tountas, Karen (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=40c04fef6f1e46f5b750753cd5a14f93-tountaskh]; Vincent, Mike Woodcock, Janet (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9bc3fc3ebfcf48879f92169bd7644e29-Janet.Woodc] CC: Colvis, Christine (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4b7e84cce098457896b2df19fa172c87-ccolvis]; Hughes, Eric Lowy, Douglas (NCI) (b) (6) Jansen, Kathrin [(b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=54fa75fe6e304e34ba567c66b832baa0-drl.helix.n]; Read, Sarah (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=527b160038004a199ae6e0bac2226099-readsa]; Young, John Adam, Stacey (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (b) (6) (FYDIBOHF23SPDLT)/cn=Recipients/cn=dcd875f0679648859e1cf101c0943414-adamsi4]; Anderson, Margaret Melencio, Cheryl (FNIH) [T] (b) (6) Carluccio, Dana [(b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=279e14fa7428415bb86087d08b628e6f-melencioc]; Collins, Francis (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=410e1ca313f44ced9938e50d2ff0b6c2-collinsf]; Gonzalez, Nina [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user3c2f486d]; Heaton, Penny [James, Stephanie (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f0032ef62ca343dfb4bf79577e2aa8d1-jamesst]; Li, Menetski, Joseph (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5001af52dc4a427ea3d34f1e072f8cb7-menetskijp]; Santos, Michael (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ab38cb6836de44e18ef4cc6952f65f80-santosmr]; Tuvesson, Nancy Wachtel, Jonathan [(b) (6)]; Wholley, David (FNIH) [T] (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]; Criffield, Robin Hamilton, Nancy [Melencio, Cheryl (FNIH) [T] (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=279e14fa7428415bb86087d08b628e6f-melencioc]; Minnich, Beth Mueller-Reichenstein, Petra [Katz, Rebecca (b)(6)(NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=8e2b174d9bf748e9aa5ed901b4c5a3d9-katzrd]; Thomas, Ashley (FDA/CDER)

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=1bcd5d3f7c1e4309a251d013e1cc89b0-Ashley.Thom]; Hill, Zoe (NIH/NHLBI)

[C] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=a19ee51dca2a443d883a15e025d6e1e0-hillzs]

Subject: Clinical Trial Capacity Working Group Meeting #2 Summary

Attachments: Clinical_Trial_Capacity_Working_Group_Meeting #2_Summary_FINAL.pdf

Dear Clinical Trial Capacity Working Group colleagues,

Attached is the Summary of meeting #2 of the Clinical Trial Capacity Working Group. The subgroups are making good headway, so there will be much to report during Tuesday's meeting (April 21, 9:00 am ET USA).

Best regards, Karen

Karen H. Tountas, PhD

Scientific Program Manager

Foundation for the National Institutes of Health

(b) (6) <u>fnih.org</u>

11400 Rockville Pike, Suite 600, North Bethesda, MD 20852



Stay at the forefront of FNIH news: fnih.org/newsletter

Confidentiality Notice: Information contained in this e-mail and attachments may be legally privileged and confidential. If you are not an intended recipient, you are hereby notified that dissemination, distribution or copying this e-mail and attachments is strictly prohibited; please delete the e-mail and attachments immediately.

From: Lowy, Douglas (NIH/NCI) [E] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP

(FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=F1B7B8FE4739478BB17840C56902718A-LOWYD]

Sent: 7/3/2020 4:09:15 PM

To: Fauci, Anthony (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=df38103d75134f658ae2d356f0396b94-afauci]; Collins, Francis (NIH/OD) [E]

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=410e1ca313f44ced9938e50d2ff0b6c2-collinsf]; Lane, Cliff (NIH/NIAID) [E]

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=2d7e368a3137473bbce161547a82f2de-clane]; Mascola, John (NIH/VRC) [E]

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=7f78b40a596b4ca4a2850a429d1ae3f2-jmascola]

CC: Wholley, David (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]

Subject: Re: Gallo and OPV

Flag: Follow up

Thanks, Tony. Can you suggest one or two people with whom I can discuss the issue? Doug

From: "Fauci, Anthony (NIH/NIAID) [E]" < (b) (6)

Date: Friday, July 3, 2020 at 12:07 PM

To: "Lowy, Douglas (NIH/NCI) [E]" < (b) (6) "Collins, Francis (NIH/OD) [E]"

< (b) (6) "Lane, Cliff (NIH/NIAID) [E]" < (b) (6) "Mascola, John (NIH/VRC) [E]"

(b) (6)

Cc: "Wholley, David (FNIH) [T]" < (b) (6)

Subject: RE: Gallo and OPV

This issue will not go away and so perhaps it is best to have the ACTIV Vaccines WG take a look at this and make some sort of recommendation.

From: Lowy, Douglas (NIH/NCI) [E] < (b) (6)

Sent: Friday, July 3, 2020 11:54 AM

To: Collins, Francis (NIH/OD) [E] < (b) (6) Fauci, Anthony (NIH/NIAID) [E] < (b) (6) Lane,

Cliff (NIH/NIAID) [E] < (b) (6) Mascola, John (NIH/VRC) [E] < (b) (6)

Cc: Wholley, David (FNIH) [T] < (b) (6)

Subject: Re: Gallo and OPV

Hi Francis: The vaccine working group has not discussed this topic. Doug

From: "Collins, Francis (NIH/OD) [E]" (b) (6)

Date: Friday, July 3, 2020 at 11:46 AM

To: "Fauci, Anthony (NIH/NIAID) [E]" < (b) (6) "Lane, Cliff (NIH/NIAID) [E]"

(b) (6) "Lowy, Douglas (NIH/NCI) [E]" < (b) (6) "Mascola, John (NIH/VRC) [E]"

(b) (6)

Cc: "Wholley, David (FNIH) [T]" < (b) (6)

Subject: RE: Gallo and OPV

Hi Tony, Cliff, Doug, and John (and looping in David)

Bob Gallo is back with a complaint that no one has followed up on the OPV idea. See attached. Was this discussed in the ACTIV Vaccines WG or in any other venue?

Tx, Francis

From: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)

Sent: Sunday, May 3, 2020 1:45 PM

 To: Lane, Cliff (NIH/NIAID) [E]
 (b) (6)
 ; Collins, Francis (NIH/OD) [E]
 (b) (6)

 Cc: Lowy, Douglas (NIH/NCI) [E]
 (b) (6)
 ; Mascola, John (NIH/VRC) [E]
 (b) (6)

Subject: RE: Gallo and OPV

Totally agree with Cliff's advice.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) (b) (6)
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lane, Cliff (NIH/NIAID) [E] (b)
Sent: Sunday, May 3, 2020 1:22 PM

To: Collins, Francis (NIH/OD) [E] < (b) (6)

Cc: Lowy, Douglas (NIH/NCI) [E] (b) (6) Fauci, Anthony (NIH/NIAID) [E] (b) (6) Mascola, John (NIH/VRC) [E] (b) (6)

Subject: Re: Gallo and OPV

Francis,

I am not sure you need any sort of detailed response. I would just send a thank-you and indicate you will be sure those working on this at NIH are aware.

Cliff

On May 3, 2020, at 12:55 PM, Collins, Francis (NIH/OD) [E] (b) (6) wrote:

Hi all.

I'm a bit at a loss to know how to respond to Bob Gallo. The aggressive manner in which he is promoting OPV causes me to worry he has lost objectivity about its promise. But is there any chance he has something here that could work?

Francis

From: Gallo, Robert (

Sent: Sunday, May 35 2020 12:07 PM

To: Collins, Francis (NIH/OD) [E] < (b) (6)

Subject: RE: Your query to Dr. Kadlec

Dear Francis,

It was a pleasure to hear from you, and yes, it has been a long time since we met or even spoke. Moons ago I was set to write to you after reading your wonderful book, but I ended up instead speaking with others about it. I should add at this point that I did not quickly respond to your email of a few days ago because I simply missed it.

It is true that I strongly suggest that OPV be quickly (already it is not quickly) brought forward for induction of a strong innate immune response to prevent or markedly reduce SARS-CoV-2 infection and/or severity until the field obtains a proven safe and efficacious vaccine producing a long lasting, adaptive immunity. OPV is very safe (notably for OPV 1 and 3 as bOPV which we will use and completely safe in a vaccinated population), simple, cheap, rather obvious, yet unique among the massive number of vaccines many (maybe most) of which are the same or at least if not exactly the same aiming at the same mechanism (targeting the spike and searching for the putative correlate of neutralizing Abs.).

OPV should work for a few months and possibly longer. Also it should be working multiple times so I think could cover more than a few months, giving us time for a proven vaccine of adaptive immunity, which might be very long lasting as is hoped.

In the main the WHO comments are correct. Of course we sought and have letters of support from them as well as from many others. Though they are again supportive in their notes to you, there is one item that surprises me. They add that there was no clinical efficacy results as yet. They know or certainly should know that there is plenty of clinical data for this concept with BCG, OPV, and live Measles vaccine. Needless to say this is what turned me on during our regular Global Virus Network (GVN)conference calls. (Incidentally GVN is an organization I have thought of bringing to your attention. I think you would find it impressive and useful). I would be happy to share with you the clinical observations with OPV if you wish.

I would like to take a small diversion, but I suspect you are aware of these things. My colleagues and I respect the WHO because of its representation and because we have colleagues/friends there as well. However, sometimes bureaucracy of a massive degree leads to inaction or even much worse—political expediency. I won't bother you with details of these unless you ask, but I had such experiences with HTLV-1 which we discovered in 1980 as the 1st human retrovirus and which cause not only the highest incidence of cancer (% of infections) of any virus and other fatal diseases as well but mainly in less developed countries (plus Japan) and again with HIV in 1984. Behavior was not beneficial. Perhaps it will be of relevance in the future because a few at WHO took a position to remove OPV (Sabin) in favor of IPV (Salk) in their polio eradication scheme. It was a huge failure. As my FDA collaborator, Konstantin Chumakov, says "Blessed be Bill Gates" because he saved OPV and saved the day and in so doing has produced a still better OPV.

There is indeed data also for BCG as well as live Measles though I know less of the latter. BCG is less available, requires injection, harder to make, not as safe, and we think unlikely to be as effective as OPV. Nonetheless, we favor its use too. The mechanisms will be similar.

You asked whether monkey trials are planned. For several reasons definitely not --though we are planning some monkey experiments, but not large enough for "clinical" conclusions. The main reasons are: 1) cost; 2) that billions not thousands or millions have received OPV safely and in our collective view (and we know the studies pretty well) protection has been clinically shown; 3) In a pandemic we wished to move quickly (so far we must say that has not been achieved). A typical monkey vaccine study will take time, but 4) in this case it would be a huge amount of lost time as monkeys require great doses of polio for infection and monkeys have to be trained to drink their orange juice. It would be hard to imagine that such studies would even give us useful information.

On a final digression Francis I have had 36 years of on/off experiences with glycosylated spike proteins—their analyses immunologically and especially regarding use in vaccines and developing neutralizing Abs. I believe it will be a mistake to put most eggs in that basket. The risks: shortened antibody half life; 2) protection NOT correlating with neutralizing Abs; 3) sometimes hazards from them. Admittedly, they might work, but I trust and hope that not everything is going in this bag. If you wish to discuss this again I will be available.

Finally, I hd no idea you were into vaccines or SARS-2 nor any part of CoVID-19 disease, but I am very happy to learn this.

Thanks.

Bob Gallo

From: Collins, Francis (NIH/OD) [E] (b)(6)Sent: Thursday, April 30, 2020 5:00 PM To: Gallo, Robert (b) (6) Cc: Disbrow, Gary (OS/ASPR/BARDA) < ; Kadlec, Robert (OS/ASPR/IO) (b)(6)(b) (6) ; Tabak, Lawrence (NIH/OD) [E] (; Shuy, Bryan Johnson, Robert (OS/ASPR/BARDA) (OS/ASPR/IO) < (b) (6) (b) (6) Mascola, John (NIH/VRC) [E] (b) (6) ; Lane, Cliff (NIH/NIAID) [E] (b)(6)Subject: Your query to Dr. Kadlec

CAUTION: This message originated from a non UMB, UMSOM, FPI, or UMMS email system. Whether the sender is known or not known, hover over any links before clicking and use caution opening attachments.

Dear Bob,

It's been quite a while since we've chatted. Bob Kadlec asked me to respond to your query about the possible use of OPV to activate innate immunity and provide COVID-19 protection. Has this been tested in a non-human primate model? I note the recommendation below that says a clinical trial is planned – can you tell me more about that?

As you can imagine, we are all flat out on the vaccine development pathway!

Francis

The use of oral polio vaccine (OPV) to prevent SARS-CoV2 (Polio Eradication Campaign)

There is no evidence that oral poliovirus vaccine (OPV) protects people against infection with COVID-19 virus.

A clinical trial addressing this question is planned in the USA, and WHO will evaluate the evidence when it is available.

In the absence of evidence, WHO does not recommend OPV vaccination for the prevention of COVID-19. WHO continues to recommend OPV as part of essential immunization services to prevent poliomyelitis and as part of global polio eradication efforts.

There are experimental signals from various studies over the years that OPV has non-specific effects on the immune system. These effects have not been well characterized and their clinical relevance is unknown. Such non-specific effects may not be limited to OPV, as other live vaccines have also been associated with non-specific protective effects (such as BCG vaccine against tuberculosis). Nonlive vaccines in contrast do not seem to have the same effects.

The exact mechanism of non-specific protection induced by live vaccines needs to be elucidated further. Clinical studies could begin immediately because the vaccines in question are licensed and have an excellent safety record. Clinical trials involving off-label use of various drugs licensed for other indications are currently underway. The existing scientific rationale suggests that the same should be done for OPV and other live vaccines. A study is currently being discussed with various partners and vaccine manufacturers, including the US FDA, the outcomes of which will be carefully assessed to determine potential use in the context of the spread of SARS-CoV2 until the time when specific vaccines and antiviral therapies are ready.

From: Kadlec, Robert (0	OS/ASPR/IO)	(b	0) (6)	
Sent: Thursday, April 30	0, 2020 10:28 A	M		
To: Gallo, Robert	(b) (6)		Collins, Francis (NIH/OD) [E]	(b) (6)
Tabak, Lawrence (NIH/	OD) [E]	(b) (6)	>; Shuy, Bryan (OS/AS	PR/IO)
(b) (6)				
Subject: Re: Respone				

Dr Gallo thank you for your note and I appreciate you reaching out to me. I have copied Dr Collins and Dr Tabak to consider the ACTIV forum they have created to bring industry academia and government to consider scientific base approaches That you have described. Dr Collins has organized a vaccine group and I assess could be the best and fastest place to discuss your concept. I am sure they will connect with you soonest

Best

Bob Kadlec.

Sent from my iPhone

Dear Dr. Kaldec,

I have not heard from you in over a week. You mentioned getting back to me in a day or two. Time is passing. I am asking you to look at OPV 1 plus 3 serotypes as a bivalent, completely safe vaccine with powerful stimulation of innate immunity lasting several weeks, which can be given a second or third time, and with a historical track record of preventing other infections from entirely different RNA viruses (such as protecting against influenza). Therefore, it should be really helpful for some months, and I think get us past a second wave of SARS-CoV-2, and help people return to work safely. I don't understand delays or apparent lack of interest. Who can possibly be against this? If you hear of hypothetical problems we can show you that these are false. Just ask the questions, and we can give you the evidence.

However, no answer from you suggests no interest and must quickly make alternative pathways. I am though quite surprised and fear you are receiving "fake news" if you will pardon the expression. Some have been against this who defend their old and failed position on polio eradication with their promotion of the use of the inactivated polio virus vaccine. Please note that in the US between 1962 and 1985 we received (safely) the oral polio (OPV). Moreover, if vaccinated already there has not been a single case of a complication and BILLIONS have received it. No it will not last long as innate immunity is short lived, but we strongly believe that we can break the back of the SARS-CoVID-2 spread. Also note that this is what Bill Gates is doing now in India and much of the Eastern hemisphere.

There are countries outside the US wanting to move fast on this. We are waiting for your reply.

Robert Gallo
Director, Institute of Human Virology,
Professor of Medicine and Professor of Microbiology,
UMB, School of Medicine, Baltimore,

And

Co-founder and International Science Advisor of the Global Virus Network (GVN)

From: Lowy, Douglas (NIH/NCI) [E] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP

(FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=F1B7B8FE4739478BB17840C56902718A-LOWYD]

Sent: 7/20/2020 9:02:35 PM

To: Collins, Francis (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=410e1ca313f44ced9938e50d2ff0b6c2-collinsf]

CC: Wholley, David (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]; Mascola, John (NIH/VRC)

[E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=7f78b40a596b4ca4a2850a429d1ae3f2-jmascola]; Lane, Cliff (NIH/NIAID) [E]

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=2d7e368a3137473bbce161547a82f2de-clane]; Fauci, Anthony (NIH/NIAID)

[E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=df38103d75134f658ae2d356f0396b94-afauci]

Subject: Re: Gallo and OPV

Hi Francis,

As I mentioned at last week's ACTIV Executive Committee meeting, the vaccine working group listened to an invited presentation from Bob Gallo, who proposed two different clinical trials of oral poliovirus vaccine (OPV): a randomized controlled trial and/or a challenge study with a respiratory virus other than SARS-CoV-2, such as influenza or a standard coronavirus. In looking at the data for OPV, it appears to be observational. With BCG, by contrast, there are quite a few randomized controlled clinical trials and experimental studies that document its ability to reduce the risk of infection/disease attributable to other infectious agents. Currently, there are several RCT's being conducted in the US and other countries that are assessing the ability of BCG to reduce the risk of SARS-CoV-2 infection/disease.

The vaccine working group is planning to discuss this topic at its Wednesday meeting, and I am wondering what, if anything, you would like to do with the outcome of that discussion. Write back to Bob, or more than that?

Thanks, Doug

From: "Fauci, Anthony (NIH/NIAID) [E]" < (b) (6)

Date: Friday, July 3, 2020 at 12:07 PM

To: "Lowy, Douglas (NIH/NCI) [E]" < (b) (6) "Collins, Francis (NIH/OD) [E]"

< (b) (6) "Lane, Cliff (NIH/NIAID) [E]" < (b) (6) "Mascola, John (NIH/VRC) [E]" < (b) (6)

Cc: "Wholley, David (FNIH) [T]" < (b) (6)

Subject: RE: Gallo and OPV

This issue will not go away and so perhaps it is best to have the ACTIV Vaccines WG take a look at this and make some sort of recommendation.

From: Lowy, Douglas (NIH/NCI) [E] < (b) (6)

Sent: Friday, July 3, 2020 11:54 AM

To: Collins, Francis (NIH/OD) [E] < (b) (6) Fauci, Anthony (NIH/NIAID) [E] < (b) (6) Lane,

Cliff (NIH/NIAID) [E] < (b) (6) Mascola, John (NIH/VRC) [E] < (b) (6)

Cc: Wholley, David (FNIH) [T] < (b) (6)

Subject: Re: Gallo and OPV

Hi Francis: The vaccine working group has not discussed this topic. Doug

From: "Collins, Francis (NIH/OD) [E]" (b) (6)

Date: Friday, July 3, 2020 at 11:46 AM

To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) "Lane, Cliff (NIH/NIAID) [E]" (b) (6) "Mascola, John (NIH/VRC) [E]" (b) (6)

Cc: "Wholley, David (FNIH) [T]" < (b) (6)

Subject: RE: Gallo and OPV

Hi Tony, Cliff, Doug, and John (and looping in David)

Bob Gallo is back with a complaint that no one has followed up on the OPV idea. See attached. Was this discussed in the ACTIV Vaccines WG or in any other venue?

Tx, Francis

 From: Fauci, Anthony (NIH/NIAID) [E]
 (b) (6)

 Sent: Sunday, May 3, 2020 1:45 PM

 To: Lane, Cliff (NIH/NIAID) [E]
 (b) (6)
 ; Collins, Francis (NIH/OD) [E]
 (b) (6)

 Cc: Lowy, Douglas (NIH/NCI) [E]
 (b) (6)
 ; Mascola, John (NIH/VRC) [E]
 (b) (6)

 Subject: RE: Gallo and OPV

Totally agree with Cliff's advice.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) (b) (6)
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lane, Cliff (NIH/NIAID) [E]

Sent: Sunday, May 3, 2020 1:22 PM

To: Collins, Francis (NIH/OD) [E]

Cc: Lowy, Douglas (NIH/NCI) [E]

Mascola, John (NIH/VRC) [E]

Subject: Re: Gallo and OPV

Francis,

I am not sure you need any sort of detailed response. I would just send a thank-you and indicate you will be sure those working on this at NIH are aware.

On May 3, 2020, at 12:55 PM, Collins, Francis (NIH/OD) [E] (b) (6) wrote:

Hi all,

I'm a bit at a loss to know how to respond to Bob Gallo. The aggressive manner in which he is promoting OPV causes me to worry he has lost objectivity about its promise. But is there any chance he has something here that could work?

Francis

From: Gallo, Robert (b) (6) **Sent:** Sunday, May 3, 2020 12:07 PM

To: Collins, Francis (NIH/OD) [E] (b) (6)

Subject: RE: Your query to Dr. Kadlec

Dear Francis,

It was a pleasure to hear from you, and yes, it has been a long time since we met or even spoke. Moons ago I was set to write to you after reading your wonderful book, but I ended up instead speaking with others about it. I should add at this point that I did not quickly respond to your email of a few days ago because I simply missed it.

It is true that I strongly suggest that OPV be quickly (already it is not quickly) brought forward for induction of a strong innate immune response to prevent or markedly reduce SARS-CoV-2 infection and/or severity until the field obtains a proven safe and efficacious vaccine producing a long lasting, adaptive immunity. OPV is very safe (notably for OPV 1 and 3 as bOPV which we will use and completely safe in a vaccinated population), simple, cheap, rather obvious, yet unique among the massive number of vaccines many (maybe most) of which are the same or at least if not exactly the same aiming at the same mechanism (targeting the spike and searching for the putative correlate of neutralizing Abs.).

OPV should work for a few months and possibly longer. Also it should be working multiple times so I think could cover more than a few months, giving us time for a proven vaccine of adaptive immunity, which might be very long lasting as is hoped.

In the main the WHO comments are correct. Of course we sought and have letters of support from them as well as from many others. Though they are again supportive in their notes to you, there is one item that surprises me. They add that there was no clinical efficacy results as yet. They know or certainly should know that there is plenty of clinical data for this concept with BCG, OPV, and live Measles vaccine. Needless to say this is what turned me on during our regular Global Virus Network (GVN)conference calls. (Incidentally GVN is an organization I have thought of bringing to your attention. I think you would find it impressive and useful). I would be happy to share with you the clinical observations with OPV if you wish.

I would like to take a small diversion, but I suspect you are aware of these things. My colleagues and I respect the WHO because of its representation and because we have colleagues/friends there as well. However, sometimes bureaucracy of a massive degree leads to inaction or even much worse—political expediency. I won't bother you with details of these unless you ask, but I had such experiences with HTLV-1 which we discovered in 1980 as the 1st human retrovirus and which cause not only the highest incidence of cancer (% of infections) of any virus and other fatal diseases as well but mainly in less developed countries (plus Japan) and again with HIV in 1984. Behavior was not beneficial. Perhaps it will be of relevance in the future because a few at WHO took a position to remove OPV (Sabin) in favor of IPV (Salk) in their polio eradication scheme. It was a huge failure. As my FDA collaborator, Konstantin Chumakov, says "Blessed be Bill Gates" because he saved OPV and saved the day and in so doing has produced a still better OPV.

There is indeed data also for BCG as well as live Measles though I know less of the latter. BCG is less available, requires injection, harder to make, not as safe, and we think unlikely to be as effective as OPV. Nonetheless, we favor its use too. The mechanisms will be similar.

You asked whether monkey trials are planned. For several reasons definitely not —though we are planning some monkey experiments, but not large enough for "clinical" conclusions. The main reasons are: 1) cost; 2) that billions not thousands or millions have received OPV safely and in our collective view (and we know the studies pretty well) protection has been clinically shown; 3) In a pandemic we wished to move quickly (so far we must say that has not been achieved). A typical monkey vaccine study will take time, but 4) in this case it would be a huge amount of lost time as monkeys require great doses of polio for infection and monkeys have to be trained to drink their orange juice. It would be hard to imagine that such studies would even give us useful information.

On a final digression Francis I have had 36 years of on/off experiences with glycosylated spike proteins—their analyses immunologically and especially regarding use in vaccines and developing neutralizing Abs. I believe it will be a mistake to put most eggs in that basket. The risks: shortened antibody half life; 2) protection NOT correlating with neutralizing Abs; 3) sometimes hazards from them. Admittedly, they might work, but I trust and hope that not everything is going in this bag. If you wish to discuss this again I will be available.

Finally, I hd no idea you were into vaccines or SARS-2 nor any part of CoVID-19 disease, but I am very happy to learn this.

Thanks.

Bob Gallo

From: Collins, Francis (NIH/OD) [E] (b) (6) Sent: Thursday, April 30, 2020 5:00 PM To: Gallo, Robert (b) (6) Cc: Disbrow, Gary (OS/ASPR/BARDA) Kadlec, Robert (OS/ASPR/IO) (b) (6) Tabak, Lawrence (NIH/OD) [E] (b)(6): Shuy, Bryan : Johnson, Robert (OS/ASPR/BARDA) (OS/ASPR/IO) (b) (6) (b) (6) Mascola, John (NIH/VRC) [E] ; Lane, Cliff (NIH/NIAID) [E] (b) (6) (b)(6)**Subject:** Your query to Dr. Kadlec

CAUTION: This message originated from a non UMB, UMSOM, FPI, or UMMS email system. Whether the sender is known or not known, hover over any links before clicking and use caution opening attachments.

Dear Bob,

It's been quite a while since we've chatted. Bob Kadlec asked me to respond to your query about the possible use of OPV to activate innate immunity and provide COVID-19 protection. Has this been tested in a non-human primate model? I note the recommendation below that says a clinical trial is planned – can you tell me more about that?

As you can imagine, we are all flat out on the vaccine development pathway!

Francis

The use of oral polio vaccine (OPV) to prevent SARS-CoV2 (Polio Eradication Campaign)

There is no evidence that oral poliovirus vaccine (OPV) protects people against infection with COVID-19 virus.

A clinical trial addressing this question is planned in the USA, and WHO will evaluate the evidence when it is available.

In the absence of evidence, WHO does not recommend OPV vaccination for the prevention of COVID-19. WHO continues to recommend OPV as part of essential immunization services to prevent poliomyelitis and as part of global polio eradication efforts.

There are experimental signals from various studies over the years that OPV has non-specific effects on the immune system. These effects have not been well characterized and their clinical relevance is unknown. Such non-specific effects may not be limited to OPV, as other live vaccines have also been associated with non-specific protective effects (such as BCG vaccine against tuberculosis). Nonlive vaccines in contrast do not seem to have the same effects.

The exact mechanism of non-specific protection induced by live vaccines needs to be elucidated further. Clinical studies could begin immediately because the vaccines in question are licensed and have an excellent safety record. Clinical trials involving off-label use of various drugs licensed for other indications are currently underway. The existing scientific rationale suggests that the same should be done for OPV and other live vaccines. A study is currently being discussed with various partners and vaccine manufacturers, including the US FDA, the outcomes of which will be carefully assessed to determine potential use in the context of the spread of SARS-CoV2 until the time when specific vaccines and antiviral therapies are ready.

 From: Kadlec, Robert (OS/ASPR/IO)
 (b) (6)

 Sent: Thursday, April 30, 2020 10:28 AM

 To: Gallo, Robert (b
 Collins, Francis (NIH/OD) [E]
 (b) (6)

 Tabak, Lawrence (NIH/OD) [E] < (b) (6)</td>
 Shuy, Bryan (OS/ASPR/IO)

 (b) (6)
 Subject: Re: Respone

Dr Gallo thank you for your note and I appreciate you reaching out to me. I have copied Dr Collins and Dr Tabak to consider the ACTIV forum they have created to bring industry academia and government to consider scientific base approaches That you have described. Dr Collins has organized a vaccine group and I assess could be the best and fastest place to discuss your concept. I am sure they will connect with you soonest

Best

Bob Kadlec.

Sent from my iPhone

On Apr 30, 2020, at 10:02 AM, Gallo, Robert < (b) (6) wrote:

Dear Dr. Kaldec,

I have not heard from you in over a week. You mentioned getting back to me in a day or two. Time is passing. I am asking you to look at OPV 1 plus 3 serotypes as a bivalent, completely safe vaccine with powerful stimulation of innate immunity lasting several weeks, which can be given a second or third time, and with a historical track record of preventing other infections from entirely different RNA viruses (such as protecting against influenza). Therefore, it should be really helpful for some months, and I think get us past a second wave of SARS-CoV-2, and help people return to work safely. I don't understand delays or apparent lack of interest. Who can possibly be against this? If you hear of hypothetical problems we can show you that these are false. Just ask the questions, and we can give you the evidence.

However, no answer from you suggests no interest and must quickly make alternative pathways. I am though quite surprised and fear you are receiving "fake news" if you will pardon the expression. Some have been against this who defend their old and failed position on polio eradication with their promotion of the use of the inactivated polio virus vaccine. Please note that in the US between 1962 and 1985 we received (safely) the oral polio (OPV). Moreover, if vaccinated already there has not been a single case of a complication and BILLIONS have received it. No it will not last long as innate immunity is short lived, but we strongly believe that we can break the back of the SARS-CoVID-2 spread. Also note that this is what Bill Gates is doing now in India and much of the Eastern hemisphere.

There are countries outside the US wanting to move fast on this. We are waiting for your reply.

Robert Gallo Director, Institute of Human Virology, Professor of Medicine and Professor of Microbiology, UMB, School of Medicine, Baltimore, Co-founder and International Science Advisor of the Global Virus Network (GVN)

From: Pangalos, Mene [(b) (6)

Sent: 6/5/2020 10:55:10 AM

To: Collins, Francis (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=410e1ca313f44ced9938e50d2ff0b6c2-collinsf]

CC: Esser, Mark [(b) (6) Villafana, Tonya [(b) (6)

Subject: RE: combinatorics and monoclonal Abs - Data Shared In Confidence

Francis,

We do these assays ourselves and with collaborators... they are often done in oncology as I am sure you know. This is data from two of our mAbs that demonstrated what we are looking for.

Please do not share this data set as is yet to be published and I am sharing in confidence but hopefully gives you a sense of what we do and what we hope to observe. Our cocktail moving forward will take the two mAbs with the best synergistic effect in neut assays into the clinic (which we have in fact already selected).

These sorts of assays could be used to test a variety of antibodies from different sources to find combinations that work and will be important if resistance emerges.

Mene

		-		mAb.		ng/mL)				
		250	125	62.5	31.3	15.6	7.8	3.9	2	1	0
		1	2	3	4	5	6	7	8	9	10
250	Α	100	100	100	100	100	99	99	95	94	96
125	В	100	100	100	100_	100	95	94	85	83	81
63	С	100	100	100	99	96	93	64	29	— ₁₀ >	0
31	D	100	100	99	99	90	66	4	0	0	0
16	Ε	100	100	99	97	83	30	0	0	0	0
8	F	100	99	98	91	66	0	0	0	0	0
4	G	100	99	93	75	46	0	0	0	0	0
0	Н	97	91	83	46	6	0	0	0	0	0

Sir Menelas N Pangalos PhD FRSB FMedSci

EVP & President BioPharmaceuticals R&D AstraZeneca, Melbourn Science Park, Cambridge Road, Royston, Herts SG8 6EE

Work: (b) (6)

Mobile E-Mail: (b) (6)

Check out our open innovation http://openinnovation.astrazeneca.com

From: Collins, Francis (NIH/OD) [E] < (b) (6)

Sent: 05 June 2020 02:26

To: Pangalos, Mene < (b) (6)

Cc: Wholley, David (FNIH) [T] < (b) (6)

Subject: combinatorics and monoclonal Abs

Hi Mene,

I think I heard you say something during the ACTIV call yesterday about ways to optimize the choice of mAbs that would be synergistic. For the upcoming inpatient and outpatient trials of mAbs against SARS-CoV-2, it would be great to have available a preclinical in vitro assay that could predict that kind of synergy in vivo. Do you have an approach that you or someone on your staff would be willing to tell me about?

Best, Francis

AstraZeneca UK Limited is a company incorporated in England and Wales with registered number:03674842 and its registered office at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA.

This e-mail and its attachments are intended for the above named recipient only and may contain confidential and privileged information. If they have come to you in error, you must not copy or show them to anyone; instead, please reply to this e-mail, highlighting the error to the sender and then immediately delete the message. For information about how AstraZeneca UK Limited and its affiliates may process information, personal data and monitor communications, please see our privacy notice at www.astrazeneca.com

From: Melencio, Cheryl (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=279E14FA7428415BB86087D08B628E6F-MELENCIOC] on behalf of Wholley, David (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=CD9E702FCF28414883D0B6996D677257-WHOLLEYD] Sent: 11/23/2020 4:17:50 PM To: Austin, Christopher (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=17597cabc42247548e596778304f781f-austinc]; Bancel, Stephane Carter, Kara | Cavaleri, Marco (b) (6) (b) (6) Cihlar, Tomas Collins, Francis (NIH/OD) [E] (b) (6) (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=410e1ca313f44ced9938e50d2ff0b6c2-collinsf]; Corey, Larry Culp, Michelle (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4e38fa37e0424217aa0a283cba9e5098-mculp]; Victoria Davey [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2c8291f38ec342f895243c0617e115ec-victoria.da]; Disbrow, Gary (OS/ASPR/BARDA) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=62a151e39ab942d88a813b449f9f6ccb-Gary.Disbro]; Dolsten, Mikael Erbelding, Emily (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e976ebf7b14142fbb3c5c294efb334fe-erbeldingej]; Erck, Stan Fauci, Anthony (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=df38103d75134f658ae2d356f0396b94-afauci]; Freire, Maria (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=8598d551d1d3455eaf14854c83f41d84-freiremc]; Gadbois, Ellen (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0243d1d6e6f248268d2edec566c26c2a-gadboisel]; Gibbons, Gary (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b71b953b50a5495ca0f2869ab13bc407-gibbonsgh]; Hudson, Thomas James, Stephanie (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (b) (6) (FYDIBOHF23SPDLT)/cn=Recipients/cn=f0032ef62ca343dfb4bf79577e2aa8d1-jamesst]; Johnson, Robert (OS/ASPR/BARDA) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=feb0b05457404e2f8b88af78e9ac4dd9-Robert.John]; Kramer, Lynn Lane, Cliff (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (b)(6)(FYDIBOHF23SPDLT)/cn=Recipients/cn=2d7e368a3137473bbce161547a82f2de-clane]; Lepore, John Marks, Peter (FDA/CBER) [/o=ExchangeLabs/ou=Exchange Administrative Group (b) (6) (FYDIBOHF23SPDLT)/cn=Recipients/cn=b2e527dbda2b4a86b8d72f06b813d471-MarksP.fda]; Marston, Hilary (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ab30660917b942ffba9ae95d631116f3-marstonhd]; Mascola, John (NIH/VRC) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=7f78b40a596b4ca4a2850a429d1ae3f2-jmascola]; Meeker, David]; Menetski, Joseph (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5001af52dc4a427ea3d34f1e072f8cb7-menetskijp]; Messonnier, Nancy (CDC/DDID/NCIRD/OD) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=441f65db836c4a89a42aecb9a0d9b96c-NAR5]; Pandya, Hitesh Pangalos, Mene [Pao, William (b) (6) (b) (6) Parker, Ashley (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (b) (6) (FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras]; Paul, Steve Perlmutter, Roger [Plenge, Robert [(b) (6) (b) (6) (b) (6) Rachel Ramoni [/o=ExchangeLabs/ou=Exchange Administrative Group Plump, Andy [(b) (6) (FYDIBOHF23SPDLT)/cn=Recipients/cn=d3f6cb5237a44b75887b8a1ca1f9bb91-Rachel.Ramo]; Reed, John Rouse, Doris [(b) (6) Santos, Michael (FNIH) Reese, David [(b) (6) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ab38cb6836de44e18ef4cc6952f65f80-santosmr]; Skovronsky, Daniel Stein, Peter (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (b) (6) (FYDIBOHF23SPDLT)/cn=Recipients/cn=b4a14118481b4b39ba7e62a8d6425f79-Peter.Stein]; Stoffels, Paul Tabak, Lawrence (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=02e22836b5ff4e9988e3770cfc7ee770-tabakl]; Talley, Michael Tsai, John [(b) (6) Vessey, Rupert []; Virgin, (b) (6) (b) (6)

```
Wholley, David (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group
              Skip [
                       (b) (6)
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]; Woodcock, Janet
              (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=9bc3fc3ebfcf48879f92169bd7644e29-Janet.Woodc]; Young, John
                                         Colvis, Christine (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative
                         (b) (6)
              Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4b7e84cce098457896b2df19fa172c87-ccolvis]; Desrosiers, Betsy
                            (b)(6)
                                               Eric Hughes [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=f97951a53cd54153b5daa9d99ad4ec90-EricHughes]; Jansen, Kathrin
                                         Kurilla, Michael (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=dc4e85061e3943b9b8ad3f426727861f-mkurilla]; Lowy, Douglas (NCI)
              [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=54fa75fe6e304e34ba567c66b832baa0-drl.helix.n]; Read, Sarah (NIH/NIAID)
              [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=527b160038004a199ae6e0bac2226099-readsa]; Young, John
                        (b) (6)
CC:
              Anderson, James (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=73143d1860bc42458be254ca21573b23-andersonjm]; Burklow, John
              (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=2e57f267323b43c08be856acb5b964ca-burklowj]; Carluccio, Dana
                                                  Castillejos, Carlos [
                                                                                        FNIH Central Account
                             (b) (6)
                                                                          (b) (6)
                                        Gadbois, Ellen (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
                        (b)(6)
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=0243d1d6e6f248268d2edec566c26c2a-gadboisel]; Hallett, Adrienne
              (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=f1705e2e7c254b84a77f058dbf75b31b-hallettaa]; Lane, Cliff (NIH/NIAID) [E]
              [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=2d7e368a3137473bbce161547a82f2de-clane]; Parker, Ashley (NIH/OD) [E]
              [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras]; Tabak, Lawrence (NIH/OD)
              [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=02e22836b5ff4e9988e3770cfc7ee770-tabakl]; Wolinetz, Carrie (NIH/OD) [E]
              [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=1c655040d47346c7b04d7bc11a403ecb-wolinetzcd]; Gorman, Greta (FNIH)
              [T] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=280703da933d491586841696e460f062-gormanmj]; Meltzer, Abbey (FNIH)
              [T] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=c341d86cf7404a78ac8f852e698e5382-meltzerak]; Myles, Renate (NIH/OD)
              [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=7d317f5626934585b3692a1823c1b522-mylesr]; Wolinetz, Carrie (NIH/OD)
              [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=1c655040d47346c7b04d7bc11a403ecb-wolinetzcd]; Adam, Stacey (FNIH) [T]
              [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=dcd875f0679648859e1cf101c0943414-adamsj4]; Margaret Anderson
              [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=ab9a138f1e284c689fedfb10b8cc5295-marganderso]; Appell, Evan
              [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user7ee69e83]; Chen,
              Helen Q. [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=user34aa917e]; Connelly, Sarah [/o=ExchangeLabs/ou=Exchange
              Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user3ed93bab]; Gonzalez, Nina
              [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user3c2f486d]; Hawk,
              Harrison [/o=ExchangeLabs/ou=Exchange Administrative Group]
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=user280c84f8]; Mendelson, Jesse
                                                                                                           Menetski,
                                                                                           (b) (6)
              Joseph (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=5001af52dc4a427ea3d34f1e072f8cb7-menetskijp]; Santos, Michael (FNIH)
              [T] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=ab38cb6836de44e18ef4cc6952f65f80-santosmr]; asorosa
              [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=userffc6da86];
              Stratton, Benjamin [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=usere3ed7188]; btolman [/o=ExchangeLabs/ou=Exchange Administrative
```

Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user7b137a1e]; Tountas, Karen (FNIH) [T]

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=40c04fef6f1e46f5b750753cd5a14f93-tountaskh]; Wachtel, Jonathan (b) (6) Wholley, David (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]

Subject: Notes from Thursday's ACTIV Leadership Team Meeting

Attachments: 2020-11-19_ACTIV_Leadership_Team_Meeting_Summary_v3.docx

Dear Leadership Team members and meeting attendees:

Please see the notes from our teleconference this past Thursday, November 19. Please let me know any additional comments, questions, or suggestions regarding these notes or the action items.

Thank you again for all your support of and contributions to ACTIV.

Regards,

David

David Wholley
Senior Vice-President, Research Partnerships
Foundation for the National Institutes of Health
(b) (6)

fnih.org

11400 Rockville Pike Suite 600 North Bethesda, MD 20852

In 2019, the FNIH earned the highest rating from Charity Navigator for the fifth consecutive year and was recognized as an organization that exceeds industry standards.

From: Santos, Michael (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=AB38CB6836DE44E18EF4CC6952F65F80-SANTOSMR] Sent: 5/18/2020 7:21:29 PM To: Lowy, Douglas (NIH/NCI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (b) (6) (FYDIBOHF23SPDLT)/cn=Recipients/cn=f1b7b8fe4739478bb17840c56902718a-lowyd]; Arvin, Ann [/o=ExchangeLabs/ou=Exchange Administrative Group (b) (6) (FYDIBOHF23SPDLT)/cn=Recipients/cn=3bbf6108d53148f684dad333fce983de-aarvin.stan]; Beth Bell Cavaleri Marco (b) (6) (b) (6) (b) (6) (b)(6)(b) (6) (b) (6) Greg Glenn [(b)(6)(b)(6)(b) (6) Haynes, Barton [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5d4a05845b5b4069ad0447fb60ebfa79-hayne002.mc]; hotez@bcm.edu; Marks, Peter (FDA/CBER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b2e527dbda2b4a86b8d72f06b813d471-MarksP.fda]; Mascola, John (NIH/VRC) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=7f78b40a596b4ca4a2850a429d1ae3f2-imascola]; Messonnier, Nancy (CDC/DDID/NCIRD/OD) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=441f65db836c4a89a42aecb9a0d9b96c-NAR5]; Michael, Nelson L CIV USARMY MEDCOM WRAIR (USA) [Offit, Paul [/o=ExchangeLabs/ou=Exchange (b) (6) Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cbd9cc56fdbe4598a57b423d484dcf9f-offit.email]; Seals, Jonathan (OS/ASPR/BARDA) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d7a87d49ccba4e3caaf5eb5d3586b1cc-Jonathan.Se]; Tal Zaks [(b) (6) (b) (6) CC: Tolman, Brett [Jessica. (b) (6) Hopps, Markay [(b) (6) (b) (6) Kozlowski, Mary (NIH/NCI) [C] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=15373a5a1d8a4fa89d49ba9c8561cc94-kozlowskimt]; Johnson, Maureen (NIH/NCI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0cb4ad1bebe64791b0415a7eb4bf71db-johnsonr]; Jeneffer Haynes (b) (6) (b) (6) Austin, Sarah (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange (b) (6) (b) (6) Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=292fcb760f9f4f199ebe343e08ef1781-austinsj]; Isabel Ramsey [Parker, Ashley (NIH/OD) [E] (b) (6) (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras]; Marston, Hilary (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ab30660917b942ffba9ae95d631116f3-marstonhd1; Qashu, Felicia (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=366447a553f44696b2c79484d90e41e5-qashufm]; Wholley, David (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]; Melencio, Cheryl (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=279e14fa7428415bb86087d08b628e6f-melencioc]; Menetski, Joseph (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5001af52dc4a427ea3d34f1e072f8cb7-menetskijp]; Adam, Stacey (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dcd875f0679648859e1cf101c0943414-adamsj4]; Tountas, Karen (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=40c04fef6f1e46f5b750753cd5a14f93-tountaskh]; James, Stephanie (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f0032ef62ca343dfb4bf79577e2aa8d1-jamesst]; Colvis, Christine (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4b7e84cce098457896b2df19fa172c87-ccolvis]; Desrosiers, Betsy Hughes, Eric [Kurilla, Michael (NIH/NCATS) [E] (b) (6) (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dc4e85061e3943b9b8ad3f426727861f-mkurilla]; Read, Sarah (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=527b160038004a199ae6e0bac2226099-readsa]; Young, John

	(b) (6)	Paul Gillard [(b) (6)	Hamilton, Holli (OS/ASI	PR/BARDA)
	[/o=ExchangeLabs/ou=Exch	ange Administrati			
	(FYDIBOHF23SPDLT)/cn=Re	cipients/cn=a28fc	2f8eb134b00b5eaa42	22d0576cc-Holli.Hamil]; Modjarrad, Kayvon CIV
	USARMY MEDCOM WRAIR	(USA) [(b) (6)	Kathleen Neuzil [/o=E	xchangeLabs/ou=Exchange
	Administrative Group (FYDI	BOHF23SPDLT)/cr		8e1252cf4266bffc8d94	988f5715-kneuzil.som];
	Schrag, Stephanie (CDC/DD	D/NCIRD/DBD) [/	o=ExchangeLabs/ou=E	xchange Administrativ	e Group
	(FYDIBOHF23SPDLT)/cn=Rei	cipients/cn=9be29	9b344ba14363bdecaa	43582ca226-ZHA6]; Ve	erani, Jennifer R.
	(CDC/DDID/NCIRD/DBD) [/c	=ExchangeLabs/o	u=Exchange Administ	rative Group	
	(FYDIBOHF23SPDLT)/cn=Re	cipients/cn=7c249	0692151d46d6ac80cb2	28ada3d3a0-qzr7]; Tho	rnburg, Natalie
	(CDC/DDID/NCIRD/DVD) [/c	=ExchangeLabs/o	u=Exchange Administ	rative Group	
	(FYDIBOHF23SPDLT)/cn=Re	cipients/cn=c8d07	9e00a5649639c6f142	25f3bb075f-nax3]; Gon	zalez, Nina
	[/o=ExchangeLabs/ou=Exch	ange Administrati	ve Group (FYDIBOHF2	3SPDLT)/cn=Recipients	s/cn=user3c2f486d];
	Wachtel, Jonathan	(b) (6)	Stratton, Benjamin [(b) (6)	Anderson, Margaret
	(b) (6)		(b) (6)	; Bethany Stokes
	(b) (6)				
Subject:	ACTIV Vaccines Working Great	oup meeting			
ocation:	Webex: https://nih.webex.d	om,	(b) (6)		
Start:	5/28/2020 6:00:00 PM				
ind:	5/28/2020 7:00:00 PM				
Show Time As:	Tentative				
Required	(b) (6)	Lowy, Douglas (N	IIH/NCI) [E]:	(b) (6)	Arvin, Ann; Beth Bell
teganea	(b) (6)	LOWY, Douglas (I	tilly itely [L],	(b) (6)	Aivili, Allii, Detii Deli

Required	(b) (6)	Lowy, Doug	las (NIH/NCI) [E];	(b) (6)	Arvin, A	nn; Beth Bell
Attendees:	(b) (6)	(b) (6)	Cavaleri	Marco; (b) (6)	
	(b) (6)		(b) (6)	Greg Glenn;	(b) (6)	Haynes,
	Barton; (b) (6	(b) (6)	.ch; Marks, Pe	ter (FDA/CBER); Mase	cola, John (NIH/V	/RC) [E];
	Messonnier, Nancy	(CDC/DDID/NCIRD/C	D); Michael, Nelson	L CIV USARMY MEDC	OM WRAIR (USA); Offit, Paul;
	(b) (6)	Seals, Jonathan (C	OS/ASPR/BARDA);	(b) (6)	Tal Zaks	
Optional	Tolman, Brett;	(b) (6)	Hopps, Markay; Ko	ozlowski, Mary (NIH/I	NCI) [C]; Johnson	, Maureen
Attendees:	(NIH/NCI) [E];	(b) (6)	Jeneffer Haynes;	(b) (6)		(b) (6)
	(b) (6)	Austin, Sarah	(NIH/NIAID) [E];	(b) (6)	Isabel R	amsey; Parker,
	Ashley (NIH/OD) [E]; Marston, Hilary (NI	H/NIAID) [E]; Qashu,	Felicia (NIH/OD) [E];	Wholley, David (I	FNIH) [T];
	Melencio, Cheryl (F	NIH) [T]; Menetski, Jo	oseph (FNIH) [T]; Ada	m, Stacey (FNIH) [T];	Tountas, Karen (FNIH) [T]; James,
	Stephanie (FNIH) [7]; Colvis, Christine (N	IH/NCATS) [E]; Desro	siers, Betsy; Hughes,	Eric; Kurilla, Mic	hael (NIH/NCATS)
	[E]; Read, Sarah (NI	H/NIAID) [E]; Young,	John; Paul Gillard; Ha	amilton, Holli (OS/ASI	PR/BARDA); Mod	jarrad, Kayvon CIV
	USARMY MEDCOM	WRAIR (USA); Kathle	en Neuzil; Schrag, St	ephanie (CDC/DDID/I	NCIRD/DBD); Ver	ani, Jennifer R.
	(CDC/DDID/NCIRD/	DBD); Thornburg, Na	talie (CDC/DDID/NCII	RD/DVD); Gonzalez, N	lina; Wachtel, Jo	nathan; Stratton,
	Benjamin; Anderso	n, Margaret; rose.	(b) (6)	(b) ((6)	Bethany Stokes

⁻⁻ Do not delete or change any of the following text. --

Join Webex meeting

Meeting number (access code): (b) Meeting password: (b) (6)

Join from a video system or application

Dial (b) (6) @nih.webex.com

You can also dial (b) (6) and enter your meeting number.

Join by phone

Tap to call in from a mobile device (attendees only)

(b) (6) Call-in toll number (US/Canada)

Global call-in numbers

lain uning	Minrocoft	una or Miar	nonft Chunn	for Ducinocc
Join using	MILLOSOIL	ALIC OL MICE	OSUIL SKYDE	for Business

Dial (b) (6) Inc. webex.com Can't join the meeting?

If you are a host, go here to view host information. IMPORTANT NOTICE: Please note that this Webex service allows audio and other information sent during the session to be recorded, which may be discoverable in a legal matter. By joining this session, you automatically consent to such recordings. If you do not consent to being recorded, discuss your concerns with the host or do not join the session.

From: Myles, Renate (NIH/OD) [E] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP

(FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=7D317F5626934585B3692A1823C1B522-MYLESR]

Sent:

4/16/2020 12:10:13 PM

To:

Parker, Ashley (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras]

CC:

Wolinetz, Carrie (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=1c655040d47346c7b04d7bc11a403ecb-wolinetzcd]

Subject:

RE: PLEASE READ: Draft Email to Collect Communication Contact Information

Attachments: Master list for ACTIV.xlsx

I pulled the names from the attached that you sent earlier in the week. There isn't a Takeda contact on this list. Would you send it to me?

From: Parker, Ashley (NIH/OD) [E] < (b) (6)

Sent: Thursday, April 16, 2020 8:03 AM

To: Myles, Renate (NIH/OD) [E] <

(b) (6)

Cc: Wolinetz, Carrie (NIH/OD) [E] <

(b) (6)

Subject: RE: PLEASE READ: Draft Email to Collect Communication Contact Information

Good morning Renate,

Our rep at Takeda, Andy Plump is included on the master list. I am confirming with Francis that he used our master list for his email that went out last night – I should be able to confirm this for you this morning.

I hope you are staying safe and healthy; maybe even getting some rest in between the constant COVID activities.

Thanks, Ashley

From: Myles, Renate (NIH/OD) [E] (b)

Sent: Thursday, April 16, 2020 7:14 AM

To: Parker, Ashley (NIH/OD) [E] (b) (6) **Cc**: Wolinetz, Carrie (NIH/OD) [E] (b) (6)

Subject: FW: PLEASE READ: Draft Email to Collect Communication Contact Information

Importance: High

Hi Ashley:

I'm not sure if Francis added a Takeda contact to his email. I could not find one on the master contact list. I have not heard from their organizations yet. Would you let me know if you provided that to him last night or if they are missing from this email? Need to send it to this group this morning.

Thanks, Renate

From: Myles, Renate (NIH/OD) [E]

Sent: Wednesday, April 15, 2020 9:11 PM

To: Collins, Francis (NIH/OD) [E] < (b) (6)

Cc: Wood, Gretchen (NIH/OD) [E] (b) (6) McManus, Ay

McManus, Ayanna (NIH/OD) [E]

(b) (6) Burklow, John (NIH/OD) [E] (

(b) (6)

(b) (6)

>; Parker,

Ashley (NIH/OD) [E]

(b) (6)

Subject: PLEASE READ: Draft Email to Collect Communication Contact Information Importance: High Hi Francis: We need to collect the communication contacts from the partner organizations so we can share the release with them for review. Below is 1) a draft email for you to send to the company participants, 2) the contacts for the companies we list in the release except for Takeda (I could not find a Takeda contact on the master list; hoping Ashley can provide); 3) those who should be copied (feel free to add others). Dear ACTIV colleagues: As I mentioned earlier today, we would like to announce the plans for a public-private partnership as expeditiously as possible. Please provide the name of the most appropriate communication contact from your company so that we may share a draft of the embargoed press release for your review. Please send the contact information to Renate Myles at (b) (6) and Abbey Meltzer (b) (6) this evening, if possible. BCC: (b)(6)

(b) (6)

Thanks, Renate

CC:

From:	Adam, Stacey (FNIH) [T] [/O=EXCHANGEL (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN			4]
Sent:				
Sent: To:	(FYDIBOHF23SPDLT)/cn=Recipients/cn=b [T)/cn=Recipients/cn=527b Mellors, John W [, ts/cn=user257cb364]; Nair abs/ou=Exchange Administration b7e84cce098457896b2df er (FDA/CDER) [/o=Exchan, b4a14118481b4b39ba7e62 hman, Tim (OS/ASPR/BAR) T)/cn=Recipients/cn=00f8 Keith Gottesdiene [/o=ExchangeLabs/ou=Exc mish Patel [(b) strative Group 19fa172c87-ccolvis]; You geLabs/ou=Exchange Adr 2a8d6425f79-Peter.Stein] DA) (CTR) [/o=ExchangeLa a853d8d740f8a8cdd55cb er [(b) (6) Koroshetz, Walter (NIH	c2226099-readsa]; hange Administrative (6) Colvis, ng, John ministrative Group l; Poole, Mike abs/ou=Exchange f8eb9da-Tim.Buchman]; Elliott Levy /NINDS) [E]
CC:	(FYDIBOHF23SPDLT)/cn=Recipients/cn=0 Elizabeth Kim [(b) (6) Me	0601ca55a82841aba16353 (NIH/NHLBI) [E] [/o=Exch 036113c7be0f42f897d1294 netski, Joseph (FNIH) [T] [/	b96cff8ca9-ehiggs]; Carlo angeLabs/ou=Exchange A 4cfbb99c10-goffdc] /o=ExchangeLabs/ou=Exc	dministrative Group hange Administrative
	Group (FYDIBOHF23SPDLT)/cn=Recipient			
	Maria [(b) (6) Salath Parker, Ashley (NIH/OD) [E] [/o=Exchang	in, Carla (b) (c		(b) (6)
	(FYDIBOHF23SPDLT)/cn=Recipients/cn=3 [/o=ExchangeLabs/ou=Exchange Administry of the control of t	strative Group d9e702fcf28414883d0b69 ninistrative Group 179e14fa7428415bb86087 Walker, Paula (NIH/NIND9 T)/cn=Recipients/cn=fbe8 ngeLabs/ou=Exchange Adn	996d677257-wholleyd]; N d08b628e6f-melencioc]; S) [E] [/o=ExchangeLabs/d 1b9b832e40acbf5fd03bcd ninistrative Group	Melencio, Cheryl (FNIH) Lucas Smalldon pu=Exchange
Subject:	ACTIV TX-Clinical Agent Prioritization Sub	group #9		
Location:	https://fnih.zoom.	(b) (6)		
Start: End: Show Time As:	5/12/2020 5:00:00 PM 5/12/2020 6:00:00 PM Tentative			
Required Attendees: Optional	Eric Hughes; Read, Sarah (NIH/NIAID) [E] (NIH/NCATS) [E]; Young, John; Stein, Pete Vincent, Michael; Keith Gottesdiener; Ell Elizabeth (NIH/NIAID) [E]; Carlos O Garne Elizabeth Kim; Menetski, Joseph (FNIH) [er (FDA/CDER); Poole, Mik iott Levy; Wung, Peter /US er; Goff, David (NIH/NHLBI	e; Buchman, Tim (OS/ASF S; Koroshetz, Walter (NIH, I) [E]	PR/BARDA) (CTR); /NINDS) [E]; Higgs,
Attendees:	Parker, Ashley (NIH/OD) [E]; Wholley, Da (NIH/NINDS) [E]; Ward, Jackie (NIH/OD)	vid (FNIH) [T]; Melencio, (
Stacey Adam	is inviting you to a scheduled Zoo	om meeting.		
Join Zoom M	leeting			
https://fnih.z		(b) (6)		

Meeting ID: (b) (6) Password: (b) (6) One tap mobile (b) (6) US (New York) US (Germantown) Dial by your location (b) (6) US (New York) US (Germantown) US (Chicago) US (San Jose) US (Tacoma) US (Houston) US (San Jose) Meeting ID: (b) (6) Password: (b) (6)

From:	(FYDIBOHF2	ey (FNIH) [T] [3SPDLT)/CN=										
Sent:	5/20/2020 6											
То:		ey (FNIH) [T] [3SPDLT)/cn=							damsid	1]· Judy (Currier	
		(b) (6)		Hughes [(b) (6)		LaVange				
	Sandeep Me							el (NIH/NIA			(b) (6)	
				(6)							(b) (6)	Dishin
		(NIH/NIAID)		(b) (6)				DA/CDER) [(b) (Rubin,
	Daniel B. (FD		(b) (6)		-arley, Jo	nn (FDA/C	200 (100 (100 (100 10 0)	(l	b) (6)		en Lynn
	Price [(b) (6)			(b) (6)			(b) (6)			(b) (6	5)
	(b)	(6)		(b) (6))		(b)) (6)		Eron, Jo	e	
	(b) ((6) Ja	van, Arzh	ang (NIH	/NIAID)	[E] [(b) (6	5)	Roa, J	hoanna	(b) (6))
	(b) (6)		eter (NIH,	/NIAID) [E	1[(b) (6)		onathan Li	ſ	(b) (6		Λarks,
	Gilbert (OS/	ASPR/BARDA			b) (6)			rina (OS/AS	7		,	,
	and the second second second second	(6)	(=)	-		(55111	1) (T) ((1) (1)				
CC:	Demarcus [(b)				ren (FNI		(b) (6)			l, Jonathan	
		(6)	Elizabet		` '	(6)	Parker	r, Ashley (N	NIH/OD) [E]		
		geLabs/ou=Ex :3SPDLT)/cn=					95aaaafe	06ebd70-p	oarkera	s]; Jhoar	nna Roa	
		(b) (6)		n, Joseph			0) (6)		nith, Da			
		(b) (6)		l Klekotka		(b) (6		Ajay Nir			(6)	Elsaid,
	Olivia [(b) (6)		pert Jan B	•		(b) (6)			Shen [(b) (6)	Libara
	Olivia	(0) (0)	Nok	Jeit Jaii b	enscho	9	(0) (0)	, Lei	JIICII [(0) (0)	
Subject: Attachments:	5401 Protoc	ACTIV TX-Clir ol Synopsis 0										
Location:	https://fnih.	.zoom.us,			(b) (6)						
Start: End:	5/20/2020 1 5/20/2020 1											
Show Time As:	50: 15	11.00.001111										
Show Time As:	Territative											
Required	Judy Currier	; Eric Hughes	; LaVange	e, Lisa M;	Sandee	p Menon	Proschar	n, Michael	(NIH/N	IAID) [E]	; Read, Sar	ah
Attendees:	(NIH/NIAID)	[E]; Price, Di	onne (FD/	A/CDER):	Rubin, I	Daniel B.	FDA/CDE	R): Farley.	John (F	DA/CDE	R): Karen L	vnn Price:
	(b) (c		T 1 T 1 T 1 T 1 T 1 T 1 T 1 T 1 T 1 T 1	(b) (6)			(b) (6			(b) (6)		,,
	, , ,	,			(6)				hana () ID) [E]; Roa	lhoanna.
		o) (6)	-+/NIU.I		(6)							
	(b) (6)		eter (NIH)	/NIAID) [E	:]; Jona	nan Li; iv	iarks, Glib	pert (US/AS	PR/BA	RDA) (CI	ΓR); Kozak,	iviarina
	(OS/ASPR/B	26										
Optional	Demarcus; 1	Tountas, Kare	n (FNIH)	[T]; Wach	tel, Jon	athan; Eli	zabeth Kir	m; Parker,	Ashley	(NIH/O	D) [E]; Jhoar	nna Roa;
Attendees:	Eron, Joseph	n J Jr; Smith, I	David; Par	ul Klekotk	a; Ajay	Nirula; El	said, Olivi	ia; Robert J	an Ben	schop; L	ei Shen	
Door on Alb O	utustiant V	7.										
Dear mAb O	utpatient v	v 1,										
It seems like	we can stil	Il get quoru	m, so I	think wo	e shou	ld proce	ed with	who we	have.			
						•						
Thanks,												
Stacey												
Join Zoom M	Lecting											
	_				45.4							
https://fnih.z	oom.us/				(b) (5)						
Meeting ID: Password: ((b) (6)											
L dob ii Old.	/ (-/											

```
One tap mobile
                    (b) (6)
                                                US (Germantown)
                                                US (Chicago)
Dial by your location (b) (6)
                        US (Germantown)
                        US (Chicago)
                        US (New York)
                        US (Tacoma)
                        US (Houston)
                        US (San Jose)
            (b) (6)
                        US (San Jose)
Meeting ID:
                  (b) (6)
Password: (b) (6)
Find your local number: <a href="https://fnih.zoom.u">https://fnih.zoom.u</a>
                                                    (b) (6)
```

From: Melencio, Cheryl (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=279E14FA7428415BB86087D08B628E6F-MELENCIOC] Sent: 11/12/2020 5:10:25 PM To: Melencio, Cheryl (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=279e14fa7428415bb86087d08b628e6f-melencioc]; Austin, Christopher (NIH/NCATS) [E] (b)(6); Carter, Kara [(b) (6) Cavaleri, Marco Cihlar, Tomas ; Collins, Francis (NIH/OD) [E] (b)(6)(b) (6) Culp, Michelle (NIH/OD) [E] [Corey, Larry (b) (6) (b)(6)Disbrow, Gary (OS/ASPR/BARDA) [Dolsten, Mikael [Erbelding, (b) (6) (b)(6)Emily (NIH/NIAID) [E] []; Erck, Stan [Gadbois, Ellen (NIH/OD) [E] (b)(6)(b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0243d1d6e6f248268d2edec566c26c2a-gadboisel]; Gibbons, Gary (NIH/NHLBI) [E] Hudson, Thomas [James, Stephanie (FNIH) (b)(6)(b) (6) Johnson, Robert (OS/ASPR/BARDA) [Kramer, Lvnn [T] (b)(6)(b) (6) Lane, Cliff (NIH/NIAID) [E] [Marks, Peter (FDA/CBER) (b)(6)(b)(6)Marston, Hilary (NIH/NIAID) [E] [hila (b) (6) Mascola, John (NIH/VRC) [E] Menetski, Joseph (FNIH) [T] (b)(6)Meeker, David [Messonnier, Nancy (CDC/DDID/NCIRD/OD) [Pandya, Hitesh (b)(6)(b) (6) Parker, Ashley (NIH/OD) [E] [Perlmutter, Roger [hi (b) (6) (b)(6)Rachel Ramoni [Plenge, Robert [(b) (6) (b) (6) (b) (6) Rasi, Guido (b) (6) ; Rouse, Doris (b) (6) ; Santos, Michael (FNIH) [T] Skovronsky, Daniel [Stein, Peter (FDA/CDER) (b)(6)Stoffels, Paul [.com]; Tabak, Lawrence (NIH/OD) [E] (b) (6) (b) (6) Talley, Michael [Vessey, Rupert | (b)(6)(b) (6) Wholley, David (FNIH) [T] [Woodcock, Janet (FDA/CDER) [(b) (6) (b) (6) Young, John [(b)(6)Colvis, Christine (NIH/NCATS) [E] [christ (b)(6)Desrosiers, Betsy [el Eric Hughes [(b) (6) Jansen, Kathrin (b) (6) Kurilla, Michael (NIH/NCATS) [E] [Lowy, Douglas (NCI) (b) (6) (b)(6)Read, Sarah (NIH/NIAID) [E] [Victoria Davey [(b) (6) (b)(6)(b) (6) Villafana, Tonya [tonya.vil Bancel, Stephane (b)(6)(b) (6) Fauci, Anthony (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=df38103d75134f658ae2d356f0396b94-afauci]; Lepore, John Pangalos, Mene [Pao, William (b)(6)(b) (6) Paul, Steve [Plump, Andy [Reed, (b)(6)(b) (6) (b)(6); Reese, David [Johr Tsai, John [john. (b) (6) (b)(6)(b) (6) CC: Anderson, James (NIH/OD) [E] [(b)(6)]; Burklow, John (NIH/OD) [E] [(b) (6) Carluccio, Dana | Castillejos, Carlos FNIH Central (b)(6)(b) (6) Account [fn (b) (6) Hallett, Adrienne (NIH/OD) [E] [adrienne.hallett@nih.gov]; Myles, Renate .gov]; Wolinetz, Carrie (NIH/OD) [E] [Adam, Stacey (FNIH) (NIH/OD) [E] [(b) (6) (b) (6) Margaret Anderson [[T] [Appell, Evan [(b)(6)(b)(6)(b) (6) Chen, Helen Q. [(b) (6) Connelly, Sarah [(b) (6) Gonzalez, Nina [ningonza Hawk, Harrison []; Mendelson, Jesse [ml; (b)(6)(b) (6) (b) (6) asorosa [Stratton, Benjamin (b)(6)btolman [(b) (6) (b)(6)Tountas, Karen (FNIH) [T] ; Wachtel, Jonathan [Gorman, Greta (FNIH) (b)(6)(b)(6); Austin, Sarah (NIH/NIAID) [E] [T] [Meltzer, Abbey (FNIH) [T] (b) (6) (b)(6)Barasch, Kimberly (NIH/NIAID) [C] [kimberly.ba Bell, Julie (b)(6)(b) (6) Burrus-Shaw, Cyndi (NIH/OD) [E] [Carver, Trea (NIH) [C] (b) (6) (b) (6) Caulfied, Anita [Coan, Amanda | (b) (6) (b) (6) (b) (6)]; Conrad, Patricia (NIH/NIAID) [E] [conradpa@niaid.nih.gov]; Dimishkov, Roxanne (NIH/NHLBI) [C]]; Edl, Susan [susan.ed (b) (6) Fuhrer, Nicole [(b)(6)(b) (6) Giorgi, Sara [Hoffstetter, Renata (FNIH) [T] [Iberdemaj, Vaide (b)(6)(b)(6)Jenkins, Christine S. [Lagos, Enrique (NIH/NCATS) [E] (b) (6)]; Lever, Susan [susan. McManus, Ayanna (NIH/OD) [E] (b) (6) (b) (6) Minnich, Beth [Perala, Mie [mie.pera (b)(6)(b)(6)(b) (6) Protasiewicz, Ann [ann. Riccobene, Kim [Riggin, Mary (b)(6)(b) (6) Schuster, Donna (b)(6)Ripley, Nadege (b)(6)Sepulveda, Dorina (FNIH) [T] [Simon, Dina (NIH/OD) [C]

(b) (6)

(b) (6)

[(b) (6)	Suhar	na, Tina (NIH/VRC) [E][(b) (6)]; Thomas, A	shley (FDA/CDER)
[(b) (6)]; Wood, Gretchen (NIH/OD) [E] [(b) (6)]; H	ughes, Karen (NIH/OD) [E]
[karen.	(b) (6)]; Taj	alli, Ada (NIH/OD) [E]	(b) (6)]; Togashi, Mieko	(NIH/NCI) [E]
[(b) (6)]; Underwood, Nano	cy [(b) (6)	Zottoli, Jessica
[(b) (6)		Vessey, Rupert [(b) (6)	Regan, Donna	M
[(b) (6)		Grant, Sarah [(b) (6)	Plenge, Robert	(b) (6)
Lowy, D	ouglas (NIH/NC	(I) [E]	(b) (6)	Nasr, Hana [(b) (6)	Hoban, Michelle
[(b) (6)					

Subject: ACTIV Leadership Team Meeting #11

Location: https://fnih.zoom.us/ (b)(6)

Start: 12/16/2020 3:00:00 PM 12/16/2020 4:30:00 PM End:

Show Time As: Busy

Required Attendees: Austin, Christopher (NIH/NCATS) [E]; Bancel, Stephane; Carter, Kara; Cavaleri, Marco; Cihlar, Tomas; Collins, Francis (NIH/OD) [E]; Corey, Larry; Culp, Michelle (NIH/OD) [E]; Disbrow, Gary (OS/ASPR/BARDA); Dolsten, Mikael; Erbelding, Emily (NIH/NIAID) [E]; Erck, Stan; Fauci, Anthony (NIH/NIAID) [E]; Gadbois, Ellen (NIH/OD) [E]; Gibbons, Gary (NIH/NHLBI) [E]; Hudson, Thomas; James, Stephanie (FNIH) [T]; Johnson, Robert (OS/ASPR/BARDA); Kramer, Lynn; Lane, Cliff (NIH/NIAID) [E]; Lepore, John; Marks, Peter (FDA/CBER); Marston, Hilary (NIH/NIAID) [E]; Mascola, John; Meeker, David; Menetski, Joseph (FNIH) [T]; Messonnier, Nancy (CDC/DDID/NCIRD/OD); Pandya, Hitesh; Pangalos, Mene; Pao, William; Parker, Ashley (NIH/OD) [E]; Paul, Steve; Perlmutter, Roger; Plenge, Robert; Plump, Andy; Ramoni, Rachel; Rasi, Guido; Reed, John; Reese, David; Rouse, Doris; Santos, Michael (FNIH) [T]; Skovronsky, Daniel; Stein, Peter (FDA/CDER); Stoffels, Paul; Tabak, Lawrence (NIH/OD) [E]; Talley, Michael; Tsai, John; Vessey, Rupert; Wholley, David (FNIH) [T]; Woodcock, Janet (FDA/CDER); Young, John; Colvis, Christine (NIH/NCATS) [E]; Desrosiers, Betsy; Hughes, Eric; Jansen, Kathrin; Kurilla, Michael (NIH/NCATS) [E]; Lowy, Douglas (NCI); Read, Sarah (NIH/NIAID) [E]; Victoria Davey; Villafana, Tonya (b)(6)

Optional Attendees:

Anderson, James (NIH/OD) [E]; Burklow, John (NIH/OD) [E]; Carluccio, Dana; Castillejos, Carlos; FNIH Central Account; Hallett, Adrienne (NIH/OD) [E]; Myles, Renate (NIH/OD) [E]; Wolinetz, Carrie (NIH/OD) [E]; Adam, Stacey (FNIH) [T]; Anderson, Margaret; Appell, Evan; Chen, Helen; Connelly, Sarah; Gonzalez, Nina; Hawk, Harrison;

Mendelson, Jesse; Sorosa, Alex; Stratton, Ben; Tolman, Brett; Tountas, Karen (FNIH) [T]; Wachtel, Jonathan; Gorman, Greta (FNIH) [T]; Meltzer, Abbey (FNIH) [T]; Austin, Sarah (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]; Bell, Julie; Burrus-Shaw, Cyndi (NIH/OD) [E]; Carver, Trea (NIH) [C]; Caulfied, Anita; Coan, Amanda; Conrad, Patricia (NIH/NIAID) [E]; Dimishkov, Roxanne (NIH/NHLBI) [C]; Edl, Susan; Fuhrer, Nicole; Giorgi, Sara; Hoban, Michelle; Hoffstetter, Renata (FNIH) [T]; Iberdemaj, Vaide; Jenkins, Christine S.; Krack, Kimberly; Lagos, Enrique (NIH/NCATS) [E]; Lever, Susan; McManus, Ayanna (NIH/OD) [E]; Minnich, Beth; Perala, Mie; Protasiewicz, Ann; Riccobene, Kim; Riggin, Mary; Ripley, Nadege; Schuster, Donna; Sepulveda, Dorina (FNIH) [T]; Simon, Dina (NIH/OD) [C]; Suhana, Tina (NIH/VRC) [E]; Thomas, Ashley (FDA/CDER); Wood, Gretchen (NIH/OD) [E]; Hughes, Karen (NIH/OD) [E]; Tajalli, Ada (NIH/OD) [E]; Togashi, Mieko (NIH/NCI) [E]; Underwood, Nancy; Zottoli, Jessica; Vessey, Rupert; Regan, Donna M; Grant, Sarah; Plenge, Robert; Lowy, Douglas (NIH/NCI) [E]; Nasr, Hana

Extending the call by 30 minutes per discussion at Nov. 19 Leadership Team call

Joseph Menetski is inviting you to a scheduled Zoom meeting.

Join Zoom Meeting https://fnih.zoom.u: (b) (6) Meeting ID: (b) (6) Passcode: (b) One tap mobile (b) (6) US (Washington D.C) US (Chicago)

Dial by your location

US (Washington D.C) (b) (6)

US (Chicago) US (New York)

```
(b)(6)
                                 JS (San Jose)
                                 JS (San Jose)
JS (Tacoma)
                                 JS (Houston)
                                 lgium
∍lgium
                                 elgium
                                 elgium
elgium
                                 elgium
                                 Canada
                                 Canada
                                 Canada
                                 Canada
                                 Canada
                                 Canada
                                 France
                                 France
                                 France
                                 -rance
                                 France
                                 Japan
                                 Japan
                                 Japan
                                  Italy
                                     Italy
                                  Italy
                                  Switzerland
                                  Switzerland
                                  Switzerland
                                  Switzerland
                                  Switzerland
                                  Switzerland
                                  United Kingdom
United Kingdom
United Kingdom
United Kingdom
                                  United Kingdom
                                  United Kingdom
                     (b) (6)
(b) (6)
                                  United Kingdom
Meeting ID: (b) (6)
Passcode: (b) (6)
Find your local number: https://fnih.zoom.
                                                               (b) (6)
```

From:		하늘 사람이 가게 하는 것이 하는데			ADMINISTRATIVE GROUP
Sent:	4/30/2020 5:18:10				
То:	LaVange, Lisa M [[/o=ExchangeLabs/	(b) (6) ou=Exchange Adn		(b) (6)	; Adam, Stacey (FNIH) [T] 43414-adamsj4]; Bozzette, Sam (NIH/NCATS)
	[E] [/o=ExchangeLa	bs/ou=Exchange A	Administrative Group		c88d-bozzettesaa]; Butterton, Joan
	[/o=ExchangeLabs/	ou=Exchange Adn	ninistrative Group		190c3-joan_butter]; Collins, Sylva
	(FDA/CDER) [/o=Ex	changeLabs/ou=E	xchange Administrati	ve Group	
	[/o=ExchangeLabs/			98810832c238	7725-Sylva.Colli]; Judy Currier
			:n=890082c7c1e3490 xchange Administrati		16650-jscurrier.m]; De Claro, R. Angelo
					62448-DECLAROR.fd]; Mark Eisner
	(b) (6)	Keith Gott		(b) (6)	Eric Hughes
	(b) (6)		p Menon [(b) (6)	Amanda Peppercorn
	(b) (d	5) Re	ead, Sarah (NIH/NIAIE) [E] [/o=Excha	angeLabs/ou=Exchange Administrative
	Group (FYDIBOHF2	3SPDLT)/cn=Recip	ients/cn=527b16003	8004a199ae6e	Obac2226099-readsa]; Amanda Peppercorn
	(b) (/			ngeLabs/ou=Exchange Administrative Group
					bee21-priced.fda]; Rubin, Daniel B.
			xchange Administrati :n=35c289105913411		42aad-RUBIND.fda]; Shen, Yuan Li
	(FDA/CDER) [/o=Ex	changeLabs/ou=E	xchange Administrati	ve Group	a1802-shenyu.fda]; Farley, John (FDA/CDER)
	[/o=ExchangeLabs/			1437341667237	a1002-3hehyu.hdaj, Fahley, John (F <i>DA)</i> eDEN
					a09bc-FARLEYJ.fda]; Goff, David (NIH/NHLBI)
	(FYDIBOHF23SPDLT		Administrative Group :n=036113c7be0f42f8		99c10-goffdc]; Vincent, Michael
cc.	(b) (6)	4) (6)	DaMarria Farrant		Macana Fuin
CC:	Mary Biggs [[(b) (6)	Tountas, Karei			xchange Administrative Group
	(FYDIBOHF23SPDLT (b) (6))/cn=Recipients/c Elizabeth K			4f93-tountaskh]; Wachtel, Jonathan shley (NIH/OD) [E]
	[/o=ExchangeLabs/		ninistrative Group		
	2				ebd70-parkeras]; Butcher, Tina
	(b) (6) (EVDIROHE23SPDLT			200.0	s/ou=Exchange Administrative Group 77257-wholleyd]; Melencio, Cheryl (FNIH)
	57	7000	Administrative Group		77237 Wildingyaj, Welchelo, Chery (11111)
					528e6f-melencioc]; Wung, Peter /US
	(b) (6)	Qashu, F	elicia (NIH/OD) [E] [/d	=ExchangeLab	s/ou=Exchange Administrative Group
	(FYDIBOHF23SPDLT)/cn=Recipients/c	:n=366447a553f4469	6b2c79484d90	e41e5-qashufm]; Stratton, Benjamin
	(b) (6)				
Subject:	RE: ACTIV TX-Clinic	al Master Protoco	Subgroup Meeting #	ŧ7	
	t the intent is to for as not been finalize				o+remdesivir versus remdesivir), ample size.
Mike.					
From: LaVan	ge, Lisa M <	(b) (6)			
	ay, April 30, 2020 1	1:19 AM			
To: 'Levy, Elli	iott' < (b) (6)	Adam,	Stacey (FNIH) [T] <	(b) (6)	Bozzette, Sam (NIH/NCATS) [E]
c (b)) (6) Butte	rton loan <	(b) (6)	Collin	s Sylva (FDA/CDFR)

<sylva.co< th=""><th>llins@fda.hhs</th><th>s.gov>; Judy (</th><th>Currier <</th><th>(b) (6)</th><th>De</th><th>Claro, R. Ange</th><th>lo (FDA/CDER)</th></sylva.co<>	llins@fda.hhs	s.gov>; Judy (Currier <	(b) (6)	De	Claro, R. Ange	lo (FDA/CDER)
<	(b) (6)	Ma	rk Eisner <	(b) (6)	Keit	h Gottesdiene	r
<	(b) (6)	E	Eric Hughes <	(b) ((6)	Sandeep Mer	non
<	(b) (6)		Amanda Pepper	corn <	(b) (6)	Proschan, Michael
(NIH/NIAI	D) [E] <	(b) (6)	Read, S	arah (NIH/N	VIAID) [E] <	(b) (6)	Amanda Peppercorn
<	(b) (6)		Price, Dionne (FDA/CDER)	< ((b) (6)	Rubin, Daniel B.
(FDA/CDE	R) <daniel.< td=""><td>(b) (6)</td><td>Shen, Yua</td><td>n Li (FDA/C</td><td>DER) <</td><td>(b) (6)</td><td>Farley, John</td></daniel.<>	(b) (6)	Shen, Yua	n Li (FDA/C	DER) <	(b) (6)	Farley, John
(FDA/CDE	R) <	(b) (6)	Goff, David	(NIH/NHLE	II) [E] <	(b) (6)	Vincent, Michael
<michael.< td=""><td>(b) (6</td><td>)</td><td></td><td></td><td></td><td></td><td></td></michael.<>	(b) (6)					
Cc: Mary	Biggs <	(b) (6)	DeMarcus	, Forrest <	(b)	(6)	Macone, Erin
< ((b) (6)	Tountas, Ka	ren (FNIH) [T] <	(b) (6) Wad	htel, Jonathan	(b) (6)
Elizabeth	Kim <	(b) (6)	Parker, Ashle	y (NIH/OD)	[E] <ashley.pa< td=""><td>a (b) (6)</td><td>Butcher, Tina</td></ashley.pa<>	a (b) (6)	Butcher, Tina
<	(b) (6)	Whol	ley, David (FNIH)	[T] <	(b) (6)	Melencio, C	heryl (FNIH) [T]
<	(b) (6)	Wung, Pete	er /US <	(b) (6)	Qashu	ı, Felicia (NIH/0	OD) [E]
<felicia.< td=""><td>(b) (6)</td><td>Stratton,</td><td>Benjamin <</td><td>(b) (6)</td><td></td><td></td><td></td></felicia.<>	(b) (6)	Stratton,	Benjamin <	(b) (6)			
Subject: F	RE: ACTIV TX-	Clinical Mast	er Protocol Subg	roup Meeti	ng #7		

My concern with the target RRR is whether another agent will be superior to an effective drug to the same extent as remdesivir was to a less effective SoC. Might we need to lower the RRR beyond 1.25? And these emails highlight why it is probably better to discuss as a group—sorry! Talk to everyone soon,

From: Lev	y, Elliott	(b)	(6)							
Sent: Thur	sday, April 3	30, 2020 10	0:24 AM							
To: LaVang	ge, Lisa M <	(b) (6)	Adam, S	stacey (FNIH)	[T] <		(b) (6)	Bozzette, Sam (N	IIH/NCATS
[E] <	(b) (6)	Bu	itterton, Joan		(b) (6)			Collins, Sylv	va (FDA/CDER)	
	(b) (6)	Ju	dy Currier		(b) (6)	;	>; De (Claro, R. Ang	gelo (FDA/CDER)	
<	(b) (6)		Mark Eisner		(b) (6)	;	Keith	Gottesdien	er	
<	(b) (6)		Eric Hughe	s <	(b) (6)		1	Sandeep Me	enon	
	(b) (6)		: Amanda P	epperco	rn		(b) (6)		Proschan, Mich	nael
(NIH/NIAII	D) [E] <	(b) (6) R	Read, Sar	ah (NIH/NIAI	D) [E] <	(b) (6)	Amanda	Peppercor
<	(b) (6)		Price, Dic	onne (FD	A/CDER) <		(b)	(6)	Rubin, Daniel	В.
(FDA/CDEI	R)	(b) (6)	She	n, Yuan	Li (FDA/CDEF	(5)		(b) (6)	>; Farley, Jo	hn
(FDA/CDEI	R)	(b) (6)	; Goff,	David (I	VIH/NHLBI) [I	E] <		(b) (6)	Vincent, Michael	el
	(b) (6)									
Cc: Mary E	Biggs	(b) (6)	>; DeN	∕larcus, F	orrest		(b) (6)	>	; Macone, Erin	
< (1	b) (6)	Tountas,	Karen (FNIH)	[T]	(b) (6)	;	Wach	tel, Jonatha	n (b) (6)	
Elizabeth I	Kim	(b) (6)	: Parker,	Ashley (NIH/OD) [E]		(b)	(6)	>; Butcher, Tina	
	(b) (6)	; W	holley, David	(FNIH)[r] < (b	(6)		Melencio,	Cheryl (FNIH) [T]	
(b) (6)	; Wung, P	eter /US	(b)	(6)	>; Q	ashu,	Felicia (NIH,	/OD) [E]	
(b) (6)		Stratto	on, Benjamin -	<	(b) (6)					
Subject: R	E: ACTIV TX-	Clinical M	aster Protoco	l Subgro	up Meeting #	‡ 7				

I agree that remdesivir will need to become background therapy in all treatment arms. This gives us to opportunity to test regimens which target both the virus and the host, which is exciting.

With regard to the target RRR, in my view the emerging data confirm the need to power for 1.25, rather than something larger:

-Remdesivir (a rationally designed therapy) exhibited an effect of 1.31 in ACCT1 on TTR, and a somewhat smaller effect (1.23) in the terminated Chinese trial. These are our best estimates for what a rationally designed therapy can do.

- -In ACCT1, an effect of 1.31 was associated with a reduction in duration of hospital stay by 4 days, which would be meaningful from a health care system perspective.
- -I would not expect other therapies we test to exhibit a larger effect than remdesivir. They were not designed to address the pathophysiology of COVID-19, about which we know little, and their benefit might be partially attenuated when used in combination with another active agent.
- -A smaller effect for the experimental therapy would still be meaningful, if one could infer the combination of experimental therapy + remdesivir had an effect of 1.5 or more.

Elliott

From: LaVange, Lisa	М	(b) (6)					
Sent: Thursday, April	30, 2020 6:	50 AM					
To: Adam, Stacey (FN	IIH) [T]	(b) (6)	Bozzette, Sa	m (NIH/N	CATS) [E] <	(b) (6)	Butterton,
Joan (b)	(6)	Collins, Sy	/lva (FDA/CDE	R)	(b) (6)	; Judy Currier	
(b) (6)	; D	e Claro, R. Ang	elo (FDA/CDE	R)	(b) (6)	>; Mark Eisr	ner
(b) (6)	Keith	Gottesdiener	((b) (6)	>; Eric H	ughes	
(b) (6)	: Le	evy, Elliott	(b) (6)	; San	deep Menon	(b) (6)	
Amanda Peppercorn		(b) (6)	Pro	schan, Mi	chael (NIH/NIAID)	[E] (b)	(6)
Read, Sarah (NIH/NIA	(ID) [E]	(b) (6)	>; Amano	la Pepper	corn	(b) (6)	>; Price,
Dionne (FDA/CDER)	(b) (6)	; Rubin, Da	niel B. (FD	A/CDER) (b		Shen, Yua
Li (FDA/CDER)	(b) (6)	>; Fa	rley, John (FD	A/CDER)	(b) (6)	Goff, D	avid
(NIH/NHLBI) [E]	(b) (6)	; Vincent	, Michael	((b) (6)		
Cc: Mary Biggs	(b) (6)	>; DeMa	arcus, Forrest		(b) (6)	; Macone, Erin	
(b) (6)	: Tountas,	Karen (FNIH) [T] (b)	(6)	Wachtel, Jonath	an (b)	(6)
Elizabeth Kim < <u>el</u>	(b) (6)	Parker, A	shley (NIH/O	D) [E] <	(b) (6)	Butcher, Tin	а
(b) (6)	: W	holley, David (F	NIH) [T]	(b) (6)	; Melencio	, Cheryl (FNIH) [T	1
(b) (6)	; Wung, P	eter /US	(b) (6)		Qashu, Felicia (NI	H/OD) [E]	
(b) (6)	>; Stratto	n, Benjamin	(b) (6)			
Cubiacte [External] D.	. ACTIVITY	Clinical Master	Drotocal Cub	aroun Ma	ating #7		

Subject: [External] Re: ACTIV TX-Clinical Master Protocol Subgroup Meeting #7

Agree, thanks for raising this, Sam. There are other implications as well. We may need to revisit the meds we will allow as background therapy, now that we have a true standard of care consistent across all sites. And is the target RRR we want to be powered to detect (1.25) the appropriate target relative to Remdesivir?

Looking forward to talking further later today.

Lisa

From: Adam, Stacey (FNIH) [T] <		(b) (6)			
Sent: Thursday,	April 30, 2020 9:	44 AM			
To: Bozzette, Sam (NIH/NCATS) [(b) (6)	: Butterton, J	loan (b) ((6) >; Collins,
Sylva (FDA/CDEF	(b)	(6) Judy Cur	rier <	(b) (6) De	e Claro, R. Angelo
(FDA/CDER)	(b) (6)	>; Mark Eisner	(b) (6)	; Keith Go	ttesdiener
(b)	(6)	Eric Hughes	(b) (6)	>; LaVange, Lisa M	(b) (6)
Elliott Levy	(b) (6)	>; Sandeep Menon	(b) (6)	Amar	nda Peppercorn
(b) (6)	Proschan, Michael (N	VIH/NIAID) [E]	(b) (6)	Read, Sarah
(NIH/NIAID) [E]	(b) (6)	: Amanda Peppe	ercorn	(b) (6)	; Price, Dionne
(FDA/CDER)	(b) (6)	Rubin, Daniel	B. (FDA/CDER)	(b) (6)	: Shen, Yuan Li
(FDA/CDER)	(b) (6)	Farley, John (FDA/CDER)	(b) (6)	Goff, David (NIH/NHLB

[E] <	(b) (6)	; Vincen	t, Michael <	(b)	(6)			
Cc: Mary B	Biggs	(b) (6)	>; DeMai	rcus, Forres	t	(b) (6)	: Macone, Erin	
(b)	(6)	>; Tountas, k	(aren (FNIH) [T] < (b) (6)	Wachtel, Jonatha	n (b) (6)	;
Elizabeth k	(im	(b) (6)	>; Parker, As	hley (NIH/C	D) [E]	(Butcher, Tina	
	(b) (6)	>; Wh	olley, David (FI	(HIV	(b) (6)	b; Melencio,	Cheryl (FNIH) [T]	
(b)) (6)	; Wung, Pe	ter /US	(b) (6)	>;	>; Qashu, Felicia (NIH/OD) [E]		
(b) (6)	>; Strattor	n, Benjamin	(b)	(6)			

Subject: RE: ACTIV TX-Clinical Master Protocol Subgroup Meeting #7

Hi Sam,

I think you are correct and we can discuss more today and tomorrow. I am currently trying to figure out what the outreach procedure should be, but I agree it likely needs to sooner rather than later.

Thanks, Stacey

Stacey J. Adam, PhD

Director, Cancer Research Partnerships

Direct: (b) Mobile: (b)

From: Bozzette, Sam (NIH/NCATS) [E]		TS) [E]	(b) (6)					
Sent: Thursday, April 30, 2020 9:19 AM								
To: Adam, Stacey (Fi	NIH) [T] <	(b) (6)	Butterton, Joan		(b) (6)	>; Collins, Sylva		
(FDA/CDER)	(b) (6)	>; Judy	Currier	(b) (6)	>; De Cla	ro, R. Angelo (FDA/CDER)		
(b) (6)		Mark Eisner	(b) (6)	>; K	eith Gottesdiener			
(b) (6)		Eric Hughes	(b) (6)		>; LaVange, Lisa N	(b) (6)		
Elliott Levy < <u>el</u>	(b) (6)	: Sandeep M	lenon	(b) (6)	; Ama	anda Peppercorn		
(b) (6)		>; Proschan, I	Michael (NIH/NIA	ID) [E]	(b) (6)	Read, Sarah		
(NIH/NIAID) [E]	(b) (6)	Amar	nda Peppercorn		(b) (6)	>; Price, Dionne		
(FDA/CDER) <	(b) (6)	Rub	in, Daniel B. (FDA	/CDER) <	(b) (6)	Shen, Yuan Li		
(FDA/CDER)	(b) (6)	Farl	ey, John (FDA/CD	ER)	(b) (6)	>; Goff, David (NIH/NHLBI)		
[E] (b) (6)	Vince	nt, Michael <	(b) (6)					
Cc: Mary Biggs <	(b) (6)	Dem	arcus <	(b) (6)	: Macone, I	` / ` /		
Tountas, Karen (FNII		(b) (6)	: Wachtel, Jonatl	nan	(b) (6)	Elizabeth Kim		
(b) (6)	>; Parker,	Ashley (NIH/O	O) [E] < (b) (6)	Butcher, Tina			
(b) (6)	Wholley, David (I		FNIH) [T]	(b) (6)	Melencio, Cheryl (FNIH) [T]			
(b) (6)	Wung, P	Peter /US	(b) (6)	Qas	nu, Felicia (NIH/OD) [E]			
< (b) (6)	Stratton, Benjamin		(b) (6)					
Subject: Re: ACTIV TX-Clinical Master Protocol Subgroup Meeting #7								

Good morning all:

It would seem that our active control arm had been identified. Should we get in the queue with Gilead sooner rather than later - or have we already reached out to them?

S

From: "Adam, Stacey (FNIH) [T]" < (b) (6)

Date: Thursday, April 23, 2020 at 8:31:00 PM

To: "Bozzette, Sam (N	IH/NCATS) [E]"	(b) (6)	>, "Butterto	n, Joan" < joan	(b) (6)
"Collins, Sylva (FDA/CI	DER)" (b)) (6) >	, "Judy Currier"	(b) (6)	"De Claro, R.
Angelo (FDA/CDER)"	(b) (6)		ark Eisner" <	(b) (6)	"Keith Gottesdiener"
(b) (6)	"Eric H	lughes" < (1	b) (6)	"LaVange, Lisa	a M"
(b) (6)	"Elliott Levy" <	(b) (6)	"Sandeep	Menon"	(b) (6)
"Amanda Peppercorn'	(b)	(6)	, "Proschan, Mi	chael (NIH/NIAID) [E]"
(b) (6)	"Read, Saral	(NIH/NIAID) [E]" < (b) (6) , "Amanda	Peppercorn"
< (b) (6)	, "Pri	ce, Dionne (FDA	/CDER)" <	(b) (6)	"Rubin, Daniel B.
(FDA/CDER)"	(b) (6)	, "Shen, Yuan L	i (FDA/CDER)"	(b) (6)	>, "Farley, John
(FDA/CDER)" (b) (6)	<u>/</u> >	, "Goff, David (N	IIH/NHLBI) [E]"	(b) (6)	"Vincent, Michael"
(b) (6)					
Cc: "Mary Biggs" <	(b) (6)	"Demarcus"	(b) (6)) "Macoi	ne, Erin"
(b) (6)	"Tountas, Karen (FNIH) [T]"	(b) (6)	"Wachtel, Jonathan)"
(b) (6)	. "Elizabeth Kin	(b) (6)		er, Ashley (NIH/OD)	
(b) (6)	"Butcher, Tina	" (b)	(6)	Wholley, David (FNI	H) [T]"
(b) (6)	"Melencio, Cheryl	(FNIH) [T]"	(b) (6)	, "Wung, Peter /U	S"
(b) (6)	"Qashu, Feli	cia (NIH/OD) [E]	(b) (6)	, "Stratton	, Benjamin"
(b) (6)	.>				

Subject: RE: ACTIV TX-Clinical Master Protocol Subgroup Meeting #7

Dear TX-Clinical Master Protocol Subgroup,

US

Please find attached the materials for tomorrow's meeting.

- 1. Agenda
- 2. Slides for discussion updated with the decisions from today
- 3. A useful resource about current standard clinical treatment guidelines from the front lines for COVID. This may be a useful resource in selecting how to do minimal data collection and trying to understand SOC.

Please let me know if you have questions or other things you think would be helpful for the group to review.

Thanks, Stacey Stacey J. Adam, PhD Director, Cancer Research Partnerships Direct: (b) (6) | Mobile: (b)(6)Join Zoom Meeting https://fnih.zoom. (b) (6) Meeting ID: (b) (6) Password: (b) (6) One tap mobile (b) (6) US (Chicago) US (New York) Dial by your location (b)(6)US (Chicago) US (New York) US (San Jose) US (San Jose)

(b) (6) JS JS (Houston)

Meeting ID: (b) (6)
Password: (b) (6)

Find your local number: https://fnih.zoom.u (b) (6)

From: Sent:	LaVange, Lisa M [4/30/2020 3:18:57	(b) (6) 7 PM						
То:	'Levy, Elliott' [(FYDIBOHF23SPDL [E] [/o=ExchangeL (FYDIBOHF23SPDL [/o=ExchangeLabs (FYDIBOHF23SPDL (FDA/CDER) [/o=ExchangeLabs (FYDIBOHF23SPDL [/o=ExchangeLabs	(b) (6) T)/cn=Recipient: abs/ou=Exchang T)/cn=Recipient: /ou=Exchange A T)/cn=Recipient: xchangeLabs/ou= T)/cn=Recipient: /ou=Exchange A T)/cn=Recipient:	s/cn=dcd875f0 e Administration s/cn=85f05a36 dministrative s/cn=219ecace Exchange Ad s/cn=f6b8f588 dministrative s/cn=890082c	0679648859e1 ive Group 619cf47c7ae39 Group 4faae4ebab8a4 ministrative Gr 8067140fe988f Group 7c1e34902b0f	cf101c0943414- d7bcf0aac88d-b 45ce8ee2490c3-j oup 0832c2387725-5	/ou=Exchange Administrative Group adamsj4]; Bozzette, Sam (NIH/NCATS) pozzettesaa]; Butterton, Joan joan_butter]; Collins, Sylva Sylva.Colli]; Judy Currier pjscurrier.m]; De Claro, R. Angelo		
						-DECLAROR.fd]; Mark Eisner		
	(b) (6)	Keith Go	ottesdiener [(b)	(6)	Eric Hughes		
	(b) (6)		eep Menon [(6)	Amanda Peppercorn		
	(b) (angeLabs/ou=Exchange		
	Read, Sarah (NIH/	NIAID) [E] [/o=Ex	changeLabs/o	u=Exchange A	dministrative Gr			
						readsa]; Amanda Peppercorn s/ou=Exchange Administrative Group		
	(p)			17 50 000	70 T	-priced.fda]; Rubin, Daniel B.		
						-priced.ida], Ndbiri, Dairier B.		
	(FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=35c2891059134111a3ed28f929042aad-RUBIND.fda]; Shen, Yuan Li							
	(FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group							
	(FYDIBOHF23SPDLT)/cn=Recipients/cn=ae30a02e983e4e8a979dfec7257a1802-shenyu.fda]; Farley, John (FDA/CDER)							
	[/o=ExchangeLabs					, , , , , , , , , , , , , , , , , , , ,		
					31fe7bcaa09bc-	FARLEYJ.fda]; Goff, David (NIH/NHLBI)		
	[E] [/o=ExchangeL							
	(FYDIBOHF23SPDL	T)/cn=Recipients	s/cn=036113c	7be0f42f897d1	L294cfbb99c10- ₈	goffdc]; Vincent, Michael		
	(b) (6)							
CC:	Mary Biggs [(b) (6)	DeMarcus,		(b) (6)	Macone, Erin		
	(b) (6)					ge Administrative Group		
						ountaskh]; Wachtel, Jonathan		
	(b) (6)	Elizabeth		(b) (6)	Parker, Ashley (NIH/OD) [E]		
	[/o=ExchangeLabs							
	53					parkeras]; Butcher, Tina		
	(b) (6)					xchange Administrative Group		
	[T] [/o=ExchangeL	5000)D699606/725/-	wholleyd]; Melencio, Cheryl (FNIH)		
					007400h620a6f	-melencioc]; Wung, Peter /US		
	(b) (6)					Exchange Administrative Group		
			14. [1] [1] [1] [1] [1] [1] [1] [1] [1] [1]		2000 (1997) (1997) (1997) (1997) (1997) (1997) (1997) (1997)	-qashufm]; Stratton, Benjamin		
	(b) (6)	i jį cii–itecipielit.	// 511-55044/ a	333177030020	, 5 10 10 50 61 165	qualitating, actuation, benjamin		
Subject:	RE: ACTIV TX-Clinic	cal Master Proto	col Subgroup	Meeting #7				

My concern with the target RRR is whether another agent will be superior to an effective drug to the same extent as remdesivir was to a less effective SoC. Might we need to lower the RRR beyond 1.25?

And these emails highlight why it is probably better to discuss as a group—sorry!

Talk to everyone soon,

Lisa

From: Levy, Elliott [mailto: (b) (6) Sent: Thursday, April 30, 2020 10:24 AM

To: LaVange, Lisa M <	lisa. (b) (6)	Adam, Stacey	(FNIH) [T] < ((b) (6) Bozze	ette, Sam (NIH/NCATS)
[E] < (b) (6)	Butterton, Jo	an < (b) (6)	Collins, Sylva (FD)	A/CDER)
(b) (6)	Judy Currier	(b) (6) De Cl	laro, R. Angelo (Fl	DA/CDER)
(b) (6)	Mark Eisne	er < (b) (e	5) Keith (Gottesdiener	
(b) (6)	Eric Hug	ghes < (b) (6)	andeep Menon	
(b) (6)	Amand	la Peppercorn <ar< td=""><td>nanda.f. (b</td><td>b) (6) Pro</td><td>oschan, Michael</td></ar<>	nanda.f. (b	b) (6) Pro	oschan, Michael
(NIH/NIAID) [E] <	(b) (6)	Read, Sarah (NI	H/NIAID) [E] <	(b) (6)	Amanda Peppercorn
(b) (6)	Price,	Dionne (FDA/CDE	R) < (b)	(6) Ru	ıbin, Daniel B.
(FDA/CDER) <daniel.< td=""><td>(b) (6)</td><td>Shen, Yuan Li (FDA</td><td>/CDER) <</td><td>(b) (6)</td><td>Farley, John</td></daniel.<>	(b) (6)	Shen, Yuan Li (FDA	/CDER) <	(b) (6)	Farley, John
(FDA/CDER) <	(b) (6) G	off, David (NIH/NI	HLBI) [E] < (1	b) (6) Vind	cent, Michael
<michael.vi (b)<="" td=""><td>(6)</td><td></td><td></td><td></td><td></td></michael.vi>	(6)				
Cc: Mary Biggs <	(b) (6)	DeMarcus, Forrest	(b) (6)) Macc	one, Erin
< (b) (6)	Tountas, Karen (FN	[T] < (b)	(6) Wacht	el, Jonathan <	(b) (6)
Elizabeth Kim <	(b) (6) Park	er, Ashley (NIH/O	D) [E] < (b) (6) Bu	tcher, Tina
< (b) (6)	Wholley, Day	vid (FNIH) [T] <	(b) (6)	Melencio, Cheryl	(FNIH) [T]
< (b) (6)	Wung, Peter /US <	(b) (6)	Qashu, F	elicia (NIH/OD) [I	E]
< (b) (6)	Stratton, Benjam	in < (b)	(6)		
(FDA/CDER) <	(b) (6) G (6) E Tountas, Karen (FN (b) (6) Park Wholley, Dav Wung, Peter /US < Stratton, Benjam	off, David (NIH/NI DeMarcus, Forrest IH) [T] < (b) er, Ashley (NIH/O vid (FNIH) [T] < (b) (6) in < (b)	HLBI) [E] < (b) (6) (6) Wacht D) [E] < (b) (6) Qashu, F (6)	b) (6) Vind) Macc cel, Jonathan < b) (6) Bu Melencio, Cheryl	cent, Michael one, Erin (b) (6) tcher, Tina

Subject: RE: ACTIV TX-Clinical Master Protocol Subgroup Meeting #7

I agree that remdesivir will need to become background therapy in all treatment arms. This gives us to opportunity to test regimens which target both the virus and the host, which is exciting.

With regard to the target RRR, in my view the emerging data confirm the need to power for 1.25, rather than something larger:

- -Remdesivir (a rationally designed therapy) exhibited an effect of 1.31 in ACCT1 on TTR, and a somewhat smaller effect (1.23) in the terminated Chinese trial. These are our best estimates for what a rationally designed therapy can do.
- -In ACCT1, an effect of 1.31 was associated with a reduction in duration of hospital stay by 4 days, which would be meaningful from a health care system perspective.
- -I would not expect other therapies we test to exhibit a larger effect than remdesivir. They were not designed to address the pathophysiology of COVID-19, about which we know little, and their benefit might be partially attenuated when used in combination with another active agent.
- -A smaller effect for the experimental therapy would still be meaningful, if one could infer the combination of experimental therapy + remdesivir had an effect of 1.5 or more.

Elliott

From: LaVange, Lisa	M (b)	(6)					
Sent: Thursday, Apr	il 30, 2020 6:50	AM					
To: Adam, Stacey (F	NIH) [T] (b	>;	Bozzette, Sam (NIH/NCATS) [E]	(b)	(6)	; Butterton,
Joan < <u>joan</u>	(b) (6)	Collins, Sylv	va (FDA/CDER) <	(b) ((6)	Judy Currie	r
(b) (6)	De C	laro, R. Ange	lo (FDA/CDER)	(b) ((6)	>; Mark Eisi	ner
(b) (6)	>; Keith Go	ttesdiener	(b)	(6)	; Eric Hugh	es	
(b) (6)	>; Levy,	Elliott <elliot< td=""><td>ttl@amgen.com</td><td>>; Sandeep Me</td><td>enon <</td><td>(b) (6)</td><td>;</td></elliot<>	ttl@amgen.com	>; Sandeep Me	enon <	(b) (6)	;
Amanda Peppercorr	1 <	(b) (6)	Prosch	an, Michael (NI	H/NIAID) [E]	(b	(6)
Read, Sarah (NIH/NI	IAID) [E]	(b) (6)	; Amanda P	eppercorn <	(1	b) (6)	Price,
Dionne (FDA/CDER)	(b) (6)	; Rubin, Daniel	B. (FDA/CDER)	(b) (6)	Shen, Yuar
Li (FDA/CDER) <	(b) (6)	Farl	ley, John (FDA/0	CDER) <	(b) (6)	Goff, [David
(NIH/NHLBI) [E]	(b) (6)	Vincent,	Michael	(b) (6)			
Cc: Mary Biggs <	(b) (6)	DeMar	cus, Forrest	(b) (6)	ı	Macone, Erin	

< (b) (6)	Tountas, Karen (FNIH)	[T] <	(b) (6)	Wachtel, Jonathan	(b) (6)	;
Elizabeth Kim	(b) (6) ; Parker,	Ashley (NII	H/OD) [E]	(b) (6)	>; Butcher, Tina	
(b) (6)	>; Wholley, David	(FNIH) [T]	(b) (6)	; Melencio, (Cheryl (FNIH) [T]	
(b) (6)	; Wung, Peter /US	(b) (6)	;	Qashu, Felicia (NIH/	OD) [E]	
(b) (6)	; Stratton, Benjamin <	:	(b) (6)			

Subject: [External] Re: ACTIV TX-Clinical Master Protocol Subgroup Meeting #7

Agree, thanks for raising this, Sam. There are other implications as well. We may need to revisit the meds we will allow as background therapy, now that we have a true standard of care consistent across all sites. And is the target RRR we want to be powered to detect (1.25) the appropriate target relative to Remdesivir?

Looking forward to talking further later today. Lisa

From: Adam, Stacey (FNIH) [T] < (b) (6) Sent: Thursday, April 30, 2020 9:44 AM To: Bozzette, Sam (NIH/NCATS) [E] (b) (6) >; Butterton, Joan (b Collins, Sylva (FDA/CDER) (b) (6) Judy Currier (b) (6) ; De Claro, R. Angelo (FDA/CDER) (b) (6) >; Mark Eisner (b) (6) >; Keith Gottesdiener (b) (6) Eric Hughes (b) (6) ; LaVange, Lisa M (b) Elliott Levy (b) (6) Sandeep Menon (b) (6) >; Amanda Peppercorn (b) (6) Froschan, Michael (NIH/NIAID) [E] (b) (6) Frice, Dionne (FDA/CDER) (b) (6) Rubin, Daniel B. (FDM/CDER) (b) (6) Farley, John (FDA/CDER) (b) (6) Farley, John (FDA/CDER) (b) (6) Goff, David (NIH/NHL [E] (b) (6) Farley, John (FDA/CDER) (b) (6) Formation (b) (6)								
To: Bozzette, Sam (NIH/NCATS) [E] (b) (6) >; Butterton, Joan (b Collins, Sylva (FDA/CDER) (b) (6) Judy Currier (b) (6) ; De Claro, R. Angelo (FDA/CDER) (b) (6) ; Mark Eisner (b) (6) >; Keith Gottesdiener (b) (6) Eric Hughes (b) (6) ; LaVange, Lisa M (b) Elliott Levy (b) (6) ; Sandeep Menon (b) (6) >; Amanda Peppercorn (b) (6) ; Proschan, Michael (NIH/NIAID) [E] (b) (6) >; Read, Sarah (NIH/NIAID) [E] (b) (6) ; Amanda Peppercorn Price, Dionne (FDA/CDER) (b) (6) ; Shen, Yuan Li (FDA/CDER) (b) (6) ; Shen, Yuan Li (FDA/CDER) (b) (6) ; Vincent, Michael (b) (6) (E] (b) (6) ; Vincent, Michael (b) (6) >; Macone, Erin (b) (6) ; Vincent, Michael (b) (6) >; Macone, Erin (b) (6) ; Parker, Ashley (NIH/OD) [E] (b) (6) Butcher, Tina (b) (6) ; Wung, Peter / US (b) (6) Qashu, F	From: Adam, Stacey	(FNIH) [T] <	(b) (6)			***************************************		b-1000000000000000000000000000000000000
Sylva (FDA/CDER) (b) (6) Judy Currier (b) (6) ; De Claro, R. Angelo (FDA/CDER) (b) (6) ; Mark Eisner (b) (6) >; Keith Gottesdiener (b) (6) Eric Hughes (b) (6) ; LaVange, Lisa M (b) Elliott Levy (b) (6) ; Sandeep Menon (b) (6) >; Amanda Peppercorn (b) (6) ; Proschan, Michael (NIH/NIAID) [E] (b) (6) >; Read, Sarah (NIH/NIAID) [E] (b) (6) ; Amanda Peppercorn (Price, Dionne (FDA/CDER) (b) (6) Rubin, Daniel B. (FDM/CDER) (b) (6) >; Shen, Yuan Li (FDA/CDER) (b) (6) Farley, John (FDA/CDER) (b) (6) Goff, David (NIH/NHL [E] (b) (6) ; Vincent, Michael (b) (6) >; Macone, Erin (b) (6) ; Vincent, Michael (b) (6) >; Macone, Erin (b) (6) ; Parker, Ashley (NIH/OD) [E] (b) (6) Butcher, Tina (b) (6) ; Wholley, David (FNIH) [T] (b) (6) Melencio, Cheryl (FNIH) [T] (b) (6) ; Stratton, Benjamin (b) (Sent: Thursday, Apr	il 30, 2020 9:4	4 AM					
(FDA/CDER) (b) (6) >; Mark Eisner (b) (6) >; Keith Gottesdiener (b) (6) Eric Hughes (b) (6) ; LaVange, Lisa M (b) Elliott Levy (b) (6) Sandeep Menon (b) (6) >; Amanda Peppercorn (b) (6) ; Proschan, Michael (NIH/NIAID) [E] (b) (6) >; Read, Sarah (NIH/NIAID) [E] (b) (6) Rubin, Daniel B. (FDM/CDER) (b) (6) >; Shen, Yuan Li (FDA/CDER) (b) (6) Farley, John (FDA/CDER) (b) (6) Soff, David (NIH/NHL [E] (b) (6) ; Vincent, Michael (b) (6) >; Macone, Erin Cc: Mary Biggs (b) (6) DeMarcus, Forrest (b) (6) >; Macone, Erin (b) (6) Tountas, Karen (FNIH) [T] (b) (6) Wachtel, Jonathan (b) (6) Elizabeth Kim (b) (6) >; Parker, Ashley (NIH/OD) [E] (b) (6) Butcher, Tina (b) (6) >; Wholley, David (FNIH) [T] (b) (6) Melencio, Cheryl (FNIH) [T] (b) (6) ; Stratton, Benjamin (b) (6) Sashu, Felicia (NIH/OD) [E]	To: Bozzette, Sam (N	VIH/NCATS) [E	(b) (6	5) >;	Butterton, Joa	an (b	; Co	ollins,
(b) (6)	Sylva (FDA/CDER)	(b) (6	5) J	udy Currier	(b)	(6) ;	De Claro, R. Angelo	
Elliott Levy (b) (6) Sandeep Menon (b) (6) >; Amanda Peppercorn (b) (6) ; Proschan, Michael (NIH/NIAID) [E] (b) (6) >; Read, Sarah (NIH/NIAID) [E] (b) (6) ; Amanda Peppercorn (Price, Dionne (FDA/CDER) (b) (6) Rubin, Daniel B. (FDA/CDER) (b) (6) >; Shen, Yuan Li (FDA/CDER) (b) (6) Farley, John (FDA/CDER) (b) (6) Goff, David (NIH/NHL [E] (b) (6) ; Vincent, Michael (b) (6) Cc: Mary Biggs (b) (6) DeMarcus, Forrest (b) (6) >; Macone, Erin (b) (6) Tountas, Karen (FNIH) [T] < (b) (6) Wachtel, Jonathan (b) (6) Elizabeth Kim (b) (6) >; Parker, Ashley (NIH/OD) [E] (b) (6) Butcher, Tina (b) (6) >; Wholley, David (FNIH) [T] (b) (6) Melencio, Cheryl (FNIH) [T] (b) (6) Stratton, Benjamin (b) (6) >	(FDA/CDER)	(b) (6)	>; Mar	k Eisner	(b) (6)	>; Keith C	Gottesdiener	
(NIH/NIAID) [E] (b) (6) ; Proschan, Michael (NIH/NIAID) [E] (b) (6) >; Read, Sarah (NIH/NIAID) [E] (b) (6) ; Amanda Peppercorn (Price, Dionne (FDA/CDER) (b) (6) Rubin, Daniel B. (FDA/CDER) (b) (6) >; Shen, Yuan Li (FDA/CDER) (b) (6) Goff, David (NIH/NHL [E] (b) (6) ; Vincent, Michael (b) (6) Cc: Mary Biggs (b) (6) DeMarcus, Forrest (b) (6) >; Macone, Erin (b) (6) Tountas, Karen (FNIH) [T] < (b) (6) Wachtel, Jonathan (b) (6) Elizabeth Kim (b) (6) >; Parker, Ashley (NIH/OD) [E] (b) (6) Butcher, Tina (b) (6) >; Wholley, David (FNIH) [T] (b) (6) Melencio, Cheryl (FNIH) [T] (b) (6) ; Stratton, Benjamin (b) (6) >	(b) (6)		Eric Hughes	(b) (6)	; LaVange, Lisa	M (b)	
(NIH/NIAID) [E] (b) (6) Amanda Peppercorn (Price, Dionne (FDA/CDER) (b) (6) Rubin, Daniel B. (FDM/CDER) (b) (6) >; Shen, Yuan Li (FDA/CDER) (b) (6) Farley, John (FDA/CDER) (b) (6) Goff, David (NIH/NHL [E] (b) (6) ; Vincent, Michael (b) (6) Cc: Mary Biggs (b) (6) DeMarcus, Forrest (b) (6) >; Macone, Erin (b) (6) Tountas, Karen (FNIH) [T] (b) (6) Wachtel, Jonathan (b) (6) Elizabeth Kim (b) (6) >; Parker, Ashley (NIH/OD) [E] (b) (6) Butcher, Tina (b) (6) >; Wholley, David (FNIH) [T] (b) (6) Melencio, Cheryl (FNIH) [T] (b) (6) ; Stratton, Benjamin (b) (6) Qashu, Felicia (NIH/OD) [E]	Elliott Levy	(b) (6)	Sandeep Mer	non	(b) (6)	>; Am	anda Peppercorn	
(FDA/CDER) (b) (6) Rubin, Daniel B. (FDA/CDER) (b) (6) >; Shen, Yuan Li (FDA/CDER) (b) (6) Farley, John (FDA/CDER) (b) (6) Goff, David (NIH/NHL [E] (b) (6) ; Vincent, Michael (b) (6) Cc: Mary Biggs (b) (6) DeMarcus, Forrest (b) (6) >; Macone, Erin <	(b) (6)		; Proschan, Mi	chael (NIH/NI	AID) [E]	(b) (6)	>; Read, Sarah	
(FDA/CDER) (b) (6) Farley, John (FDA/CDER) (b) (6) Goff, David (NIH/NHL [E] (b) (6) ; Vincent, Michael (b) (6) Cc: Mary Biggs (b) (6) DeMarcus, Forrest (b) (6) >; Macone, Erin <	(NIH/NIAID) [E] (b)	(6)	; Amanda	a Peppercorn	(Price, Dionne	•
[E] (b) (6) ; Vincent, Michael (b) (6) Cc: Mary Biggs (b) (6) DeMarcus, Forrest (b) (6) >; Macone, Erin < (b) (6) Tountas, Karen (FNIH) [T] < (b) (6) Wachtel, Jonathan (b) (6) Elizabeth Kirr (b) (6) >; Parker, Ashley (NIH/OD) [E] (b) (6) Butcher, Tina (b) (6) >; Wholley, David (FNIH) [T] (b) (6) Melencio, Cheryl (FNIH) [T] (b) (6) Wung, Peter /US < (b) (6) Qashu, Felicia (NIH/OD) [E] (b) (6) ; Stratton, Benjamin (b) (6) >	(FDA/CDER)	(b) (6)	: Rubin,	Daniel B. (FD	A/CDER	(b) (6)	>; Shen, Yuan	ı Li
Cc: Mary Biggs (b) (6) DeMarcus, Forrest (b) (6) >; Macone, Erin <	(FDA/CDER)	(b) (6)	Farley	, John (FDA/C	DER)	(b) (6)	Goff, David (NIH	/NHLBI
<	[E] (b) (6)	; Vincent	, Michael	(b) (6))			
Elizabeth Kim (b) (6) >; Parker, Ashley (NIH/OD) [E] (b) (6) Butcher, Tina (b) (6) >; Wholley, David (FNIH) [T] (b) (6) Melencio, Cheryl (FNIH) [T] (b) (6) Wung, Peter /US < (b) (6) Qashu, Felicia (NIH/OD) [E] (b) (6) ; Stratton, Benjamin (b) (6) >	Cc: Mary Biggs	(b) (6)	DeMar	cus, Forrest	(b) (6) >; 1	Macone, Erin	
(b) (6)	< (b) (6)	Tountas, K	aren (FNIH) [T]	< (b) (c	5) : Wa	chtel, Jonathan	(b) (6)	;
(b) (6) Wung, Peter /US < (b) (6) Qashu, Felicia (NIH/OD) [E] (b) (6) ; Stratton, Benjamin (b) (6) >	Elizabeth Kim	(b) (6)	;>; Parker, Ash	aley (NIH/OD)	[E]	(b) (6)	Butcher, Tina	
(b) (6) ; Stratton, Benjamin (b) (6) >	(b) (6)	>; Who	olley, David (FN	IH) [T]	(b) (6)	Melencio, Ch	neryl (FNIH) [T]	
	(b) (6)	: Wung, Pet	ter /US <	(b) (6)	Qash	u, Felicia (NIH/O	D) [E]	
Subject: RF: ACTIV TX-Clinical Master Protocol Subgroup Meeting #7	(b) (6)	; Stratton	, Benjamin	(b) (6)	.>			
Subject NE. Notify 17 Children Nation 1 Total Color Subject Necessity 17	Subject: RE: ACTIV T	X-Clinical Mas	ter Protocol Su	bgroup Meet	ing #7			

Hi Sam,

I think you are correct and we can discuss more today and tomorrow. I am currently trying to figure out what the outreach procedure should be, but I agree it likely needs to sooner rather than later.

Thanks, Stacey

Stacey J. Adam, PhD Director, Cancer

Research Partnerships

Direct: (b) (6) Mobile: (b) (6)

From: Bozzette, Sam (NIH/NCATS) [E] (b

Sent: Thursday, April 30, 2020 9:19 AM

To: Adam, Stacey (FNIH) [T] (b) (6) Butterton, Joan (b) (6) Collins, Sylva

(FDA/CDER)		(b) (6)	; J	udy Currie	er	(b)	(6)	De Clar	o, R.	Angelo (FDA/CDEI	R)
	(b) (6)	>; 1	∕lark Eisne	er	(b) (6)	;	>; Keith	Gottesdiener			
	(b) (6)	_>	; Eric Hug	hes	(b) ((6)		LaVange, Lisa M	<	(b) (6)	
Elliott Levy	(b) (6)		Sandee	p Menon	(b			Amai	nda P	eppercorn	
	(b) (6)		; Proscha	an, Michae	el (NIH/NI	AID) [E]		(b) (6)		; Read, Sarah	
(NIH/NIAID)	[E]	(b) (6)	>; A	manda Pe	ppercorn			(b) (6)		Price, Dionne	
(FDA/CDER)		(b) (6)		Rubin, Dar	niel B. (FD	A/CDER)	(b) (6)		Shen, Yuan Li	
(FDA/CDER)		(b) (6)	;	Farley, Joh	nn (FDA/C	DER)		(b) (6)	Go	off, David (NIH/NH	ILBI)
[E] <	(b) (6)	Vincen	t, Michael	l	(b) (6)						
Cc: Mary Big	ggs	(b) (6)	>; D	emarcus		(b) (6)		>; Macone, Ei	rin	(b) (6)	;
Tountas, Ka	ren (FNIH)	[T]	(b) (6)	; Wac	htel, Jona	than <		(b) (6)	Eliz	abeth Kim	
(b)	(6)	; Parker, A	shley (NIF	I/OD) [E] <	<	(b) (6)		Butcher, Tina			
	(b) (6)	: Wh	olley, Dav	rid (FNIH)	[T]	(b) (6)	,	; Melencio, Che	ryl (F	NIH) [T]	
(b)	(6)	; Wung, Pe	eter/US	((b) (6)		Qashu,	Felicia (NIH/OD) [E]		
< (b) (6)	Stratto	n, Benjam	in	(b) (6)		>				
		ol:		101							

Subject: Re: ACTIV TX-Clinical Master Protocol Subgroup Meeting #7

Good morning all:

It would seem that our active control arm had been identified. Should we get in the queue with Gilead sooner rather than later - or have we already reached out to them?

S

From: "Adam, Stacey (FNIH) [T]" Date: Thursday, April 23, 2020 at 8:31:00 PM To: "Bozzette, Sam (NIH/NCATS) [E]" < "Butterton, Joan" < joan (b)(6)"Collins, Sylva (FDA/CDER)" "Judy Currier" >, "De Claro, R. (b)(6)(b)(6)Angelo (FDA/CDER)" "Mark Eisner" , "Keith Gottesdiener" (b) (6) (b) (6) "Eric Hughes" < "LaVange, Lisa M" (b)(6)(b) (6) "Sandeep Menon" "Elliott Levy" (b) (6) (b) (6) , "Proschan, Michael (NIH/NIAID) [E]" "Amanda Peppercorn" (b) (6) , "Read, Sarah (NIH/NIAID) [E]" < "Amanda Peppercorn" (b)(6)(b) (6) "Price, Dionne (FDA/CDER)" < "Rubin, Daniel B. (b) (6) (b)(6)(FDA/CDER)" < "Shen, Yuan Li (FDA/CDER)" , "Farley, John (b)(6)(b)(6)(FDA/CDER)" < (b) (6) "Goff, David (NIH/NHLBI) [E]" < (b) (6) "Vincent, Michael" (b)(6)Cc: "Mary Biggs" < "Demarcus" (b)(6)"Macone, Erin" (b) (6) "Tountas, Karen (FNIH) [T]" "Wachtel, Jonathan" (b) (6) (b) (6) , "Elizabeth Kim" >, "Parker, Ashley (NIH/OD) [E]" (b) (6) (b)(6)"Butcher, Tina" "Wholley, David (FNIH) [T]" (b)(6)(b) (6) org>, "Melencio, Cheryl (FNIH) [T]" >, "Wung, Peter /US" (b) (6) (b) (6) >, "Qashu, Felicia (NIH/OD) [E]" , "Stratton, Benjamin" (b) (6) (b)(6)(b)(6)

Subject: RE: ACTIV TX-Clinical Master Protocol Subgroup Meeting #7

Dear TX-Clinical Master Protocol Subgroup,

Please find attached the materials for tomorrow's meeting.

- 1. Agenda
- 2. Slides for discussion updated with the decisions from today

3. A useful resource about current standard clinical treatment guidelines from the front lines for COVID. This may be a useful resource in selecting how to do minimal data collection and trying to understand SOC.

Please let me know if you have questions or other things you think would be helpful for the group to review.

(b) (6)

Thanks, Stacey Stacey J. Adam, PhD Director, Cancer Research Partnerships Direct: (b) (6) | Mobile: (b) (6) Join Zoom Meeting https://fnih.zoom.us/ (b)(6)Meeting ID: (b) (6) Password: (b) (6) One tap mobile (b) (6) US (Chicago) US (New York) Dial by your location (b)(6)US (Chicago) US (New York) US (San Jose) US (San Jose) US US US (Houston) Meeting ID: (b) (6) Password: (b) (6) Find your local number: https://fnih.zoom.us

Adam, Stacey (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP From: (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=DCD875F0679648859E1CF101C0943414-ADAMSJ4] Sent: 7/10/2020 2:41:18 PM To: Sandeep Menon [(b) (6) Rachel Harrigan [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=80023e7be2dd4554b54d1604fa60df18-rachel.h.ha]; Erhardt, William (HHS/IOS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=86d3f82263b04011a1ff30220cd2d612-William.Erh]; Roger Paredes Andrew Phillips [(b) (6) CC: Tountas, Karen (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Demarcus [(b) (6) Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=40c04fef6f1e46f5b750753cd5a14f93-tountaskhl; Wachtel, Jonathan Parker, Ashley (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras]; Chen, Helen Q. Eron, Joseph J Jr Chew, Kara M.D. (b) (6) (b) (6) Daar, Eric [rg]; Erhardt, William (HHS/IOS) (b)(6)(b) (6) (b)(6)Subject: Canceled: ACTIV-3 Standing Protocol Team Meeting Location: https://fnih.zoom.u (b)(6)Start: 6/29/2020 3:00:00 PM End: 6/29/2020 4:00:00 PM Show Time As: Free Weekly Recurrence: every Monday from 11:00 AM to 12:00 PM Required Jens Lundgren; Wentworth, Debby; (b) (6) Ajay Nirula - Lilly; (b)(6)Attendees: Patterson, Amy (NIH/NHLBI) [E]; Andrew Phillips; (b)(6)(b) (6) Birgit Grund (Lane, Cliff (b)(6)(b) (6) (b)(6)(NIH/NIAID) [E]; Higgs, Elizabeth (NIH/NIAID) [E]; (b)(6)(b)(6)(b)(6)(b)(6)Ginny Kan; Baker, Jason; Neaton, Jim; (b) (6) (b)(6)Judy Currier; Reineck, Lora (NIH/NHLBI) (b)(6)(b)(6)(b)(6)[E]; Kozak, Marina (OS/ASPR/BARDA); Miller, Marissa A (NIH/NHLBI) [E]; Mark Polizzotto; (b)(6)Proschan, Michael (NIH/NIAID) [E]; Aggarwal, Neil (NIH/NHLBI) [E]; Paul Klekotka - Lilly; Harrigan, Rachel (HHS/IOS); Cavan, Reilly; Roger Paredes; Read, Sarah (NIH/NIAID) [E]; (b) (6) Shweta Sharma; Taylor Thompson; (b) (6) (b) (6) Rosenberg, Yves (NIH/NHLBI) [E]: Denning, Eileen; Larson, Gregg; Peter Smith, M.D. (Thoracic Surgery); Davey, Victoria ((b) (6) Katharina Krapp; John Rule; Aileen M Ilaria Optional Daniel Dawson Murray; Lisbeth Jørgensen; Nicole Engen; RH-FP-CHIP-ACTIV3-Attendees: INSIGHT014; Tierney, John (NIH/NIAID) [E]; Marie Helleberg; Cate Carey; Vjecha, Michael; Hudson, Fleur; Pett, Sarah; Bitten Aagaard; Charlotte Bjernved Nielsen; Kent P Hassett; Lilian Gonzalez; Andrew G Koustenis; Eccard-Koons, Vanessa (NIH) [C]; Buehn, Molly (NIH) [C]; MacDonald, Leah (NIH) [C]; Ganapathy Gopalrathnam; Janice Evans; Janelle A Sabo; Carlos O Garner - Lilly; Tonya L Combs; Lori J Stephens; Lau, Chuen-Yen (NIH/NIAID) [E]; Herpin, Betsey (NIH/NIAID) [E]; Barrett, Kevin (NIH/NIAID) [E]; Smolskis, Mary (NIH/NIAID) [E]; Engel, Theresa (NIH) [C]; Osborne, Cynthia (NIH) [C]; Simpson, Shelly (NIH) [C]; Vogel, Susan (NIH/NIAID) [E]; Grace, Beth (NIH/NIAID) [C]; Proffitt, Calvin (NIH) [C]; Hohn, Matt (NIH) [C]; McNay, Laura (NIH/NIAID) [E]; Pierson, Jerome (b) (6) (NIH/NIAID) [C]; Mock, Rebecca (NIH/NIAID) [E]; Segal Raim, Sharon (NIH) [E]; Miller, Tracey (NIH) [C]; Parrish, David (NIH/NIAID) [E]; Galcik, Michael (NIH) [C]; Dighero-Kemp, Bonnie (NIH/NIAID) [C]; Hensley, Lisa (NIH/NIAID) [E] Stacey Adam is inviting you to a scheduled Zoom meeting. Join Zoom Meeting https://fnih.zoom. (b)(6)Meeting ID: (b) (6) Password: (b) (6) One tap mobile (New York) (b) (6) (Germantown)

```
Dial by your location
(b) (6) US (New York)

+ (b) (6) US (Germantown)

+ (b) (6) US (Chicago)

+ (b) (6) US (Tacoma)

+ (b) (6) US (Houston)

+ (b) (6) US (San Jose)

Meeting ID: (b) (6)

Password: (b) (6)

Find your local number: https://fnih.zoom.u (b) (6)
```

From: Menetski, Joseph (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=5001AF52DC4A427EA3D34F1E072F8CB7-MENETSKIJP] Sent: 7/8/2020 5:49:38 PM To: Hild, Sheri (NIH/OD) [E] (b) (6) (b) (6) (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=edd7f1939fb94be3bf063f925ac15f02-hildsa]; (b)(6)(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) Baric, Ralph [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=48e35ab1d3044465a7790ee4ded5bc32-rbaric.emai]; Ottinger, Elizabeth (NIH/NCATS [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ad34123055944f97bedbef038d375cd7-ottingerea]; Colvis, Christine (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4b7e84cce098457896b2df19fa172c87-ccolvis]; Hewitt, Judith (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2d0a7dadfcbd42cbb4014d9b26af30cc-ihewitt]; Deming, Damon (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=8a5ace9923ae415aa3d85ac09cb76f85-DEMINGD.fda]; Parker, Ashley (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange (b) (6) (b) (6) Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras]; ; Adams, Peter (OS/ASPR/BARDA) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f6e22f801f9146ef90116c4311c6f3ee-Peter.Adams]; Rao, Srinivas Qashu, Felicia (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=366447a553f44696b2c79484d90e41e5-gashufm]; Tomas Cihlar Pitt, Margaret L CIV USARMY MEDCOM USAMRIID (USA) [(b) (6) Punturieri, Antonello (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ca7f3106e5f24b5cb5e933c6ee7a6bc7-punturieria]; Charette, Marc (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a7fa2baf951848b5bf1f76a049a0eca6-charettemf]; Fessel, Josh (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=294e2bb481d94b83a1917f15338dfe19-fesseljp] CC: Diamond, Michael [Austin, Christopher (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange (b) (6) Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=17597cabc42247548e596778304f781f-austinc]; Florence, Clint (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5e032d0bc8554e8787e844a7773295fe-florencewc]; Simon, Dina (NIH/OD) [C] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e02345fa5d1d4d7eaf4e0f3da58bc1ac-simondm]; Wholley, David (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]; Melencio, Cheryl (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=279e14fa7428415bb86087d08b628e6f-melencioc]; Colvis, Christine (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4b7e84cce098457896b2df19fa172c87-ccolvis]; Desrosiers, Betsy Hughes, Eric [(b) (6) Jansen, Kathrin (b) (6) Kurilla, Michael (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (b)(6)(FYDIBOHF23SPDLT)/cn=Recipients/cn=dc4e85061e3943b9b8ad3f426727861f-mkurilla]; Lowy, Douglas (NCI) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=54fa75fe6e304e34ba567c66b832baa0-drl.helix.n]; Read, Sarah (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=527b160038004a199ae6e0bac2226099-readsa]; Tountas, Karen (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=40c04fef6f1e46f5b750753cd5a14f93-tountaskh]; Santos, Michael (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ab38cb6836de44e18ef4cc6952f65f80-santosmr]; Adam, Stacey (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dcd875f0679648859e1cf101c0943414-adamsj4]; James, Stephanie (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=f0032ef62ca343dfb4bf79577e2aa8d1-jamesst]; Alvarez, Rosa Maria

Kim, Elizabeth [Tolman, Brett [Wachtel, (b) (6) (b) (6) (b) (6) Jonathan Prabhavathi Fernandes [prabha. Rose Li (b) (6) (b) (6) ; Lagos, Enrique (NIH/NCATS) Dana Carluccio (b) (6) (b)(6)[E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ae9041ab27204d83b06752f67a44b0d1-lagoses]; Jonson, Samantha (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ce2f69369d654bef89b0d39b145d69a7-jonsonsg]; Gonzalez, Nina [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user3c2f486d]; Burrus-Shaw, Cyndi (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5bbac95b1f6e4514a299b318030c31f6-shawcy]; Rodriguez, Robin D ; Dave Frankowski [(b)(6)(b) (6) Baric, Toni C Lowy, Douglas (NIH/NCI) [E] [/o=ExchangeLabs/ou=Exchange Administrative [(b) (6) Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f1b7b8fe4739478bb17840c56902718a-lowyd]; Nancy Haigwood [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=03d589f440d84691ac0a530e4ba6ceb5-haigwoon.oh]; Stratton, Benjamin Gadbois, Ellen (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0243d1d6e6f248268d2edec566c26c2a-gadboisel]; Anderson, James (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=73143d1860bc42458be254ca21573b23-andersonjm] ACTIV Preclinical full working group

Subject:

Attachments: 2020-07-01_Preclinical_WG_Summary_F1.docx

Dear Preclinical Working group and attendees,

I apologize for not providing the minutes from last week's meeting. Here they are for your review.

Sincerely, Joe

Joseph P. Menetski Ph.D.

Associate Vice President, Research Partnerships

Foundation for the National Institutes of Health

(b)(6)fnih.org

11400 Rockville Pike, Suite 600. North Bethesda, MD 20852



Donate to the FNIH's Pandemic Response Fund to combat COVID-19: fnih.org/pandemic



Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f1b7b8fe4739478bb17840c56902718a-lowyd]; Marks,

APAR0000020025-2517013

Peter (FDA/CBER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b2e527dbda2b4a86b8d72f06b813d471-MarksP.fda]; Messonnier, Nancy (CDC/DDID/NCIRD/OD) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=441f65db836c4a89a42aecb9a0d9b96c-NAR5]; Offit, Paul [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cbd9cc56fdbe4598a57b423d484dcf9f-offit.email]; (b) (6) Seals, Jonathan (OS/ASPR/BARDA) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d7a87d49ccba4e3caaf5eb5d3586b1cc-Jonathan.Se]; Arvin, Ann [/o=ExchangeLabs/ou=Exchange Administrative (b) (6) Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3bbf6108d53148f684dad333fce983de-aarvin.stan]; (b) (6) (b)(6)(b)(6)(b) (6) (b)(6)(b)(6)Johnson, Maureen (b)(6)(NIH/NCI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0cb4ad1bebe64791b0415a7eb4bf71db-johnsonr]; Kozlowski, Mary (NIH/NCI) [C] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=15373a5a1d8a4fa89d49ba9c8561cc94-kozlowskimt]; Austin, Sarah (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=292fcb760f9f4f199ebe343e08ef1781-austinsj]; Victoria Davey [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2c8291f38ec342f895243c0617e115ec-victoria.da]; Jintanat Ananworanich Verani, Jennifer R. (b) (6) Michael Watson (x) (b) (6) (CDC/DDID/NCIRD/DBD) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=7c249692151d46d6ac80cb28ada3d3a0-qzr7]; Schrag, Stephanie (CDC/DDID/NCIRD/DBD) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9be29b344ba14363bdecaa43582ca226-ZHA6]; Marovich, Mary (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=bfd0192d165d4643accf6347728dbaeb-marovichma]; Hamilton, Nancy Mascola, John (NIH/VRC) [E] [/o=ExchangeLabs/ou=Exchange Administrative (b)(6)Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=7f78b40a596b4ca4a2850a429d1ae3f2-jmascola] Attachments: Clinical Trial Capacity Working Group Meeting Agenda 05122020.pdf https://zoom.us/ (b) (6) 5/12/2020 3:00:00 PM 5/12/2020 4:00:00 PM Show Time As: Busy every Tuesday and Friday from 9:00 AM to 10:00 AM Bascles, Lionel; Cohen, Myron; Corey, Larry; Desrosiers, Betsy; Dickens, Jim (NIH/NCATS) [C]; Doroshow, James (NIH/NCI) [E]; Goff, David (NIH/NHLBI) [E]; King, James; Kurilla, Mike; Nayak, Seema (NIH/NIAID) [E]; Parker, Ashley (NIH/OD) [E]; Payton, Manzine; Resnansky, Laura; Srinivasan, Badhri; Stein, Peter (FDA/CDER); Vincent, Mike; Wachtel, Jonathan; Garner, Carlos; Sizemore, Christine (NIH/FIC) [E]; Qashu, Felicia Colvis, Christine (NIH/NCATS) [E]; Hughes, Eric; Jansen, Kathrin; Lowy, Douglas (NCI); Read, Sarah (NIH/NIAID) [E]; Young, John; Adam, Stacey (FNIH) [T]; Anderson, Margaret; Carluccio, Dana; Cheryl (FNIH) Melencio [T] Francis Collins; Gonzalez, Nina; Heaton, Penny; James, Stephanie; Li, Rose; Menetski, Joseph (FNIH) [T]; Santos, Michael (FNIH); Tuvesson, Nancy; Wholley, David (FNIH) [T]; Criffield, Robin; Hamilton, Nancy; Minnich, Beth; Rebecca (NIH/NCATS) Katz [E] (Stratton, Benjamin; Tolman, Brett; Kenny, (b) (6) Dermot; (b) (6) (b)(6)(b)(6)Haynes, Barton; (b)(6)(b) (6) (b)(6)Lowy, Douglas (NIH/NCI) [E]; Marks, Peter (FDA/CBER); Mascola, John (NIH/VRC) [E]; (b) (6) Messonnier, Nancy (CDC/DDID/NCIRD/OD); Offit, Paul; .com; Seals, (b)(6)Jonathan (OS/ASPR/BARDA); Arvin, Ann; (b)(6)(b) (6) (b) (6) (b)(6)christine.van-(b)(6)(b)(6)Johnson, Maureen (b)(6)(b) (6) (b)(6)(NIH/NCI) [E]; Kozlowski, Mary (NIH/NCI) [C]; Austin, Sarah (NIH/NIAID) [E]; Davey, Victoria; Jintanat Ananworanich;

Location:

Recurrence:

Required

Optional

Attendees:

Attendees:

Start:

End:

Michael Watson (x); Verani, Jennifer R. (CDC/DDID/NCIRD/DBD); Schrag, Stephanie (CDC/DDID/NCIRD/DBD); Marovich, Mary (NIH/NIAID) [E]

Apologies for the repeat emails, updated agenda is attached. Karen

Dear Colleagues, Attached is the meeting agenda. Looking forward to a robust discussion about vaccine protocols and capacity needs! Karen

ACTIV: Accelerating COVID-19 Therapeutic Interventions and Vaccines

Dear Clinical Trial Capacity Working Group members,

In anticipation of this working group making rapid progress on identified action items and other activities, the co-chairs have agreed that it will be important to hold twice-weekly calls to evaluate progress made by each subgroup, to identify areas of need, and to determine next steps. We ask that you make every effort possible to join each of these meetings, but understand that at times you may have competing priorities. To place a hold on your calendar, please accept this meeting invite with a response; later you can decline an individual meeting if you have a conflict.

An agenda and other meeting materials, as needed, will be distributed prior to each call.

With best regards, Karen

Karen H. Tountas, PhD Scientific Program Manager Foundation for the National Institutes of Health

Join Zoom Meeting https://zoom. (b)(6)Meeting ID: (b) (6) Password: (b) (6) One tap mobile (b)(6)US (Chicago) US (New York) Dial by your location (b)(6)JS (Chicago) JS (New York) JS JS (Houston) JS (San Jose) JS (San Jose) JS Meeting (b)(6)Password: (b) (6) Find your local number: https://zoom.u (b) (6)

From: Collins, Francis (NIH/OD) [E] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP

(FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=410E1CA313F44CED9938E50D2FF0B6C2-COLLINSF]

Sent:

5/30/2020 12:32:00 AM

To:

Wholley, David (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]

CC:

Adam, Stacey (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=dcd875f0679648859e1cf101c0943414-adamsj4]; Freire, Maria (FNIH) [T]

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=8598d551d1d3455eaf14854c83f41d84-freiremc]; Gonzalez, Nina [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user3c2f486d];

Parker, Ashley (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras]

Subject:

RE: Key messages re: immunomodulators for slides for Moncef meeting tomorrow 5/30

Hoping these are coming to me soon, as I may want to do some editing -- and then I wanted to run them past Janet tonight.

FC

(b)(6)

From: Wholley, David (FNIH) [T] < (b) (6) Sent: Friday, May 29, 2020 7:41 PM To: Collins, Francis (NIH/OD) [E] < (b)(6)Cc: Adam, Stacey (FNIH) [T] < Freire, Maria (FNIH) [T] < Gonzalez, Nina (b) (6) (b) (6) < Parker, Ashley (NIH/OD) [E] < Freire, Maria (FNIH) [T] (b) (6)

Subject: RE: Key messages re: immunomodulators for slides for Moncef meeting tomorrow 5/30

Have seen and offered a few changes to the complete slide deck. They should be coming back to you as soon as Deloitte makes the changes.

From: Collins, Francis (NIH/OD) [E] < (b) (6) Sent: Friday, May 29, 2020 5:59 PM To: Wholley, David (FNIH) [T] (b)(6)Cc: Adam, Stacey (FNIH) [T] (b) (6) ; Freire, Maria (FNIH) [T] (b) (6) Gonzalez, Nina Parker, Ashley (NIH/OD) [E] (b) (6) (b) (6)

Subject: RE: Key messages re: immunomodulators for slides for Moncef meeting tomorrow 5/30

Hi all,

I have received information from Amy Patterson about the anticoagulant trial, and I'd like to have that incorporated into the slide set that Deloitte is currently working on. Attached is the document from Amy. I have highlighted the main points that I would want to have included in the slides, trying if possible to mirror the same features that are going to be included in the description of the immunomodulator study.

See what you think. I stand ready to look at ppts anytime this evening.

One question about the immunomodulator trial that I noticed in Moncef's note - has FDA agreed with the plan to move straight into phase 3 from a safety and efficacy standpoint?

Thanks, Francis

From: Wholley, David (FNIH) [T] (b) (6)

Sent: Friday, May 29, 2020 1:59 PM

To: Collins, Francis (NIH/OD) [E] (b) (6)

Cc: Adam, Stacey (FNIH) [T] (b) (6) ; Freire, Maria (FNIH) [T] < (b) (6) Gonzalez, Nina (b) (6) Parker, Ashley (NIH/OD) [E] (b) (6)

Subject: Key messages re: immunomodulators for slides for Moncef meeting tomorrow 5/30

Francis:

Here is the outline of the slides I am asking Deloitte to work to put together with key messages. I don't know if you or Ashley have a good version of slide #1; it is more of an OWS slide than an ACTIV one. I also don't know what input NHLBI wants to provide; I took the liberty of naming the anticoag MP as "ACTIV-4" in the interest of teaming up on a commonly branded strategy, hope that is OK. I am providing this to Deloitte now so they can get going on starting the slides, but please feel free to highlight maybe in red any wording you want changed or additions you would add in the meantime, and copy all on the reply.

- Maybe a diagram slide just reminding Moncef that OWS/Therapeutics and ACTIV are working together
- OWS/ACTIV Therapeutics has been taking a portfolio approach to addressing the dramatic health and economic
 challenges posed by the pandemic, with harmonized efforts that address both disease etiology and
 symptomology.
 - ACTIV Baricitinib (ACTT2, sponsored by NIAID) in progress
 - ACTIV hiVIG (sponsored by NIAID) in progress
 - ACTIV-1 Inpatient Master Protocol of 3 host-targeted immune modulators (using CRO) (Phase III) ready to launch late June
 - ACTIV-2*— Neutralizing Monoclonal Antibodies Outpatient Master Protocol (using NIAID ACTG Network + CRO) – (Phase II/III) – projected launch June
 - ACTIV-3* Neutralizing Monoclonal Antibodies Inpatient Master Protocol (NIAID INSIGHT Network + NHLBI PETAL Network + CRO) – (Phase II/III) – projected launch July
 - ACTIV-4 Inpatient Master Protocols of 3+ Anticoagulant Therapies, and eventually,
 Anticoagulant+Immune Modulator Combinations (NHLBI-NINDS "Master" Network) (Phase II/III) –
 projected launch late June
 - ACTIV-5 De Novo Master Protocol Structure to test promising agents not effectively evaluated elsewhere (e.g., antivirals) similar design to the mAb protocols, networks/sites/agents in discussions now projected launch August (if needed; i.e. if agents are not incorporated into mAb protocols)
 * current priority

[for this slide I think you can use the Agent Prioritization Snapshot slide (#12) from May 20 ACTIV EC call as a base

- Prioritization Process (v 2.0) for ACTIV: (slide 14 from May 20 EC deck)
- Results of First Agent Prioritization Reviews (slide 13 from May 20 deck)
 [Key Criteria for Scoring (slide 15 from 5/20) can go to backup
- Prioritization and Protocol Design: Who is Involved two-box slide containing names and affiliations of those involved in the Proritization and MP Subgroups (quality folks!)
- ACTIV-1 Protocol for immunomodulators
 - Agent prioritization included input from COVID R&D Leadership Consortium planned testing of 8-9 repurposed agents funded by industry (2 highest priority agents switched to ACTIV-1)
 - 3 agents chosen are well-established anti-inflammatories with solid rationale for MOA in COVID-19, not already being adequately tested elsewhere
 - All 3 either have initial Phase II data or are currently running company-sponsored Phase II trials
 = high POS
 - Phase III master protocol design for ACTIV-1 includes aggressive efficacy and futility assessments to allow for early stopping at 25%, 50%, and 75% accrual, in order to quickly drop agents not showing efficacy (like a Phase II/III progression design, but design was faster for quicker launch)

- Companies have agreed to share data + common control arm+ common endpoints + DSMB = efficiency and ability to compare results across arms (this does not happen if companies test separately)
- Protocol is 80% complete
 - Substantial input from 25+ industry, academic, and government experts, including FDA clinical and stats
 - Statisticians include some of the best in the world for master protocol design: Lisa LaVange (UNC), Karen Price (Lilly), Michael Proschan (NIAID), Sandeep Menon (Pfizer)
 - All three companies have written their sections of the protocols, which are being merged into the master design
- Working with OWS/BARDA on choice of CRO to run the trial;

(b)(5)

- "ACTIV-4" Protocol for anticoagulants
 - Need bullets from NHBLI on this. Should emphasize similar themes (robust choice of agents through ACTIV process, powered by NHLBI/NINDS "network of networks" with rapid contracting and startup practices, protocol being drafted in parallel (ACTIV WG review), inclusion of vital natural history disease/treatment data, cost and justification, etc.)
- Maybe a final slide summarizing the budget asks? Should it include preclinical or just the clinical stuff? And perhaps NIH (Ashley) should draft that one given the sensitivity around the numbers?

David Wholley Senior Vice-President, Research Partnerships Foundation for the National Institutes of Health (b) (6)

fnih.org

11400 Rockville Pike Suite 600 North Bethesda, MD 20852

In 2019, the FNIH earned the highest rating from Charity Navigator for the fifth consecutive year and was recognized as an organization that exceeds industry standards.

Tick Hughes (b) (6) Read, Sarah (NHI-NNAID) El foreschangelabs/ou=schanage Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=257b160368004a13996e60bac2226093-readsal; Ruxandra Draghia-Akil (b) (6) .com]; Mellors, John W foreschangelabs/ou=schange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user257cb364]; Naimish Patel (b) (6) .ColVs, Christine (NHI/RCATS) El fore-schanagelabs/ou=schangelabs/ou=schangelabs/ou=schangelabs/ou=schangelabs/ou=schangelabs/ou=schangelabs/ou=schangelabs/ou=schangelabs/ou=schangelabs/ou=schangelabs/ou=schange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=bala118481b4b39ba7e62a36642579-Peter-Stein); Poole, Mike	From:			HANGELABS/OU=EXCHANGE A NTS/CN=DCD875F0679648859			SJ4]	
Administrative Group (FVDIBOH23SPDLIT)/cn=Recipients/cn=527b160388004a199ae6e0bac2226099-readsal; Ruxandra Draphia-Akil (b) (c) com; Mellors, John W (1)-6exchangealab/sou=Exchange Administrative Group (FVDIBOH23SPDLIT)/cn=Recipients/cn=user257ch3a61; Naimish Patel (b) (c) Christine (NHH/RCATS) (El I/o=Exchangealabs/ou=Exchange Administrative Group (FYDIBOH23SPDLIT)/cn=Recipients/cn=4b7e84cec098457896b2df19fa172c87-ccolvis); Young, John (b) (6) Stein, Peter (FDA/CDRR) (Joherschangealabs/ou=Exchange Administrative Group (FYDIBOH23SPDLIT)/cn=Recipients/cn=04b118481b439b3b7e263e36d32759-Peter5-tes/ten); Pools, Mike (b) (6) Buchman, Tim (CS/ASPR/BARDA) (CTR) (Jo=Exchangealabs/ou=Exchange Administrative Group (FYDIBOH23SPDLIT)/cn=Recipients/cn=0508835d87409886d55c198e9d3-tim Buchman) CC: Elizabeth Kim (b) (6) Menetski, Joseph (FNHI) (T] (/o=Exchangealabs/ou=Exchange Administrative Group (FYDIBOH23SPDLIT)/cn=Recipients/cn=0501853d8d7409886d55c198e9d3-tim Buchman) CC: Elizabeth Kim (b) (6) Rose Li Central Account (b) (6) Use Smalldon (b) (6) Rose Li Central Account (b) (6) Use Smalldon (b) (6) Rose Li Central Account (b) (6) Use Smalldon (b) (6) Rose Li Central Account (b) (6) Use Smalldon (FYDIBOH23SPDLIT/cn=Recipients/cn=0306b24d610fa195a3aaaf4606b470-parkeras) Subject: ACTIV TX-Clinical WG Agent Prioritization Subgroup - 1st Meeting Dear ACTIV TX-Clinical WG Agent Prioritization Subgroup - 1st Meeting Dear ACTIV Therapeutics-Clinical WG, Thank you for your interest and participation in the Agent Prioritization sub-group. We are appreciative of your time and lock forward to a focused discussion on identifying Review Committee members and facilitating the prioritization of credible therapeutic candidates for Covid-19. Our first meeting will take place today, Tuesday April 14th from 5:30pm-6:30pm ET. Dial-in instructions are below, similar to the zoom call we had yesterday. We wanted to notify you promptly of the meeting time and will follow up with an agenda and any necessary materials this afternoon prior to the	Sent:	4/14/2020 1:52	:53 PM					
Administrative Group (FVDIBOH23SPDLIT)/cn=Recipients/cn=527b160388004a199ae6e0bac2226099-readsal; Ruxandra Draphia-Akil (b) (c) com; Mellors, John W (1)-6exchangealab/sou=Exchange Administrative Group (FVDIBOH23SPDLIT)/cn=Recipients/cn=user257ch3a61; Naimish Patel (b) (c) Christine (NHH/RCATS) (El I/o=Exchangealabs/ou=Exchange Administrative Group (FYDIBOH23SPDLIT)/cn=Recipients/cn=4b7e84cec098457896b2df19fa172c87-ccolvis); Young, John (b) (6) Stein, Peter (FDA/CDRR) (Joherschangealabs/ou=Exchange Administrative Group (FYDIBOH23SPDLIT)/cn=Recipients/cn=04b118481b439b3b7e263e36d32759-Peter5-tes/ten); Pools, Mike (b) (6) Buchman, Tim (CS/ASPR/BARDA) (CTR) (Jo=Exchangealabs/ou=Exchange Administrative Group (FYDIBOH23SPDLIT)/cn=Recipients/cn=0508835d87409886d55c198e9d3-tim Buchman) CC: Elizabeth Kim (b) (6) Menetski, Joseph (FNHI) (T] (/o=Exchangealabs/ou=Exchange Administrative Group (FYDIBOH23SPDLIT)/cn=Recipients/cn=0501853d8d7409886d55c198e9d3-tim Buchman) CC: Elizabeth Kim (b) (6) Rose Li Central Account (b) (6) Use Smalldon (b) (6) Rose Li Central Account (b) (6) Use Smalldon (b) (6) Rose Li Central Account (b) (6) Use Smalldon (b) (6) Rose Li Central Account (b) (6) Use Smalldon (FYDIBOH23SPDLIT/cn=Recipients/cn=0306b24d610fa195a3aaaf4606b470-parkeras) Subject: ACTIV TX-Clinical WG Agent Prioritization Subgroup - 1st Meeting Dear ACTIV TX-Clinical WG Agent Prioritization Subgroup - 1st Meeting Dear ACTIV Therapeutics-Clinical WG, Thank you for your interest and participation in the Agent Prioritization sub-group. We are appreciative of your time and lock forward to a focused discussion on identifying Review Committee members and facilitating the prioritization of credible therapeutic candidates for Covid-19. Our first meeting will take place today, Tuesday April 14th from 5:30pm-6:30pm ET. Dial-in instructions are below, similar to the zoom call we had yesterday. We wanted to notify you promptly of the meeting time and will follow up with an agenda and any necessary materials this afternoon prior to the	To:	Eric Hughes [(b) (6)	Read, Sarah (NIH/NIA	ID) [E] [/o=Exch	angeLabs/d	ou=Exchange	
Ruxandra Draghia-Akil (b) (6)com); Mellors, John W /o=ExchangeLabs/ou=Exchange Administrative Group (FVIBIOH23SPDLT)/cn=Recipients/cn=uesz-275c364); Almisins Patel (b) (6) Colvis, Christine (NIH/NCATS) [F]-Recipients/cn=ub-7e84cce098457896b2df19fa172c87-ccolvis]; Young, John (B) (6) Stein, Peter (FDA/CDR) /o=Exchange Administrative Group (FVDIBOH23SPDLT)/cn=Recipients/cn=b47e84cce098457896b2df19fa172c87-ccolvis]; Young, John (B) (6) (6) Buchman, Tim (GS/ASPR/BARDA) (CTR) /o=Exchange Administrative Group (FVDIBOH23SPDLT)/cn=Recipients/cn=b414118/81b4a93ba7e228d6425779-Peter. Stein]; Poole, Mike [dsal:
Group (FVDIBOHF23SPDLT)/cn=Recipients/cn=user257c1364); Namish Patel (b) (6) Colvis, Christine (NIH/MCATS) [E] (70-ExchangeLabs/ou-Exchange Administrative Group (FVDIBOHF23SPDLT)/cn=Recipients/cn=4b7e84cce098457896b2df19fa172c87-ccolvis); Young, John (b) (6) Stein, Peter (FDA/CDR) [/o-ExchangeLabs/ou-Exchange Administrative Group (FVDIBOHF23SPDLT)/cn=Recipients/cn=04b1418861ba93ba97e-2386d42579-Peter-Stein]; Poole, Mike [
Christine (NIH/NCATS) [E] [/o-ExchangeLabs/oue-Exchange Administrative Group (FYDIBOHE23SPDIT/cn-Recipients/cn-b24e2de269385789642df15f1a172a57-ccolvis]; Young, John (b) (6) Stein, Peter (FDA/CDER) [/o-ExchangeLabs/ou-Exchange Administrative Group (FYDIBOHE23SPDIT/cn-Recipients/cn-b4a14118481b4a39ba7e62a36df425f79-Peter.fstein]; Poole, Mike (b) (6) Buchman, Tim (Gy/ASPR/BARDA) (TRI) [/o-ExchangeLabs/oue-Exchange Administrative Group (FYDIBOHE23SPDIT)/cn-Recipients/cn-5001af52de4a27ea3d847lo07382cdd55cbf8eb9da-Tim Buchman] CC: Elizabeth Kim (b) (6) Menetski, Joseph (FNIH) [I] /O-Exchangelabs/oue-Exchange Administrative Group (FYDIBOHE23SPDIT)/cn-Recipients/cn-5001af52de4a92ra3d34f1e072f8cb7-menetskip); Alvarez, Rosa Maria [b) (6) Salathin, Carla [ca (b) (6) [Lucas Smalldon [b) (6) Parker, Ashley (NIH/OD)] [E] [/o-Exchangelabs/oue-Exchange Administrative Group (FYDIBOHE23SPDIT/cn-Recipients/cn-306b224466140fa3e3ba3aa4606ebd70-parkeras)] Subject: ACTIV Tx-Clinical WG Agent Prioritization Subgroup - 1st Meeting Dear ACTIV Therapeutics-Clinical WG, Thank you for your interest and participation in the Agent Prioritization sub-group. We are appreciative of your time and look forward to a focused discussion on identifying Review Committee members and facilitating the prioritization of credible therapeutic candidates for Covid-19. Our first meeting will take place today, Tuesday April 14 th from 5:30pm-6:30pm ET. Dial-in instructions are below, similar to the zoom call we had yesterday. We wanted to notify you promptly of the meeting time and will follow up with an agenda and any necessary materials this afternoon prior to the call. Please note that this is not a fixed timeslot for upcoming sub-group meetings. After this first sub-group meeting, we will send out a scheduling link to coordinate the best time for sub group meetings moving forward. Kind regards, Stacey, J. Adam, PhD Director, Caneer Research Partnerships Foundation for the National Institutes of Health Director, (b) (6) Mobile: (b) (6)								
[FYDIBOHF23SPDLT]/cn=Recipients/cn=4b/re84cce998457896b2df19fa172c87-colvis]; Young, John (b) (6) Subneth (FDVCDFI) [/o=ExchangeLabs/ou=Exchan							6)	COIVIS,
(b) (6) Stein, Peter (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHE73SPDLT)/cn=Recipients/cn=bala118-81 bada59a*re2 aadde42579-Peter Stein); Poole, Mike [b) (6) Buchman, Tim (OS/ASPR/BARDA) (CTR) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHE72SPDLT)/cn=Recipients/cn=00f38653d8d740f88adcd55cf8ebdsd-a11m Buchman] CC: Elizabeth Kim [b) (6) Menetski, Joseph (FINIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHE72SPDLT)/cn=Recipients/cn=5001af52dc4a427ea3d3f1e072f6cb*-menetskijp); Alvarez, Rosa Maria [
(FYDIBOHF23SPDLT)/cm-Recipients/cm-b4a14118481bda39ba7e62a8d6425f79-Peter Stein]; Poole, Mike (b) (6) Buchman, Tim (CS/ASPR/BARDA) (CTR) [/o=Exchange1abs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cm-Recipients/cm-00f8a85a8da740f8a8cdd55cbf8e69da-Tim Buchman] CC: Elizabeth Kim (b) (6) Menetsk, Joseph (FNIH) [T] [Jo-Exchange1abs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cm-Recipients/cm-5001af25dc4a427ea3d34f1c972f8cb7-menetskip); Alvarez, Rosa Maria (b) (6) Rose LI Central Account (b) (6) Lucas Smalldon (b) (6) Parker, Ashley (NIH/OD) [E] [Jo=Exchange4abs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cm-Recipients/cm-306b2244466f140faa95aaaafe06ebd70-parkeras] Subject: ACTIV TX-Clinical WG Agent Prioritization Subgroup - 1st Meeting ACTIV TX-Clinical WG Agent Prioritization Subgroup - 1st Meeting ACTIV TX-Clinical WG Agent Prioritization in the Agent Prioritization sub-group. We are appreciative of your time and lock forward to a focused discussion on identifying Review Committee members and facilitating the prioritization of credible therapeutic candidates for Covid-19. Our first meeting will take place today, Tuesday April 14th from 5:30pm-6:30pm ET. Dial-in instructions are below, similar to the zoom call we had yesterday. We wanted to notify you promptly of the meeting time and will follow up with an agenda and any necessary materials this afternoon prior to the call. Please note that this is not a fixed timeslot for upcoming sub-group meetings. After this first sub-group meeting, we will send out a scheduling link to coordinate the best time for sub group meetings moving forward. Kind regards, Stacey, on behalf of the ACTIV TX-Clinical WG JS (Chicago) JS (New York) JS (Chicago) JS (Ohicago) JS (Oh						Consideration of the second section of the second		
(b) (6) Buchman, Tim (05/ASPR/BARDA) (CTR) [/o=ExchangeLabs/ou=Exchange Administrative Group (FVDIBOHF23SPDLT)/cn=Recipients/cn=00f8a853d8d740f8a8cdd55cbf8eb9da-Tim Buchman)								oup
Administrative Group (FVDIBOHE23SPDLT)/cn=Recipients/cn=00f8a85348c740f8a8cdd55cbf8eb9da-Tim Buchman] CC: Elizabeth Kim [(b) (6) Menetski, Joseph (FNHH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FVDIBOHE23SPDLT)/cn=Recipients/cn=5001af52dc4a427ea3d3d1e072f8cb7-menetskiip); Alvarez, Rosa Maria [(b) (6) Rose Li Central Account [(b) (6) Lucas Smalldon [(b) (6) Salathin, Carla (ca (b) (6) (b) (6) [(b) (6) Parker, Ashley (NHH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FVDIBOHE23SPDLT)/cn=Recipients/cn=30E32d4466140faa95aaaafe06ebd70-parkeras] Subject: ACTIV TX-Clinical WG Agent Prioritization Subgroup - 1st Meeting Dear ACTIV Therapeutics-Clinical WG, Thank you for your interest and participation in the Agent Prioritization sub-group. We are appreciative of your time and look forward to a focused discussion on identifying Review Committee members and facilitating the prioritization of credible therapeutic candidates for Covid-19. Our first meeting will take place today, Tuesday April 14th from 5:30pm-6:30pm ET. Dial-in instructions are below, similar to the zoom call we had yesterday. We wanted to notify you promptly of the meeting time and will follow up with an agenda and any necessary materials this afternoon prior to the call. Please note that this is not a fixed timeslot for upcoming sub-group meetings. After this first sub-group meeting, we will send out a scheduling link to coordinate the best time for sub group meetings moving forward. Kind regards, Stacey, on behalf of the ACTIV TX-Clinical WG Join Zoom Meeting https://zoom.us/ (b) (6) Director, Caneer Research Partnerships Foundation for the National Institutes of Health Director, Caneer Research Partnerships Foundation for the National Institutes of Health Director (b) (6) Mobile: (b) (6)		(FYDIBOHF23SP	DLT)/cn=Recipier	nts/cn=b4a14118481b4b39ba7	e62a8d6425f79	9-Peter.Stei	n]; Poole, Mike	
Administrative Group (FVDIBOHE23SPDLT)/cn=Recipients/cn=00f8a85348d749f8a8dcd5s5bf8eb9da-Tim Buchman] CC: Elizabeth Kim! (b) (6) Menetski, Joseph (FNIH) T] (Jose-ExchangeLabs/ous-Exchange Administrative Group (FVDIBOHE23SPDLT)/cn=Recipients/cn=5001af52dc4a427ea3d34f1e072f8cb7-menetskijp); Alvarez, Rosa Maria (b) (6) Rose LI Central Account (b) (6) Lucas Smalldon (b) (6) Salathin, Carla (ca (b) (6) (b) (6) (b) (6) Parker, Ashley (NIH/OD) [E] (JosephangeLabs/ous-Exchange Administrative Group (FVDIBOHE23SPDLT)/cn=Recipients/cn=30s22444661d07a935aaaafe06ebd70-parkeras] Subject: ACTIV TX-Clinical WG Agent Prioritization Subgroup - 1st Meeting Dear ACTIV Therapeutics-Clinical WG, Thank you for your interest and participation in the Agent Prioritization sub-group. We are appreciative of your time and look forward to a focused discussion on identifying Review Committee members and facilitating the prioritization of credible therapeutic candidates for Covid-19. Our first meeting will take place today, Tuesday April 14th from 5:30pm-6:30pm ET. Dial-in instructions are below, similar to the zoom call we had yesterday. We wanted to notify you promptly of the meeting time and will follow up with an agenda and any necessary materials this afternoon prior to the call. Please note that this is not a fixed timeslot for upcoming sub-group meetings. After this first sub-group meeting, we will send out a scheduling link to coordinate the best time for sub group meetings moving forward. Kind regards, Stacey, on behalf of the ACTIV TX-Clinical WG Join Zoom Meeting (b) (6) Password: (b) (6) One tap mobile (b) (6) Mobile: (b) (6) Mobile: (b) (6) Mobile: (b) (6) Mobile: (b) (6)		[b) (6)	Buchman, Tim (OS/ASPR/B	ARDA) (CTR) [/d	=Exchange	Labs/ou=Exchar	nge
CC: Elizabeth Kim [(b) (6) Menetski, Joseph (FNIH) TI] (Jo=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5001aF52dc4a427ea3d3df1e072f8cb7-menetskijp); Alvarez, Rosa Maria [(b) (6) Rose Li Central Account (b) (6) Lucas Smalldon (b) (6) Parker, Ashley (NIH/DD) [E] (Jo=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95saaafe06ebd70-parkeras) Subject: ACTIV TX-Clinical WG Agent Prioritization Subgroup - 1st Meeting Dear ACTIV Therapeutics-Clinical WG, Thank you for your interest and participation in the Agent Prioritization sub-group. We are appreciative of your time and look forward to a focused discussion on identifying Review Committee members and facilitating the prioritization of credible therapeutic candidates for Covid-19. Our first meeting will take place today, Tuesday April 14 th from 5:30pm-6:30pm ET. Dial-in instructions are below, similar to the zoom call we had yesterday. We wanted to notify you promptly of the meeting time and will follow up with an agenda and any necessary materials this afternoon prior to the call. Please note that this is not a fixed timeslot for upcoming sub-group meetings. After this first sub-group meeting, we will send out a scheduling link to coordinate the best time for sub group meetings moving forward. Kind regards, Stacey, on behalf of the ACTIV TX-Clinical WG Join Zoom Meeting https://zoom.us/ (b) (6) Meeting ID: (b) (6) Password: (b) (6) One tap mobile (b) (6) Mobile: (b) (6) Mobile: (b) (6) Mobile: (b) (6) Mobile: (b) (6)		Administrative (Group (FYDIBOHF	23SPDLT)/cn=Recipients/cn=00	0f8a853d8d740	f8a8cdd55	cbf8eb9da-Tim.E	Buchman]
Group (FYDIBOHF23SPDIT)/cn=Recipients/cn=5001af52dc4a427ea3d3df1e072f8cb7-menetskijp); Alvarez, Rosa Maria (b) (6) Rose Li Central Account (b) (6) Lucas Smalldon (b) (6) (c) (b) (6) (c) (d) (d) (e) (e) (e) (e) (e) (e) (e) (e) (e) (e	CC:							
Maria [(b) (6) Rose Li Central Account (b) (6) Lucas Smalldon (b) (6) Salathin, Carla [ca (b) (6) (b) (6) (b) (6) Parker, Ashley [NIH/OD] [E] [/o-ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHE 23SPDLT)/Cn=Recipients/cn=306b2244466t140faa95aasafe06ebd70-parkeras] Subject: ACTIV TX-Clinical WG Agent Prioritization Subgroup - 1st Meeting Dear ACTIV Therapeutics-Clinical WG, Thank you for your interest and participation in the Agent Prioritization sub-group. We are appreciative of your time and look forward to a focused discussion on identifying Review Committee members and facilitating the prioritization of credible therapeutic candidates for Covid-19. Our first meeting will take place today, Tuesday April 14 th from 5:30pm-6:30pm ET. Dial-in instructions are below, similar to the zoom call we had yesterday. We wanted to notify you promptly of the meeting time and will follow up with an agenda and any necessary materials this afternoon prior to the call. Please note that this is not a fixed timeslot for upcoming sub-group meetings. After this first sub-group meeting, we will send out a scheduling link to coordinate the best time for sub group meetings moving forward. Kind regards, Stacey, on behalf of the ACTIV TX-Clinical WG Join Zoom Meeting https://zoom.us/ (b) (6) Meeting ID: (b) (6) Password: (b) (6) One tap mobile (b) (6) JS (Chicago) JS (New York) Stacey J. Adam, PhD Director, Caneer Research Partnerships Foundation for the National Institutes of Health Director, Caneer Research Partnerships Foundation for the National Institutes of Health Director (b) (6) Mobile: (b) (6)								
(b) (6) Salathin, Carla [ca (b) (6) (b) (6) [h) (6) [h] (b) (6) [h] (b) (6) [h] (b) (6) [h] (a) [h] (b) (6) [h] (b								, 11034
(FyDiBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras] Subject: ACTIV TX-Clinical WG Agent Prioritization Subgroup - 1st Meeting Dear ACTIV Therapeutics-Clinical WG, Thank you for your interest and participation in the Agent Prioritization sub-group. We are appreciative of your time and lock forward to a focused discussion on identifying Review Committee members and facilitating the prioritization of credible therapeutic candidates for Covid-19. Our first meeting will take place today, Tuesday April 14th from 5:30pm-6:30pm ET. Dial-in instructions are below, similar to the zoom call we had yesterday. We wanted to notify you promptly of the meeting time and will follow up with an agenda and any necessary materials this afternoon prior to the call. Please note that this is not a fixed timeslot for upcoming sub-group meetings. After this first sub-group meeting, we will send out a scheduling link to coordinate the best time for sub group meetings moving forward. Kind regards, Stacey, on behalf of the ACTIV TX-Clinical WG Join Zoom Meeting https://zoom.us/ (b) (6) Password: (b) (6) One tap mobile (b) (6) JS (Chicago) JS (New York) Stacey J. Adam, PhD Director, Cancer Research Partnesships Foundation for the National Institutes of Health Direct: (b) (6) Mobile: (b) (6)		Iviaria (, , , ,	, 1.		
(FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras] Subject: ACTIV TX-Clinical WG Agent Prioritization Subgroup - 1st Meeting Dear ACTIV Therapeutics-Clinical WG, Thank you for your interest and participation in the Agent Prioritization sub-group. We are appreciative of your time and look forward to a focused discussion on identifying Review Committee members and facilitating the prioritization of credible therapeutic candidates for Covid-19. Our first meeting will take place today, Tuesday April 14th from 5:30pm-6:30pm ET. Dial-in instructions are below, similar to the zoom call we had yesterday. We wanted to notify you promptly of the meeting time and will follow up with an agenda and any necessary materials this afternoon prior to the call. Please note that this is not a fixed timeslot for upcoming sub-group meetings. After this first sub-group meeting, we will send out a scheduling link to coordinate the best time for sub group meetings moving forward. Kind regards, Stacey, on behalf of the ACTIV TX-Clinical WG Join Zoom Meeting https://zoom.us/ (b) (6) Meeting ID: (b) (6) One tap mobile (b) (6) Stacey J. Adam, PhD Director, Cancer Research Partnesships Foundation for the National Institutes of Health Direct (b) (6) (Mobile: (b) (6)			` ' ' '					
Dear ACTIV TX-Clinical WG Agent Prioritization Subgroup - 1st Meeting Dear ACTIV Therapeutics-Clinical WG, Thank you for your interest and participation in the Agent Prioritization sub-group. We are appreciative of your time and look forward to a focused discussion on identifying Review Committee members and facilitating the prioritization of credible therapeutic candidates for Covid-19. Our first meeting will take place today, Tuesday April 14 th from 5:30pm-6:30pm ET. Dial-in instructions are below, similar to the zoom call we had yesterday. We wanted to notify you promptly of the meeting time and will follow up with an agenda and any necessary materials this afternoon prior to the call. Please note that this is not a fixed timeslot for upcoming sub-group meetings. After this first sub-group meeting, we will send out a scheduling link to coordinate the best time for sub group meetings moving forward. Kind regards, Stacey, on behalf of the ACTIV TX-Clinical WG Join Zoom Meeting https://zoom.us/ (b) (6) Password: (b) (6) One tap mobile (b) (6) JS (Chicago) JS (Chicago) JS (New York) Stacey J. Adam, PhD Director, Cancer Research Partnerships Foundation for the National Institutes of Health Direct: (b) (6) Mobile: (b) (6)							tive Group	
Dear ACTIV Therapeutics-Clinical WG, Thank you for your interest and participation in the Agent Prioritization sub-group. We are appreciative of your time and look forward to a focused discussion on identifying Review Committee members and facilitating the prioritization of credible therapeutic candidates for Covid-19. Our first meeting will take place today, Tuesday April 14 th from 5:30pm-6:30pm ET. Dial-in instructions are below, similar to the zoom call we had yesterday. We wanted to notify you promptly of the meeting time and will follow up with an agenda and any necessary materials this afternoon prior to the call. Please note that this is not a fixed timeslot for upcoming sub-group meetings. After this first sub-group meeting, we will send out a scheduling link to coordinate the best time for sub group meetings moving forward. Kind regards, Stacey, on behalf of the ACTIV TX-Clinical WG Join Zoom Meeting https://zoom.us/ (b) (6) Password: (b) (6) One tap mobile (b) (6) JS (Chicago) JS (New York) Stacey J. Adam, PhD Director, Caneer Research Partnerships Foundation for the National Institutes of Health Direct: (b) (6) Mobile: (b) (6)						-parkeras]		
Thank you for your interest and participation in the Agent Prioritization sub-group. We are appreciative of your time and look forward to a focused discussion on identifying Review Committee members and facilitating the prioritization of credible therapeutic candidates for Covid-19. Our first meeting will take place today, Tuesday April 14 th from 5:30pm-6:30pm ET. Dial-in instructions are below, similar to the zoom call we had yesterday. We wanted to notify you promptly of the meeting time and will follow up with an agenda and any necessary materials this afternoon prior to the call. Please note that this is not a fixed timeslot for upcoming sub-group meetings. After this first sub-group meeting, we will send out a scheduling link to coordinate the best time for sub group meetings moving forward. Kind regards, Stacey, on behalf of the ACTIV TX-Clinical WG Join Zoom Meeting https://zoom.us/ (b) (6) Meeting ID: (b) (6) JS (Chicago) JS (Chicago) JS (New York) Stacey J. Adam, PhD Director, Cancer Research Partnerships Foundation for the National Institutes of Health Direct: (b) (6) Mobile: (b) (6)	Subject:	ACTIV TX-Clinica	al WG Agent Prior	ritization Subgroup - 1st Meetir	ng			
Thank you for your interest and participation in the Agent Prioritization sub-group. We are appreciative of your time and look forward to a focused discussion on identifying Review Committee members and facilitating the prioritization of credible therapeutic candidates for Covid-19. Our first meeting will take place today, Tuesday April 14 th from 5:30pm-6:30pm ET. Dial-in instructions are below, similar to the zoom call we had yesterday. We wanted to notify you promptly of the meeting time and will follow up with an agenda and any necessary materials this afternoon prior to the call. Please note that this is not a fixed timeslot for upcoming sub-group meetings. After this first sub-group meeting, we will send out a scheduling link to coordinate the best time for sub group meetings moving forward. Kind regards, Stacey, on behalf of the ACTIV TX-Clinical WG Join Zoom Meeting https://zoom.us/ (b) (6) Meeting ID: (b) (6) JS (Chicago) JS (Chicago) JS (New York) Stacey J. Adam, PhD Director, Cancer Research Partnerships Foundation for the National Institutes of Health Direct: (b) (6) Mobile: (b) (6)								
Thank you for your interest and participation in the Agent Prioritization sub-group. We are appreciative of your time and look forward to a focused discussion on identifying Review Committee members and facilitating the prioritization of credible therapeutic candidates for Covid-19. Our first meeting will take place today, Tuesday April 14 th from 5:30pm-6:30pm ET. Dial-in instructions are below, similar to the zoom call we had yesterday. We wanted to notify you promptly of the meeting time and will follow up with an agenda and any necessary materials this afternoon prior to the call. Please note that this is not a fixed timeslot for upcoming sub-group meetings. After this first sub-group meeting, we will send out a scheduling link to coordinate the best time for sub group meetings moving forward. Kind regards, Stacey, on behalf of the ACTIV TX-Clinical WG Join Zoom Meeting https://zoom.us/ (b) (6) Meeting ID: (b) (6) JS (Chicago) JS (Chicago) JS (New York) Stacey J. Adam, PhD Director, Cancer Research Partnerships Foundation for the National Institutes of Health Direct: (b) (6) Mobile: (b) (6)								
Thank you for your interest and participation in the Agent Prioritization sub-group. We are appreciative of your time and look forward to a focused discussion on identifying Review Committee members and facilitating the prioritization of credible therapeutic candidates for Covid-19. Our first meeting will take place today, Tuesday April 14 th from 5:30pm-6:30pm ET. Dial-in instructions are below, similar to the zoom call we had yesterday. We wanted to notify you promptly of the meeting time and will follow up with an agenda and any necessary materials this afternoon prior to the call. Please note that this is not a fixed timeslot for upcoming sub-group meetings. After this first sub-group meeting, we will send out a scheduling link to coordinate the best time for sub group meetings moving forward. Kind regards, Stacey, on behalf of the ACTIV TX-Clinical WG Join Zoom Meeting https://zoom.us/ (b) (6) Meeting ID: (b) (6) JS (Chicago) JS (Chicago) JS (New York) Stacey J. Adam, PhD Director, Cancer Research Partnerships Foundation for the National Institutes of Health Direct: (b) (6) Mobile: (b) (6)	Dear ACTIV Th	eraneutics-Clir	nical WG					
look forward to a focused discussion on identifying Review Committee members and facilitating the prioritization of credible therapeutic candidates for Covid-19. Our first meeting will take place today, Tuesday April 14 th from 5:30pm-6:30pm ET. Dial-in instructions are below, similar to the zoom call we had yesterday. We wanted to notify you promptly of the meeting time and will follow up with an agenda and any necessary materials this afternoon prior to the call. Please note that this is not a fixed timeslot for upcoming sub-group meetings. After this first sub-group meeting, we will send out a scheduling link to coordinate the best time for sub group meetings moving forward. Kind regards, Stacey, on behalf of the ACTIV TX-Clinical WG Join Zoom Meeting https://zoom.us/ (b) (6) Password: (b) (6) One tap mobile (b) (6) JS (Chicago) JS (New York) Stacey J. Adam, PhD Director, Caneer Research Partnerships Foundation for the National Institutes of Health Direct: (b) (6) Mobile: (b) (6)	Deal Activity	icrapeaties em	near vvo,					
look forward to a focused discussion on identifying Review Committee members and facilitating the prioritization of credible therapeutic candidates for Covid-19. Our first meeting will take place today, Tuesday April 14 th from 5:30pm-6:30pm ET. Dial-in instructions are below, similar to the zoom call we had yesterday. We wanted to notify you promptly of the meeting time and will follow up with an agenda and any necessary materials this afternoon prior to the call. Please note that this is not a fixed timeslot for upcoming sub-group meetings. After this first sub-group meeting, we will send out a scheduling link to coordinate the best time for sub group meetings moving forward. Kind regards, Stacey, on behalf of the ACTIV TX-Clinical WG Join Zoom Meeting https://zoom.us/ (b) (6) Password: (b) (6) One tap mobile (b) (6) JS (Chicago) JS (New York) Stacey J. Adam, PhD Director, Caneer Research Partnerships Foundation for the National Institutes of Health Direct: (b) (6) Mobile: (b) (6)		12 101 13	190 (02:02 02:0				2 521 191	1001
Our first meeting will take place today, Tuesday April 14 th from 5:30pm-6:30pm ET . Dial-in instructions are below, similar to the zoom call we had yesterday. We wanted to notify you promptly of the meeting time and will follow up with an agenda and any necessary materials this afternoon prior to the call. Please note that this is not a fixed timeslot for upcoming sub-group meetings. After this first sub-group meeting, we will send out a scheduling link to coordinate the best time for sub group meetings moving forward. Kind regards, Stacey, on behalf of the ACTIV TX-Clinical WG Join Zoom Meeting https://zoom.us/ (b) (6) Meeting ID: (b) (6) Password: (b) (6) One tap mobile (b) (6) JS (Chicago) JS (New York) Stacey J. Adam, PhD Director, Cancer Research Partnerships Foundation for the National Institutes of Health Direct: (b) (6) Mobile: (b) (6)								
Our first meeting will take place today, Tuesday April 14 th from 5:30pm-6:30pm ET . Dial-in instructions are below, similar to the zoom call we had yesterday. We wanted to notify you promptly of the meeting time and will follow up with an agenda and any necessary materials this afternoon prior to the call. Please note that this is not a fixed timeslot for upcoming sub-group meetings. After this first sub-group meeting, we will send out a scheduling link to coordinate the best time for sub group meetings moving forward. Kind regards, Stacey, on behalf of the ACTIV TX-Clinical WG Join Zoom Meeting https://zoom.us/ (b) (6) Meeting ID: (b) (6) Password: (b) (6) One tap mobile (b) (6) Stacey J. Adam, PhD Director, Cancer Research Partnerships Foundation for the National Institutes of Health Direct: (b) (6) Mobile: (b) (6)	look forward t	to a focused dis	cussion on ider	itifying Review Committee n	nembers and f	acilitating	the prioritizati	ion of
Our first meeting will take place today, Tuesday April 14 th from 5:30pm-6:30pm ET . Dial-in instructions are below, similar to the zoom call we had yesterday. We wanted to notify you promptly of the meeting time and will follow up with an agenda and any necessary materials this afternoon prior to the call. Please note that this is not a fixed timeslot for upcoming sub-group meetings. After this first sub-group meeting, we will send out a scheduling link to coordinate the best time for sub group meetings moving forward. Kind regards, Stacey, on behalf of the ACTIV TX-Clinical WG Join Zoom Meeting https://zoom.us/ (b) (6) Meeting ID: (b) (6) Password: (b) (6) One tap mobile (b) (6) Stacey J. Adam, PhD Director, Cancer Research Partnerships Foundation for the National Institutes of Health Direct: (b) (6) Mobile: (b) (6)	credible thera	peutic candida	tes for Covid-19).		_		
similar to the zoom call we had yesterday. We wanted to notify you promptly of the meeting time and will follow up with an agenda and any necessary materials this afternoon prior to the call. Please note that this is not a fixed timeslot for upcoming sub-group meetings. After this first sub-group meeting, we will send out a scheduling link to coordinate the best time for sub group meetings moving forward. Kind regards, Stacey, on behalf of the ACTIV TX-Clinical WG Join Zoom Meeting https://zoom.us/ (b) (6) Meeting ID: (b) (6) Password: (b) (6) One tap mobile (b) (6) JS (Chicago) JS (New York) Stacey J. Adam, PhD Director, Cancer Research Partnerships Foundation for the National Institutes of Health Direct: (b) (6) Mobile: (b) (6)	0. 00	pour our ruinu						
similar to the zoom call we had yesterday. We wanted to notify you promptly of the meeting time and will follow up with an agenda and any necessary materials this afternoon prior to the call. Please note that this is not a fixed timeslot for upcoming sub-group meetings. After this first sub-group meeting, we will send out a scheduling link to coordinate the best time for sub group meetings moving forward. Kind regards, Stacey, on behalf of the ACTIV TX-Clinical WG Join Zoom Meeting https://zoom.us/ (b) (6) Meeting ID: (b) (6) Password: (b) (6) One tap mobile (b) (6) JS (Chicago) JS (New York) Stacey J. Adam, PhD Director, Cancer Research Partnerships Foundation for the National Institutes of Health Direct: (b) (6) Mobile: (b) (6)	o (I a dath C = 20	C 30 FT D			
with an agenda and any necessary materials this afternoon prior to the call. Please note that this is not a fixed timeslot for upcoming sub-group meetings. After this first sub-group meeting, we will send out a scheduling link to coordinate the best time for sub group meetings moving forward. Kind regards, Stacey, on behalf of the ACTIVTX-Clinical WG Join Zoom Meeting https://zoom.us/ (b) (6) Meeting ID: (b) (6) Password: (b) (6) One tap mobile (b) (6) JS (Chicago) JS (New York) Stacey J. Adam, PhD Director, Cancer Research Partnerships Foundation for the National Institutes of Health Direct: (b) (6) Mobile: (b) (6)				[1] [1] [2] [2] [1] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2				
Please note that this is not a fixed timeslot for upcoming sub-group meetings. After this first sub-group meeting, we will send out a scheduling link to coordinate the best time for sub group meetings moving forward. Kind regards, Stacey, on behalf of the ACTIV TX-Clinical WG Join Zoom Meeting https://zoom.us/ Meeting ID: (b) (6) Password: (b) (6) One tap mobile (b) (6) JS (Chicago) JS (New York) Stacey J. Adam, PhD Director, Cancer Research Partnerships Foundation for the National Institutes of Health Direct: (b) (6) Mobile: (b) (6)	similar to the	zoom call we h	ad yesterday. W	e wanted to notify you pror	nptly of the m	neeting tim	ne and will follo	ow up
Please note that this is not a fixed timeslot for upcoming sub-group meetings. After this first sub-group meeting, we will send out a scheduling link to coordinate the best time for sub group meetings moving forward. Kind regards, Stacey, on behalf of the ACTIV TX-Clinical WG Join Zoom Meeting https://zoom.us/ Meeting ID: (b) (6) Password: (b) (6) One tap mobile (b) (6) JS (Chicago) JS (New York) Stacey J. Adam, PhD Director, Cancer Research Partnerships Foundation for the National Institutes of Health Direct: (b) (6) Mobile: (b) (6)	with an agend	la and any nece	essary materials	this afternoon prior to the o	all.			
send out a scheduling link to coordinate the best time for sub group meetings moving forward. Kind regards, Stacey, on behalf of the ACTIV TX-Clinical WG Join Zoom Meeting https://zoom.us/ (b) (6) Meeting ID: (b) (6) Password: (b) (6) One tap mobile (b) (6) JS (Chicago) JS (New York) Stacey J. Adam, PhD Director, Cancer Research Partnerships Foundation for the National Institutes of Health Direct: (b) (6) Mobile: (b) (6)		,	,	, , , , , , , , , , , , , , , , , , ,				
send out a scheduling link to coordinate the best time for sub group meetings moving forward. Kind regards, Stacey, on behalf of the ACTIV TX-Clinical WG Join Zoom Meeting https://zoom.us/ (b) (6) Meeting ID: (b) (6) Password: (b) (6) One tap mobile (b) (6) JS (Chicago) JS (New York) Stacey J. Adam, PhD Director, Cancer Research Partnerships Foundation for the National Institutes of Health Direct: (b) (6) Mobile: (b) (6)	DI L LI		·					-11
Kind regards, Stacey, on behalf of the ACTIV TX-Clinical WG Join Zoom Meeting https://zoom.us/ Meeting ID: (b) (6) Password: (b) (6) One tap mobile (b) (6) JS (Chicago) JS (New York) Stacey J. Adam, PhD Director, Cancer Research Partnerships Foundation for the National Institutes of Health Direct: (b) (6) Mobile: (b) (6)				7.7			-group meetin	g, we will
Stacey, on behalf of the ACTIV TX-Clinical WG Join Zoom Meeting https://zoom.us/ Meeting ID: (b) (6) Password: (b) (6) One tap mobile (b) (6) JS (Chicago) JS (New York) Stacey J. Adam, PhD Director, Cancer Research Partnerships Foundation for the National Institutes of Health Direct: (b) (6) Mobile: (b) (6)	send out a sch	neduling link to	coordinate the	best time for sub group mee	etings moving	forward.		
Stacey, on behalf of the ACTIV TX-Clinical WG Join Zoom Meeting https://zoom.us/ Meeting ID: (b) (6) Password: (b) (6) One tap mobile (b) (6) JS (Chicago) JS (New York) Stacey J. Adam, PhD Director, Cancer Research Partnerships Foundation for the National Institutes of Health Direct: (b) (6) Mobile: (b) (6)								
Stacey, on behalf of the ACTIV TX-Clinical WG Join Zoom Meeting https://zoom.us/ Meeting ID: (b) (6) Password: (b) (6) One tap mobile (b) (6) JS (Chicago) JS (New York) Stacey J. Adam, PhD Director, Cancer Research Partnerships Foundation for the National Institutes of Health Direct: (b) (6) Mobile: (b) (6)	Kind regards							
Join Zoom Meeting https://zoom.us/ (b) (6) Meeting ID: (b) (6) Password: (b) (6) One tap mobile (b) (6) JS (Chicago) JS (New York) Stacey J. Adam, PhD Director, Cancer Research Partnerships Foundation for the National Institutes of Health Direct: (b) (6) Mobile: (b) (6)		If - f + b - A CTI	VTV 61:-:1 W	_				
https://zoom.us/ (b) (6) Meeting ID: (b) (6) Password: (b) (6) One tap mobile (b) (6) JS (Chicago) JS (New York) Stacey J. Adam, PhD Director, Cancer Research Partnerships Foundation for the National Institutes of Health Direct: (b) (6) Mobile: (b) (6)	stacey, on ber	iall of the ACTI	V IX-Clinical VV	3				
https://zoom.us/ (b) (6) Meeting ID: (b) (6) Password: (b) (6) One tap mobile (b) (6) JS (Chicago) JS (New York) Stacey J. Adam, PhD Director, Cancer Research Partnerships Foundation for the National Institutes of Health Direct: (b) (6) Mobile: (b) (6)								
https://zoom.us/ (b) (6) Meeting ID: (b) (6) Password: (b) (6) One tap mobile (b) (6) JS (Chicago) JS (New York) Stacey J. Adam, PhD Director, Cancer Research Partnerships Foundation for the National Institutes of Health Direct: (b) (6) Mobile: (b) (6)	Join Zoom Me	eting						
Meeting ID: (b) (6) Password: (b) (6) One tap mobile (b) (6) JS (Chicago) JS (New York) Stacey J. Adam, PhD Director, Cancer Research Partnerships Foundation for the National Institutes of Health Direct: (b) (6) Mobile: (b) (6)		_		(b) (6)				
Password: (b) (6) One tap mobile (b) (6) JS (Chicago) JS (New York) Stacey J. Adam, PhD Director, Cancer Research Partnerships Foundation for the National Institutes of Health Direct: (b) (6) Mobile: (b) (6)	111139-1112			(6) (6)				
Password: (b) (6) One tap mobile (b) (6) JS (Chicago) JS (New York) Stacey J. Adam, PhD Director, Cancer Research Partnerships Foundation for the National Institutes of Health Direct: (b) (6) Mobile: (b) (6)								
One tap mobile (b) (6) JS (Chicago) JS (New York) Stacey J. Adam, PhD Director, Cancer Research Partnerships Foundation for the National Institutes of Health Direct: (b) (6) Mobile: (b) (6)	Meeting ID:	(b) (6)						
(b) (6) JS (Chicago) JS (New York) Stacey J. Adam, PhD Director, Cancer Research Partnerships Foundation for the National Institutes of Health Direct: (b) (6) Mobile: (b) (6)	Password: (b)	(6)						
(b) (6) JS (Chicago) JS (New York) Stacey J. Adam, PhD Director, Cancer Research Partnerships Foundation for the National Institutes of Health Direct: (b) (6) Mobile: (b) (6)	One tap mobil	le						
Stacey J. Adam, PhD Director, Cancer Research Partnerships Foundation for the National Institutes of Health Direct: ((b) (6) Mobile: (b) (6)				IS (Chicago)				
Stacey J. Adam, PhD Director, Cancer Research Partnerships Foundation for the National Institutes of Health Direct: ((b) (6) Mobile: (b) (6)		(0) (0)		[] [i] i i i i i i i i i i i i i i i i i				
Director, Cancer Research Partnerships Foundation for the National Institutes of Health Direct: ((b) (6) Mobile: (b) (6))5 (New York)				
Director, Cancer Research Partnerships Foundation for the National Institutes of Health Direct: ((b) (6) Mobile: (b) (6)								
Director, Cancer Research Partnerships Foundation for the National Institutes of Health Direct: ((b) (6) Mobile: (b) (6)								
Director, Cancer Research Partnerships Foundation for the National Institutes of Health Direct: ((b) (6) Mobile: (b) (6)	Starge I Ada	m PhD						
Research Partnerships Foundation for the National Institutes of Health Direct: ((b) (6) Mobile: (b) (6)								
Foundation for the National Institutes of Health Direct: ((b) (6) Mobile: (b) (6)								
Direct: ((b) (6) Mobile: (b) (6)			was some and					
	Foundation f	or the Nationa	I Institutes of I	lealth				
	Direct: ((b) (6) Mo	bile: (b) (6	5)				
	fnih.org		. , ,					

11400 Rockville Pike, Suite 600, North Bethesda, MD 20852

Stay at the forefront of FNIH news: fnih.org/newsletter

From: Brodd, Lauren (NIH/OD) [E] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP

(FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=BA665DEA08E54171B3D6890C2518DDB9-LEPONELM]

Sent: 8/14/2020 5:32:07 PM

To: Gadbois, Ellen (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=0243d1d6e6f248268d2edec566c26c2a-gadboisel]

Subject: RE: ACTIV website updates per EC slides/meeting today

Thanks for the update!!

From: Gadbois, Ellen (NIH/OD) [E] < (b) (6)

Sent: Friday, August 14, 2020 1:07 PM

To: Brodd, Lauren (NIH/OD) [E] < (b) (6)

Subject: RE: ACTIV website updates per EC slides/meeting today

They are going to run "ACTIV-associated trials" by the Leadership committee somehow before implementing.

From: Gadbois, Ellen (NIH/OD) [E]
Sent: Friday, August 14, 2020 1:04 PM

To: Brodd, Lauren (NIH/OD) [E] < (b) (6)

Subject: RE: ACTIV website updates per EC slides/meeting today

Great. And FC is proposing that the talk about a label of 'ACTIV-associated trials" for things that ACTIV partner companies are pursuing but aren't technically ACTIV trials (not following an ACTIV master protocol, I guess). This would probably apply to IVIG trials (hyper immune globulin from patients). Reaction seemed positive.

From: Brodd, Lauren (NIH/OD) [E] < (b) (6)

Sent: Friday, August 14, 2020 12:35 PM

To: Gadbois, Ellen (NIH/OD) [E] < (b) (6)

Subject: RE: ACTIV website updates per EC slides/meeting today

Hi Ellen,

Thanks for flagging! Ashley and I have been working with Renate and her team to revise the website to provide more detailed information about each of the working groups. In the updated version, we include language about the clinical trial capacity group being finished as of 7/31 and the vaccines group now only meeting on an ad hoc basis. Not sure the exact timeline (FNIH is currently reviewing the drafts) but those groups will be addressed when the updated version goes live.

Thanks, Lauren

From: Gadbois, Ellen (NIH/OD) [E] (b) (6)

Sent: Friday, August 14, 2020 12:18 PM

To: Brodd, Lauren (NIH/OD) [E] (b) (6)

Subject: ACTIV website updates per EC slides/meeting today

Importance: High

You may want to revise how the working groups are listed on the website since clinical trials capacity is done, and vaccine is suspended (may be reconvened if needed)—see slides.

```
From: Melencio, Cheryl (FNIH) [T] <
                                            (b) (6)
                                                          On Behalf Of Wholley, David (FNIH) [T]
Sent: Thursday, August 13, 2020 10:20 PM
To: Collins, Francis (NIH/OD) [E] (b) (6)
                                                        Disbrow, Gary (OS/ASPR/BARDA)
                                                                                                     (b)(6)
Dolsten, Mikael
                                                Fauci, Anthony (NIH/NIAID) [E]
                                                                                                       >; Gibbons, Gary
                            (b)(6)
                                                                                        (b)(6)
(NIH/NHLBI) [E]
                                           Marks, Peter (FDA/CBER)
                                                                                                 >; Pao, William
                          (b) (6)
                                                                                (b) (6)
                            Plump, Andrew <
                                                                              Stoffels, Paul
                                                                                                     (b) (6)
           (b)(6)
                                                           (b) (6)
Woodcock, Janet (FDA/CDER)
                                            (b)(6)
                                                                ; Colvis, Christine (NIH/NCATS) [E]
                            Desrosiers, Betsy
                                                                                    : Eric Hughes
          (b)(6)
                                                              (b)(6)
                            >; Jansen, Kathrin <
                                                                             ; Kurilla, Michael (NIH/NCATS) [E]
           (b)(6)
                                                           (b)(6)
                            Lowy, Douglas (NCI)
                                                                    Read, Sarah (NIH/NIAID) [E]
           (b)(6)
                                                       (b) (6)
                                                                                                          (b)(6)
Young, John <
                                           : Wholley, David (FNIH) [T] <
                          (b)(6)
                                                                                (b)(6)
Cc: Anderson, James (NIH/OD) [E] <
                                                                : Austin, Christopher (NIH/NCATS) [E]
                                               (b) (6)
                       >; Burklow, John (NIH/OD) [E] <
                                                                                Castillejos, Carlos
        (b)(6)
                                                                (b)(6)
                                                                                                           (b)(6)
Culp, Michelle (NIH/OD) [E]
                                      (b)(6)
                                                       FNIH Central Account <
                                                                                          (b)(6)
                                                                                                             Freire, Maria
(FNIH) [T]
                              ; Gadbois, Ellen (NIH/OD) [E]
                                                                                     ; Hallett, Adrienne (NIH/OD) [E]
                 (b) (6)
                                                                      (b)(6)
           (b) (6)
                            ; Lane, Cliff (NIH/NIAID) [E]
                                                                                ; Myles, Renate (NIH/OD) [E]
                                                                 (b) (6)
                         Parker, Ashley (NIH/OD) [E] (
                                                                                       , Lawrence (NIH/OD) [E]
(b)(6)
                                                                                        Melencio, Cheryl (FNIH) [T]
                             Wolinetz, Carrie (NIH/OD) [E]
<
           (b) (6)
                                                                      (b)(6)
        (b)(6)
                      ; Adam, Stacey (FNIH) [T]
                                                        (b) (6)
                                                                    ; Alvarez, Rosa
                                                                                               (b)(6)
Anderson, Margaret
                                                     ; Chen, Helen
                                                                                               ; Elsaid, Olivia
                                  (b)(6)
                                                                              (b)(6)
         (b)(6)
                          Gonzalez, Nina <
                                                                         Hawk, Harrison
                                                      (b) (6)
                                                                                                  (b) (6)
Menetski, Joseph (FNIH) [T]
                                                  >; Santos, Michael (FNIH) [T]
                                                                                        (b) (6)
                                                                                                      Stratton, Benjamin
                                    (b) (6)
          (b)(6)
                            Tolman, Brett <
                                                                      Tountas, Karen (FNIH) [T]
                                                      (b) (6)
                                                                                                         (b) (6)
Wachtel, Jonathan
                             (b)(6)
Subject: Materials for August 14 ACTIV Executive Committee Teleconference
```

Importance: High

Dear ACTIV EC members, Working Group Co-Chairs, and meeting participants:

Please see attached the PowerPoint slides, including the agenda, for our meeting (via Zoom) from 12:00 – 1:00 PM Eastern U.S. time tomorrow, Friday, August 14. I have also attached notes from our July 29 Leadership Team meeting as well as our last EC meeting on July 15. As you know we will be hearing from two Working Groups instead of four, so the co-chairs have decided to make this call as well as future EC and LT calls going forward 60 minutes in length instead of 90 minutes.

```
The Zoom information is:
Join Zoom Meeting
https://fnih.zoom.u
                                               (b)(6)
Meeting ID:
               (b) (6)
Passcode: (b) (6)
One tap mobile
                   (b)(6)
                                             US (Germantown)
                                             US (Chicago)
Dial by your location
          (b) (6)
                     US (Germantown)
                     US (Chicago)
                     US (New York)
                     US (San Jose)
```

```
(b)(6)
                      S (San Jose)
                      S (Tacoma)
                      S (Houston)
                     gium
                     lgium
                     lgium
                     lgium
                     Igium
                     Igium
                     anada
                     anada
                     anada
                     anada
                     anada
                     anada
                     rance
                     rance
                     rance
                     rance
                     rance
                     apan
                     apan
                     apan
                     Italy
                       Italy
                     Italy
                     witzerland
                     witzerland
                     witzerland
                     witzerland
                     witzerland
                     witzerland
                     United Kingdom
                     United Kingdom
                     United Kingdom
                     United Kingdom
                     United Kingdom
                     United Kingdom
                     United Kingdom
Meeting ID:
               (b) (6)
Find your local number: https://fnih.zooi
                                            (b)(6)
```

Passcode: (b) (6)

Please let Cheryl Melencio here at FNIH (copied) know if you are having any problems connecting. I look forward to a productive meeting.

Regards,

David

David Wholley Senior Vice-President, Research Partnerships

Foundation for the National Institutes of Health

(b) (6)

fnih.org

11400 Rockville Pike Suite 600 North Bethesda, MD 20852

In 2019, the FNIH earned the highest rating from Charity Navigator for the fifth consecutive year and was recognized as an organization that exceeds industry standards.

From: Adam, Stacey (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=DCD875F0679648859E1CF101C0943414-ADAMSJ4] Sent: 4/21/2020 3:34:50 AM To: Bozzette, Sam (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=85f05a3619cf47c7ae39d7bcf0aac88d-bozzettesaa]; Butterton, Joan [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=219ecac4faae4ebab8a45ce8ee2490c3-joan_butter]; De Claro, R. Angelo (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c495c3ee25ca461ba6a829b124062448-DECLAROR.fd]; Draghia-Akli, Ruxandra | Eisner, Mark [Gottesdiener, Keith (b)(6)(b) (6) (b)(6)Hughes, Eric [**Judy Currier** (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=890082c7c1e34902b0f535320cd16650-jscurrier.m]; Kim, Elizabeth LaVange, Lisa [Levy, Elliot [Mellors, John W (b) (6) (b) (6) (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user257cb364]; Menon, Sandeep [Parker, Ashley (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange (b) (6) Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras]; Patel, Naimish [naimish.patel@sanofi.com]; Peppercorn, Amanda [Poole, Mike (b) (6) Proschan, Michael (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=7b45059209b4468bb4ba02b0dfbbb3e4-proscham]; Read, Sarah (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=527b160038004a199ae6e0bac2226099-readsa]; Santos, Michael (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ab38cb6836de44e18ef4cc6952f65f80-santosmr]; Shen, Yuan Li (FDA/CDER) I/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ae30a02e983e4e8a979dfec7257a1802-shenyu.fda]; Stein, Peter (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b4a14118481b4b39ba7e62a8d6425f79-Peter.Stein]; Buchman, Tim (OS/ASPR/BARDA) (CTR) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=00f8a853d8d740f8a8cdd55cbf8eb9da-Tim.Buchman]; Collins, Sylva (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f6b8f588067140fe988f0832c2387725-Sylva.Colli]; Amanda Peppercorn (b) (6) CC: Butcher, Tina [Demarcus [Macone, Erin (b) (6) (b) (6) Melencio, Cheryl (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=279e14fa7428415bb86087d08b628e6f-melencioc]; Salathin, Carla (b) (6) (b) (6) Mary Biggs [RE: ACTIV Therapeutics-Clinical Working Group - Meeting Scheduling for the Week of Apr 27-May1 Subject: Dear ACTIV TX-Clinical WG Members, If you have not already responded with your availability for meetings next week at the times below, please send by COB tomorrow, so we an get these held on everyone's calendars. Thanks, Stacey Stacev J. Adam. PhD Director, Cancer Research Partnerships Direct: (b) (6) Mobile: (b) (6)

From: Adam, Stacey (FNIH) [T] Sent: Sunday, April 19, 2020 8:04 PM To: Bozzette, Sam (NIH/NCATS) [E] < De Claro, Butterton, Joan < (b) (6) (b) (6) R. Angelo (FDA/CDER) < (b)(6)Draghia-Akli, Ruxandra < (b)(6)Eisner, Mark (b)(6)Gottesdiener, Keith < (b)(6)Hughes, Eric < Judy Currier < (b)(6)Kim, Elizabeth < (b) (6) (b) (6) Levy, Elliot < Mellors, John < LaVange, Lisa < (b) (6) (b)(6)(b) (6) Menon, Sandeep < (b)(6)Parker, Ashley (NIH/OD) [E] < (b)(6)Patel, Naimish Peppercorn, Amanda < Poole, Mike < (b) (6) (b) (6) Proschan, Michael < Read, Sarah < (b)(6)(b)(6)Santos, Michael (FNIH) [T] < Shen, Yuan Li (FDA/CDER) < (b)(6)(b) (6) Buchman, Tim (OS/ASPR/BARDA) (b)(6)Stein, Peter (FDA/CDER) < (b)(6)< Collins, Sylva (FDA/CDER) < Amanda Peppercorn (CTR) < (b) (6) (b)(6)(b) (6) < Macone, Erin Cc: Butcher, Tina < Demarcus < (b) (6) (b)(6)Melencio, Cheryl (FNIH) [T] < Salathin, Carla (b)(6)(b)(6)Mary Biggs < < (b) (6) (b)(6)(b) (6) Subject: ACTIV Therapeutics-Clinical Working Group - Meeting Scheduling for the Week of Apr 27-May1

Importance: High

Dear ACTIV Therapeutics-Clinical WG Members,

I hope you all have had a great weekend! While we have a solid agenda planned for this week, we are already looking ahead to ensure we have the time we need on your calendars for following week. With this in mind we were wondering if we could keep the same cadence of meetings next week for the main group and the subgroup that we have this week, or if we need repoll. If we keep the same cadence the meetings would on the follow days.

Monday April 27th

- Therapeutics Clinical Master Protocol Subgroup Meeting #5 (2:00PM 3:00PM US EST)
- Tuesday April 28th
 - Therapeutics Clinical Master Protocol Subgroup Meeting #6 (1:00PM 2:00PM US EST)
- Therapeutics Clinical Agent Prioritization Subgroup Meeting #4 (2:00PM 3:00PM US EST)
 Wednesday April 29th
- Therapeutics Clinical Agent Prioritization Subgroup Meeting #5 (2:00PM 3:00PM US EST)
 Thursday April 30th
 - Therapeutics Clinical Work Group Meeting #4 (2:00PM 3:00PM US EST)

Please let us know as soon as you can if these times can be held for standing meetings, understanding that we may need a few adhoc meetings, as well.

Thanks, Stacey

Stacev J. Adam, PhD

Director, Cancer

Research Partnerships

Foundation for the National Institutes of Health

Direct: (b) (6)

(b) (6) | Mobile: (

(b) (6)

min.org

11400 Rockville Pike, Suite 600, North Bethesda, MD 20852



Stay at the forefront of FNIH news: fnih.org/newsletter

From: Tountas, Karen (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=40C04FEF6F1E46F5B750753CD5A14F93-TOUNTASKH] Sent: 6/8/2020 6:35:39 PM To: Stein, Peter (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b4a14118481b4b39ba7e62a8d6425f79-Peter.Stein]; Vincent, Mike Bascles, Lionel | Cohen, Myron (b) (6) (b)(6)[/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2141b9e28c1a421fb3c1c4f75dd4c457-myron cohen]; Corey, Larry Victoria Davey [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2c8291f38ec342f895243c0617e115ec-victoria.da]; Desrosiers, Betsy Dickens, Jim (NIH/NCATS) [C] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=12591c90404e46caba73079cf4a5e2ea-dickensj]; Doroshow, James (NIH/NCI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a1d0fb9f055940c39b387cae2485faa6-doroshoj]; Garner, Carlos Goff, David (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=036113c7be0f42f897d1294cfbb99c10-goffdc]; Kurilla, Michael (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dc4e85061e3943b9b8ad3f426727861f-mkurilla]; Mensah, George (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=284d85649e634a0a91bb0b9aac84846c-mensahga]; Nayak, Seema (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=51d5ee6848004578b5bf9c808eca8f6f-nayaksu]; Payton, Manizhe (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=81d1c1824bfa438a94da81520a8bca90-paytonma]; Resnansky, Laura Sizemore, Christine (NIH/FIC) [E] [/o=ExchangeLabs/ou=Exchange Administrative (b) (6) Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=05494833e0fc47a9acac194cd338b201-csizemore]; Srinivasan, Badhri Weinmann, Gail (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative (b) (6) Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f38a543b4021483ba67e42af1165dcad-weinmang]; Kublin MD, MPH, James Ferguson, Sue (b) (6) (b) (6) CC: Kenny, Dermot [(b) (6) Takas, Therese [(b) (6) Eileen-Colvis, Christine (NIH/NCATS) [E] Wachtel, Jonathan [(b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4b7e84cce098457896b2df19fa172c87-ccolvis]; Hughes, Eric Jansen, Kathrin [(b) (6) Lowy, Douglas (NCI) (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=54fa75fe6e304e34ba567c66b832baa0-drl.helix.n]; Read, Sarah (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=527b160038004a199ae6e0bac2226099-readsa]; Young, John Adam, Stacey (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (b) (6) (FYDIBOHF23SPDLT)/cn=Recipients/cn=dcd875f0679648859e1cf101c0943414-adamsj4]; Anderson, Margaret (b) (6) Parker, Ashley (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras]; Carluccio, Dana Melencio, Cheryl (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=279e14fa7428415bb86087d08b628e6f-melencioc]; Gonzalez, Nina [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user3c2f486d]; James, Stephanie (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Heaton, Penny [(b) (6) Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f0032ef62ca343dfb4bf79577e2aa8d1-jamesst]; Li, ; Menetski, Joseph (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Rose Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5001af52dc4a427ea3d34f1e072f8cb7-menetskijp]; Qashu, Felicia (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=366447a553f44696b2c79484d90e41e5-qashufm]; Santos, Michael (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ab38cb6836de44e18ef4cc6952f65f80-santosmr]; Tuvesson, Nancy Wholley, David (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]; Criffield, Robin Hamilton, Nancy [(b) (6) Hill, Zoe (NIH/NHLBI) [C] [/o=ExchangeLabs/ou=Exchange Administrative Group

	(FYDIBOHF23SPDLT)/cn=Recipie	nts/cn=a19ee51dca2a443d883a15	e025d6e1e0-hillzs]; Minn	ich, Beth
	(b) (6) ; Mue	eller-Reichenstein, Petra [(b) (6)	Pico, Dianna
		bs/ou=Exchange Administrative Gr		
	(FYDIBOHF23SPDLT)/cn=Recipie	nts/cn=471cb6a63c8846a69073e1	e968f3964c-picodfl; Quad	dros, Nora
		tz, Rebecca (NIH/NCATS) [E] [/o=Ex		
		nts/cn=8e2b174d9bf748e9aa5ed9		
	[/o=ExchangeLabs/ou=Exchange		oibacsasas katziaj, cuip	, where it (with ob) [E]
			2 0 5002 1 1 6 11	FII (NIII I (OD) [F]
		nts/cn=4e38fa37e0424217aa0a283	3cba9e5098-mculp]; Gadi	ools, Ellen (NIH/OD) [E]
	[/o=ExchangeLabs/ou=Exchange		WARREST TRANSPORTED SERVICES (SEA	
	(FYDIBOHF23SPDLT)/cn=Recipie	nts/cn=0243d1d6e6f248268d2ede	c566c26c2a-gadboisel];	
	(b) (6)			
Subject:	ACTIV Clinical Trial Capacity Wor	king Group - reporting meeting		
Attachments:	Clinical Trial Capacity Working G	roup Meeting Agenda_06092020.p	odf	
Location:	https://fnih.zoom.	(b) (6)		
		(6) (6)		
Start:	6/9/2020 1:00:00 PM			
End:	6/9/2020 2:00:00 PM			
Show Time As:	Tentative			
_				
Recurrence:	Weekly			
	every Tuesday from 9:00 AM to	10:00 AM		
Required	Stein, Peter (FDA/CDER); Vincen	t, Mike; Bascles, Lionel; Cohen, My	ron; Corey, Larry; Davey,	Victoria; Desrosiers,
Attendees:	Betsy; Dickens, Jim (NIH/NCATS)	[C]; Doroshow, James (NIH/NCI) [8	E]; Garner, Carlos; Goff, D	avid (NIH/NHLBI) [E];
	Kurilla, Mike; Mensah, George; I	Nayak, Seema (NIH/NIAID) [E]; Payt	ton, Manzine; Resnansky,	Laura; Sizemore,
		n, Badhri; Weinmann, Gail ; Kublin		
Optional	Kenny, Dermot; Takas, Therese;		htel, Jonathan; Colvis, Chi	
Attendees:		wy, Douglas (NCI); Read, Sarah (NI		
Attenuees.				
	[T]; Anderson, Margaret; Ashley			na; Cheryl (FNIH)
	Melencio [T] ((b) (6)	Gonzalez, Nina; Heaton, Penny		
	(FNIH) [T]; Qashu, Felicia; Santos	, Michael (FNIH); Tuvesson, Nancy	; Wholley, David (FNIH) [T]; Criffield, Robin;
	Hamilton, Nancy; Hill, Zoe (NIH/	NHLBI) [C]; Minnich, Beth; Mueller	 Reichenstein, Petra; Pico 	, Dianna; Quadros, Nora;
	Rebecca (NIH/NCATS) Katz [E] ((b) (6) Culp, Miche	elle (NIH/OD) [E]; Gadbois	, Ellen (NIH/OD) [E];
	(b) (6)			
Dear Collean	es - Attached is the agenda fo	r the call. Looking forward to a	n interesting call and vo	ur constructive
_	dback. Best regards, Karen	the can. Looking forward to a	if interesting can and ye	di constituctive
uasiiooaru lee	uback. Best fegalus, Kalen			
	22 22			
		thanks for all the hard work the		
mandate - lo	oking forward to operationalization	ing the outcomes of your efforts	. Let's continue to meet	regularly through the
month of June	(once a week) to continue to l	build out the inventories of CRC	Os/SMOs/Networks/Site	s and
		to integrate with other ACTIV w		
	on (treatment and prevention).		88-111	r
mprementation	in (treatment and prevention).	Dest regards, Raien		
77 T		177		
Karen Tounta	s is inviting you to a scheduled	Zoom meeting.		
Join Zoom Mo	eeting			
https://fnih.zo	om	(b) (6)		
Meeting ID:	(b) (6)			
Password: (b)				
One tap mobil	(b) (6)	HC OL - V - L		
	(0) (0)	US (New York)		
		US (Germantown)		
Dial by your l	ocation			
T 7				

GADB0000003544-2517018

(b) (6) US (New York)
US (Germantown)
US (Chicago)
US (San Jose)
US (San Jose)
US (Tacoma)
US (Houston)

Meeting ID: (b) (6) Password: (b) (6)

Find your local number: https://fnih.zoom.u (b) (6)

From: Menetski, Joseph (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=5001AF52DC4A427EA3D34F1E072F8CB7-MENETSKIJP] Sent: 7/17/2020 6:47:58 PM To: Parker, Ashley (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras] CC: Alvarez, Rosa Maria [(b) (6) Subject: RE: ACTIV Preclinical full working group Sorry Ashley, I will follow up with Rosa to make sure you are always on the list (good list, not bad list 😂) Joe From: Parker, Ashley (NIH/OD) [E] < (b)(6)Sent: Friday, July 17, 2020 2:43 PM To: Menetski, Joseph (FNIH) [T] < Subject: RE: ACTIV Preclinical full working group Hi Joe, Following up to let you know I did not receive the calendar invites to the preclinical subgroup meetings. I hope to be included soon. Thank you, Ashley From: Menetski, Joseph (FNIH) [T] < (b)(6)Sent: Wednesday, July 8, 2020 2:51 PM To: Parker, Ashley (NIH/OD) [E] (b)(6)Subject: RE: ACTIV Preclinical full working group Will do. I have sent a note to Rosa Alvarez to make sure you are added to the subgroups. Joe From: Parker, Ashley (NIH/OD) [E] (b)(6)Sent: Wednesday, July 8, 2020 1:52 PM To: Menetski, Joseph (FNIH) [T] Subject: RE: ACTIV Preclinical full working group Thanks, Joe! Can you also please add me to the preclinical subgroup meetings? Ashley From: Menetski, Joseph (FNIH) [T] (b)(6)Sent: Wednesday, July 8, 2020 1:50 PM ; Hild, Sheri (NIH/OD) [E] To: (b)(6)(b)(6)(b)(6)(b) (6) (b) (6) ; Baric, Ralph ; Ottinger, Elizabeth (NIH/NCATS [E] < (b)(6)Colvis, Christine (b) (6) (NIH/NCATS) [E] (b)(6)>; Hewitt, Judith (NIH/NIAID) [E] (b)(6)>; Deming, Damon

(FDA	A/CDER)	(b) (6)				Parker, A	shley (NIH)	/OD) [E]
		(b) (6)		😲 Adar	ns, Peter (OS/ASPR/E	BARDA)		
	(b) (6)	>; Rao, Srinivas	(b) ((6)	; Qashu, I	Felicia (NIH	/OD) [E]		
	(b	Tomas Cihlar	(b) (6)		: Pitt, Ma	rgaret LCI	V USARMY M	EDCOM US	AMRIID
(USA	(b)	(6) ; Pu	nturieri, Anto	nello (NIH/N	HLBI) [E]	((b) (6)	; Chare	tte, Marc
(NIH	I/NHLBI) [E]	(b) (6)	>; Fessel, Jos	h (NIH/NHLB	I) [E]	(b) (6)	>		
Cc: [Diamond, Michael	(b) (6)	Austi	in, Christophe	er (NIH/NO	CATS) [E]	(b) (6)	; F	lorence,
Clint	t (NIH/NIAID) [E]	(b) (6)	; Simon	, Dina (NIH/O	D) [C] <	(b) (6) : Wh	olley, David	(FNIH)
[T]	(b) (6)	>; Melencio, Che	ryl (FNIH) [T]	(b) (6)) >	Colvis, Chi	ristine (NIH/N	CATS) [E]	
	(b) (6)	Desrosiers, E	Betsy	(b) (6)		Hugl	hes, Eric		
	(b) (6)	Jansen, Ka	thrin	(b) (6)	3	Kurilla, Mid	chael (NIH/NO	CATS) [E]	
	(b) (6)	Lowy, Dougla	as (NCI) <	(b) (6)	Read, Sara	ah (NIH/NIA	AID) [E]	(b) (6)	:
Tou	ntas, Karen (FNIH)	[T] (b) (6)	Santo	os, Michael (F	NIH) [T]	(b) (6) : Ada	m, Stacey (FNIH) [T]
	(b) (6) Ja	ames, Stephanie (F	NIH) [T]	(b) (6)	: Alvarez,	, Rosa Mari	a (b) (6)	>;
Kim,	, Elizabeth <	(b) (6) To	olman, Brett <	(b)	(6)	Wachte	l, Jonathan		
	(b) (6)	Prabhavathi F	ernandes	(b) (6)	>; [Rose Li		
	(b) (6)	: Dana Ca	rluccio	(b)	(6)	.>	; Lagos, Enriq	ue (NIH/NO	CATS) [E]
<	(b) (6)	Jonson, Sama	4000 - 600 - 600 등 특성하스 124 일본 시간 [1] 10 [1]			(6)	>; Gonzale:	z, Nina	
	(b) (6)	Burrus-Sh	aw, Cyndi (NII	H/OD) [E] <	((b) (6)	·; Rodri	guez, Robir	ı D
	(b) (6)	>; Dave Frankows	ki	(b) (6))	B	aric, Toni C		
	(b) (6)	Lowy	, Douglas (NI	H/NCI) [E]	(b) ((6)	Nancy Haigw	/ood	
	(b) (6)	: Stratton, Benjar	min	(b) (6)	Ga	dbois, Eller	n (NIH/OD) [E]	
	(b) (6)	; Anderson, Jam	es (NIH/OD)	[E] <	(b) (6)				

Subject: ACTIV Preclinical full working group

Dear Preclinical Working group and attendees,

I apologize for not providing the minutes from last week's meeting. Here they are for your review.

Sincerely, Joe

Joseph P. Menetski Ph.D.

Associate Vice President, Research Partnerships

Foundation for the National Institutes of Health

(b) (6) fnih.org

11400 Rockville Pike, Suite 600, North Bethesda, MD 20852



Donate to the FNIH's Pandemic Response Fund to combat COVID-19: fnih.org/pandemic



From: Santos, Michael (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=AB38CB6836DE44E18EF4CC6952F65F80-SANTOSMR] Sent: 6/30/2020 2:17:53 AM To: Jansen, Kathrin [(b) (6) (b) (6) (b) (6) Gruber, Marion (FDA/CBER) [/o=ExchangeLabs/ou=Exchange Administrative Group (b) (6) (FYDIBOHF23SPDLT)/cn=Recipients/cn=ebf7a8eb8dd541b2883a966ea5afd809-GRUBER.fda]; Marks, Peter (FDA/CBER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b2e527dbda2b4a86b8d72f06b813d471-MarksP.fda]; Arvin, Ann [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=001a98d300d14b20b18c01181eb843e0-Arvinam.Sta]; Nelson Michael [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=7c3323ab6a02468689fa2c51a87c43cc-NelsonMicha]; Bett, Andrew J Gilbert PhD, Peter B [Kathleen Neuzil (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=33958e1252cf4266bffc8d94988f5715-kneuzil.som]; Modjarrad, Kayvon CIV USARMY MEDCOM WRAIR (USA) Thornburg, Natalie (CDC/DDID/NCIRD/DVD) (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c8d079e00a5649639c6f1425f3bb075f-nax3]; Greg Glenn (b) (6) Cheryl Keech [Cavaleri Marco [(b) (6) (b) (6) Kelly, Beth [(b) (6) CC: Tolman, Brett [(b)(6)(b) (6) (b) (6) Jeneffer Haynes []; Menetski, Joseph (FNIH) [T] (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5001af52dc4a427ea3d34f1e072f8cb7-menetskijp]; Alvarez, Rosa Maria Wholley, David (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]; Parker, Ashley (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras]; Neil Formica (Contractor) Joyce Plested Kayvon Modjarrad (b) (6) (b) (6) (b) (6) Subject: Cancellation of this week's Protective Immune Responses Sub-Group meeting and additional updates Attachments: Thornburg assay work group 20200623-compressed.pptx; Assay Panel Production-JLL.pptx; 240620 ACTIV Meeting_MSV2.0.pdf; 2020-06-24 Vaccines Working Group meeting Summary Notes.docx

Dear Protective Immune Responses Sub-Group members,

We are cancelling tomorrow's (Tuesday's) sub-group meeting, in part because of scheduling conflicts and in part because of lack of progress on the important action item of further understanding the planned innate and cellular immune analyses in the COVID-19 Prevention Network efficacy trials. We continue to work on that front.

In the meantime, you may recall from our last meeting that Janet Lathey offered this group to participate in the US Government SARS-CoV-2 Assay Working Group. We offered to attend these meetings when possible and report back. Attached are the presentations from the most recent meeting:

- Considerations of using viruses in SARS-CoV-2 neutralization assays (by Natalie)
- SARS-CoV-2 Assay Concordance Panels (by Janet Lathey)

We also plan to attend the next meeting.

In addition, because not everyone in this group is in the main Working Group, we have attached the presentation that CEPI shared last week and the associated meeting notes: slide 14 covers the assay standardization and animal model topics that CEPI plans to take on within their Enabling Sciences task forces, which may be of interest to this group. They also said that they are in contact with Janet Lathey and the USG Working Group.

Finally, we would like to make this group aware of an opportunity. The National Center for Advancing Translational Sciences (NCATS) at NIH is hosting the dashboard developed by the Clinical Trial Capacity Working Group on trial

networks and sites and survey data on therapeutic compounds; in the future this system may host additional tools and information on pre-clinical and clinical datasets. NIH staff already have access, but if anyone outside of NIH would like access, please let us know by Wednesday (this access is available only to members of the ACTIV groups).

As always, please reach out with any feedback. We look forward to connecting again soon.

Best regards, Brett and Mike

Michael Santos, PhD Associate Vice President, Science Foundation for the National Institutes of Health

(b) (6) fnih.org

11400 Rockville Pike, Suite 600, North Bethesda, MD 20852

f in y 🖸

Stay at the forefront of FNIH news: fnih.org/newsletter

Adam, Stacey (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP From: (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=DCD875F0679648859E1CF101C0943414-ADAMSJ4] Sent: 6/11/2020 6:59:57 PM To: Adam, Stacey (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dcd875f0679648859e1cf101c0943414-adamsj4]; Jim Neaton Jens Lundgren [Eric Hughes [Read, (b) (6) (b) (6) Sarah (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=527b160038004a199ae6e0bac2226099-readsa]; Higgs, Elizabeth (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0601ca55a82841aba16353b96cff8ca9-ehiggs]; Kozak, Marina (OS/ASPR/BARDA) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ff3881f41df744ad9dc3caa8f497a421-Marina.Koza]; Patterson, Amy (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=afad1ca74b3e449d8b4f3191d65bb70f-pattersa]; Aggarwal, Neil (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d4c9de6615504ff9889f3b0c44a63526-aggarwalnr]; Reineck, Lora (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a62d88ba0c3b44e3bb922236c61304b3-reineckla]; Judy Currier [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=890082c7c1e34902b0f535320cd16650-jscurrier.m]; Karen Lynn Price (b) (6) LaVange, Lisa M (b) (6) Sandeep Menon Proschan, Michael (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange (b)(6)Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=7b45059209b4468bb4ba02b0dfbbb3e4-proscham]; Miller, Marissa A (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=afea8bcd1c054bcd9250da63e1dbe947-millerma2]; Rachel Harrigan [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=80023e7be2dd4554b54d1604fa60df18-rachel.h.ha]; William Erhardt Gelijns, Annetine [(b)(6)(b) (6) (b)(6)Moskowitz, Alan [Ab Babiker [Cavan, Reilly (b)(6)(b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=995fe0f1a53c443a832f96f003f0f2c5-cavanr.bios]; Phillips, Andrew Birgit Grund [(b)(6)Neaton, Jim (b) (6) (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f2b26b051964d9da6868e53c9cc6c49-jim.ccbr.um]; Joe Koopmeiners David Vock [Thomas Murray [Max Parmar (b) (6) (b) (6) (b) (6) (b) (6) Mark Polizzotto [(b) (6) Ginny Kan [(b) (6) Lane, Cliff (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2d7e368a3137473bbce161547a82f2de-clane]; Baker, Jason Roger Paredes [(b) (6) (b)(6)(b)(6)Rosenberg, Yves (b)(6)(b)(6)(b)(6)(b) (6) (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a5cb3e9a3a2747c38c42f68f5c8e40cf-rosenbey]; Emilia.bagiel Ajay Nirula [(b) (6) Paul Klekotka [(b)(6)CC: Demarcus [Tountas, Karen (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative (b) (6) Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=40c04fef6f1e46f5b750753cd5a14f93-tountaskh]; Wachtel, Jonathan Parker, Ashley (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras]; Chen, Helen Q. Eron, Joseph J Jr [Chew, Kara M.D. (b)(6)(b) (6) (b) (6) Daar, Eric [(b) (6) Bagiella, Emilia [emilia. (b) (6) Subject: **ACTIV-3 Writing Team** ACTIV TX-Clinical ACTIV-3 Writing Team Meeting Agenda 20200615.pdf; Attachments: INSIGHT014 ACTIV3 protocol v0.44 14June2020 PAK Lilly.docx Location: https://fnih.zoom.us/ (b) (6) Start: 6/15/2020 3:00:00 PM End: 6/15/2020 4:00:00 PM

Show Time As: Busy

Find your local number: https://fnih.zoom.u

Required Jim Neaton; Jens Lundgren; Eric Hughes; Read, Sarah (NIH/NIAID) [E]; Higgs, Elizabeth (NIH/NIAID) [E]; Kozak, Marina Attendees: (OS/ASPR/BARDA); Patterson, Amy (NIH/NHLBI) [E]; Aggarwal, Neil (NIH/NHLBI) [E]; Reineck, Lora (NIH/NHLBI) [E]; Judy Currier; Karen Lynn Price; Lisa LaVange; Sandeep Menon; Proschan, Michael (NIH/NIAID) [E]; Miller, Marissa A (NIH/NHLBI) [E]; Rachel Harrigan; William Erhardt; Gelijns, Annetine; Moskowitz, (b) (6) Alan; Ab Babiker; Cavan, Reilly; Phillips, Andrew (Birgit Grund; Neaton, Jim; Joe (b)(6)Koopmeiners; David Vock; Thomas Murray; Max Parmar; Mark Polizzotto; Ginny Kan; Lane, Cliff (NIH/NIAID) [E]; Baker, Jason; Roger Paredes; (b) (6) (b)(6)(b)(6)Rosenberg, Yves (NIH/NHLBI) [E]; (b)(6)(b)(6)(b)(6)(b)(6)Ajay Nirula; Paul Klekotka Optional Demarcus; Tountas, Karen (FNIH) [T]; Wachtel, Jonathan; Parker, Ashley (NIH/OD) [E]; Chen, Helen Q.; Eron, Joseph J Attendees: Jr; Chew, Kara M.D.; Daar, Eric; Bagiella, Emilia Dear ACTIV-3 Writing Team, Please find the agenda for today's meeting and the current version of the protocol. Thanks, Stacey Join Zoom Meeting https://fnih.zoom. (b)(6)Meeting ID: (b) (6) Password: (b) (6) One tap mobile (b)(6)US (Germantown) US (Chicago) Dial by your location (b) (6) US (Germantown) US (Chicago) US (New York) US (Houston) US (San Jose) US (San Jose) US (Tacoma) Meeting ID: (b)(6)Password: (b) (6)

(b)(6)

From:) [T] [/O=EXCHANGE /CN=RECIPIENTS/CN								
Sent:	6/11/2020 7:02:07	PM								
То:	Jim Neaton [(b) (6) Jens	Lundgren [(b) (6)	Read, Sarah (NIH)	/NIAID) [E]				
	[/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=527b160038004a199ae6e0bac2226099-readsa]; Eric Hughes									
	(b) (6)				abs/ou=Exchange Ad					
	(FYDIBOHF23SPDLT)/cn=Recipients/cn=0601ca55a82841aba16353b96cff8ca9-ehiggs]; Srinivasan, Badhri									
	[(b) (6) Goff, David (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=036113c7be0f42f897d1294cfbb99c10-goffdc]; Nayak, Seema									
		ExchangeLabs/ou=E			obaacto-gomacj; ivay	yak, seema				
					if-nayaksu]; Victoria	Davev				
		ou=Exchange Admini			,					
	(FYDIBOHF23SPDLT)	/cn=Recipients/cn=	2c8291f38ec342f89	5243c0617e115e	c-victoria.da]; Kozak	, Marina				
		(OS/ASPR/BARDA) [/o=ExchangeLabs/ou=Exchange Administrative Group								
	(FYDIBOHF23SPDLT)/cn=Recipients/cn=ff3881f41df744ad9dc3caa8f497a421-Marina.Koza]; McNay, Laura									
	(NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group									
	(FYDIBOHF23SPDLT)/cn=Recipients/cn=d089e838a3824b60b91b6c394fedd335-lmcnay]; Tierney, John (NIH/NIAID)									
	[E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=61553b35beb7479789a06defda628627-jtierney]; Aggarwal, Neil (NIH/NHLBI)									
	[E] [/o=ExchangeLabs/ou=Exchange Administrative Group									
	(FYDIBOHF23SPDLT)/cn=Recipients/cn=d4c9de6615504ff9889f3b0c44a63526-aggarwalnr]; Rosenberg, Yves									
	(NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group									
	(FYDIBOHF23SPDLT)/cn=Recipients/cn=a5cb3e9a3a2747c38c42f68f5c8e40cf-rosenbey]; Patterson, Amy									
	(NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group									
	(FYDIBOHF23SPDLT)/cn=Recipients/cn=afad1ca74b3e449d8b4f3191d65bb70f-pattersa]; Miller, Marissa A (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group									
		(FYDIBOHF23SPDLT)/cn=Recipients/cn=afea8bcd1c054bcd9250da63e1dbe947-millerma2]; Rachel Harrigan								
	[(b) (6) William Erhardt [(b) (6) Reineck, Lora (NIH/NHLBI) [E]									
	[/o=ExchangeLabs/ou=Exchange Administrative Group									
	70 (7)	/cn=Recipients/cn=		b922236c61304	b3-reineckla];	(b) (6)				
	Gelijns, Annetine [(b) (6)	Mark I	Polizzotto [(b) (6)	Ginny Kan				
	(b) (6)	Baker, Jason [(b) (6)	Roger Pared	` ' ' ' '	Thompson,				
	Taylor, M.D.	(b) (6)	Babiker, Ab	· · · · · ·		/ (FNIII) (T)				
CC:	Chen, Helen Q. [(b) (6)	Wachtel, Jonatha	n [(b) (6) Tounta	s, Karen (FNIH) [T]				
		ou=Exchange Admini		50752cd5a14f02	-tountaskh]; Desrosi	ore Elizabeth A				
						ange Administrative				
					5727861f-mkurilla]; F					
	(b) (6)	5.70			os/ou=Exchange Adn					
					'0-parkeras]; Pett, Sa					
		: [1] [1] Here Here Here Here Here Here Here Her	보면 하다 하는 소리를 가득하다면 그리고 하는데	현기 회사 아이들이 구나는 때 아이는 그 사람이 하는 것이 모르는 것이다.	nge Administrative G					
				cf6472505f68cd	8-bgrace]; Barrett, K	evin (NIH/NIAID) [E]				
		ou=Exchange Admini		=== 100=6464444						
				/3/d02/f4fddd8	31-barrettk2]; Dennir	ng, Eileen				
		ou=Exchange Admini //cn=Recipients/cn=		704a01abd12b3	b4-eileen.ccbr]					
		5. 181 5.			950					
Subject:	ACTIV-3 Operations		41/6							
Location:	https://fnih.zoom.u		(b) (6)							
Start:	6/16/2020 4:00:00 [PM								
Fnd:	6/16/2020 5:00:00 1									

Show Time As: Tentative

APAR0000016901-2517025

Required

Jim Neaton; Jens Lundgren; Read, Sarah (NIH/NIAID) [E]; Eric Hughes; Higgs, Elizabeth (NIH/NIAID) [E]; Srinivasan,

Badhri; Goff, David (NIH/NHLBI) [E]; Nayak, Seema (NIH/NIAID) [E]; Victoria Davey; Kozak, Marina (OS/ASPR/BARDA);

McNay, Laura (NIH/NIAID) [E]; Tierney, John (NIH/NIAID) [E]; Aggarwal, Neil (NIH/NHLBI) [E]; Rosenberg, Yves

(NIH/NHLBI) [E]; Patterson, Amy (NIH/NHLBI) [E]; Miller, Marissa A (NIH/NHLBI) [E]; Rachel Harrigan; William

Erhardt; Reineck, Lora (NIH/NHLBI) [E];

(b) (6)

Gelijns, Annetine; Mark Polizzotto; Ginny Kan; Baker,

Jason; Roger Paredes; Thompson, Taylor, M.D.; Babiker, Ab

Optional

Chen, Helen Q.; Wachtel, Jonathan; Tountas, Karen (FNIH) [T]; Desrosiers, Elizabeth A.; Kurilla, Michael (NIH/NCATS)

[E]; Kenny, Dermot; Parker, Ashley (NIH/OD) [E]; Pett, Sarah; Grace, Beth (NIH/NIAID) [C]; Barrett, Kevin (NIH/NIAID)

Stacey Adam is inviting you to a scheduled Zoom meeting.

Join Zoom Meeting

https://fnih.zoom.us/

Meeting ID: (b) (6)

Password: (b) (6)

One tap mobile

(b) (6)

US (Germantown)

US (Chicago)

Dial by your location

(b) (6) US (Germantown) (b)(6)US (Chicago) + (b)(6)US (New York) (b)(6)US (San Jose) (b)(6)US (Tacoma) (b)(6)US (Houston) + (b) (6) US (San Jose) +

Meeting ID: (b) (6)

Password: (b) (6)

Find your local number: https://fnih.zoom.us (b) (6)

То:	Menetski, Joseph (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5001af52dc4a427ea3d34f1e072f8cb7-menetskijp]; Hild, Sheri (NIH/OD) [E]									
			Exchange Admi			4110072100	b) meneraki	ijpj, riiic	, 311011 (1111) 00) [2]	
	(FYDIBOHF2	3SPDLT)/cn	=Recipients/cn	edd7f1939fb9	94be3bf063	3f925ac15f0	02-hildsa];	(b) (6)	
	(b)	(6)	(b) (6)	(b) (6	5)	(b) (6)	Bari	c, Ralph	
	[/o=Exchang	eLabs/ou=l	Exchange Admi	nistrative Grou	р					
	(FYDIBOHF2	3SPDLT)/cn	=Recipients/cn	=48e35ab1d30	44465a779	90ee4ded5k	oc32-rbaric.e	emai];		
		(b) (6)	Ottinge	er, Elizabeth (N	IH/NCATS	[E] [(b) (6)	(Colvis, Christine	
	(NIH/NCATS	[E] [(b) (6)	Hewitt, Judit	h (NIH/NIA	(ID) [E]	(b) (6)	Demin	g, Damon	
	(FDA/CDER)	[/o=Exchan	geLabs/ou=Exc	hange Adminis	strative Gro	oup				
	(FYDIBOHF2	3SPDLT)/cn	=Recipients/cn	=8a5ace9923a	e415aa3d8	35ac09cb76	f85-DEMING	D.fda];		
	(t) (6)	(b) (6)	(b) (6)	P	arker, Ashle	y (NIH/C	DD) [E]	
	[/o=Exchang	eLabs/ou=	Exchange Admi	nistrative Grou	р					
	(FYDIBOHF2	3SPDLT)/cn	=Recipients/cn	=306b2244466	140faa95a	aaafe06ebo	d70-parkeras	s]; Collin	s, Francis (NIH/OD)	
	[E] [/o=Exch	angeLabs/o	u=Exchange Ad	lministrative G	roup					
	(FYDIBOHF2	3SPDLT)/cn	=Recipients/cn	=410e1ca313f4	44ced9938	e50d2ff0b6	c2-collinsf];			
		(b) (6)						ou=Excl	nange Administrative	
	Group (FYDI			14 100 mm : [- [- [- [- [- [- [- [- [- [이 경기에 보면 이 기가 있는 그 이 이 시간에 되었다면 것		ns]; Qashu, Felicia	
			ngeLabs/ou=Ex						The state of the s	
			=Recipients/cn				1e5-gashufn	nl: Tom	as Cihlar	
		b) (6)		aret L CIV USA					(b) (6)	
			IIH/NHLBI) [E] [roup	(0) (0)	
			=Recipients/cn						rette. Marc	
			hangeLabs/ou=				or pariture.	,	area, mare	
						전경 - (1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.	a6-charetten	nfl: Fess	el, Josh (NIH/NHLBI)	
			u=Exchange Ac			040 1540 000	ar cital cital	,, 1 000	ici, sosii (ttiri, ttirebi)	
			=Recipients/cn		일이 다양에 선생하는 나무게 그리고 나왔다.	17f15338df	e19-fesselin	1.		
		o) (6)		(b) (6)	Rao, Srin		(b) (6)	1,		
	(((b) (6)		(0) (0)	nao, sini	ivas į	(0) (0)			
CC:	Gadhois Elle		[E] [/o=Exchar	gel ahs/nu=Fx	change Ad	ministrative	Group			
CC.			107 STON	177	1.77			ell: Who	olley, David (FNIH) [T]	
	3	3777	Exchange Admi			:ucc300c20	cza-gaubois	Cij, Wiic	mey, David (Tivili) [1]	
			=Recipients/cn			h6996d677	257-whollew	dl. Austi	n Christopher	
	- 70 IN MANY MAY SHE WAS INSULED FOR		changeLabs/ou				237 WHOTE Y	u], Austi	ii, cii istopiici	
						영경 : 10 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	81f_austincl	Melen	cio, Cheryl (FNIH) [T]	
			Exchange Admi			7077030417	ori-austinej,	ivicienc	io, chery (i Miri) [1]	
			=Recipients/cn			1974095629	ef-malanci	ocl. Col	vic Christina	
	D3		changeLabs/ou				eoi-meienci	ocj, coi	vis, cillistille	
			=Recipients/cn				97 ccoluicle	Docroci	ore Potev	
	(FIDIBOHEZ	(b) (6)	172.0	nsen, Kathrin [0.77		ael (NIH/NCATS) [E]	
	[/o=Evchang		Exchange Admi			(b) (6)	Kuriii	a, which	aer (Min/MCA15) [L]	
			=Recipients/cn			42f/167270	61f_mkurilla	1. Loung	Douglas (NCI)	
			Exchange Admi			3314207276	O II - I II KUI III a	j, LOWy,	Douglas (NCI)	
	- 1000 March 1000 Marc	리 위에 있어 하다 시간 하는 것이 없는 ^^ ^^			TOTAL SECTION SECTION	7.66h022h	an del boliv	nl. Doo	d, Sarah (NIH/NIAID)	
			u=Exchange Ac			/(00003200	aav-un.nenx.	.iij, nead	a, Sarah (MIH/MAID)	
	5	-				C-0h2226	.000 roadcal	. Tourst	os Varan /ENILL\ [T]	
	31		2002			beubaczzze	ouss-readsaj	; Tounta	as, Karen (FNIH) [T]	
	-		Exchange Admi			C2-4C-1 460	2	1. C+-	- Michael (FNIIII) [T]	
	(FYDIBOHF23SPDLT)/cn=Recipients/cn=40c04fef6f1e46f5b750753cd5a14f93-tountaskh]; Santos, Michael (FNIH) [T]									
	- 5.80 C	[/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ab38cb6836de44e18ef4cc6952f65f80-santosmr]; Adam, Stacey (FNIH) [T]								
						CC69521651	ou-santosmr]; Adam	i, stacey (FINIH) [1]	
			Exchange Admi			£404 -0040	144 - 1	1	Charles in Jeans 10	
						T101c09434	114-adamsj4	j; James	, Stephanie (FNIH) [T]	
			Exchange Admi		*					
	27		=Recipients/cn				-			
) (6)	Kim, Elizab) (6)	Tolman, E	985	(b) (6		
	Jonathan	(b) (-/	bhavathi Fern			b) (6)		Rose Li	
	l	(b) (6)	Dana C	arluccio [(b) (6)		Lagos, E	nrique (NIH/NCATS)	

[E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ae9041ab27204d83b06752f67a44b0d1-lagoses]; Jonson, Samantha (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ce2f69369d654bef89b0d39b145d69a7-jonsonsg]; Gonzalez, Nina Simon, Dina (NIH/OD) [C] [/o=ExchangeLabs/ou=Exchange Administrative Group (b) (6) (FYDIBOHF23SPDLT)/cn=Recipients/cn=e02345fa5d1d4d7eaf4e0f3da58bc1ac-simondm]; Burrus-Shaw, Cyndi (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5bbac95b1f6e4514a299b318030c31f6-shawcy]; Dave Frankowski Lowy, Douglas (NIH/NCI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f1b7b8fe4739478bb17840c56902718a-lowyd]; Florence, Clint (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5e032d0bc8554e8787e844a7773295fe-florencewc]; Nancy Haigwood [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=03d589f440d84691ac0a530e4ba6ceb5-haigwoon.oh]; Stratton, Benjamin Culp, Michelle (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4e38fa37e0424217aa0a283cba9e5098-mculp]; Diamond, Michael Rodriguez, Robin D [(b) (6) Gadbois, Ellen (NIH/OD) [E] (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0243d1d6e6f248268d2edec566c26c2a-gadboisel]; Baric, Toni C Hughes, Eric [eric. (b) (6) (b) (6)

Start: 6/17/2020 2:00:00 PM End: 6/17/2020 3:00:00 PM

Recurrence: (none)

Required Attendees:

(b) (6)	Hild, Sher	i (NIH/OD) [E];	(b) (6)		(b) (6)	;
(b) (6)		(b) (6)	(b) (6)	(b) ((6)
(b) (6)	(b) (6)	(b) (6)		(b) (6)	(b)	
(b) (6)	(b) (6)	(b) (6)		(b) (6)		(b) (6)
(b) (6) Parker, Ashley (NIH/OD) [E]; Collins, Francis (NIH/OD) [E];						
(b) (6)) Ad	ams, Peter (OS/ASPR	(BARDA); Rao,	Srinivas; Qas	shu, Felicia (NIH/OD) [E]
Tomas Cihlar; Pitt, N	Margaret L CIV USA	RMY MEDCOM USAI	MRIID (USA); Pu	ınturieri, Ant	tonello (NIH,	/NHLBI) [E];

Charette, Marc (NIH/NHLBI) [E]; Fessel, Josh (NIH/NHLBI) [E]

Optional Attendees: Culp, Michelle (NIH/OD) [E]; Gadbois, Ellen (NIH/OD) [E]; Diamond, Michael; Wholley, David (FNIH) [T]; Austin, Christopher (NIH/NCATS) [E]; Melencio, Cheryl (FNIH) [T]; Colvis, Christine (NIH/NCATS) [E]; Desrosiers, Betsy; Hughes, Eric; Jansen, Kathrin; Kurilla, Michael (NIH/NCATS) [E]; Lowy, Douglas (NCI); Read, Sarah (NIH/NIAID) [E]; Tountas, Karen (FNIH) [T]; Santos, Michael (FNIH) [T]; Adam, Stacey (FNIH) [T]; James, Stephanie (FNIH) [T]; Alvarez, Rosa Maria; Kim, Elizabeth; Tolman, Brett; Wachtel, Jonathan; Prabhavathi Fernandes; Rose Li; Dana Carluccio; Lagos, Enrique (NIH/NCATS) [E]; Jonson, Samantha (NIH/NCATS) [E]; Gonzalez, Nina; Simon, Dina (NIH/OD) [C]; Burrus-Shaw, Cyndi (NIH/OD) [E]; Rodriguez, Robin D; Dave Frankowski; Baric, Toni C; Lowy, Douglas (NIH/NCI) [E]; Florence, Clint (NIH/NIAID) [E]; Nancy Haigwood; Stratton, Benjamin

From:	Adam, Stacey (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=DCD875F0679648859E1CF101C0943414-ADAMSJ4]								
Sent:	4/28/2020 8:37:13 P	M							
To:	Adam, Stacey (FNIH)	[T] [/o=Exchange	geLabs/ou=	Exchange Adm	inistrative (Group			
	(FYDIBOHF23SPDLT)	/cn=Recipients/	cn=dcd875	f0679648859e	1cf101c094	13414-ad	amsj4]; Eri	c Hughes	
	(b) (6)]; Read,	Sarah (NIH	/NIAID) [E] [(b) (6)];	Ruxandra	Draghia-Akli	
	(b) (6)	Mellors, Jo	ohn W [(b) (6)]; N	Naimish Pat	el [(b) (6) Colvis,	
	Christine (NIH/NCAT	S) [E] [(b) (6)]; Young, Jo	ohn [(b)	(6)	Stein, Peter	
	(FDA/CDER) [(b) (6)	Poole,	Mike [(b) (6	5)	Bu	chman, Tim	
	(OS/ASPR/BARDA) (O	TR) [(1	b) (6)	Vincent, N	lichael [(b) (6)	Keith	
	Gottesdiener [(b) (6)		Elliott Levy [(b) (6)	Wung, Pet	ter /US	
	(b) (6)	Koroshe	tz, Walter	(NIH/NINDS) [E][(b) (6)		Higgs, Elizabeth	
	(NIH/NIAID) [E] [(b) (6)	Carlos	O Garner [(b) (6	5)			
CC:	Elizabeth Kim [(b) (6)	Menetski	, Joseph (FNIH)	[T] [(b) (6)	Alva	rez, Rosa Maria	
	(b) (6)	Salathin	, Carla [(b) (6)		(1	b) (6)	(b) (6)	
	Parker, Ashley (NIH/								
	(FYDIBOHF23SPDLT)	/cn=Recipients/	cn=306b22	244466140faa9	5aaaafe06e	ebd70-pa	rkeras]; W	holley, David (FNIH) [T]	
	(b) (6)	Melencio, Che		\ / \		Lucas Sm	alldon		
	(b)	(6)	Walke	er, Paula (NIH/N	IINDS) [E] [((b) (6)]; Ward, Jackie	
	(NIH/NINDS) [E] [jack	(ie. (b) (6)							
Subject:	ACTIV TX-Clinical Age			1277					
Attachments:	ACTIV Therapeutics	Clinical_Agent P	Prioritizatio	n Sub-Group M	eeting Age	nda_050	12020v2.p	df	
Location:	https://fnih.zoom.			(b) (6)					
Start:	5/1/2020 7:00:00 PN								
End:	5/1/2020 8:30:00 PN	1							
Show Time As:	Busy								
Required	Eric Hughes; Read, S			[[[[[[[[[[[[[[[[[[[
Attendees:	(NIH/NCATS) [E]; You	Maria Andrew Maria and a superior of the contract of the co							
	Vincent, Michael; Ke			vy; Wung, Pete	r /US; Koro	shetz, W	alter (NIH/	'NINDS) [E]; Higgs,	
	Elizabeth (NIH/NIAID	7.75							
Optional	Elizabeth Kim; Mene						(b) (6)		
Attendees:			*	26 70 70	0.5	(FNIH) [T]; Lucas Sm	nalldon; Walker, Paula	
	(NIH/NINDS) [E]; Wa	rd, Jackie (NIH/	OD) [E] (jac	kie.ward@nih.	gov)				
Dear TX-Clinic	al Agent Prioritizati	on Subgroup,							
Please find att	ached the agenda f	or today's call	l. We will	be continuing	the discus	ssions fr	om vester	rdav.	
							200000000000000000000000000000000000000		
Thanks,									
Stacey									
	o 100								
Join Zoom M	leeting								
https://fnih.ze	oom.us/		(b)	(6)					
6700									
Meeting ID:	(b) (6)								
Password: (b									
One tap mob			TIC (CI						
	(b) (6)		US (Ch						
			US (Ne	w York)					

```
Dial by vour location
(b) (6)

US (Chicago)

US (New York)

US (Germantown)

US (San Jose)

US (San Jose)

US (Tacoma)

US (Houston)

Meeting ID:
(b) (6)

Password: (b) (6)

Find your local number: <a href="https://fnih.zoom.us">https://fnih.zoom.us</a>
(b) (6)
```

From: Wholley, David (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=CD9E702FCF28414883D0B6996D677257-WHOLLEYD] Sent: 4/24/2020 4:40:40 PM To: Wholley, David (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]; Austin, Christopher (NIH/NCATS) [E] [(b) (6) Collins, Francis (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=410e1ca313f44ced9938e50d2ff0b6c2-collinsf]; Corey, Disbrow, Gary (OS/ASPR/BARDA) [Dolsten, Mikael (b) (6) (b)(6)Erbelding, Emily (NIH/NIAID) [E] [Fauci. Anthony (b)(6)(b)(6)(NIH/NIAID) [E] [Hudson, Thomas [James, Stephanie (FNIH) [T] (b) (6) (b)(6)(b)(6)Johnson, Robert (OS/ASPR/BARDA) | Kramer, Lynn (b)(6)]; Lane, Cliff (NIH/NIAID) [E] [Marks, Peter (FDA/CBER) (b) (6) (b)(6)Marston, Hilary (NIH/NIAID) [E] [Mascola, John (NIH/VRC) [E] (b) (6) (b) (6) Meeker, David [Menetski, Joseph (FNIH) [T] (b)(6)(b) (6) (b) (6) Pangalos, Mene [Pao, William [(b)(6)(b)(6)Paul, Steve (b)(6)Perlmutter, Roger [(b) (6) Plump, Andy Rasi, Guido ; Reed, John [(b)(6)(b)(6)(b) (6) Rouse, Doris ; Santos, Michael (FNIH) [T] [Skovronsky, Daniel (b) (6) (b)(6)Stein, Peter (FDA/CDER) [Stoffels, Paul (b) (6) (b) (6) Tabak, Lawrence (NIH/OD) [E] []; Tsai, John (b) (6) (b)(6)(b)(6)Vessey, Rupert [(b)(6)]; Virgin, Skip [(b)(6)Woodcock, Janet (FDA/CDER) [Colvis, Christine Young, John (b) (6) (b)(6)(NIH/NCATS) [E] [Desrosiers, Betsy [Hughes, Eric (b) (6) (b)(6)Jansen, Kathrin [Kurilla, Michael (NIH/NCATS) [E] (b)(6)(b)(6)Lowy, Douglas (NCI) [Read, Sarah (NIH/NIAID) [E] (b) (6) (b)(6)(b)(6)Freire, Maria (FNIH) [T] [(b)(6)Adam, Stacey (FNIH) [T] [(b)(6)Alvarez, Rosa [(b)(6)Anderson, Margaret [Gonzalez, Nina (b)(6)Stratton, Ben [(b)(6)Kim, Elizabeth [(b)(6)Tolman, Brett [(b)(6)Tountas, Karen (FNIH) [T] [Wachtel, Jonathan (b) (6) Rachel Ramoni [(b)(6)(b)(6)Plenge, Robert | (b) (6) Talley. Michael [(b)(6)Cavaleri, Marco [Lee, William (b)(6)Anderson, James (NIH/OD) [E] []; Bianchi, Diana (NIH/NICHD) (b)(6)(b) (6)]; Brennan, Patti (NIH/NLM) [E] [Byrnes, Noni (NIH/CSR) [E] [E] (b)(6)(b)(6)Carter, Robert (NIH/NIAMS) [E] [Glass, Roger (NIH/FIC) [E] (b)(6)(b) (6) Gregurick, Susan (NIH/OD) [E] [Hodes, Richard (NIH/NIA) [E] (b) (6) (b) (6) (b)(6)Horsford, Jonathan (NIH/NIDCR) [E] [(b)(6)1: Koroshetz, Walter (NIH/NINDS) [E] [.gov]; Norris, Andrea (NIH/CIT) [E] [(b)(6)Rodgers, Griffin (b) (6) (NIH/NIDDK) [E] [(b)(6)Schwetz, Tara (NIH/OD) [E] [tara. (b)(6)Sharpless, Norman (NIH/NCI) [E] [Tucci, Debara (NIH/NIDCD) [E] | (b)(6)]; (b) (6) Tumminia, Santa (NIH/NEI) [E] []; Volkow, Nora (NIH/NIDA) [E] [(b) (6) (b)(6)Wolinetz, Carrie (NIH/OD) [E] [Wilder, Elizabeth (NIH/OD) [E] [(b) (6) (b)(6)Grieder, Franziska (NIH/OD) [E] [Clayton, Janine (NIH/OD) [E] (b)(6)(b) (6) Lankford, David (NIH/OD) [E] [(b)(6)Gibbons, Gary (NIH/NHLBI) [E]]; Zajicek, Anne (NIH/OD) [E] [Koob, George (NIH/NIAAA) [E] (b)(6)(b) (6) Hallett, Adrienne (NIH/OD) [E] [Valantine, Hannah (NIH/OD) [E] (b)(6)(b)(6)(b)(6)Burrus-Shaw, Cyndi (NIH/OD) [E] (b) (6) CC: Barasch, Kimberly (NIH/NIAID) [C] [(b)(6)]; Carver, Trea (NIH) [C] [Conrad, Patricia (NIH/NIAID) [E] (b) (6) (b)(6)Hoffstetter, Renata (FNIH) [T] [rhoffstetter@fnih.org]; Iberdemaj, Vaide Lagos, Enrique (NIH/NCATS) [E] []; McManus, Ayanna (b)(6)(b)(6)(NIH/OD) [E] [Melencio, Cheryl (FNIH) [T] [Protasiewicz, Ann (b)(6)(b)(6)Simon, Dina (NIH/OD) [C] ; Thomas, Ashley (FDA/CDER) (b)(6)(b)(6)]; Wood, Gretchen (NIH/OD) [E] [**FNIH Central Account** (b)(6)(b)(6)Sepulveda, Dorina (FNIH) [T] [(b)(6)Li, Rose (b)(6)Zottoli, Jessica [Lowy, Douglas (NIH/NCI) [E] (b)(6)(b)(6)Parker, Ashley (NIH/OD) [E] [Gladman, Jordan (NIH/OD) [E] (b)(6)(b) (6)]; Elsaid, Olivia [(b)(6)Best, Cindy (NIH/NEI) [E] [(b)(6)

Bronson, Charlette (N	IH/NIA) [E] [(b) (6)]; Dzokoto-Pomenya	, Caroline (NII	H/OD) [C]	
(b) (6)	Hamid, Kha	awar (NIH/CSR) [E] [(b) (6)	Hardes	sty, Rebecca
(NIH/OD) [C] [(b) (6)	Hughes	, Karen (NIH/OD) [E] [karen.	(b) (6)	Kellto	n, Karen
(NIH/OD) [C] [(b) (6)	Mowery, Pe	enny (NIH/NIDDK) [E] [(b) (6)	Ne	w, Suzanne
(NIH/NIDCR) [E] [(b) (6)		dra (NIH/NICHD) [E]	(b) (6)	Salley	, Jasmine
(NIH/NIDDK) [C]	(b) (6)	Schulke	e, Hilda (NIH/NIDA) [E] [(b) (6)]; Sha	oiro-Loser,
Beth (NIH/NIDDK) [E]	(b) (6)	Stover, Kathleen (NIH/FIC		(b) (6)]; Togashi,
Mieko (NIH/NCI) [E] [(b) (6)	Wade, Portia (NIH/CIT) [E]	(b)	(6)	Barnett,
Sylvia (NIH/OD) [E] [(b) (6)	Dimi	shkov, Roxanne (NIH/NHLBI)) [C] [(b) (6)	
Pirrone, Jen (NIH/OD)		(6)	Castillejos zenteno, Carlos [JRDUS] [(b) (6)	
Oresanya, Jejelola (NI	H/OD) [C] [(b) (6)	1			

Subject: ACTIV Response Partnership Leadership Team Meeting #3 Location: https://fnih.zoom.us/ (b) (6)

Start: 5/6/2020 7:30:00 PM **End**: 5/6/2020 9:00:00 PM

Show Time As: Tentative

Required Attendees:

Wholley, David (FNIH) [T]; Austin, Christopher (NIH/NCATS) [E]; Collins, Francis (NIH/OD) [E]; Corey, Larry; Disbrow, Gary (OS/ASPR/BARDA); Dolsten, Mikael; Erbelding, Emily (NIH/NIAID) [E]; Fauci, Anthony (NIH/NIAID) [E]; Hudson, Thomas; James, Stephanie (FNIH) [T]; Johnson, Robert (OS/ASPR/BARDA); Kramer, Lynn; Lane, Cliff (NIH/NIAID) [E]; Marks, Peter (FDA/CBER); Marston, Hilary (NIH/NIAID) [E]; Mascola, John; Meeker, David; Menetski, Joseph (FNIH) [T]; Pangalos, Mene; Pao, William; Paul, Steve; Perlmutter, Roger; Plump, Andy; Rasi, Guido; Reed, John; Rouse, Doris; Santos, Michael (FNIH) [T]; Skovronsky, Daniel; Stein, Peter (FDA/CDER); Stoffels, Paul; Tabak, Lawrence (NIH/OD) [E]; Tsai, John; Vessey, Rupert; Virgin, Skip; Woodcock, Janet (FDA/CDER); Young, John; Colvis, Christine (NIH/NCATS) [E]; Desrosiers, Betsy; Hughes, Eric; Jansen, Kathrin; Kurilla, Michael (NIH/NCATS) [E]; Lowy, Douglas (NCI); Read, Sarah (NIH/NIAID) [E]; Freire, Maria (FNIH) [T]; Adam, Stacey (FNIH) [T]; Alvarez, Rosa; Anderson, Margaret; Gonzalez, Nina; Kim, Elizabeth; Stratton, Ben; Tolman, Brett; Tountas, Karen (FNIH) [T]; Wachtel, Jonathan; Rachel Ramoni; Plenge, Robert; Talley, Michael; Cavaleri, Marco; Lee, William; Anderson, James (NIH/OD) [E]; Bianchi, Diana (NIH/NICHD) [E]; Brennan, Patti (NIH/NLM) [E]; Byrnes, Noni (NIH/CSR) [E]; Carter, Robert (NIH/NIAMS) [E]; Glass, Roger (NIH/FIC) [E]; Gregurick, Susan (NIH/OD) [E]; Hodes, Richard (NIH/NIA) [E]; Horsford, Jonathan (NIH/NIDCR) [E]; Koroshetz, Walter (NIH/NINDS) [E]; Norris, Andrea (NIH/CIT) [E]; Rodgers, Griffin (NIH/NIDDK) [E]; Schwetz, Tara (NIH/OD) [E]; Sharpless, Norman (NIH/NCI) [E]; Tucci, Debara (NIH/NIDCD) [E]; Tumminia, Santa (NIH/NEI) [E]; Volkow, Nora (NIH/NIDA) [E]; Wilder, Elizabeth (NIH/OD) [E]; Wolinetz, Carrie (NIH/OD) [E]; Grieder, Franziska (NIH/OD) [E]; Clayton, Janine (NIH/OD) [E]; Lankford, David (NIH/OD) [E]; Gibbons, Gary (NIH/NHLBI) [E]; Zajicek, Anne (NIH/OD) [E]; Koob, George (NIH/NIAAA) [E]; Hallett, Adrienne (NIH/OD) [E]; Valantine, Hannah (NIH/OD) [E]

Optional Attendees:

Barasch, Kimberly (NIH/NIAID) [C]; Burrus-Shaw, Cyndi (NIH/OD) [E]; Carver, Trea (NIH) [C]; Conrad, Patricia (NIH/NIAID) [E]; Hoffstetter, Renata (FNIH) [T]; Iberdemaj, Vaide; Lagos, Enrique (NIH/NCATS) [E]; McManus, Ayanna (NIH/OD) [E]; Melencio, Cheryl (FNIH) [T]; Protasiewicz, Ann; Simon, Dina (NIH/OD) [C]; Thomas, Ashley (FDA/CDER); Wood, Gretchen (NIH/OD) [E]; FNIH Central Account; Sepulveda, Dorina (FNIH) [T]; Li, Rose; Zottoli, Jessica; Lowy, Douglas (NIH/NCI) [E]; Parker, Ashley (NIH/OD) [E]; Gladman, Jordan (NIH/OD) [E]; Elsaid, Olivia; Best, Cindy (NIH/NEI) [E]; Bronson, Charlette (NIH/NIA) [E]; Dzokoto-Pomenya, Caroline (NIH/OD) [C]; Hamid, Khawar (NIH/CSR) [E]; Hardesty, Rebecca (NIH/OD) [C]; Hughes, Karen (NIH/OD) [E]; Kellton, Karen (NIH/OD) [C]; Mowery, Penny (NIH/NIDDK) [E]; New, Suzanne (NIH/NIDCR) [E]; Ott, Sandra (NIH/NICHD) [E]; Salley, Jasmine (NIH/NIDDK) [C]; Schulke, Hilda (NIH/NIDA) [E]; Shapiro-Loser, Beth (NIH/NIDDK) [E]; Stover, Kathleen (NIH/FIC) [E]; Togashi, Mieko (NIH/NCI) [E]; Wade, Portia (NIH/CIT) [E]; Barnett, Sylvia (NIH/OD) [E]; Dimishkov, Roxanne (NIH/NHLBI) [C]; Pirrone, Jen (NIH/OD) [E]; Castillejos zenteno, Carlos [JRDUS]; Oresanya, Jejelola (NIH/OD) [C]

Join Zoom Meeting

https://fnih.zoom. (b) (6)

Meeting ID: (b) (6)
Password: (b) (6)
One tap mobile

```
(b) (6)

US (Germantown)
US (Chicago)

Dial by vour location
(b) (6)

US (Germantown)
US (Chicago)
US (New York)
US (Houston)
US (San Jose)
US (San Jose)
US (San Jose)
US (Tacoma)

Meeting ID: (b) (6)

Password: (b) (6)
```

(b) (6)

Find your local number: https://fnih.zoom.

From: Melencio, Cheryl (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=279E14FA7428415BB86087D08B628E6F-MELENCIOC] Sent: 8/18/2020 2:59:40 PM To: Melencio, Cheryl (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=279e14fa7428415bb86087d08b628e6f-melencioc]; Collins, Francis (NIH/OD) Disbrow, Gary (OS/ASPR/BARDA) [(b)(6)Dolsten, Mikael (b) (6) Fauci, Anthony (NIH/NIAID) [E] []; Gibbons, Gary (NIH/NHLBI) [E] (b)(6)(b) (6) Marks, Peter (FDA/CBER) []; Pao, William (b) (6) (b)(6)Plump, Andrew [Stoffels, Paul [(b)(6)(b)(6)(b) (6) Woodcock, Janet (FDA/CDER) [Colvis, Christine (NIH/NCATS) [E] (b) (6) Desrosiers, Betsy [(b)(6)Eric Hughes (b)(6)Jansen, Kathrin [Kurilla, Michael (NIH/NCATS) [E] (b)(6)(b)(6)Read, Sarah (NIH/NIAID) [E] Lowy, Douglas (NCI) [(b)(6)(b)(6)Young, John Anderson, James (NIH/OD) [E] (b) (6) (b)(6)(b)(6)Austin, Christopher (NIH/NCATS) [E] [(b)(6)Burklow, John (NIH/OD) [E][(b)(6)Castillejos, Carlos [(b)(6)Culp, Michelle (NIH/OD) [E] Gadbois, Ellen (NIH/OD) [E] FNIH Central Account [(b)(6)(b)(6)[/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0243d1d6e6f248268d2edec566c26c2a-gadboisel]; Hallett, Adrienne (NIH/OD) [E] []; Lane, Cliff (NIH/NIAID) [E] [Myles, Renate (NIH/OD) (b) (6) (b)(6)[E] [(b)(6)Parker, Ashley (NIH/OD) [E] [(b)(6)Tabak, Lawrence (NIH/OD) [E] Wolinetz, Carrie (NIH/OD) [E] [Adam, Stacey (FNIH) [T] (b) (6) (b)(6)Alvarez, Rosa [(b)(6)Anderson, Margaret [(b)(6)(b) (6) Gonzalez, Nina Chen, Helen [Elsaid, Olivia [(b)(6)(b) (6) Menetski, Joseph (FNIH) [T] Hawk, Harrison [(b)(6)(b)(6)(b)(6)Santos, Michael (FNIH) [T] [(b)(6)Stratton, Benjamin [(b)(6)Tolman, Brett [Tountas, Karen (FNIH) [T] [(b)(6)Wholley, David (FNIH) [T] (b)(6)Sorosa, Alex [Connelly, Sarah (b)(6)Appell, Evan [(b)(6)(b) (6) Wachtel, Jonathan (b)(6)CC: Barasch, Kimberly (NIH/NIAID) [C] [Conrad, Patricia (NIH/NIAID) [E] (b) (6) McManus, Ayanna (b)(6)Dimishkov, Roxanne (NIH/NHLBI) [C] [(b) (6) (NIH/OD) [E] [ayanna. (b)(6)]; Perala, Mie [Protasiewicz, Ann (b)(6)Riccobene, Kim [Thomas, Ashley (FDA/CDER) (b)(6)(b)(6)]; Wood, Gretchen (NIH/OD) [E] [Burrus-Shaw, Cyndi (NIH/OD) (b) (6) (b)(6)Hughes, Karen (NIH/OD) [E] [E] [cyndi. Carver, Trea (NIH) [C] [(b) (6) (b)(6)Lagos, Enrique (NIH/NCATS) [E] [(b)(6)1; Sepulveda, Dorina (FNIH) [T] (b) (6) ; Simon, Dina (NIH/OD) [C] Tajalli, Ada (NIH/OD) [E] (b)(6)(b)(6)]; Togashi, Mieko (NIH/NCI) [E] [1: Underwood, Nancy (b)(6)(b)(6)Zottoli, Jessica [Jessica. Dana Carluccio (b) (6) (b) (6) Lowy, Douglas (NIH/NCI) [E] [(b)(6).gov]; Hamilton, Nancy (b) (6) (b) (6) Subject: ACTIV EC & Working Group Co-Chair Meeting Location: https://fnih.zoom. (b)(6)Start: 10/7/2020 2:00:00 PM

Required Attendees:

Show Time As: Busy

End:

10/7/2020 3:00:00 PM

Melencio, Cheryl (FNIH) [T]; Collins, Francis (NIH/OD) [E]; Disbrow, Gary (OS/ASPR/BARDA); Dolsten, Mikael; Fauci, Anthony (NIH/NIAID) [E]; Gibbons, Gary (NIH/NHLBI) [E]; Marks, Peter (FDA/CBER); Pao, William; Plump, Andrew; Stoffels, Paul; Woodcock, Janet (FDA/CDER); Colvis, Christine (NIH/NCATS) [E]; Desrosiers, Betsy; Hughes, Eric; Jansen, Kathrin; Kurilla, Michael (NIH/NCATS) [E]; Lowy, Douglas (NCI); Read, Sarah (NIH/NIAID) [E]; Young, John; Anderson, James (NIH/OD) [E]; Austin, Christopher (NIH/NCATS) [E]; Burklow, John (NIH/OD) [E]; Castillejos, Carlos; Culp, Michelle (NIH/OD) [E]; FNIH Central Account; Gadbois, Ellen (NIH/OD) [E]; Hallett, Adrienne (NIH/OD) [E]; Lane,

Cliff (NIH/NIAID) [E]; Myles, Renate (NIH/OD) [E]; Parker, Ashley (NIH/OD) [E]; Tabak, Lawrence (NIH/OD) [E]; Wolinetz, Carrie (NIH/OD) [E]; Adam, Stacey (FNIH) [T]; Alvarez, Rosa; Anderson, Margaret; Chen, Helen; Elsaid, Olivia; Gonzalez, Nina; Hawk, Harrison; Menetski, Joseph (FNIH) [T]; Santos, Michael (FNIH) [T]; Stratton, Ben; Tolman, Brett; Tountas, Karen (FNIH) [T]; Wachtel, Jonathan; Wholley, David (FNIH) [T]; Appell, Evan; Sorosa, Alex; Connelly, Sarah

Optional Attendees:

Join Zoom Meeting

Barasch, Kimberly (NIH/NIAID) [C]; Conrad, Patricia (NIH/NIAID) [E]; Dimishkov, Roxanne (NIH/NHLBI) [C]; McManus, Ayanna (NIH/OD) [E]; Perala, Mie; Protasiewicz, Ann; Riccobene, Kim; Thomas, Ashley (FDA/CDER); Wood, Gretchen (NIH/OD) [E]; Burrus-Shaw, Cyndi (NIH/OD) [E]; Carver, Trea (NIH) [C]; Hughes, Karen (NIH/OD) [E]; Lagos, Enrique (NIH/NCATS) [E]; Sepulveda, Dorina (FNIH) [T]; Simon, Dina (NIH/OD) [C]; Tajalli, Ada (NIH/OD) [E]; Togashi, Mieko (NIH/NCI) [E]; Underwood, Nancy; Zottoli, Jessica; Hamilton, Nancy; Dana Carluccio; Lowy, Douglas (NIH/NCI) [E]

Joseph Menetski is inviting you to a scheduled Zoom meeting.

```
https://fnih.zoom.us
                                              (b) (6)
Meeting ID:
                 (b) (6)
Passcode: (b)
One tap mobile
                    (b) (6)
                                               US (Germantown)
                                               US (Chicago)
Dial by .....
              (b) (6)
                          US (Germantown)
                          US
                             (Chicago)
                          US (New York)
                          US (San Jose)
                          US (San Jose)
                          US (Tacoma)
                          US (Houston)
                          lgium
                          elgium
                          elgium
                          elgium
                          elgium
                          elgium
                          Canada
                          Canada
                          Canada
                          Canada
                          Canada
                          Canada
                          France
                          France
                          France
                          France
                          France
                          Japan
                          Japan
                          Japan
                           Italy
                              Italy
                           Italy
                           Switzerland
                           Switzerland
                           Switzerland
                           Switzerland
                           Switzerland
                           Switzerland
                           United Kingdom
                           United Kingdom
                           United Kingdom
                           United Kingdom
                           United Kingdom
                           United Kingdom
                           United Kingdom
Meeting ID:
                 (b)(6)
Passcode: (b) (6)
Find your local number: https://fnih.zoom.
                                                  (b) (6)
```

From: Adam, Stacey (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=DCD875F0679648859E1CF101C0943414-ADAMSJ4] Sent: 5/7/2020 8:58:53 PM To: Adam, Stacey (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dcd875f0679648859e1cf101c0943414-adamsj4]; Bozzette, Sam (NIH/NCATS) Butterton, Joan [Collins, Sylva (FDA/CDER) (b)(6)(b)(6)]; Judy Currier [De Claro, R. Angelo (FDA/CDER) (b) (6) (b) (6) Keith Gottesdiener Mark Eisner (b)(6)(b) (6) Eric Hughes [LaVange, Lisa M | (b) (6) (b)(6)(b)(6)Elliott Levy [Sandeep Menon [Amanda Peppercorn (b)(6)(b)(6)Proschan, Michael (NIH/NIAID) [E] ; Read, Sarah (b)(6)(b)(6)(NIH/NIAID) [E] [Amanda Peppercorn [Price, Dionne (b)(6)(b) (6) (FDA/CDER) [Rubin, Daniel B. (FDA/CDER) [Shen, Yuan Li (b) (6) (b)(6)(FDA/CDER) [Farley, John (FDA/CDER) [Vincent, Michael (b) (6) (b)(6)(b)(6)Wung, Peter /US [(b)(6)Karen Lynn Price (b)(6)Pamela Tenaerts, M.D. Patterson, Amy (NIH/NHLBI) [E] (b) (6) [amy.patterson@nih.gov]; Esserman, Laura [Laura. Higgs, Elizabeth (NIH/NIAID) [E] (b)(6).gov]; James Palazzolo [j. Burgess, Timothy (b) (6) (b) (6) .com]; Peeters, Monika [JRDBE] Beumont-Mauviel, Maria [JRDUS] [(b) (6) (b) (6) .com]; Woodfall, Brian [JRDUS] [Van Heeswijk, Rolf [JRDBE] (b)(6)(b) (6) .com]; Goff, David (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=036113c7be0f42f897d1294cfbb99c10-goffdc] CC: Mary Biggs Demarcus [(b)(6)Macone, Erin [erinm@amgen.com]; (b)(6)Tountas, Karen (FNIH) [T] [Wachtel, Jonathan [Elizabeth Kim (b)(6)Parker, Ashley (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (b)(6)(FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras]; Butcher, Tina Wholley, David (FNIH) [T] [Melencio, Cheryl (FNIH) [T] (b)(6)(b) (6) Forster, Katherine [(b)(6)(b)(6)Subject: ACTIV TX-Clinical Master Protocol Subgroup Meeting #16 Location: https://fnih.zoom.us/j. (b) (6) Start: 5/13/2020 5:00:00 PM End: 5/13/2020 6:00:00 PM Show Time As: Busy Required Bozzette, Sam (NIH/NCATS) [E]; Joan Butterton; Collins, Sylva (FDA/CDER); Judy Currier; De Claro, R. Angelo Attendees: (FDA/CDER); Mark Eisner; Keith Gottesdiener; Eric Hughes; Lisa LaVange; Elliott Levy; Sandeep Menon; Amanda Peppercorn; Proschan, Michael (NIH/NIAID) [E]; Read, Sarah (NIH/NIAID) [E]; Amanda Peppercorn; Price, Dionne (FDA/CDER); Rubin, Daniel B. (FDA/CDER); Shen, Yuan Li (FDA/CDER); Farley, John (FDA/CDER); Goff, David (NIH/NHLBI) [E]; Vincent, Michael; Wung, Peter /US; Karen Lynn Price; Pamela Tenaerts, M.D.; Patterson, Amy (NIH/NHLBI) [E]; Esserman, Laura; Higgs, Elizabeth (NIH/NIAID) [E]; James Palazzolo; Burgess, Timothy; Beumont-Mauviel, Maria [JRDUS]; Peeters, Monika [JRDBE]; Woodfall, Brian [JRDUS]; Van Heeswijk, Rolf [JRDBE] Optional Mary Biggs; Demarcus; Macone, Erin; Tountas, Karen (FNIH) [T]; Wachtel, Jonathan; Elizabeth Kim; Parker, Ashley Attendees: (NIH/OD) [E]; Butcher, Tina; Wholley, David (FNIH) [T]; Melencio, Cheryl (FNIH) [T]; Forster, Katherine Stacey Adam is inviting you to a scheduled Zoom meeting. Join Zoom Meeting https://fnih.zoom. (b)(6)

Meeting ID:

Password: (b) (6) One tap mobile

(b) (6)

(b) (6)

US (Chicago)
US (New York)

Dial by your location

(b) (6)

US (Chicago)
US (New York)
US (Germantown)
US (San Jose)
US (San Jose)
US (Tacoma)
US (Houston)

Meeting ID: (b) (6)

Password: (b) (6)

(b)(6)

Find your local number: https://fnih.zoom.us

Wholley, David (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=CD9E702FCF28414883D0B6996D677257-WHOLLEYD] 5/13/2020 1:57:04 AM Collins, Francis (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=410e1ca313f44ced9938e50d2ff0b6c2-collinsf]; Dolsten, Mikael Fauci, Anthony (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=df38103d75134f658ae2d356f0396b94-afauci]; Gibbons, Gary (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b71b953b50a5495ca0f2869ab13bc407-gibbonsgh]; Pao, William Stoffels, Paul [JJCUS] [Woodcock, Janet (FDA/CDER) (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9bc3fc3ebfcf48879f92169bd7644e29-Janet.Woodc]; Colvis, Christine (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4b7e84cce098457896b2df19fa172c87-ccolvis]; Desrosiers, Betsy (b) (6) Hughes, Eric [(b) (6) Jansen, Kathrin Kurilla, Michael (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (b)(6)(FYDIBOHF23SPDLT)/cn=Recipients/cn=dc4e85061e3943b9b8ad3f426727861f-mkurilla]; Lowy, Douglas (NIH/NCI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f1b7b8fe4739478bb17840c56902718a-lowyd]; Read, Sarah (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=527b160038004a199ae6e0bac2226099-readsa]; Young, John Menetski, Joseph (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5001af52dc4a427ea3d34f1e072f8cb7-menetskijp]; Adam, Stacey (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dcd875f0679648859e1cf101c0943414-adamsj4]; Tountas, Karen (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=40c04fef6f1e46f5b750753cd5a14f93-tountaskh]; Santos, Michael (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ab38cb6836de44e18ef4cc6952f65f80-santosmr]; Freire, Maria (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=8598d551d1d3455eaf14854c83f41d84-freiremc]; Tabak, Lawrence (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=02e22836b5ff4e9988e3770cfc7ee770-tabakl]; Lane, Cliff (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2d7e368a3137473bbce161547a82f2de-clane]; Parker, Ashley (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras]; Anderson, James (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=73143d1860bc42458be254ca21573b23-andersonjm]; Austin, Christopher (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=17597cabc42247548e596778304f781f-austinc]; Wolf-Rodda, Julie (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=89f0a08ab7224e0b9dc5a118ff336aff-wolfrodj]; Gonzalez, Nina [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user3c2f486d] Melencio, Cheryl (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=279e14fa7428415bb86087d08b628e6f-melencioc]; Wood, Gretchen (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=549f390b39d044a8b5d1e0e1a8f76c1f-woodgs] Agenda for ACTIV EC meeting tomorrow morning at 8:00 AM Eastern US Time Attachments: Agenda ACTIV EC Meeting #1 5-13-20.docx; Proposal for ACTIV leaderhsip-vF 051220.pdf

Dear ACTIV EC members, Working Group Co-Chairs, and meeting participants:

From:

Sent:

To:

CC:

Subject:

Please see attached the agenda for our meeting tomorrow morning (via Zoom) and a copy of the letter from the Therapeutics- Clinical Working Group you received earlier today, for our discussion.

Please let Joe Menetski or Cheryl Melencio know if you are having any problems connecting. I look forward to a productive meeting.

Regards,

David

David Wholley Senior Vice-President, Research Partnerships Foundation for the National Institutes of Health (b) (6)

fnih.org

11400 Rockville Pike Suite 600 North Bethesda, MD 20852

In 2019, the FNIH earned the highest rating from Charity Navigator for the fifth consecutive year and was recognized as an organization that exceeds industry standards.

Sent: 6/8/2020 8:53:57 PM

To: Tountas, Karen (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=40c04fef6f1e46f5b750753cd5a14f93-tountaskh]; Melencio, Cheryl (FNIH) [T]

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=279e14fa7428415bb86087d08b628e6f-melencioc]

CC: Meltzer, Abbey (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=c341d86cf7404a78ac8f852e698e5382-meltzerak]; Myles, Renate (NIH/OD)

[E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=7d317f5626934585b3692a1823c1b522-mylesr]; Brodd, Lauren (NIH/OD) [E]

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=ba665dea08e54171b3d6890c2518ddb9-leponelm]

Subject: RE: another member for ACTIV Clinical Trial Capacity Working Group

Hi Karen,

I hope you are well and had a great weekend!

I think FNIH has developed a process for obtaining permissions for future participants which includes asking via email after they've indicated participation with the POC – cc'ing your very own Cheryl to confirm and who's been super helpful.

Also cc'ing Renate and Lauren Brodd for awareness only. Lauren will be working closely with me and Renate, NIH OD to assist with keeping the NIH website for ACTIV up to date.

Thanks again, Ashley

From: Tountas, Karen (FNIH) [T] < (b) (6)

Sent: Monday, June 8, 2020 4:40 PM

To: Parker, Ashley (NIH/OD) [E] < (b) (6)

Cc: Meltzer, Abbey (FNIH) [T] < (b) (6)

Subject: another member for ACTIV Clinical Trial Capacity Working Group

Hi Ashley,

I hope you had a nice weekend. Please note that the CT Capacity Working Group has a new member from AstraZeneca.

· Therese Takas

Director, Clinical Operations

AstraZeneca

Her email contact to obtain permission to list her on the NIH ACTIV website is therese.takas@astrazeneca.com

Many thanks!

Karen

Karen H. Tountas, PhD

Scientific Program Manager

Foundation for the National Institutes of Health

(b) (6) <u>fnih.org</u>

11400 Rockville Pike, Suite 600, North Bethesda, MD 20852



Donate to the FNIH's Pandemic Response Fund to combat COVID-19: fnih.org/pandemic



Confidentiality Notice: Information contained in this e-mail and attachments may be legally privileged and confidential. If you are not an intended recipient, you are hereby notified that dissemination, distribution or copying this e-mail and attachments is strictly prohibited, please delete the e-mail and attachments immediately.

From: Adam, Stacey (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=DCD875F0679648859E1CF101C0943414-ADAMSJ4] Sent: 5/22/2020 2:30:59 AM To: Adam, Stacey (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dcd875f0679648859e1cf101c0943414-adamsj4]; Eric Hughes]; Read, Sarah (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=527b160038004a199ae6e0bac2226099-readsa]; Ruxandra Draghia-Akli Mellors, John W [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user257cb364]; Naimish Patel [Colvis, Christine (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4b7e84cce098457896b2df19fa172c87-ccolvis]; Young, John Stein, Peter (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (b) (6) (FYDIBOHF23SPDLT)/cn=Recipients/cn=b4a14118481b4b39ba7e62a8d6425f79-Peter.Stein]; Poole, Mike Buchman, Tim (OS/ASPR/BARDA) (CTR) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=00f8a853d8d740f8a8cdd55cbf8eb9da-Tim.Buchman]; Vincent, Michael [Keith Gottesdiener [Elliott Levy (b) (6) (b) (6) Wung, Peter /US [Koroshetz, Walter (NIH/NINDS) [E] (b)(6)(b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e8338dd7cdcd432e986961f1548c5ec6-koroshetzw]; Higgs, Elizabeth (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0601ca55a82841aba16353b96cff8ca9-ehiggs]; Carlos O Garner Goff, David (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=036113c7be0f42f897d1294cfbb99c10-goffdc] CC: Menetski, Joseph (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Elizabeth Kim [Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5001af52dc4a427ea3d34f1e072f8cb7-menetskijp]; Alvarez, Rosa Salathin, Carla (b) (6) (b) (6) Parker, Ashley (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras]; Wholley, David (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]; Melencio, Cheryl (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=279e14fa7428415bb86087d08b628e6f-melencioc]; Lucas Smalldon Walker, Paula (NIH/NINDS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=fbe81b9b832e40acbf5fd03bcfd32930-walkerp1]; Ward, Jackie (NIH/NINDS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4114c7d13389454f89fe3411cb3a834f-wardjam]; Rose Li Central Account Chen, Helen Q. [(b)(6)Subject: ACTIV TX-Clinical Agent Prioritization Subgroup Meeting #13 Location: https://fnih.zoom.us/ (b) (6) Start: 5/28/2020 4:00:00 PM End: 5/28/2020 5:00:00 PM Show Time As: Tentative Required Eric Hughes; Read, Sarah (NIH/NIAID) [E]; Ruxandra Draghia-Akli; John Mellors; Naimish Patel; Colvis, Christine Attendees: (NIH/NCATS) [E]; Young, John; Stein, Peter (FDA/CDER); Poole, Mike; Buchman, Tim (OS/ASPR/BARDA) (CTR); Vincent, Michael; Keith Gottesdiener; Elliott Levy; Wung, Peter /US; Koroshetz, Walter (NIH/NINDS) [E]; Higgs, Elizabeth (NIH/NIAID) [E]; Carlos O Garner; Goff, David (NIH/NHLBI) [E] Optional Elizabeth Kim; Menetski, Joseph (FNIH) [T]; Alvarez, Rosa Maria; Salathin, Carla; Parker, Ashley (NIH/OD) [E]; Wholley, David (FNIH) [T]; Melencio, Cheryl (FNIH) [T]; Lucas Smalldon; Walker, Paula Attendees: (NIH/NINDS) [E]; Ward, Jackie (NIH/OD) [E] (b)(6)Rose Li Central Account; Chen, Helen Q.

Stacey Adam is inviting you to a scheduled Zoom meeting.

```
Join Zoom Meeting
https://fnih.zoom.us
                                                (b)(6)
Meeting ID:
                (b) (6)
Password: (b) (6)
One tap mobile
                  (b) (6)
                                           US (Chicago)
                                           US (New York)
Dial by your location (b) (6)
                     US (Chicago)
                     US (New York)
                     US (Germantown)
                     US (San Jose)
                     US (Tacoma)
                     US (Houston)
                     US (San Jose)
Meeting ID:
                (b)(6)
Password: (b) (6)
```

(b)(6)

Find your local number: https://fnih.zoom.u

Connelly, Sarah [(b) (6) 11/6/2020 2:29:28 PM Menetski, Joseph (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5001af52dc4a427ea3d34f1e072f8cb7-menetskijp]; Hild, Sheri (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=edd7f1939fb94be3bf063f925ac15f02-hildsa]; (b)(6)(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) Baric, Ralph [/o=ExchangeLabs/ou=Exchange Administrative Group] (FYDIBOHF23SPDLT)/cn=Recipients/cn=48e35ab1d3044465a7790ee4ded5bc32-rbaric.emai]; Ottinger, Elizabeth (NIH/NCATS [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ad34123055944f97bedbef038d375cd7-ottingerea]; Colvis, Christine (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4b7e84cce098457896b2df19fa172c87-ccolvis]; Hewitt, Judith (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2d0a7dadfcbd42cbb4014d9b26af30cc-jhewitt]; Deming, Damon (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=8a5ace9923ae415aa3d85ac09cb76f85-DEMINGD.fda]; Parker, Ashley (NIH/OD) [E] (b) (6) (b) (6) (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras]; Collins, Francis (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=410e1ca313f44ced9938e50d2ff0b6c2-collinsf]; Adams, Peter (OS/ASPR/BARDA) [/o=ExchangeLabs/ou=Exchange Administrative (b) (6) Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f6e22f801f9146ef90116c4311c6f3ee-Peter.Adams]; Rao, Srinivas Qashu, Felicia (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=366447a553f44696b2c79484d90e41e5-gashufm]; Tomas Cihlar Pitt, Margaret L CIV USARMY MEDCOM USAMRIID (USA) [(b) (6) Punturieri, Antonello (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ca7f3106e5f24b5cb5e933c6ee7a6bc7-punturieria]; Charette, Marc (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a7fa2baf951848b5bf1f76a049a0eca6-charettemf]; Fessel, Josh (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=294e2bb481d94b83a1917f15338dfe19-fesseljp]; (b) (6) Diamond, Michael [Wholley, David (FNIH) [T] [/o=ExchangeLabs/ou=Exchange (b) (6) Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]; Austin, Christopher (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=17597cabc42247548e596778304f781f-austinc]; Melencio, Cheryl (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=279e14fa7428415bb86087d08b628e6f-melencioc]; Desrosiers, Betsy Eric Hughes [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f97951a53cd54153b5daa9d99ad4ec90-EricHughes]; Jansen, Kathrin Kurilla, Michael (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dc4e85061e3943b9b8ad3f426727861f-mkurilla]; Lowy, Douglas (NCI) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=54fa75fe6e304e34ba567c66b832baa0-drl.helix.n]; Read, Sarah (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=527b160038004a199ae6e0bac2226099-readsa]; Tountas, Karen (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=40c04fef6f1e46f5b750753cd5a14f93-tountaskh]; Santos, Michael (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ab38cb6836de44e18ef4cc6952f65f80-santosmr]; Adam, Stacey (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dcd875f0679648859e1cf101c0943414-adamsj4]; James, Stephanie (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f0032ef62ca343dfb4bf79577e2aa8d1-jamesst]; Alvarez, Rosa Maria [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user706e5647]; Kim, Elizabeth [btolman [/o=ExchangeLabs/ou=Exchange Administrative Group

From:

Sent:

To:

CC:

(b) (6)

		/ CII-Recipients/ CII-	user7b137a1e]; Wachtel	i, Jonathan	(b) (6)	Prabhavathi	
	Fernandes [(b) (6)	Rose Li [(b) (6)	Dana Carluccio		
	(b) (/	Lagos, Enrique (NIH/NCA				
			LT)/cn=Recipients/cn=ae			lagoses];	
			ExchangeLabs/ou=Excha				
			ce2f69369d654bef89b0				
			strative Group (FYDIBO			:2f486d];	
			Labs/ou=Exchange Admi				
			e02345fa5d1d4d7eaf4e0		simondm]; Burrus-Sha	w, Cyndi	
	그리는 사람들이 얼마나가 되었다면 하면 하면 되는 것이 되었다.		hange Administrative Gr				
			5bbac95b1f6e4514a299			obin D	
	(b) (6)	Dave Frankows	-	` '	Baric, Toni C		
	(b) (6)		, Douglas (NIH/NCI) [E] [
			nts/cn=f1b7b8fe4739478		02/18a-lowyd]; Florenc	ce, Clint	
			xchange Administrative				
			5e032d0bc8554e8787e8	844a///329516	e-florencewc]; Nancy H	aigwood	
	[/o=ExchangeLabs/c			F20 - 41 C 1- F	thataman all Charles	D ! !	
			03d589f440d84691ac0a				
			istrative Group (FYDIBOF geLabs/ou=Exchange Adı			sea/188];	
			0243d1d6e6f248268d2e		* 1899 OH 1807 To 190	lamas	
			nange Administrative Gr		i-gauboiseij, Alidersofi,	Jailles	
			73143d1860bc42458be2		3-andersoniml: Hawk	Harrison	
	8	SC 1050 St	strative Group (FYDIBOF		12 (72) 35		
	Mason, Stephen [(b) (6)	carol	(b) (6)	(b) (6		
Subject:	RE: ACTIV Preclinica	` ' ' '	curoi	(0) (0)	(0) (0	,)	
J, J.	TIET / TOTAL TI COMMON	rian werming group					
Dear Preclinic	al working group,						
Dear Freemine	ar working group,						
Novt wook's f	ull working group m	nanting falls on Va	terans Day. Would the	aroun profo	r kooning the meetin	7 On	
						gon	
wednesday a	t its regularly sched	luled time or movi	ng it to 10-11 ET Thur	sday, Nov 12,	, 2020:		
C							
Can you pleas	e let us know whic	n of these options	work for you. We will	move the me	eeting to the most po	pular option.	
Best regards.							
Best regards,							
Best regards, Sarah							
Sarah							
Sarah Connell							
Sarah Connell Deloitte Consul	ting, LLP						
Sarah Connell	ting, LLP (b) (6)						
Sarah Connell Deloitte Consul Tel/Direct:	ting, LLP (b) (6)						
Sarah Connell Deloitte Consul Tel/Direct: www.deloitte.co	ting, LLP (b) (6)						
Sarah Connell Deloitte Consul Tel/Direct: www.deloitte.co	ting, LLP (b) (6) orn ppointment	[] < (b) (6)					
Sarah Connell Deloitte Consul Tel/Direct: www.deloitte.co Original A From: Menets	ting, LLP (b) (6) om ppointment ski, Joseph (FNIH) [
Sarah Connell Deloitte Consul Tel/Direct: www.deloitte.coOriginal A From: Menets Sent: Friday, G	ting, LLP (b) (6) pm ppointment ski, Joseph (FNIH) [October 2, 2020 2:1	L9 PM	Hild Shari	(NIH/OD) [F1-	(h) (c)		
Sarah Connell Deloitte Consul Tel/Direct: www.deloitte.co Original A From: Menets Sent: Friday, C To: Menetski,	ting, LLP (b) (6) ppointment ski, Joseph (FNIH) [October 2, 2020 2:1 Joseph (FNIH) [T];	(b) (6)		(NIH/OD) [E];			
Sarah Connell Deloitte Consul Tel/Direct: www.deloitte.coOriginal A From: Menets Sent: Friday, (To: Menetski,	ting, LLP (b) (6) ppointment ski, Joseph (FNIH) [October 2, 2020 2:1 Joseph (FNIH) [T]; (b) (6)	(b) (6) (b) (6)	(b) ((6)	(b) (6)		
Sarah Connell Deloitte Consul Tel/Direct: www.deloitte.coOriginal A From: Menets Sent: Friday, (To: Menetski,	ting, LLP (b) (6) ppointment ski, Joseph (FNIH) [October 2, 2020 2:1 Joseph (FNIH) [T]; (b) (6) Baric, Ralph;	(b) (6) (b) (6) (b) (6)	(b) (Ottinger, Eli	(6) izabeth (NIH/	(b) (6) NCATS [E]; Colvis, Ch	ristine	
Sarah Sarah Connell Deloitte Consul Tel/Direct: www.deloitte.coOriginal A From: Menets Sent: Friday, C To: Menetski, (b) (6) (NIH/NCATS)	ting, LLP (b) (6) ppointment ski, Joseph (FNIH) [October 2, 2020 2:1 Joseph (FNIH) [T]; (b) (6) Baric, Ralph; [E]; Hewitt, Judith ((b) (6) (b) (6) (b) (6) (b) (6) NIH/NIAID) [E]; De	(b) (Ottinger, Eli eming, Damon (FDA/CI	(6) izabeth (NIH/ DER);	(b) (6) NCATS [E]; Colvis, Ch (b) (6)	ristine	
Sarah Connell Deloitte Consul Tel/Direct: www.deloitte.coOriginal A From: Menets Sent: Friday, (To: Menetski,	ting, LLP (b) (6) ppointment ski, Joseph (FNIH) [October 2, 2020 2:1 Joseph (FNIH) [T]; (b) (6) Baric, Ralph;	(b) (6) (b) (6) (b) (6) (b) (6) NIH/NIAID) [E]; De 6) Parke	(b) (Ottinger, Eli eming, Damon (FDA/CI er, Ashley (NIH/OD) [E]	(6) izabeth (NIH/ DER); I; Collins, Fran	(b) (6) NCATS [E]; Colvis, Ch (b) (6) ncis (NIH/OD) [E];		
Sarah Sarah Connell Deloitte Consul Tel/Direct: www.deloitte.coOriginal A From: Menets Sent: Friday, (To: Menetski, (b) (6) (NIH/NCATS) (b) (6)	ting, LLP (b) (6) ppointment ski, Joseph (FNIH) [October 2, 2020 2:1 Joseph (FNIH) [T]; (b) (6) Baric, Ralph; [E]; Hewitt, Judith ((b) (6)	(b) (6) (b) (6) (b) (6) (b) (6) NIH/NIAID) [E]; De 6) Parke Adams, Peter (6)	(b) (Ottinger, Eli eming, Damon (FDA/Cl er, Ashley (NIH/OD) [E] OS/ASPR/BARDA); Rao	6) izabeth (NIH/ DER); l; Collins, Fran o, Srinivas; Qa	(b) (6) NCATS [E]; Colvis, Ch (b) (6) ncis (NIH/OD) [E]; shu, Felicia (NIH/OD)	[E]; Tomas	
Sarah Sarah Connell Deloitte Consul Tel/Direct: www.deloitte.coOriginal A From: Menets Sent: Friday, (To: Menetski, (b) (6) (NIH/NCATS) (b) (6)	ting, LLP (b) (6) ppointment ski, Joseph (FNIH) [October 2, 2020 2:1 Joseph (FNIH) [T]; (b) (6) Baric, Ralph; [E]; Hewitt, Judith ((b) (6)	(b) (6) (b) (6) (b) (6) (b) (6) NIH/NIAID) [E]; De 6) Parke Adams, Peter (6)	(b) (Ottinger, Eli eming, Damon (FDA/CI er, Ashley (NIH/OD) [E]	6) izabeth (NIH/ DER); l; Collins, Fran o, Srinivas; Qa	(b) (6) NCATS [E]; Colvis, Ch (b) (6) ncis (NIH/OD) [E]; shu, Felicia (NIH/OD)	[E]; Tomas	
Sarah Sarah Connell Deloitte Consul Tel/Direct: www.deloitte.coOriginal A From: Menets Sent: Friday, (To: Menetski, (b) (6) (NIH/NCATS) (b) (6) Cihlar; Pitt, M	ting, LLP (b) (6) ppointment ski, Joseph (FNIH) [October 2, 2020 2:1 Joseph (FNIH) [T]; (b) (6) Baric, Ralph; [E]; Hewitt, Judith ((b) (6)	(b) (6) (b) (6) (b) (6) (b) (6) NIH/NIAID) [E]; De 6) Parke Adams, Peter (6) MY MEDCOM USA	(b) (Ottinger, Eli eming, Damon (FDA/Cl er, Ashley (NIH/OD) [E] OS/ASPR/BARDA); Rao	6) izabeth (NIH/ DER); l; Collins, Fran o, Srinivas; Qa	(b) (6) NCATS [E]; Colvis, Ch (b) (6) ncis (NIH/OD) [E]; shu, Felicia (NIH/OD)	[E]; Tomas	
Sarah Sarah Connell Deloitte Consul Tel/Direct: www.deloitte.coOriginal A From: Menets Sent: Friday, C To: Menetski, (b) (6) (NIH/NCATS) (b) (6) Cihlar; Pitt, M (NIH/NHLBI) [cting, LLP (b) (6) ppointment ski, Joseph (FNIH) [October 2, 2020 2:1 Joseph (FNIH) [T]; (b) (6) Baric, Ralph; [E]; Hewitt, Judith ((b) (6) argaret L CIV USAR E]; Fessel, Josh (NIH)	(b) (6) (b) (6) (b) (6) (b) (6) NIH/NIAID) [E]; De 6) Parke Adams, Peter (6) MY MEDCOM USA	(b) (Ottinger, Eli eming, Damon (FDA/CI er, Ashley (NIH/OD) [E] OS/ASPR/BARDA); Rao MRIID (USA); Punturie	(6) izabeth (NIH/ DER); l; Collins, Fran o, Srinivas; Qa eri, Antonello	(b) (6) NCATS [E]; Colvis, Ch (b) (6) ncis (NIH/OD) [E]; shu, Felicia (NIH/OD) (NIH/NHLBI) [E]; Cha	[E]; Tomas arette, Marc	
Sarah Sarah Connell Deloitte Consul Tel/Direct: www.deloitte.coOriginal A From: Menets Sent: Friday, C To: Menetski, (b) (6) (NIH/NCATS) (b) (6) Cihlar; Pitt, M (NIH/NHLBI) [Cc: Diamond,	cting, LLP (b) (6) ppointment ski, Joseph (FNIH) [Cotober 2, 2020 2:1 Joseph (FNIH) [T]; (b) (6) Baric, Ralph; [E]; Hewitt, Judith ((b) (6) argaret L CIV USAR E]; Fessel, Josh (NIH) Michael; Wholley,	(b) (6) (b) (6) (b) (6) (b) (6) NIH/NIAID) [E]; De 6) Parke Adams, Peter (0 MY MEDCOM USA H/NHLBI) [E]; David (FNIH) [T]; A	(b) (Ottinger, Eli eming, Damon (FDA/CI er, Ashley (NIH/OD) [E] OS/ASPR/BARDA); Rao MRIID (USA); Punturie (b) (6)	(6) izabeth (NIH/ DER); l; Collins, Fran o, Srinivas; Qa eri, Antonello	(b) (6) NCATS [E]; Colvis, Ch (b) (6) ncis (NIH/OD) [E]; Ishu, Felicia (NIH/OD) (NIH/NHLBI) [E]; Cha) [E]; Tomas arette, Marc NIH) [T];	

[T]; Alvarez, Rosa Maria; Kim, Elizabeth; Tolman, Brett; Wachtel, Jonathan; Prabhavathi Fernandes; Rose Li; Dana Carluccio; Lagos, Enrique (NIH/NCATS) [E]; Jonson, Samantha (NIH/NCATS) [E]; Gonzalez, Nina; Simon, Dina (NIH/OD) [C]; Burrus-Shaw, Cyndi (NIH/OD) [E]; Rodriguez, Robin D; Dave Frankowski; Baric, Toni C; Lowy, Douglas (NIH/NCI) [E]; Florence, Clint (NIH/NIAID) [E]; Nancy Haigwood; Stratton, Benjamin; Gadbois, Ellen (NIH/OD) [E]; Anderson, James (NIH/OD) [E]; Hawk, Harrison; Mason, Stephen; (b) (6) Connelly, Sarah;

Subject: ACTIV Preclinical full working group

Find your local number: https://fnih.zoom.u

When: Thursday, November 5, 2020 10:00 AM-11:00 AM (UTC-05:00) Eastern Time (US & Canada).

Where: https://fnih.zoom. (b) (6)

While not unanimous, more people were able to make the 5th at 10am. We will go over the discussion at the Executive committee meeting, future strategic topics and then our normal reviews.

Changing time for preclinical WG

(b) (6)

Join Zoom Meeting

Joseph Menetski is inviting you to a scheduled Zoom meeting.

```
https://fnih.zoom.us/
                                                  (b) (6)
Meeting ID:
                (b) (6)
Passcode: (b) (6)
One tap mobile
                    (b) (6)
                                                JS (Germantown)
                                                JS (Chicago)
Dial by your location
          (b) (6)
                     US (Germantown)
                     US (Chicago)
                     US (New York)
                     JS (San Jose)
                     US (San Jose)
                     US (Tacoma)
                     US (Houston)
Meeting ID:
                (b) (6)
Passcode: (b) (6)
```

This message (including any attachments) contains confidential information intended for a specific individual and purpose, and is protected by law. If you are not the intended recipient, you should delete this message and any disclosure, copying, or distribution of this message, or the taking of any action based on it, by you is strictly prohibited.

Deloitte refers to a Deloitte member firm, one of its related entities, or Deloitte Touche Tohmatsu Limited ("DTTL"). Each Deloitte member firm is a separate legal entity and a member of DTTL. DTTL does not provide services to clients. Please see www.deloitte.com/about to learn more.

(b) (6)

From: Collins, Francis (NIH/OD) [E] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=410E1CA313F44CED9938E50D2FF0B6C2-COLLINSF) Sent: 7/16/2020 4:20:44 PM To: Wholley, David (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd] CC: Tountas, Karen (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=40c04fef6f1e46f5b750753cd5a14f93-tountaskh] Subject: RE: ACTIV Home Nursing Playbook ready for use! Flag: Follow up Excellent, thanks! From: Wholley, David (FNIH) [T] < (b) (6) Sent: Thursday, July 16, 2020 12:12 PM To: Collins, Francis (NIH/OD) [E] < (b)(6)Cc: Tountas, Karen (FNIH) [T] < (b) (6) Subject: FW: ACTIV Home Nursing Playbook ready for use! Since you asked... From: Tountas, Karen (FNIH) [T] (b)(6)Sent: Thursday, July 16, 2020 11:05 AM To: Wholley, David (FNIH) [T] (b) (6) Subject: RE: ACTIV Home Nursing Playbook ready for use! Just an FYI... I sent this final version to the ACTIV-2 ops team and received this from Judy Currier - "Thanks Karen, This is really helpful and just in time as we work to finalize our plans for home health in ACTIV-2. It will be of great value to the ACTIV-2 team." Good to know all that work was not in vain! Let's hope the next four are also helpful for ACTIV. (3)

From: Tountas, Karen (FNIH) [T] Sent: Thursday, July 16, 2020 8:58 AM To: Colvis, Christine (NIH/NCATS) [E] : Hughes, Eric >; Jansen, (b) (6) (b) (6) Kathrin ; Lowy, Douglas (NCI) < Read, Sarah (NIH/NIAID) [E] (b)(6)(b) (6) (b) (6) ; Young, John (b) (6) Cc: Adam, Stacey (FNIH) [T] < (b)(6)James, Stephanie (FNIH) [T] < (b)(6)>; Menetski, Joseph (FNIH) [T] Santos, Michael (FNIH) [T] >; Wholley, David (FNIH) [T] (b)(6)(b)(6)Kurilla, Michael (NIH/NCATS) [E] (b) (6) Desrosiers, Betsy (b)(6)(6)Kelly, Eileen Wachtel, Jonathan (b)(6)(b)(6)(b) (6) Subject: ACTIV Home Nursing Playbook ready for use!

Dear ACTIV Working Group co-chairs,

On behalf of the ACTIV Clinical Trial Capacity Working Group, I am pleased to announce the completion of the ACTIV Home Nursing Playbook (attached). Many thanks to Betsy Desrosiers and Eileen Kelly (cc'd) and their teams at Merck and Novartis, respectively, for sharing their knowledge, lessons learned, and materials to enhance and accelerate ACTIV's clinical trial efforts. And, many thanks to Jonathan and Olivia (Deloitte) for creating an organized and user-friendly structure for these playbooks.

We know that the ACTIV-2 operations team, who has used an earlier draft of this playbook, found the details enclosed very useful and we hope that other COVID-focused clinical trial protocol and operations teams will also. Please feel free to distribute to your teams, and provide any and all feedback (positive and constructive critiques).

Of note, Betsy and Eileen have offered to make themselves and their team members available to walk through the playbook with clinical trials teams as requested.

With best regards, Karen

Karen H. Tountas, PhD

Scientific Program Manager

Foundation for the National Institutes of Health

(b) (6) fnih.org

11400 Rockville Pike, Suite 600, North Bethesda, MD 20852



Donate to the FNIH's Pandemic Response Fund to combat COVID-19: fnih.org/pandemic



Confidentiality Notice: Information contained in this e-mail and attachments may be legally privileged and confidential. If you are not an intended recipient, you are hereby notified that dissemination, distribution or copying this e-mail and attachments is strictly prohibited; please delete the e-mail and attachments immediately.

То:		e, Sam (NIH/N			(6) cn=Recipie				[/o=Exchang 59e1cf101c09		
		n, Joan [(b)					A/CDER) [) (6)];
		Akli, Ruxand		(b) (6)		sdiener,		,, ((b) (6)		ric Hughes
		(b) (6)		dy Currier [b) (6)		Kim, Eliz		(b) (6)	
	LaVange	, Lisa [lisa.	(b) (6)		ors, John W		(6)		, Sandeep	(0) (0)	
	[(b) (6)	(0) (0)		shley (NIH)	-		(b) (6)		, Naimish	
	í	(b) (6)	Pe	ppercorn, A		// 1	(b) (6)	. , . ,	Poole, I		
	Í	(b) (6)			an, Michae	(NIH/NI			(b) (6)		Sarah
	(NIH/NI	AID) [E] [(b) (6)		tos, Michae			(b) (6)		Yuan Li (FC	
	1	(b) (6)		ein, Peter (F			(b) (6)		Wholley, Da		
	į ((b) (6)		Tim (OS/AS				(b) (6)		s, Sylva (FE	
	Ì	(b) (6)		anda Peppe			(b) (6)	(=) (=)		lizabeth (N	
	[E] [(b) (6)		shetz, Walt		IDS) [E] [(b) (6)		imothy Bu	
	[(b) (6)		Reineck, Lor				b) (6)			H/NHLBI) [E]
	ĺ	(b) (6)		berg, Yves (I) (6)		avid (NIH/N	
	i o			remy (NIH/I			(b) (6)		Gadbois, Elle		
		nangeLabs/or					(0) (0)		,		, ,
							edec566	c26c2a-g	adboisel]; Cu	lp. Michelle	e (NIH/OD)
	[E] [(b) (6)		queline Kirc			(b)			Beigel, Joh	
		(b) (6)	7.1	L Revell CIV		USA) [b) (6)		ck, Martha	
	MITLL [(b) (6		(b)					H/FIC) [E]	,	
	[(b) (6)		arry Tsai [(b) (6			Peter K [(b)	(6)	Garner,
	Carl [(b) (c							abs/ou=Excha		
									88d-bozzette		
		(b) (6)								1,,	
CC:		hristine (NIH	/NCATS) [E	1[(b) (6)	l: Jan	sen, Kat	hrin [(b) (6))	Lowy,
	Douglas			Young, John		(b) (6)			Mary [(b) (6)	
	Butcher		(b) (6)		Demarcus [(-) (-)	(b) (6)		Macone, Er		
		(b) (6)		, Cheryl (FN		(b) (d		Salathir			
	[(b) (6)		Menetski, Jo	seph (FNIH		(b) ((6)	Dana Carlud	ccio	
		(b) (e Li Centra			(b) (6)	Lucas Sma	alldon
	[(b)			(b) (6)		, , ,	Linda /US		
	[(b) (6)		shu, Felicia			(b) (6	5)	Patterson, A	Amy (NIH/N	IHLBI) [E]
	[(b) (6)	Rubi	n, Daniel B.	FDA/CDER] ((b) (d		Marston,	Hilary (NII	H/NIAID) [E]
		(b) (6)		, Helen Q. [(6)			eith (NIH/NE	HLBI) [E]	
	[(b) (6)	Groe	sch, Mary (N	IIH/NHLBI)	[E] [(b) ((6)	Shipp, Alla	an (NIH/NH	ILBI) [E]
		b) (6)	Kindzels	ki, Andrei (N	IH/NHLBI)	[E] [(6)	Hone,	David M (D	ave) CIV
		(ÚSA) [david		(b) (6)					D JPEO CBRN		- 000
	[(b) (6)		Walker, Pau				(b) (6)		sa, Alex Da	vid
	[(b) (6)		en, Joanne				b) (6)			(NIH/NIAID)
	[E]	(b) (6)		bry, Alan (N		J. P. S. S. S. S. S. S. S. S.	(b) (Dally, Nico		The state of the s
		(b) (6)									
		. / . /									

Start: 4/22/2021 5:00:00 PM **End**: 4/22/2021 6:00:00 PM

Recurrence: (none)

Melencio, Cheryl (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=279E14FA7428415BB86087D08B628E6F-MELENCIOC] 4/24/2020 4:46:03 PM Austin, Christopher (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=17597cabc42247548e596778304f781f-austinc]; Collins, Francis (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=410e1ca313f44ced9938e50d2ff0b6c2-collinsf]; Corey, Larry Disbrow, Gary (OS/ASPR/BARDA) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=62a151e39ab942d88a813b449f9f6ccb-Gary.Disbro]; Dolsten, Mikael Erbelding, Emily (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e976ebf7b14142fbb3c5c294efb334fe-erbeldingej]; Fauci, Anthony (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=df38103d75134f658ae2d356f0396b94-afauci]; Hudson, Thomas James, Stephanie (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (b) (6) (FYDIBOHF23SPDLT)/cn=Recipients/cn=f0032ef62ca343dfb4bf79577e2aa8d1-jamesst]; Johnson, Robert (OS/ASPR/BARDA) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=feb0b05457404e2f8b88af78e9ac4dd9-Robert.John]; Kramer, Lynn [lynn_kramer@eisai.com]; Lane, Cliff (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2d7e368a3137473bbce161547a82f2de-clane]; Marks, Peter (FDA/CBER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b2e527dbda2b4a86b8d72f06b813d471-MarksP.fda]; Marston, Hilary (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ab30660917b942ffba9ae95d631116f3-marstonhd]; Mascola, John (NIH/VRC) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=7f78b40a596b4ca4a2850a429d1ae3f2-imascolal: Meeker, David Menetski, Joseph (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5001af52dc4a427ea3d34f1e072f8cb7-menetskijp]; Pangalos, Mene Pao, William [Paul, Steve [(b) (6) (b) (6) (b) (6) Perlmutter, Roger [Plump, Andy [Rasi, Guido (b)(6)(b) (6) Reed, John (b) (6) (b) (6) Rouse, Doris (b) (6) Santos, Michael (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ab38cb6836de44e18ef4cc6952f65f80-santosmr]; Skovronsky, Daniel Stein, Peter (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b4a14118481b4b39ba7e62a8d6425f79-Peter.Stein]; Stoffels, Paul Tabak, Lawrence (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (b) (6) (FYDIBOHF23SPDLT)/cn=Recipients/cn=02e22836b5ff4e9988e3770cfc7ee770-tabakl]; Tsai, John Vessey, Rupert [Virgin, Skip [(b) (6) (b)(6)(b) (6) Woodcock, Janet (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9bc3fc3ebfcf48879f92169bd7644e29-Janet.Woodc]; Young, John Colvis, Christine (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4b7e84cce098457896b2df19fa172c87-ccolvis]; Desrosiers, Betsy Hughes, Eric [Jansen, Kathrin (b) (6) (b) (6) (b) (6) Kurilla, Michael (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dc4e85061e3943b9b8ad3f426727861f-mkurilla]; Lowy, Douglas (NCI) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=54fa75fe6e304e34ba567c66b832baa0-drl.helix.n]; Read, Sarah (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=527b160038004a199ae6e0bac2226099-readsa]; Freire, Maria (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=8598d551d1d3455eaf14854c83f41d84-freiremc]; Adam, Stacey (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dcd875f0679648859e1cf101c0943414-adamsj4]; Alvarez, Rosa Gonzalez, Nina Anderson, Margaret [(b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user3c2f486d]; Kim, Elizabeth [Stratton, Ben [Tolman, Brett [(b) (6) (b)(6)(b) (6) Tountas, Karen (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group

From:

Sent:

To:

(FYDIBOHF23SPDLT)/cn=Recipients/cn=40c04fef6f1e46f5b750753cd5a14f93-tountaskh]; Wachtel, Jonathan Barasch, Kimberly (NIH/NIAID) [C] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ea5fad4c52f64f80b7daee4982ae495f-baraschk]; Burrus-Shaw, Cyndi (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5bbac95b1f6e4514a299b318030c31f6-shawcy]; Carver, Trea (NIH) [C] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ac05f976df484ed69022b8663cd448d3-carverkr]; Conrad, Patricia (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=7ea3e3ea7daa432887495d6825c9e588-conradpa]; Hoffstetter, Renata (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c3e9758570bf4ca08552ea377170ec2a-hoffstetter]; Iberdemaj, Vaide Lagos, Enrique (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ae9041ab27204d83b06752f67a44b0d1-lagoses]; McManus, Ayanna (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=bcf06de08ba845249b9b36ad216e237e-amcmanus]; Melencio, Cheryl (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=279e14fa7428415bb86087d08b628e6f-melencioc]; Protasiewicz, Ann Simon, Dina (NIH/OD) [C] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e02345fa5d1d4d7eaf4e0f3da58bc1ac-simondm]; Thomas, Ashley (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1bcd5d3f7c1e4309a251d013e1cc89b0-Ashley.Thom]; Wood, Gretchen (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=549f390b39d044a8b5d1e0e1a8f76c1f-woodgs]; Sepulveda, Dorina (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=675efcc8cf7b4f6986d1eb3c3ed1fd96-sepulvedade]; FNIH Central Account (b) (6) Li, Rose [(b) (6)

Subject: ACTIV Response Partnership Leadership Team Meeting #4

Location: Dial-in coordinates to be supplied

Start: 5/20/2020 7:30:00 PM **End**: 5/20/2020 9:00:00 PM

Show Time As: Tentative

Required Attendees:

CC:

Austin, Christopher (NIH/NCATS) [E]; Collins, Francis (NIH/OD) [E]; Corey, Larry; Disbrow, Gary (OS/ASPR/BARDA); Dolsten, Mikael; Erbelding, Emily (NIH/NIAID) [E]; Fauci, Anthony (NIH/NIAID) [E]; Hudson, Thomas; James, Stephanie (FNIH) [T]; Johnson, Robert (OS/ASPR/BARDA); Kramer, Lynn; Lane, Cliff (NIH/NIAID) [E]; Marks, Peter (FDA/CBER); Marston, Hilary (NIH/NIAID) [E]; Mascola, John; Meeker, David; Menetski, Joseph (FNIH) [T]; Pangalos, Mene; Pao, William; Paul, Steve; Perlmutter, Roger; Plump, Andy; Rasi, Guido; Reed, John; Rouse, Doris; Santos, Michael (FNIH) [T]; Skovronsky, Daniel; Stein, Peter (FDA/CDER); Stoffels, Paul; Tabak, Lawrence (NIH/OD) [E]; Tsai, John; Vessey, Rupert; Virgin, Skip; Woodcock, Janet (FDA/CDER); Young, John; Colvis, Christine (NIH/NCATS) [E]; Desrosiers, Betsy; Hughes, Eric; Jansen, Kathrin; Kurilla, Michael (NIH/NCATS) [E]; Lowy, Douglas (NCI); Read, Sarah (NIH/NIAID) [E]; Freire, Maria (FNIH) [T]; Adam, Stacey (FNIH) [T]; Alvarez, Rosa; Anderson, Margaret; Gonzalez, Nina; Kim, Elizabeth; Stratton, Ben; Tolman, Brett; Tountas, Karen (FNIH) [T]; Wachtel, Jonathan

Optional Attendees: Barasch, Kimberly (NIH/NIAID) [C]; Burrus-Shaw, Cyndi (NIH/OD) [E]; Carver, Trea (NIH) [C]; Conrad, Patricia (NIH/NIAID) [E]; Hoffstetter, Renata (FNIH) [T]; Iberdemaj, Vaide; Lagos, Enrique (NIH/NCATS) [E]; McManus, Ayanna

(NIH/OD) [E]; Melencio, Cheryl (FNIH) [T]; Protasiewicz, Ann; Simon, Dina (NIH/OD) [C]; Thomas, Ashley (FDA/CDER);

Wood, Gretchen (NIH/OD) [E]; Sepulveda, Dorina (FNIH) [T]; FNIH Central Account; Li, Rose

Dial-in coordinates to be supplied at a later date

Sent: 7/1/2020 10:33:10 AM

To: Collins, Francis (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=410e1ca313f44ced9938e50d2ff0b6c2-collinsf]; Wholley, David (FNIH) [T]

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]

CC: Melencio, Cheryl (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=279e14fa7428415bb86087d08b628e6f-melencioc]; Adam, Stacey (FNIH) [T]

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=dcd875f0679648859e1cf101c0943414-adamsj4]; Menetski, Joseph (FNIH) [T]

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=5001af52dc4a427ea3d34f1e072f8cb7-menetskijp]; Tountas, Karen (FNIH) [T]

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=40c04fef6f1e46f5b750753cd5a14f93-tountaskh]; Santos, Michael (FNIH) [T]

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=ab38cb6836de44e18ef4cc6952f65f80-santosmr]; Allen-Gifford, Patrice

(NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=67262490d6d441b48efec1aff0700250-allengiffor]

Subject: RE: ACTIV Invitations for Leadership Meeting 6/3

Attachments: RE: GSK follow up on FNIH COVID call; RE: URGENT: Invitation to join the Vaccines Working Group of the COVID PPP;

RE: Other Companies to give a heads up

Hi Francis and David,

ES did not find emails inviting John Lepore, GSK and David Reese, Amgen to join the ACTIV leadership group. Invitations to GSK's Emmanuel Hannon, David Payne, and Amanda Peppercorn were sent to join the vaccines, preclinical, and clinical capacity WGs. John Lapore responded to Francis' email inviting Hannon to join the GSK vaccine WG -2^{nd} attachment. David Reese did not receive an invitation considering Amgen already had Elliott Levy on the TX clinical working group - last attachment.

We would need to send notes if they should join the leadership meeting tomorrow and include one to Kara Carter.

Please let me know if you need anything else.

Thanks, Ashley

From: Collins, Francis (NIH/OD) [E] < (b) (6)

Sent: Monday, June 1, 2020 9:03 PM

To: Wholley, David (FNIH) [T] < (b) (6) Parker, Ashley (NIH/OD) [E] < (b) (6)

Cc: Melencio, Cheryl (FNIH) [T] < (b) (6) Adam, Stacey (FNIH) [T] < (b) (6) Menetski, Joseph

(FNIH) [T] < (b) (6) Tountas, Karen (FNIH) [T] < (b) (6) Santos, Michael (FNIH) [T]

< (b) (6) Allen-Gifford, Patrice (NIH/OD) [E] < (b) (6)

Subject: RE: ACTIV Invitations for Leadership Meeting 6/3

I also thought we reached out to Lepore and Reese, but I can't locate those e-mails. I'm looping in Exec Sec to see if they can find something.

FC

From: Wholley, David (FNIH) [T] (b) (6)

Sent: Monday, June 1, 2020 6:10 PM

To: Parker, Ashley (NIH/OD) [E] (b) (6) ; Collins, Francis (NIH/OD) [E] (b) (6)

 Cc: Melencio, Cheryl (FNIH) [T]
 (b) (6)
 Adam, Stacey (FNIH) [T]
 (b) (6)
 ; Menetski, Joseph

 (FNIH) [T]
 (b) (6)
 ; Tountas, Karen (FNIH) [T]
 (b) (6)
 ; Santos, Michael (FNIH) [T]

Subject: RE: ACTIV Invitations for Leadership Meeting 6/3

I thought we had invited John Lepore from GSK and David Reese from Amgen? If not, we should. I would not invite BMGF – their relationship as observer is clear, and we could certainly ask about Evotech, since Kara Carter has been very good from what I have heard.

From: Parker, Ashley (NIH/OD) [E] (b) (6)

Sent: Monday, June 1, 2020 5:37 PM

To: Collins, Francis (NIH/OD) [E] (b) (6) Wholley, David (FNIH) [T] (b) (6)

Cc: Melencio, Cheryl (FNIH) [T] (b) (6)

Subject: Re: ACTIV Invitations for Leadership Meeting 6/3

Hi Francis and David,

We did not have the opportunity to discuss the difference between participants and ACTIV leadership orgs on the 5/21 war room call – Francis was unexpectantly pulled into another meeting. A small number of companies/foundations were not originally listed as leadership partners with ACTIV, therefore they were not included in previous leadership meetings. As of May 20th, we currently have all partners listed on the ACTIV webpage as leadership.

I wanted to raise the question – do we need to invite a member from Amgen, Evotec, GSK, and BMGF to the leadership meeting on Wednesday and include for future meetings?

Thank you, Ashley

From: Parker, Ashley (NIH/OD) [E]

Sent: Wednesday, May 20, 2020 10:51 AM **To:** Wholley, David (FNIH) [T] (b) (6) **Cc:** Melencio, Cheryl (FNIH) [T] (b) (6)

Subject: Re: FOR YOUR REVIEW: ACTIV Web Page Updates

Hi David,

OCPL is in the process of finalizing the <u>ACTIV webpage</u> and Francis asked to include BMGF as a non-profit organization and I let him know they are not one of the "leadership organizations", along with a few companies, and academics which are not included. Francis would like to discuss on our war room call tomorrow morning – he's not clear on the distinction between participants and leadership group members.

I've worked with Cheryl to figure out who is currently on the leadership list and identified who is not to help with sorting this out.

Non leadership partners:

Companies: (Amgen, Evotec, GSK) – seems there should be more here?

Non-profits: BMGFAcademics: all

Leadership partners:

7 government: NIH, FDA, BARDA, CDC, VA, DOD, EMA,

- 16 companies: Pfizer, AbbVie, Eisai, Gilead, KSQ Therapeutics, AstraZeneca, Roche/Genentech, Karuna Therapeutics, Merk, Takeda, Sanofi, Eli Lilly, J&J, Novartis, BMS, Vir Bio
- Non-profit: FNIH, Fred Hutchinson Cancer Research Center, RTI International

All companies along with BMGF are listed on the <u>ACTIV webpage</u>. Depending on the outcome of our discussion tomorrow, we may need to change the language on the webpage.

Thanks, Ashley

From: Collins, Francis (NIH/OD) [E] (b) (6)

Sent: Wednesday, May 20, 2020 10:02 AM

To: Parker, Ashley (NIH/OD) [E] (b) (6) >; Myles, Renate (NIH/OD) [E] (b) (6)

Cc: Tabak, Lawrence (NIH/OD) [E] (b) (6) Burklow, John (NIH/OD) [E] (b) (6)

Wolinetz, Carrie (NIH/OD) [E] (b) (6)

Subject: RE: FOR YOUR REVIEW: ACTIV Web Page Updates

I guess I'm not quite clear on the distinction between participants and leadership group members. Maybe we can discuss at our next War Room conversation?

From: Parker, Ashley (NIH/OD) [E] (b) (6)

Sent: Wednesday, May 20, 2020 9:57 AM

To: Myles, Renate (NIH/OD) [E] (b) (6) Collins, Francis (NIH/OD) [E] (b) (6)

Cc: Tabak, Lawrence (NIH/OD) [E] (b) (6) Burklow, John (NIH/OD) [E] (b) (6) ;

Wolinetz, Carrie (NIH/OD) [E] (b) (6)

Subject: RE: FOR YOUR REVIEW: ACTIV Web Page Updates

Hi Francis and Renate,

Francis – we originally decided not to include all organizations represented on the WGs for the list of "leadership organizations" — BMGF, a small group of companies, and academics are not included.

Is the preference to list BMGF as a leadership organization? If so, we will need to invite someone from BMGF to join the ACTIV leadership group.

Looks great, Renate. The new EC members: Gary Disbrow, BARDA; Peter Marks, FDA; Andrew (Andy) Plump, Takeda.

Thank you, Ashley

 From: Myles, Renate (NIH/OD) [E]
 (b) (6)

 Sent: Wednesday, May 20, 2020 8:05 AM

 To: Collins, Francis (NIH/OD) [E] < (b) (6)</td>
 Tabak, Lawrence (NIH/OD) [E]
 (b) (6)

 Cc: Burklow, John (NIH/OD) [E]
 (b) (6)
 Wolinetz, Carrie (NIH/OD) [E] < (b) (6)</td>

 Parker, Ashley (NIH/OD) [E] < (b) (6)</td>

Subject: RE: FOR YOUR REVIEW: ACTIV Web Page Updates

Great, thanks Francis. I'll add BMGF.

Ashley: would you send me the list of the additional EC members?

 From: Collins, Francis (NIH/OD) [E] < (b) (6)</td>

 Sent: Wednesday, May 20, 2020 6:44 AM

 To: Myles, Renate (NIH/OD) [E] (b) (6)
 Tabak, Lawrence (NIH/OD) [E] (b) (6)

 Cc: Burklow, John (NIH/OD) [E] < (b) (6)</td>
 Wolinetz, Carrie (NIH/OD) [E] (b) (6)

 Parker, Ashley (NIH/OD) [E] < (b) (6)</td>

Subject: RE: FOR YOUR REVIEW: ACTIV Web Page Updates

Looking good. I prefer the org chart with rectangles instead of circles. Note that we are adding three more members to the Exec Comm today, and that will need to be reflected. I also think we should include BMGF in the non-profit category – they have reps on three of the WGs and have been engaged.

FC

From: Myles, Renate (NIH/OD) [E]	(b) (6)			
Sent: Tuesday, May 19, 2020 9:40 P	M			
To: Collins, Francis (NIH/OD) [E] <	(b) (6)	Tabak, Lawrence (NIH/OD) [E]	(b) (6)	
Cc: Burklow, John (NIH/OD) [E] <	(b) (6)	Wolinetz, Carrie (NIH/OD) [E]	(b) (6)	
Parker, Ashley (NIH/OD) [E]	(b) (6)			
Subject: FOR YOUR REVIEW: ACTIV	Web Page Update	s		

Hi Francis and Larry:

We soft launched the <u>ACTIV webpage</u> pretty quickly with the intention of spiffing it up a bit with a little more time. Attached is a PDF version of the website with a few graphical touches to the main and leadership pages, and another PDF with slightly revised presentation of the organization chart. Let me know if the treatment and images look okay to you and we'll have the online branch incorporate them on the page. Once completed, we'll do a harder launch of the webpage with a feature on the NIH.gov homepage and some social media promotion.

Thanks, Renate From: Collins, Francis (NIH/OD) [E] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP

(FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=410E1CA313F44CED9938E50D2FF0B6C2-COLLINSF]

Sent: 7/10/2020 2:22:08 AM

To: (b) (6)

CC: Wholley, David (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]

Subject: Invitation to Join ACTIV Leadership Team

Dear Mr. Erck,

I greatly appreciate Gregory Glenn serving on the ACTIV vaccines working group as a representative for Novavax. We have lots of activity across our ACTIV working groups moving at rapid speed. ACTIV (Accelerating COVID-19 Therapeutic Interventions and Vaccines) has a leadership team that meets once a month to discuss progress and we typically invite the CEO's of the biotech companies to join. It would be great to have you join future leadership meetings to represent Novavax as a partner.

Please let me know if you would be able to join our leadership team and David Wholley, cc'd who manages the ACTIV partnership will ensure you receive the meeting invite for our next meeting scheduled for Wednesday, July 29, 2:30-4:00pm.

Thanks, Francis

Francis Collins M.D., Ph.D. NIH Director

```
Menetski, Joseph (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=5001af52dc4a427ea3d34f1e072f8cb7-menetskijp]; Hild, Sheri (NIH/OD) [E]
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=edd7f1939fb94be3bf063f925ac15f02-hildsa];
                                                                                      (b) (6)
                                                             Baric, Ralph [/o=ExchangeLabs/ou=Exchange
                               (b)(6)
                                                  (b) (6)
Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=48e35ab1d3044465a7790ee4ded5bc32-rbaric.emai];
                            Ottinger, Elizabeth (NIH/NCATS [E] [
                                                                                      Colvis, Christine
           (b) (6)
                                                                      (b) (6)
(NIH/NCATS) [E] [
                                   ]; Hewitt, Judith (NIH/NIAID) [E]
                                                                                 Deming, Damon
                      (b) (6)
                                                                     (b) (6)
(FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=8a5ace9923ae415aa3d85ac09cb76f85-DEMINGD.fda1;
                                                   Parker, Ashley (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange
                                   (b) (6)
Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras];
                                Adams, Peter (OS/ASPR/BARDA) [/o=ExchangeLabs/ou=Exchange Administrative
Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f6e22f801f9146ef90116c4311c6f3ee-Peter.Adams]; Qashu, Felicia
(NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=366447a553f44696b2c79484d90e41e5-gashufm]; Tomas Cihlar
                          Pitt, Margaret L CIV USARMY MEDCOM USAMRIID (USA) [
                                                                                         (b) (6)
Punturieri, Antonello (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=ca7f3106e5f24b5cb5e933c6ee7a6bc7-punturieria]; Charette, Marc
(NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=a7fa2baf951848b5bf1f76a049a0eca6-charettemf]; Fessel, Josh (NIH/NHLBI)
[E] [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=294e2bb481d94b83a1917f15338dfe19-fesseljp]; Isis.
                                                                                            (b) (6)
                                                     Rao, Srinivas
          (b) (6)
                                    (b) (6)
                                                                           (b) (6)
                                                                                                (b) (6)
            (b)(6)
Nancy Haigwood [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=03d589f440d84691ac0a530e4ba6ceb5-haigwoon.oh]; Wholley, David (FNIH)
[T] [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]; Austin, Christopher
(NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=17597cabc42247548e596778304f781f-austinc]; Melencio, Cheryl (FNIH) [T]
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=279e14fa7428415bb86087d08b628e6f-melencioc]; Colvis, Christine
(NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=4b7e84cce098457896b2df19fa172c87-ccolvis]; Desrosiers, Betsy
                                 Eric Hughes [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=f97951a53cd54153b5daa9d99ad4ec90-EricHughes]; Jansen, Kathrin
                           Kurilla, Michael (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=dc4e85061e3943b9b8ad3f426727861f-mkurilla]; Lowy, Douglas (NCI)
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=54fa75fe6e304e34ba567c66b832baa0-drl.helix.n]; Read, Sarah (NIH/NIAID)
[E] [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=527b160038004a199ae6e0bac2226099-readsa]; Tountas, Karen (FNIH) [T]
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=40c04fef6f1e46f5b750753cd5a14f93-tountaskh]; Santos, Michael (FNIH) [T]
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=ab38cb6836de44e18ef4cc6952f65f80-santosmr]; Adam, Stacey (FNIH) [T]
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=dcd875f0679648859e1cf101c0943414-adamsi4]; James, Stephanie (FNIH) [T]
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=f0032ef62ca343dfb4bf79577e2aa8d1-jamesst]; Alvarez, Rosa Maria
                         Kim, Elizabeth [
                                                                                            Wachtel,
                                              (b) (6)
                                                            btolman [
          (b) (6)
Jonathan
                                Prabhavathi Fernandes [
                                                                                      Rose Li
                 (b) (6)
                                                                   (b) (6)
           (b)(6)
                             Dana Carluccio
                                                                               Lagos, Enrique (NIH/NCATS)
                                                          (b)(6)
[E] [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=ae9041ab27204d83b06752f67a44b0d1-lagoses]; Jonson, Samantha
```

(NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group

To:

CC:

(FYDIBOHF23SPDLT)/cn=	Recipients/cn=ce2	2f69369d654bef89b0c	39b145d69a7-jonsons	g]; Simon, Dina (NIH/OD) [C]
[/o=ExchangeLabs/ou=Ex	xchange Administr	ative Group		
(FYDIBOHF23SPDLT)/cn=	Recipients/cn=e0	2345fa5d1d4d7eaf4e0	f3da58bc1ac-simondr	n]; Burrus-Shaw, Cyndi
(NIH/OD) [E] [/o=Exchan	geLabs/ou=Exchar	nge Administrative Gro	oup	
(FYDIBOHF23SPDLT)/cn=	Recipients/cn=5b	bac95b1f6e4514a299b	318030c31f6-shawcy	; Dave Frankowski
(b) (6)		antoinette_baric [(b) (6)	Lowy, Douglas
(NIH/NCI) [E] [/o=Exchar	ngeLabs/ou=Excha	nge Administrative Gr	oup	
(FYDIBOHF23SPDLT)/cn=	Recipients/cn=f1k	7b8fe4739478bb1784	l0c56902718a-lowyd];	Florence, Clint (NIH/NIAID)
[E] [/o=ExchangeLabs/ou	u=Exchange Admin	istrative Group		
(FYDIBOHF23SPDLT)/cn=				ewc]; Stratton, Benjamin
(b) (6)				ge Administrative Group
(FYDIBOHF23SPDLT)/cn=			_	sel]; Anderson, James
(NIH/OD) [E] [/o=Exchan	geLabs/ou=Exchar	nge Administrative Gro	oup	
(FYDIBOHF23SPDLT)/cn=	Recipients/cn=73	143d1860bc42458be2	54ca 21573b 23-anders	onjm]; Hawk, Harrison
- \ / \ /	Mason, Stephen	(/ (/	Connelly, Sara	
Lumsden, Joanne (NIH/N		그리아 가득하는 이번 이번 사람들이 되었다. 그리는 이번 가는 것이다.	(Francisco) - 10 10 10 10 10 10 10 10 10 10 10 10 10	XX 7 15
(FYDIBOHF23SPDLT)/cn=	Recipients/cn=1b	e900c2388d41f48e3f2	cbcb2fed349-lumsder	ijm]; K C Kent Lloyd
(b) (6)	(b) (6)		(b) (6)	Rodriguez, Robin D
(b) (6)	\ / \ /	n; Diamond, Michael [(b) (6)	Nancy Haigwood
[/o=ExchangeLabs/ou=E	(전기 기급) - 전기 기계(1) (전기 기급) (전기 1급) (전			
(FYDIBOHF23SPDLT)/cn=	Recipients/cn=03	d589f440d84691ac0a	30e4ba6ceb5-haigwo	on.oh]; Gonzalez, Nina
(b) (6)				

Start: 2/3/2021 3:00:00 PM End: 2/3/2021 4:00:00 PM

Recurrence: (none)

From: Parker, Ashley (NIH/OD) [E] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP

(FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=306B2244466140FAA95AAAAFE06EBD70-PARKERAS]

Sent: 8/18/2020 3:07:28 PM

To: Brodd, Lauren (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=ba665dea08e54171b3d6890c2518ddb9-leponeIm]

Subject: Fwd: Notes from Friday's ACTIV Executive Committee & Working Group Co-chair Call

Attachments: image001.png; ATT00001.htm; 2020-08-14_Executive_Committee_Meeting_Summary vFinal.docx; ATT00002.htm

Begin forwarded message:

From: "Wholley, David (FNIH) [T]" < (b) (6) Date: August 18, 2020 at 9:16:02 AM EDT To: "Collins, Francis (NIH/OD) [E]" < "Disbrow, Gary (OS/ASPR/BARDA)" (b) (6) (b) (6) "Dolsten, Mikael" < "Fauci, Anthony (b)(6)(NIH/NIAID) [E]" < "Gibbons, Gary (NIH/NHLBI) [E]" < (b) (6) (b) (6) "Marks, Peter (FDA/CBER)" < "Pao, William" < (b)(6)(b)(6)"Plump, Andrew" < "Stoffels, Paul" < "Woodcock, (b) (6) (b) (6) Janet (FDA/CDER)" < "Colvis, Christine (NIH/NCATS) [E]" (b)(6)(b) (6) , "Desrosiers, Betsy" (b) (6) Eric Hughes (6)"Jansen, Kathrin" < "Kurilla, Michael (b) (6) (b)(6)(NIH/NCATS) [E]" < "Lowy, Douglas (NCI)" < (b)(6)(b)(6)"Read, Sarah (NIH/NIAID) [E]" < "Young, John" < (b) (6) (b)(6)Cc: "Adam, Stacey (FNIH) [T]" < (b) (6) "Alvarez, Rosa" < (b)(6)"Anderson, Margaret" < "Chen, Helen" < (b) (6) (b)(6)"Elsaid, Olivia" < (b)(6)"Gonzalez, Nina" < "Hawk, (b)(6)Harrison" < "Menetski, Joseph (FNIH) [T]" < "Santos, (b)(6)(b)(6)Michael (FNIH) [T]" < "Stratton, Benjamin" < "Tolman, (b) (6) (b) (6) Brett" < "Tountas, Karen (FNIH) [T]" < "Wachtel, Jonathan" (b)(6)(b)(6)"Wholley, David (FNIH) [T]" < "Anderson, James (b)(6)(b) (6) (NIH/OD) [E]" < "Austin, Christopher (NIH/NCATS) [E]" (b) (6) (b)(6)"Burklow, John (NIH/OD) [E]" < (b) (6) "Castillejos, Carlos" "Culp, Michelle (NIH/OD) [E]" < **FNIH Central Account** < (b) (6) (b) (6) (b)(6)"Freire, Maria (FNIH) [T]" < (b)(6)"Gadbois, Ellen (NIH/OD) [E]" < "Hallett, Adrienne (NIH/OD) [E]" < (b)(6)"Lane, Cliff (b)(6)(NIH/NIAID) [E]" < "Myles, Renate (NIH/OD) [E]" < "Parker, (b) (6) (b) (6) Ashley (NIH/OD) [E]" < "Tabak, Lawrence (NIH/OD) [E]" (b)(6)"Wolinetz, Carrie (NIH/OD) [E]" < < (b) (6) "Melencio, (b) (6) Cheryl (FNIH) [T]" < (b)(6)

Subject: Notes from Friday's ACTIV Executive Committee & Working Group Co-chair Call

Dear ACTIV Executive Committee Members and meeting attendees:

Please find attached the notes from our Friday, August 14 ACTIV Executive Committee meeting. As always, please email me with any concerns, questions, or additional comments.

Regards, David David Wholley
Senior Vice President, Research Partnerships
Foundation for the National Institutes of Health
(b) (6)

fnih.org

11400 Rockville Pike Suite 600 North Bethesda, MD 20852

Donate to the FNIH's Pandemic Response Fund to combat COVID-19: fnih.org/pandemic

From: Proschan, Michael (NIH/NIAID) [E] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=7B45059209B4468BB4BA02B0DFBBB3E4-PROSCHAM] Sent: 4/29/2020 5:36:12 PM To: Adam, Stacey (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dcd875f0679648859e1cf101c0943414-adamsj4]; Bozzette, Sam (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=85f05a3619cf47c7ae39d7bcf0aac88d-bozzettesaa]; Butterton, Joan [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=219ecac4faae4ebab8a45ce8ee2490c3-joan_butter]; Collins, Sylva (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f6b8f588067140fe988f0832c2387725-Sylva.Colli]; Judy Currier [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=890082c7c1e34902b0f535320cd16650-jscurrier.m]; De Claro, R. Angelo (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c495c3ee25ca461ba6a829b124062448-DECLAROR.fd]; Mark Eisner (b) (6) Keith Gottesdiener [(b)(6)Eric Hughes Elliott Levy [LaVange, Lisa M [(b) (6) (b) (6) Sandeep (b) (6) Menon [Amanda Peppercorn [Read, Sarah (b)(6)(b) (6) (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=527b160038004a199ae6e0bac2226099-readsa]; Amanda Peppercorn (b) (6) Price, Dionne (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a583eced842c44b18bb6fcd3820bee21-priced.fda]; Rubin, Daniel B. (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=35c2891059134111a3ed28f929042aad-RUBIND.fda]; Shen, Yuan Li (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ae30a02e983e4e8a979dfec7257a1802-shenyu.fda]; Farley, John (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=40b4c4456b14464788f31fe7bcaa09bc-FARLEYJ.fda]; Goff, David (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=036113c7be0f42f897d1294cfbb99c10-goffdc]; Vincent, Michael Wung, Peter /US [(b) (6) (b) (6) CC: Mary Biggs [Demarcus [Macone, Erin [(b)(6)(b)(6)(b) (6) Tountas, Karen (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=40c04fef6f1e46f5b750753cd5a14f93-tountaskh]; Wachtel, Jonathan Elizabeth Kim [Parker, Ashley (NIH/OD) [E] (b) (6) (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras]; Butcher, Tina]; Wholley, David (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]; Melencio, Cheryl (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=279e14fa7428415bb86087d08b628e6f-melencioc) Subject: RE: Has ACTT1 been stopped? https://www.youtube.com/watch?v=0HujdC7s3tM From: Adam, Stacey (FNIH) [T] < (b) (6) Sent: Wednesday, April 29, 2020 1:27 PM To: Bozzette, Sam (NIH/NCATS) [E] < Butterton, Joan < Collins, (b) (6) (b) (6) Svlva (FDA/CDER) < Judy Currier < De Claro, R. Angelo (b) (6) (b)(6)(FDA/CDER) < Mark Eisner < Keith Gottesdiener (b)(6)(b)(6)Eric Hughes < LaVange, Lisa M < (b) (6) (b) (6) (b) (6)

(b)(6)

Elliott Levy <

(NIH/NIAID) [E] <

(b)(6)

(b) (6)

(b) (6)

Sandeep Menon <

Proschan, Michael (NIH/NIAID) [E] <

Amanda Peppercorn <

Amanda Peppercorn

(b)(6)

(b)(6)

Read, Sarah

Price, Dionne

(FDA/CDER) <	(b) (6)	Rubin, Daniel B.	(FDA/CDER) <	(b) (6)	Shen, Yuan Li
(FDA/CDER) <	(b) (6)	Farley, John (FDA	A/CDER) <	(b) (6)	Goff, David (NIH/NHLBI)
[E] < (b) (6)	Vincent, Micha	el< (b) (6)	Wung, Peter /US	
<peter. (6)<="" (b)="" td=""><td></td><td></td><td></td><td></td><td></td></peter.>					
Cc: Mary Biggs <	(b) (6)	Demarcus <	(b) (6)	Macone, Erii	n < (b) (6)
Tountas, Karen (FNIH)		Wachtel, Jo		(b) (6)	Elizabeth Kim
< (b) (6)	Parker, Ashley (N		(b) (6)	Butcher, Tina	
< (b) (6)		avid (FNIH) [T] <	(b) (6)	Melencio, Chery	/I (FNIH) [T]
< (b) (6)	,,	, , , , ,	(-) (-)		, ,,,,
Subject: RE: Has ACTT1	been stopped?				
	**				
Hi Sam,					
in Julii,					
DSMR was this week to	review interim re	sults though the t	rial has fully acc	rued so the interim	may quickly transition to
final. However, we we					
I will let Michael or oth	7			the right un ection i	next week.
will let wilchael of oth	ers weightin my	understanding was	s in correct.		
Thanks					
Thanks,					
Stacey					
Canana Y Adams DIN	ř				
Stacey J. Adam, PhD	t.				
Director, Cancer					
Research Partnerships	13/13//	1) (6)			
Direct: ((b) (6)	Mobile: ((1	b) (6)			
From: Bozzette, Sam (N	IIH/NCATS) [E] <	(b) (6)			
[1] [1] 12 14 14 15 15 15 15 15 15 15 15 15 15 15 15 15	하다 살아가 되었다면 가게 하면 하는 것이 하는데	(b) (6)			
Sent: Wednesday, Apri	l 29, 2020 1:22 PM	1	Joan <joan< td=""><td>(b) (6)</td><td>Collins, Sylva</td></joan<>	(b) (6)	Collins, Sylva
Sent: Wednesday, Apri To: Adam, Stacey (FNII-	I 29, 2020 1:22 PM I) [T] < (b) (6)	Butterton,	Joan < <u>joan</u> (b) (6)	(b) (6) De Claro	Collins, Sylva , R. Angelo (FDA/CDER)
Sent: Wednesday, Apri To: Adam, Stacey (FNIH (FDA/CDER) <	l 29, 2020 1:22 PM	Butterton, Judy Currier <	(b) (6)		Collins, Sylva , R. Angelo (FDA/CDER)
Sent: Wednesday, Apri To: Adam, Stacey (FNIH (FDA/CDER) < (b) (6)	H 29, 2020 1:22 PM H) [T] < (b) (6) (b) (6) Mark Eis	Butterton, Judy Currier < (b) ((b) (6) (6) Kei	De Claro th Gottesdiener	, R. Angelo (FDA/CDER)
Sent: Wednesday, Apri To: Adam, Stacey (FNIH (FDA/CDER) < (b) (6) (b) (6)	29, 2020 1:22 PM T < (b) (6) (b) (6) Mark Eis Eric Hu	Butterton, Judy Currier < ner < (b) ((b) (6) (6) Kei (b) (6)	De Claro th Gottesdiener LaVange, Lisa M <	, R. Angelo (FDA/CDER) (b) (6)
Sent: Wednesday, Apri To: Adam, Stacey (FNIH (FDA/CDER) < (b) (6) (b) (6) Elliott Levy < (b)	129, 2020 1:22 PM T < (b) (6) (b) (6) Mark Eis Eric Hu (6) Sando	Butterton, Judy Currier < ner < (b) (ughes < eep Menon <	(b) (6) (6) Kei (b) (6) (b) (6)	De Claro th Gottesdiener LaVange, Lisa M < Amand	, R. Angelo (FDA/CDER) (b) (6) da Peppercorn
Sent: Wednesday, Apri To: Adam, Stacey (FNIH (FDA/CDER) < (b) (6) (b) (6) Elliott Levy < (b) (6)	29, 2020 1:22 PM T < (b) (6) (b) (6) Mark Eisi Eric Hu (6) Sando Prosc	Butterton, Judy Currier < ner < (b) (ughes < eep Menon < chan, Michael (NIH)	(b) (6) (6) Kei (b) (6) (b) (6) /NIAID) [E] <	De Claro th Gottesdiener LaVange, Lisa M < Amand (b) (6)	, R. Angelo (FDA/CDER) (b) (6) da Peppercorn Read, Sarah
Sent: Wednesday, Apri To: Adam, Stacey (FNIH (FDA/CDER) <	(b) (6) Mark Eise Eric Hu (b) (6) Sande Prose (b) (6)	Butterton, Judy Currier < ner < (b) (ughes < eep Menon < chan, Michael (NIH) Amanda Pepperco	(b) (6) (6) Kei (b) (6) (b) (6) /NIAID) [E] <	De Claro th Gottesdiener LaVange, Lisa M < Amano (b) (6) (b) (6)	(b) (6) da Peppercorn Read, Sarah Price, Dionne
Sent: Wednesday, Apri To: Adam, Stacey (FNIH (FDA/CDER) <	29, 2020 1:22 PM T < (b) (6) (b) (6) Mark Eis Eric Hu (6) Sande Proso (b) (6) (b) (6)	Butterton, Judy Currier < ner < (b) (ughes < eep Menon < chan, Michael (NIH, Amanda Pepperco	(b) (6) (6) Kei (b) (6) (b) (6) /NIAID) [E] < orn < (FDA/CDER) <	De Claro th Gottesdiener LaVange, Lisa M Amano (b) (6) (b) (6) (b) (6)	(b) (6) da Peppercorn Read, Sarah Price, Dionne Shen, Yuan Li
Sent: Wednesday, Apri To: Adam, Stacey (FNIH (FDA/CDER) <	1 29, 2020 1:22 PM H) [T] < (b) (6) (b) (6) Mark Eis Eric Hu) (6) Sando Proso (b) (6) (b) (6) (b) (6)	Butterton, Judy Currier < ner < (b) (ughes < eep Menon < chan, Michael (NIH, Amanda Pepperco Rubin, Daniel B. Farley, John (FDA	(b) (6) (6) Kei (b) (6) (b) (6) /NIAID) [E] < orn < (FDA/CDER) <	De Claro th Gottesdiener LaVange, Lisa M « Amano (b) (6) (b) (6) (b) (6) (b) (6)	(b) (6) da Peppercorn Read, Sarah Price, Dionne
Sent: Wednesday, Apri To: Adam, Stacey (FNIH (FDA/CDER) <	29, 2020 1:22 PM T < (b) (6) (b) (6) Mark Eis Eric Hu (6) Sande Proso (b) (6) (b) (6)	Butterton, Judy Currier < ner < (b) (ughes < eep Menon < chan, Michael (NIH, Amanda Pepperco Rubin, Daniel B. Farley, John (FDA	(b) (6) (6) Kei (b) (6) (b) (6) /NIAID) [E] < orn < (FDA/CDER) <	De Claro th Gottesdiener LaVange, Lisa M Amano (b) (6) (b) (6) (b) (6)	(b) (6) da Peppercorn Read, Sarah Price, Dionne Shen, Yuan Li
Sent: Wednesday, Apri To: Adam, Stacey (FNIH (FDA/CDER) <	29, 2020 1:22 PM T < (b) (6) (b) (6) Mark Eis Eric Hu (6) Sande Proso (b) (6) (b) (6) (b) (6) Vincent, Micha	Butterton, Judy Currier < ner < (b) (ughes < eep Menon < chan, Michael (NIH, Amanda Pepperco Rubin, Daniel B. Farley, John (FDA	(b) (6) (6) Kei (b) (6) (b) (6) /NIAID) [E] < orn < (FDA/CDER) < A/CDER) < () (6)	De Claro th Gottesdiener LaVange, Lisa M Amano (b) (6) (b) (6) (b) (6) (b) (6) Wung, Peter /US	, R. Angelo (FDA/CDER) (b) (6) da Peppercorn Read, Sarah Price, Dionne Shen, Yuan Li Goff, David (NIH/NHLBI)
Sent: Wednesday, Apri To: Adam, Stacey (FNIH (FDA/CDER) <	129, 2020 1:22 PM T < (b) (6) (b) (6) Mark Eis Eric Hu (6) Sando Prosco (b) (6) (b) (6) (b) (6) Vincent, Michal	Butterton, Judy Currier < ner < (b) (ughes < eep Menon < chan, Michael (NIH, Amanda Pepperco Rubin, Daniel B. Farley, John (FDA ael < (b	(b) (6) (6) Kei (b) (6) (b) (6) /NIAID) [E] < orn < (FDA/CDER) < A/CDER) < (b) (6)	De Claro th Gottesdiener LaVange, Lisa M < Amano (b) (6) (b) (6) (b) (6) (b) (6) Wung, Peter /US Macone, Erin	, R. Angelo (FDA/CDER) (b) (6) da Peppercorn Read, Sarah Price, Dionne Shen, Yuan Li Goff, David (NIH/NHLBI)
Sent: Wednesday, Apri To: Adam, Stacey (FNIH (FDA/CDER) <	1 29, 2020 1:22 PM T < (b) (6) (b) (6) Mark Eis Eric Hu (6) Sando Proso (b) (6) (b) (6) (b) (6) Vincent, Michal	Butterton, Judy Currier < ner < (b) (ughes < eep Menon < chan, Michael (NIH, Amanda Pepperco Rubin, Daniel B. Farley, John (FDA eel < (b Demarcus < Wachtel, Jo	(b) (6) (6) Kei (b) (6) (b) (6) /NIAID) [E] < orn < (FDA/CDER) < A/CDER) < (b) (6) (b) (6) onathan <	De Claro th Gottesdiener LaVange, Lisa M < Amano (b) (6) (b) (6) (b) (6) (b) (6) Wung, Peter /US Macone, Erin (b) (6)	, R. Angelo (FDA/CDER) (b) (6) da Peppercorn Read, Sarah Price, Dionne Shen, Yuan Li Goff, David (NIH/NHLBI)
Sent: Wednesday, Apri To: Adam, Stacey (FNIH (FDA/CDER) <	29, 2020 1:22 PM T < (b) (6) Mark Eis Eric Hu (6) Sando Proso (b) (6) (b) (6) (b) (6) Vincent, Michallon (b) (6) T < (b) (6) Parker, Ashley (N	Butterton, Judy Currier < ner < (b) (ughes < eep Menon < chan, Michael (NIH, Amanda Pepperco Rubin, Daniel B. Farley, John (FDA eel < (b Demarcus < Wachtel, Jo	(b) (6) (6) Kei (b) (6) (b) (6) /NIAID) [E] < orn < (FDA/CDER) < A/CDER) < (b) (6) (b) (6) onathan < (b) (6)	De Claro th Gottesdiener LaVange, Lisa M < Amano (b) (6) (b) (6) (b) (6) (b) (6) Wung, Peter /US Macone, Erin (b) (6) Butcher, Tina	, R. Angelo (FDA/CDER) (b) (6) da Peppercorn Read, Sarah Price, Dionne Shen, Yuan Li Goff, David (NIH/NHLBI) n < (b) (6) Elizabeth Kim
Sent: Wednesday, Apri To: Adam, Stacey (FNIH (FDA/CDER) <	29, 2020 1:22 PM T < (b) (6) Mark Eis Eric Hu (6) Sando Proso (b) (6) (b) (6) (b) (6) Vincent, Michallon (b) (6) T < (b) (6) Parker, Ashley (N	Butterton, Judy Currier < ner < (b) (ughes < eep Menon < chan, Michael (NIH, Amanda Pepperco Rubin, Daniel B. Farley, John (FDA eel < (b Demarcus < Wachtel, Jo	(b) (6) (6) Kei (b) (6) (b) (6) /NIAID) [E] < orn < (FDA/CDER) < A/CDER) < (b) (6) (b) (6) onathan <	De Claro th Gottesdiener LaVange, Lisa M < Amano (b) (6) (b) (6) (b) (6) (b) (6) Wung, Peter /US Macone, Erin (b) (6)	, R. Angelo (FDA/CDER) (b) (6) da Peppercorn Read, Sarah Price, Dionne Shen, Yuan Li Goff, David (NIH/NHLBI) n < (b) (6) Elizabeth Kim
Sent: Wednesday, Apri To: Adam, Stacey (FNIH (FDA/CDER) <	1 29, 2020 1:22 PM T < (b) (6) (b) (6) Mark Eis Eric Hu (6) Sando Prosco (b) (6) (b) (6) (b) (6) Vincent, Michal (b) (6) Parker, Ashley (N Wholley, D	Butterton, Judy Currier < ner < (b) (ughes < eep Menon < chan, Michael (NIH, Amanda Pepperco Rubin, Daniel B. Farley, John (FDA eel < (b Demarcus < Wachtel, Jo	(b) (6) (6) Kei (b) (6) (b) (6) /NIAID) [E] < orn < (FDA/CDER) < A/CDER) < (b) (6) (b) (6) onathan < (b) (6)	De Claro th Gottesdiener LaVange, Lisa M < Amano (b) (6) (b) (6) (b) (6) (b) (6) Wung, Peter /US Macone, Erin (b) (6) Butcher, Tina	, R. Angelo (FDA/CDER) (b) (6) da Peppercorn Read, Sarah Price, Dionne Shen, Yuan Li Goff, David (NIH/NHLBI) n < (b) (6) Elizabeth Kim
Sent: Wednesday, Apri To: Adam, Stacey (FNIH (FDA/CDER) <	1 29, 2020 1:22 PM T < (b) (6) (b) (6) Mark Eis Eric Hu (6) Sando Prosco (b) (6) (b) (6) (b) (6) Vincent, Michal (b) (6) Parker, Ashley (N Wholley, D	Butterton, Judy Currier < ner < (b) (ughes < eep Menon < chan, Michael (NIH, Amanda Pepperco Rubin, Daniel B. Farley, John (FDA eel < (b Demarcus < Wachtel, Jo	(b) (6) (6) Kei (b) (6) (b) (6) /NIAID) [E] < orn < (FDA/CDER) < A/CDER) < (b) (6) (b) (6) onathan < (b) (6)	De Claro th Gottesdiener LaVange, Lisa M < Amano (b) (6) (b) (6) (b) (6) (b) (6) Wung, Peter /US Macone, Erin (b) (6) Butcher, Tina	, R. Angelo (FDA/CDER) (b) (6) da Peppercorn Read, Sarah Price, Dionne Shen, Yuan Li Goff, David (NIH/NHLBI) n < (b) (6) Elizabeth Kim
Sent: Wednesday, Apri To: Adam, Stacey (FNIH (FDA/CDER) <	29, 2020 1:22 PM T < (b) (6) (b) (6) Mark Eis Eric Ho (6) Sande Proso (b) (6) (b) (6) (b) (6) Vincent, Michallon (b) (6) Parker, Ashley (North Wholley, Dottern stopped?	Butterton, Judy Currier < ner < (b) (ughes < eep Menon < chan, Michael (NIH, Amanda Pepperco Rubin, Daniel B. Farley, John (FDA eel < (b Demarcus < Wachtel, Jo IIH/OD) [E] < avid (FNIH) [T] <	(b) (6) (6) Kei (b) (6) (b) (6) /NIAID) [E] < orn < (FDA/CDER) < A/CDER) < (b) (6) (b) (6) onathan < (b) (6) (b) (6)	De Claro th Gottesdiener LaVange, Lisa M Amano (b) (6) (b) (6) (b) (6) Wung, Peter /US Macone, Erin (b) (6) Butcher, Tina Melencio, Chery	(b) (6) da Peppercorn Read, Sarah Price, Dionne Shen, Yuan Li Goff, David (NIH/NHLBI) n < (b) (6) Elizabeth Kim
Sent: Wednesday, Apri To: Adam, Stacey (FNIH (FDA/CDER) <	29, 2020 1:22 PM T < (b) (6) (b) (6) Mark Eis Eric Ho (6) Sande Proso (b) (6) (b) (6) (b) (6) Vincent, Michallon (b) (6) Parker, Ashley (North Wholley, Dottern stopped?	Butterton, Judy Currier < ner < (b) (ughes < eep Menon < chan, Michael (NIH, Amanda Pepperco Rubin, Daniel B. Farley, John (FDA eel < (b Demarcus < Wachtel, Jo IIH/OD) [E] < avid (FNIH) [T] <	(b) (6) (6) Kei (b) (6) (b) (6) /NIAID) [E] < orn < (FDA/CDER) < A/CDER) < (b) (6) (b) (6) onathan < (b) (6) (b) (6)	De Claro th Gottesdiener LaVange, Lisa M Amano (b) (6) (b) (6) (b) (6) Wung, Peter /US Macone, Erin (b) (6) Butcher, Tina Melencio, Chery	, R. Angelo (FDA/CDER) (b) (6) da Peppercorn Read, Sarah Price, Dionne Shen, Yuan Li Goff, David (NIH/NHLBI) n < (b) (6) Elizabeth Kim
Sent: Wednesday, Apri To: Adam, Stacey (FNIH (FDA/CDER) <	29, 2020 1:22 PM T < (b) (6) (b) (6) Mark Eis Eric Ho (6) Sande Proso (b) (6) (b) (6) (b) (6) Vincent, Michallon (b) (6) Parker, Ashley (North Wholley, Dottern stopped?	Butterton, Judy Currier < ner < (b) (ughes < eep Menon < chan, Michael (NIH, Amanda Pepperco Rubin, Daniel B. Farley, John (FDA eel < (b Demarcus < Wachtel, Jo IIH/OD) [E] < avid (FNIH) [T] <	(b) (6) (6) Kei (b) (6) (b) (6) /NIAID) [E] < orn < (FDA/CDER) < A/CDER) < (b) (6) (b) (6) onathan < (b) (6) (b) (6)	De Claro th Gottesdiener LaVange, Lisa M Amano (b) (6) (b) (6) (b) (6) Wung, Peter /US Macone, Erin (b) (6) Butcher, Tina Melencio, Chery	(b) (6) da Peppercorn Read, Sarah Price, Dionne Shen, Yuan Li Goff, David (NIH/NHLBI) n < (b) (6) Elizabeth Kim
Sent: Wednesday, Apri To: Adam, Stacey (FNIH (FDA/CDER) <	29, 2020 1:22 PM T < (b) (6) (b) (6) Mark Eis Eric Ho (6) Sande Proso (b) (6) (b) (6) (b) (6) Vincent, Michallon (b) (6) Parker, Ashley (North Wholley, Dottern stopped?	Butterton, Judy Currier < ner < (b) (ughes < eep Menon < chan, Michael (NIH, Amanda Pepperco Rubin, Daniel B. Farley, John (FDA eel < (b Demarcus < Wachtel, Jo IIH/OD) [E] < avid (FNIH) [T] <	(b) (6) (6) Kei (b) (6) (b) (6) /NIAID) [E] < orn < (FDA/CDER) < A/CDER) < (b) (6) (b) (6) onathan < (b) (6) (b) (6)	De Claro th Gottesdiener LaVange, Lisa M Amano (b) (6) (b) (6) (b) (6) Wung, Peter /US Macone, Erin (b) (6) Butcher, Tina Melencio, Chery	(b) (6) da Peppercorn Read, Sarah Price, Dionne Shen, Yuan Li Goff, David (NIH/NHLBI) n < (b) (6) Elizabeth Kim
Sent: Wednesday, Apri To: Adam, Stacey (FNIH (FDA/CDER) <	129, 2020 1:22 PM T < (b) (6) (b) (6) Mark Eis Eric Hu (6) Sando Proso (b) (6) (b) (6) (b) (6) Vincent, Michal (b) (6) Parker, Ashley (N Wholley, Doen stopped?	Butterton, Judy Currier < ner < (b) (ughes < eep Menon < chan, Michael (NIH, Amanda Pepperco Rubin, Daniel B. Farley, John (FDA eel < (b Demarcus < Wachtel, Jo IIH/OD) [E] < avid (FNIH) [T] <	(b) (6) (6) Kei (b) (6) (b) (6) /NIAID) [E] < orn < (FDA/CDER) < A/CDER) < (b) (6) (b) (6) onathan < (b) (6) (b) (6)	De Claro th Gottesdiener LaVange, Lisa M Amano (b) (6) (b) (6) (b) (6) Wung, Peter /US Macone, Erin (b) (6) Butcher, Tina Melencio, Chery	(b) (6) da Peppercorn Read, Sarah Price, Dionne Shen, Yuan Li Goff, David (NIH/NHLBI) n < (b) (6) Elizabeth Kim
Sent: Wednesday, Apri To: Adam, Stacey (FNIH (FDA/CDER) <	129, 2020 1:22 PM 1 1 1 1 1 1 1 1 1	Butterton, Judy Currier < ner < (b) (ughes < eep Menon < chan, Michael (NIH, Amanda Pepperco Rubin, Daniel B. Farley, John (FDA ael < (b Demarcus < Wachtel, Jo IIH/OD) [E] < avid (FNIH) [T] <	(b) (6) (6) Kei (b) (6) (b) (6) /NIAID) [E] < orn < (FDA/CDER) < A/CDER) < (b) (6) (b) (6) onathan < (b) (6) (b) (6)	De Claro th Gottesdiener LaVange, Lisa M Amano (b) (6) (b) (6) (b) (6) Wung, Peter /US Macone, Erin (b) (6) Butcher, Tina Melencio, Chery	(b) (6) da Peppercorn Read, Sarah Price, Dionne Shen, Yuan Li Goff, David (NIH/NHLBI) n < (b) (6) Elizabeth Kim
Sent: Wednesday, Apri To: Adam, Stacey (FNIH (FDA/CDER) <	1 29, 2020 1:22 PM T <	Butterton, Judy Currier < ner < (b) (ughes < eep Menon < chan, Michael (NIH, Amanda Pepperco Rubin, Daniel B. Farley, John (FDA eel < (b Demarcus < Wachtel, Jo IIH/OD) [E] < avid (FNIH) [T] <	(b) (6) (6) Kei (b) (6) (b) (6) /NIAID) [E] < orn < (FDA/CDER) < A/CDER) < (b) (6) (b) (6) onathan < (b) (6) (b) (6)	De Claro th Gottesdiener LaVange, Lisa M Amano (b) (6) (b) (6) (b) (6) Wung, Peter /US Macone, Erin (b) (6) Butcher, Tina Melencio, Chery	(b) (6) da Peppercorn Read, Sarah Price, Dionne Shen, Yuan Li Goff, David (NIH/NHLBI) n < (b) (6) Elizabeth Kim

<	(b) (6)	M	ark Eisner <	(b) (6)	Keith Gottesdiener	
<	(b) (6)		Eric Hughes <	(b) (6)	LaVange, Lisa M <	(b) (6)
Elliott Lev	/y < (b)	(6)	Sandeep Menon	(b) ((6) Amano	da Peppercorn
<	(b) (6)		Proschan, Michael	el (NIH/NIAID) [E] <	(b) (6)	Read, Sarah
(NIH/NIA	ID) [E] <	(b) (6)	Amanda Pe	ppercorn <	(b) (6)	Price, Dionne
(FDA/CDE	ER) <	(b) (6)	Rubin, Dar	niel B. (FDA/CDER)	< (b) (6)	Shen, Yuan Li
(FDA/CDE	ER) <	(b) (6)	Farley, Joh	nn (FDA/CDER) <	(b) (6)	Goff, David (NIH/NHLBI)
[E] <	(b) (6)	Vincent	, Michael <	(b) (6)	Wung, Peter /US	
<	(b) (6)					
Cc: Mary	Biggs <	(b) (6)	Demarcus •	(b) (6)	Macone, Erii	n < (b) (6)
Tountas	Karen (FNIH) [T1 <	(b) (6) Wac	htel, Jonathan <	(b) (6)	Elizabeth Kim
Touritus,	ital cir (i raili) ['1'	(0) (0)	rice, sonatian s	(0) (0)	Eneabethittiii
	(b) (6)		hley (NIH/OD) [E] <		Butcher, Tina	
	(b) (6)	Parker, As		(b) (6)		

Subject: Of interest re remdesivir

 $\frac{https://www.statnews.com/2020/04/29/gilead-says-critical-study-of-covid-19-drug-shows-patients-are-responding-to-treatment/?utm \\source=STAT+Newsletters&utm \\campaign=f9a2a59829-$

breaking COPY 01&utm medium=email&utm term=0 8cab1d7961-f9a2a59829-152058113

----Original Appointment----

From: Adam, Stacey (FNIH) [T] < (b) (6)

Sent: Wednesday, April 29, 2020 2:44 AM

To: Bozzette, Sam (NIH/NCATS) [E]; Butterton, Joan; Collins, Sylva (FDA/CDER); Judy Currier; De Claro, R. Angelo (FDA/CDER); Mark Eisner; Keith Gottesdiener; Eric Hughes; LaVange, Lisa M; Elliott Levy; Sandeep Menon; Amanda Peppercorn; Proschan, Michael (NIH/NIAID) [E]; Read, Sarah (NIH/NIAID) [E]; Amanda Peppercorn; Price, Dionne

(FDA/CDER); Rubin, Daniel B. (FDA/CDER); Shen, Yuan Li (FDA/CDER); Farley, John (FDA/CDER); Goff, David (NIH/NHLBI)

[E]; Vincent, Michael; Wung, Peter /US

Cc: Mary Biggs; Demarcus; Macone, Erin; Tountas, Karen (FNIH) [T]; Wachtel, Jonathan; Elizabeth Kim; Parker, Ashley (NIH/OD) [E]; Butcher, Tina; Wholley, David (FNIH) [T]; Melencio, Cheryl (FNIH) [T]

Subject: Canceled: ACTIV TX-Clinical Master Protocol Subgroup Meeting #11

When: Wednesday, April 29, 2020 3:00 PM-4:00 PM (UTC-05:00) Eastern Time (US & Canada).

Where: https://fnih.zoom. (b) (6)

Importance: High

Dear TX-Clinical Master Protocol Subgroup,

The co-chairs and subgroup chair have decide that the best use of the group's time is to hold off and reconvene with CTC WG at 12pm ET on Thursday and as our team on Friday. For Thursday, you should have an invite from Karent Tountas for the meeting with the CTC group.

See you all Thursday!

Stacey

Join Zoom Meeting

https://fnih.zoom. (b) (6)

Meeting ID: (b) (6)

Password: (b) (6) One tap mobile

```
(b) (6)

US (New York)
US (Chicago)

Dial by your location
(b) (6)

US (New York)
US (Chicago)
US
US (Houston)
US (San Jose)
US

Meeting ID: (b) (6)

Password: (b) (6)
```

Find your local number: https://fnih.zoom.u (b) (6)

From: Melencio, Cheryl (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=279E14FA7428415BB86087D08B628E6F-MELENCIOC] Sent: 7/21/2020 7:13:59 PM To: Melencio, Cheryl (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=279e14fa7428415bb86087d08b628e6f-melencioc]; Collins, Francis (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=410e1ca313f44ced9938e50d2ff0b6c2-collinsf]; Disbrow, Gary (OS/ASPR/BARDA) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=62a151e39ab942d88a813b449f9f6ccb-Gary.Disbro]; Dolsten, Mikael Gibbons, Gary (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b71b953b50a5495ca0f2869ab13bc407-gibbonsgh]; Marks, Peter (FDA/CBER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b2e527dbda2b4a86b8d72f06b813d471-MarksP.fda]; Pao, William Woodcock, Janet (FDA/CDER) Stoffels, Paul I (b)(6)(b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9bc3fc3ebfcf48879f92169bd7644e29-Janet.Woodc]; Colvis, Christine (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4b7e84cce098457896b2df19fa172c87-ccolvis]; Desrosiers, Betsy Eric Hughes [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f97951a53cd54153b5daa9d99ad4ec90-EricHughes]; Jansen, Kathrin Kurilla, Michael (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dc4e85061e3943b9b8ad3f426727861f-mkurilla]; Lowy, Douglas (NCI) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=54fa75fe6e304e34ba567c66b832baa0-drl.helix.n]; Read, Sarah (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=527b160038004a199ae6e0bac2226099-readsa]; Young, John Fauci, Anthony (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (b) (6) (FYDIBOHF23SPDLT)/cn=Recipients/cn=df38103d75134f658ae2d356f0396b94-afauci]; Plump, Andrew (b) (6) CC: Adam, Stacey (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dcd875f0679648859e1cf101c0943414-adamsj4]; Alvarez, Rosa Anderson, Margaret [Chen, Helen (b) (6) (b) (6) Elsaid, Olivia [Gonzalez, Nina [(b) (6) (b) (6) (b) (6) James, Stephanie (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f0032ef62ca343dfb4bf79577e2aa8d1-jamesst]; Menetski, Joseph (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5001af52dc4a427ea3d34f1e072f8cb7-menetskijp]; Santos, Michael (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ab38cb6836de44e18ef4cc6952f65f80-santosmr]; Stratton, Benjamin Tolman, Brett [Tountas, Karen (FNIH) [T] (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=40c04fef6f1e46f5b750753cd5a14f93-tountaskh]; Wachtel, Jonathan Wholley, David (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]; Anderson, James (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=73143d1860bc42458be254ca21573b23-andersonjm]; Austin, Christopher (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=17597cabc42247548e596778304f781f-austinc]; Burklow, John (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2e57f267323b43c08be856acb5b964ca-burklowj]; Castillejos, Carlos]; Culp, Michelle (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4e38fa37e0424217aa0a283cba9e5098-mculp]; FNIH Central Account Gadbois, Ellen (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0243d1d6e6f248268d2edec566c26c2a-gadboisel]; Hallett, Adrienne (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f1705e2e7c254b84a77f058dbf75b31b-hallettaa]; Lane, Cliff (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group

```
(FYDIBOHF23SPDLT)/cn=Recipients/cn=2d7e368a3137473bbce161547a82f2de-clane]; Myles, Renate (NIH/OD) [E]
              [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=7d317f5626934585b3692a1823c1b522-mylesr]; Parker, Ashley (NIH/OD) [E]
              [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras]; Tabak, Lawrence (NIH/OD)
              [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=02e22836b5ff4e9988e3770cfc7ee770-tabakl]; Burrus-Shaw, Cyndi (NIH/OD)
              [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=5bbac95b1f6e4514a299b318030c31f6-shawcy]; Carver, Trea (NIH) [C]
              [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=ac05f976df484ed69022b8663cd448d3-carverkr]; Lagos, Enrique
              (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=ae9041ab27204d83b06752f67a44b0d1-lagoses]; Sepulveda, Dorina (FNIH)
              [T] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=675efcc8cf7b4f6986d1eb3c3ed1fd96-sepulvedade]; Simon, Dina (NIH/OD)
              [C] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=e02345fa5d1d4d7eaf4e0f3da58bc1ac-simondm]; Gorman, Greta (FNIH) [T]
              [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=280703da933d491586841696e460f062-gormanmj]; Meltzer, Abbey (FNIH)
              [T] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=c341d86cf7404a78ac8f852e698e5382-meltzerak]; Barasch, Kimberly
              (NIH/NIAID) [C] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=ea5fad4c52f64f80b7daee4982ae495f-baraschk]; Conrad, Patricia
              (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=7ea3e3ea7daa432887495d6825c9e588-conradpa]; Dimishkov, Roxanne
              (NIH/NHLBI) [C] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=d8415061971c493881c08c8c6cd75fb8-dimishkovrd]; McManus, Ayanna
              (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=bcf06de08ba845249b9b36ad216e237e-amcmanus]; Perala, Mie
                                     ]; Protasiewicz, Ann
                                                                                    Riccobene, Kim
                                                            (b) (6)
                                                                       (6)
                      (b) (6)
                     (b) (6)
                                 ]; Thomas, Ashley (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=1bcd5d3f7c1e4309a251d013e1cc89b0-Ashley.Thom]; Wood, Gretchen
              (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=549f390b39d044a8b5d1e0e1a8f76c1f-woodgs]; Togashi, Mieko (NIH/NCI)
              [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=136a73bd42274938aa467e738767f83e-togashim]; Underwood, Nancy
                                                                                    Lowy, Douglas (NIH/NCI) [E]
                           (b) (6)
                                             Zottoli, Jessica
                                                                     (b) (6)
              [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=f1b7b8fe4739478bb17840c56902718a-lowyd]; Hawk, Harrison
                                    Lucas Smalldon
                                                                                       Wolinetz, Carrie (NIH/OD) [E]
                      (b) (6)
                                                                  (b)(6)
              [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=1c655040d47346c7b04d7bc11a403ecb-wolinetzcd]; Hardesty, Rebecca
              (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=21465ceb763947408d209aaabf10af70-hardestyrs]
              ACTIV EC & Working Group Co-Chair Meeting
Attachments: Materials for August 14 ACTIV Executive Committee Teleconference
              https://fnih.zoom.
                                                         (b)(6)
              8/14/2020 4:00:00 PM
              8/14/2020 5:00:00 PM
```

Subject:

Location:

Start: End:

Show Time As: Busy

Required Collins, Francis (NIH/OD) [E]; Disbrow, Gary (OS/ASPR/BARDA); Dolsten, Mikael; Fauci, Anthony (NIH/NIAID) [E]; Attendees: Gibbons, Gary (NIH/NHLBI) [E]; Marks, Peter (FDA/CBER); Pao, William; Plump, Andrew; Stoffels, Paul; Woodcock, Janet (FDA/CDER); Colvis, Christine (NIH/NCATS) [E]; Desrosiers, Betsy; Hughes, Eric; Jansen, Kathrin; Kurilla, Michael (NIH/NCATS) [E]; Lowy, Douglas (NCI); Read, Sarah (NIH/NIAID) [E]; Young, John

Optional Attendees:

Adam, Stacey (FNIH) [T]; Alvarez, Rosa; Anderson, Margaret; Chen, Helen; Elsaid, Olivia; Gonzalez, Nina; James, Stephanie (FNIH) [T]; Menetski, Joseph (FNIH) [T]; Santos, Michael (FNIH) [T]; Stratton, Ben; Tolman, Brett; Tountas, Karen (FNIH) [T]; Wachtel, Jonathan; Wholley, David (FNIH) [T]; Anderson, James (NIH/OD) [E]; Austin, Christopher (NIH/NCATS) [E]; Burklow, John (NIH/OD) [E]; Castillejos, Carlos; Culp, Michelle (NIH/OD) [E]; FNIH Central Account; Gadbois, Ellen (NIH/OD) [E]; Hallett, Adrienne (NIH/OD) [E]; Lane, Cliff (NIH/NIAID) [E]; Myles, Renate (NIH/OD) [E]; Parker, Ashley (NIH/OD) [E]; Tabak, Lawrence (NIH/OD) [E]; Wolinetz, Carrie (NIH/OD) [E]; Burrus-Shaw, Cyndi (NIH/OD) [E]; Carver, Trea (NIH) [C]; Hardesty, Rebecca (NIH/OD) [E]; Lagos, Enrique (NIH/NCATS) [E]; Sepulveda, Dorina (FNIH) [T]; Simon, Dina (NIH/OD) [C]; Gorman, Greta (FNIH) [T]; Meltzer, Abbey (FNIH) [T]; Barasch, Kimberly (NIH/NIAID) [C]; Conrad, Patricia (NIH/NIAID) [E]; Dimishkov, Roxanne (NIH/NHLBI) [C]; McManus, Ayanna (NIH/OD) [E]; Perala, Mie; Protasiewicz, Ann; Riccobene, Kim; Thomas, Ashley (FDA/CDER); Wood, Gretchen (NIH/OD) [E]; Togashi, Mieko (NIH/NCI) [E]; Underwood, Nancy; Zottoli, Jessica; Lowy, Douglas (NIH/NCI) [E]; Hawk, Harrison; Lucas Smalldon

Shortening calls to 1 hour in length.

Joseph Menetski is inviting you to a scheduled Zoom meeting.

```
Join Zoom Meeting
https://fnih.zoom.us/
                                              (b)(6)
Meeting ID:
                (b) (6)
Passcode: (b)
One tap mobile
                                              US (Germantown)
                    (b)(6)
                                              US (Chicago)
Dial by your location (b) (6)
                           S
                             (Germantown)
                             (Chicago)
                             (New York)
                          S
                          S
                             (San Jose)
                          S
                             (San Jose)
                           S
                             (Tacoma)
                           S (Houston)
                           gium
                           lgium
                           1gium
                           1gium
                           laium
                           lgium
                           anada
                           anada
                           anada
                           anada
                           anada
                           anada
                           rance
                           rance
                           rance
                           rance
                           rance
                           apan
                           apan
                           apan
                           Italy
                             Italy
                           Italy
                           Switzerland
                           Switzerland
                           Switzerland
                           Switzerland
                           Switzerland
                           Switzerland
                           United Kingdom
                           United Kingdom
                           United Kingdom
                           United Kingdom
                           United Kingdom
                           United Kingdom
```

(b) (6)

Meeting ID: (b) (6)

Passcode: (b) (6)

Find your local number: https://fnih.zoom.u (b) (6)

rom:	Adam, Stacey (FYDIBOHF23SP										
Sent:	6/15/2020 2:29	:09 PM									
Го:	Jim Neaton [(b) (6)		ns Lundgre		(b) (6		Eric Hug			
	(b) (FYDIBOHF23SP						angeLabs/obac222609				
	[E] [/o=Exchang (FYDIBOHF23SP					ba16353	b96cff8ca9	-ehiggs]; I	Kozak, N	Marina	
	(OS/ASPR/BARD										
	(FYDIBOHF23SP	DLT)/cn=R	ecipients/cr	=ff3881f4:	1df744ads	9dc3caa8	3f497a421-	Marina.Ko	za]; Pat	terson, Am	ny
	(NIH/NHLBI) [E]	[/o=Excha	ngeLabs/ou	Exchange	Administ	rative Gr	oup				
	(FYDIBOHF23SP	DLT)/cn=R	ecipients/cr	=afad1ca7	4b3e449	d8b4f319	1d65bb70	-pattersa]; Aggan	wal, Neil (N	IIH/NHLBI)
	[E] [/o=Exchang	geLabs/ou=	Exchange A	dministrati	ve Group						
	(FYDIBOHF23SP							-aggarwa	nr]; Reir	neck, Lora	
	(NIH/NHLBI) [E]										
	(FYDIBOHF23SP					3bb9222	236c61304b	3-reineck	la]; Judy	Currier (
	[/o=ExchangeLa										
	(FYDIBOHF23SP									en Lynn Pr	rice
	(b)	` '	_	e, Lisa M [l		(b) (6)		ep Meno			
	•	0) (6)					[E] [/o=Exch				
	Administrative									bb3e4-pro	scham];
	Miller, Marissa										
	(FYDIBOHF23SP					19250da6	3e1dbe94	/-millerm	a2]; Raci	hel Harriga	in
	[/o=ExchangeLa					4-54-44		0	1 - 1 140		
	(FYDIBOHF23SP										rdt
	(b) (6	,	TTHOMPSO	N (b) (6)		s, Annetine) (6)	
	Moskowitz, Ala		(b) (6)			abiker [(b) (6)	Cavan, F	Rellly	
	[/o=ExchangeLa		T-1			0224004	002f0f2aE		al. Dhilli	na Andrai	
	(FYDIBOHF23SP		ecipients/cr								
	((b) (,	hanaa Admai	(b) (6)		Birgit Gru	ına ((b) (6)	IN.	leaton, Jim	1
	[/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f2b26b051964d9da6868e53c9cc6c49-jim.ccbr.um]; Joe Koopmeiners										
	(b) (6)		avid Vock [(b) (6)		mas Mu		(b) (6)		Max Parma	
	(b) (6)		ark Polizzott		(b)			nny Kan [b) (6)	Lane,
	Cliff (NIH/NIAID			•				my Karr [(0) (0)	Larre,
	(FYDIBOHF23SP							e-clanel: I	Baker, Ja	ason	
	(b) (6)		Roger Pare		(b) (6)			0) (6)			
	(b) (6)		(b) (M	(b) ((6)	Rosenb	erg, Yves
	(NIH/NHLBI) [E]	[/o=Excha			Administ				/ (-/		
	(FYDIBOHF23SP	DLT)/cn=R	ecipients/cr	=a5cb3e9a	a3a2747c	38c42f68	3f5c8e40cf-	rosenbey	; Emilia.	bagiel	(b) (6)
	(b) (aul Klekotka		(b) (6)		
CC:	Demarcus [(b) (6)	Tountas,	Karen (FN	(HI) [T]	o=Exchang	eLabs/ou	=Exchan	ge Admini	strative
	Group (FYDIBO	HF23SPDLT)/cn=Recipi	ents/cn=40	c04fef6f1	.e46f5b7	50753cd5a	14f93-tou	intaskh]	; Wachtel,	Jonathan
	(b) (6))	Parker, Ashl	ey (NIH/OI	D) [E] [/o=	Exchang	eLabs/ou=l	xchange	Adminis	trative Gro	up
	(FYDIBOHF23SP	DLT)/cn=R	ecipients/cr	=306b224	4466140f	aa95aaa	afe06ebd70)-parkeras	; Chen,	Helen Q.	
	(b) (6	5)	Eron, Josep	h J Jr	(b)	(6)	Che	w, Kara N	1.D.		
	(b) (Daar, Eric		b) (6)	Bag	iella, Emilia	[(b)	(6)	
Subject:	Materials for A		_	200 - 20							
Attachments:	ACTIV_TX-Clinic	3일(1) [편] [일인(1)(1)(1)(1)(1)(1)(1)	[- BOST - B				15.pdf;				
	INSIGHT014 AC	TIV/2 prot	acal va 11	1/hine202	O DAK I	Ily docy					

Dear ACTIV-3 Writing Team,

Please find the agenda for today's meeting and the current version of the protocol.

Thanks,

Stacey

Stacey J. Adam, PhD Director, Cancer Research Partnerships Direct: (b) (6) Mobile: (b) (6) Join Zoom Meeting https://fnih.zoom. (b) (6) Meeting ID: (b) (6) Password: (b) (6) One tap mobile (b) (6) US (Germantown) US (Chicago) Dial by your location (b)(6)US (Germantown) US (Chicago) US (New York) US (Houston) US (San Jose) US (San Jose) US (Tacoma)

Meeting ID: (b) (6)

Password: (b) (6)

Find your local number: https://fnih.zoom. (b) (6)

From: Amanda Peppercorn [(b) (6)

Sent: 4/16/2020 12:46:45 PM

To: Collins, Francis (NIH/OD) [E] [/o=ExchangeL

Collins, Francis (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=410e1ca313f44ced9938e50d2ff0b6c2-collinsf];

(FYDIBOHF23SPDLT)/cn=Recipients/cn=410e1ca313f44ced9938e50d2ff0b6c2-collinsf]; (b) (6) (b) (6) Kristen Neese [(b) (6)

[kathleen. (b) (6)

CC: Myles, Renate (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=7d317f5626934585b3692a1823c1b522-mylesr]; Meltzer, Abbey (FNIH) [T]

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=c341d86cf7404a78ac8f852e698e5382-meltzerak]; Burklow, John (NIH/OD)

[E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=2e57f267323b43c08be856acb5b964ca-burklowj]; John Lepore

(b) (6)

Subject: RE: URGENT: Need to know how to reach your comms contacts

Flag: Follow up

Dear Francis, Kristen Neese (cc'd) is the appropriate GSK communications contact.

Many thanks,

Amanda

Amanda Peppercorn, M.D. GSK Research & Development

mobile (b) (6)

email (b) (6)

From: Collins, Francis (NIH/OD) [E] < (b) (6)

Sent: Thursday, April 16, 2020 8:28 AM

To: (b) (6) (b) (6) Amanda Peppercorn < (b) (6) **Cc:** Myles, Renate (NIH/OD) [E] < (b) (6) Meltzer, Abbey (FNIH) [T] < (b) (6)

Subject: URGENT: Need to know how to reach your comms contacts

Importance: High

EXTERNAL

Hi Tom, William, and Amanda,

Can you provide comms contacts this morning? We are trying to post this press release later today.

Many thanks, Francis

From: Collins, Francis (NIH/OD) [E] Sent: Thursday, April 16, 2020 8:13 AM

To: (b) (6)

 Cc:
 Myles, Renate (NIH/OD) [E]
 (b) (6)
 Parker, Ashley (NIH/OD) [E]
 (b) (6)
 Burklow,

 John (NIH/OD) [E]
 (b) (6)
 Wholley, David (FNIH) [T]
 (b) (6)
 Meltzer, Abbey (FNIH) [T]

(b) (6)

Subject: Need to know how to reach your comms contacts

Importance: High

Kathleen Quinn

Dear ACTIV colleagues (once again, that's you in the bcc line):

As I mentioned yesterday, we would like to announce the plans for the ACTIV public-private partnership as expeditiously as possible. Please provide the name of the most appropriate communication contact from your company so that we may share a draft of the embargoed press release for your review. Please send the contact information to Renate Myles at (b) (6) and Abbey Meltzer (b) (6) as soon as possible.

Many thanks, Francis

GSK monitors email communications sent to and from GSK in order to protect GSK, our employees, customers, suppliers and business partners, from cyber threats and loss of GSK Information. GSK monitoring is conducted with appropriate confidentiality controls and in accordance with local laws and after appropriate consultation.

From: Melencio, Cheryl (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=279E14FA7428415BB86087D08B628E6F-MELENCIOC] Sent: 7/21/2020 7:14:01 PM To: Melencio, Cheryl (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=279e14fa7428415bb86087d08b628e6f-melencioc]; Collins, Francis (NIH/OD) Disbrow, Gary (OS/ASPR/BARDA) [(b)(6)Dolsten, Mikael (b) (6) Gibbons, Gary (NIH/NHLBI) [E] [Marks, Peter (FDA/CBER) (b)(6)(b)(6)Pao. William [Stoffels, Paul [(b) (6) (b) (6) (b) (6) Colvis, Christine (NIH/NCATS) [E] Woodcock, Janet (FDA/CDER) [(b)(6)Desrosiers, Betsy [Eric Hughes (b)(6)(b)(6)Kurilla, Michael (NIH/NCATS) [E] Jansen, Kathrin [(b)(6)(b) (6) Lowy, Douglas (NCI) [Read, Sarah (NIH/NIAID) [E] (b)(6)(b)(6)Fauci, Anthony (NIH/NIAID) [E] Young, John [(b) (6) (b)(6)[/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=df38103d75134f658ae2d356f0396b94-afauci]; Plump, Andrew (b) (6) CC: Adam, Stacey (FNIH) [T] [(b) (6) Alvarez, Rosa [(b) (6) Anderson, Margaret Chen, Helen [Elsaid, Olivia [(b) (6) (b)(6)(b) (6) Gonzalez, Nina []; Menetski, Joseph (FNIH) James, Stephanie (FNIH) [T] (b)(6)Santos, Michael (FNIH) [T] [Stratton, Benjamin [T] (b) (6) (b) (6) (b)(6)Tolman, Brett [(b)(6)Tountas, Karen (FNIH) [T] (b) (6) Wachtel, Jonathan []; Wholley, David (FNIH) [T] [; Anderson, James (b)(6)(b) (6) (NIH/OD) [E] [Austin, Christopher (NIH/NCATS) [E] [Burklow, (b)(6)(b) (6) John (NIH/OD) [E] [Castillejos, Carlos [Culp, Michelle (NIH/OD) [E] (b) (6) (b)(6)FNIH Central Account [Gadbois, Ellen (NIH/OD) [E] (b)(6)(b)(6)(b)(6)Hallett, Adrienne (NIH/OD) [E] [(b)(6)]; Lane, Cliff (NIH/NIAID) [E] Myles, Renate (NIH/OD) [E] [(b)(6)Parker, Ashley (NIH/OD) [E] (b) (6) Tabak, Lawrence (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (b)(6)(FYDIBOHF23SPDLT)/cn=Recipients/cn=02e22836b5ff4e9988e3770cfc7ee770-tabakl]; Burrus-Shaw, Cyndi (NIH/OD) Carver, Trea (NIH) [C] []; Lagos, Enrique (NIH/NCATS) [E] [E] (b) (6) (b) (6) (b)(6)]; Sepulveda, Dorina (FNIH) [T] [Simon, Dina (NIH/OD) [C] (b) (6) [dina. Gorman, Greta (FNIH) [T] [(b)(6)Meltzer, Abbey (FNIH) [T] (b)(6)Barasch, Kimberly (NIH/NIAID) [C]]; Conrad, Patricia (NIH/NIAID) (b)(6)(b) (6) [E] [.gov]; Dimishkov, Roxanne (NIH/NHLBI) [C] [(b)(6)]; McManus, (b)(6)Ayanna (NIH/OD) [E] [Perala, Mie [(b)(6)Protasiewicz, Ann (b) (6) (b)(6)Riccobene, Kim [(b)(6)Thomas, Ashley (FDA/CDER) Wood, Gretchen (NIH/OD) [E] [Togashi, Mieko (NIH/NCI) [E] (b) (6) (b)(6)Zottoli, Jessica (b) (6) 1: Underwood, Nancy [(b)(6)Lowy, Douglas (NIH/NCI) [E] [Hawk, Harrison (b) (6) (b)(6)Lucas Smalldon [Wolinetz, Carrie (NIH/OD) [E] (b)(6)(b)(6)[/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1c655040d47346c7b04d7bc11a403ecb-wolinetzcd]; Hardesty, Rebecca (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=21465ceb763947408d209aaabf10af70-hardestyrs] Subject: **ACTIV EC & Working Group Co-Chair Meeting** Location: https://fnih.zoom. (b) (6) Start: 8/14/2020 4:00:00 PM 8/14/2020 5:00:00 PM End: Show Time As: Busy

Required Collins, Francis (NIH/OD) [E]; Disbrow, Gary (OS/ASPR/BARDA); Dolsten, Mikael; Fauci, Anthony (NIH/NIAID) [E]; Attendees: Gibbons, Gary (NIH/NHLBI) [E]; Marks, Peter (FDA/CBER); Pao, William; Plump, Andrew; Stoffels, Paul; Woodcock,

Janet (FDA/CDER); Colvis, Christine (NIH/NCATS) [E]; Desrosiers, Betsy; Hughes, Eric; Jansen, Kathrin; Kurilla, Michael (NIH/NCATS) [E]; Lowy, Douglas (NCI); Read, Sarah (NIH/NIAID) [E]; Young, John

Optional Attendees:

Adam, Stacey (FNIH) [T]; Alvarez, Rosa; Anderson, Margaret; Chen, Helen; Elsaid, Olivia; Gonzalez, Nina; James, Stephanie (FNIH) [T]; Menetski, Joseph (FNIH) [T]; Santos, Michael (FNIH) [T]; Stratton, Ben; Tolman, Brett; Tountas, Karen (FNIH) [T]; Wachtel, Jonathan; Wholley, David (FNIH) [T]; Anderson, James (NIH/OD) [E]; Austin, Christopher (NIH/NCATS) [E]; Burklow, John (NIH/OD) [E]; Castillejos, Carlos; Culp, Michelle (NIH/OD) [E]; FNIH Central Account; Gadbois, Ellen (NIH/OD) [E]; Hallett, Adrienne (NIH/OD) [E]; Lane, Cliff (NIH/NIAID) [E]; Myles, Renate (NIH/OD) [E]; Parker, Ashley (NIH/OD) [E]; Tabak, Lawrence (NIH/OD) [E]; Wolinetz, Carrie (NIH/OD) [E]; Burrus-Shaw, Cyndi (NIH/OD) [E]; Carver, Trea (NIH) [C]; Hardesty, Rebecca (NIH/OD) [E]; Lagos, Enrique (NIH/NCATS) [E]; Sepulveda, Dorina (FNIH) [T]; Simon, Dina (NIH/OD) [C]; Gorman, Greta (FNIH) [T]; Meltzer, Abbey (FNIH) [T]; Barasch, Kimberly (NIH/NIAID) [C]; Conrad, Patricia (NIH/NIAID) [E]; Dimishkov, Roxanne (NIH/NHLBI) [C]; McManus, Ayanna (NIH/OD) [E]; Perala, Mie; Protasiewicz, Ann; Riccobene, Kim; Thomas, Ashley (FDA/CDER); Wood, Gretchen (NIH/OD) [E]; Togashi, Mieko (NIH/NCI) [E]; Underwood, Nancy; Zottoli, Jessica; Lowy, Douglas (NIH/NCI) [E]; Hawk, Harrison; Lucas Smalldon

Shortening calls to 1 hour in length.

Joseph Menetski is inviting you to a scheduled Zoom meeting.

```
Join Zoom Meeting
https://fnih.zoom.us/
                                              (b)(6)
Meeting ID:
                (b) (6)
Passcode: (b)
One tap mobile
                   (b)(6)
                                              US (Germantown)
                                              US (Chicago)
Dial by wour location (b) (6)
                          US (Germantown)
                          US
                             (Chicago)
                         US (New York)
                          US (San Jose)
                         US (San Jose)
                          US (Tacoma)
                          US (Houston)
                          lgium
                          elgium
                          elgium
                          elgium
                          elgium
                          elgium
                          Canada
                          Canada
                          Canada
                          Canada
                          Canada
                          Canada
                          France
                          France
                          France
                          France
                          France
                          Japan
                          Japan
                          Japan
                          Italy
                             Italy
                          Italy
                           Switzerland
                          Switzerland
                           Switzerland
                           Switzerland
                           Switzerland
                           Switzerland
                          United Kingdom
                           United Kingdom
                           United Kingdom
                           United Kingdom
                          United Kingdom
                           United Kingdom
```

(b) (6)

Meeting ID: (b) (6)

Passcode: (b) (6)

Find your local number: https://fnih.zoom. (b) (6)

Florence, Clint (NIH/NIAID) [E] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=5E032D0BC8554E8787E844A7773295FE-FLORENCEWC) 9/29/2020 6:03:32 PM Menetski, Joseph (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5001af52dc4a427ea3d34f1e072f8cb7-menetskijp]; Hild, Sheri (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=edd7f1939fb94be3bf063f925ac15f02-hildsa]; m; (b) (6) Annaliesa. (b) (6) (b) (6) (b)(6)Baric, Ralph [/o=ExchangeLabs/ou=Exchange Administrative Group (b)(6)(FYDIBOHF23SPDLT)/cn=Recipients/cn=48e35ab1d3044465a7790ee4ded5bc32-rbaric.email; Ottinger, Elizabeth (NIH/NCATS [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ad34123055944f97bedbef038d375cd7-ottingerea]; Colvis, Christine (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4b7e84cce098457896b2df19fa172c87-ccolvis]; Hewitt, Judith (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2d0a7dadfcbd42cbb4014d9b26af30cc-ihewitt]; Deming, Damon (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=8a5ace9923ae415aa3d85ac09cb76f85-DEMINGD.fda]; Parker, Ashley (NIH/OD) [E] (b) (6) (b) (6) (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras]; Collins, Francis (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=410e1ca313f44ced9938e50d2ff0b6c2-collinsf]; ; Adams, Peter (OS/ASPR/BARDA) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f6e22f801f9146ef90116c4311c6f3ee-Peter.Adams]; Rao, Srinivas Qashu, Felicia (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=366447a553f44696b2c79484d90e41e5-qashufm]; Tomas Cihlar Pitt, Margaret L CIV USARMY MEDCOM USAMRIID (USA) [(b) (6) (b) (6) Punturieri, Antonello (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ca7f3106e5f24b5cb5e933c6ee7a6bc7-punturieria]; Charette, Marc (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a7fa2baf951848b5bf1f76a049a0eca6-charettemf]; Fessel, Josh (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=294e2bb481d94b83a1917f15338dfe19-fesseljp]; Isis. (b) (6) Wholley, David (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]; Austin, Christopher (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=17597cabc42247548e596778304f781f-austinc]; Melencio, Cheryl (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=279e14fa7428415bb86087d08b628e6f-melencioc]; Colvis, Christine (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4b7e84cce098457896b2df19fa172c87-ccolvis]; Desrosiers, Betsy Eric Hughes [/o=ExchangeLabs/ou=Exchange Administrative Group (b) (6) (FYDIBOHF23SPDLT)/cn=Recipients/cn=f97951a53cd54153b5daa9d99ad4ec90-EricHughes]; Jansen, Kathrin Kurilla, Michael (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dc4e85061e3943b9b8ad3f426727861f-mkurilla]; Lowy, Douglas (NCI) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=54fa75fe6e304e34ba567c66b832baa0-drl.helix.n]; Tountas, Karen (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=40c04fef6f1e46f5b750753cd5a14f93-tountaskh]; Santos, Michael (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ab38cb6836de44e18ef4cc6952f65f80-santosmr]; Adam, Stacey (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dcd875f0679648859e1cf101c0943414-adamsj4]; James, Stephanie (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f0032ef62ca343dfb4bf79577e2aa8d1-jamesst]; Alvarez, Rosa Maria [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user706e5647]; Kim,

From:

Sent:

To:

	Elizabeth [(b) (6)	btolmar	n [/o=Exchange	Labs/ou=	Exchange A	dministrative	Group	
	(FYDIBOHF23S	PDLT)/cn=Recipi	ients/cn=u	iser7b137a1e]	; Wachtel,	Jonathan	(b) (6	5)	Prabhavathi
	Fernandes [(b) (6		Rose Li [(b) (6)		a Carluccio	
		(b) (6)		Lagos, Enrique	24 34				
	Administrative							1-lagoses];	
		ntha (NIH/NCATS							
	75	PDLT)/cn=Recipi	8		bef89b0d	39b145d69	a7-jonsonsg];	Simon, Di	na (NIH/OD) [C]
		labs/ou=Exchang	투자 성격하다 가게 되었다면 하다 하다.	[10] [10] [10] [10] [10] [10] [10] [10]					
	(FYDIBOHF23SPDLT)/cn=Recipients/cn=e02345fa5d1d4d7eaf4e0f3da58bc1ac-simondm]; Burrus-Shaw, Cyndi (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group								aw, Cyndi
							rc 1 D		
		PDLT)/cn=Recipi							Robin D
	(b) (6	/	Frankowsk	•	(b) (d)			, Toni C	
		(b) (6)		Douglas (NIH)	75 76 70 70	95		1.000	
	13 53	OHF23SPDLT)/cn	-	(5)			5902718a-low	ya]; Florer	ice, Clint
		[] [/o=ExchangeL SPDLT)/cn=Recipi					fo florencew	al. Nancy I	Haimuaad
		Labs/ou=Exchang			+60/0/604	14a///3293	ole-norencew	cj; ivancy i	Talgwood
		SPDLT)/cn=Recipi		경기를 하는데 되었다. 그렇게 하면 하네요.	160126025	30e4ha6ce	h5-haigwoon	ohl: Stratt	on Reniamin
		abs/ou=Exchang						All the second second second second	
		(NIH/OD) [E] [/d		angling angli manggara				5/ CII—03CIC	,5ca7100],
		SPDLT)/cn=Recipi	3 1000				THE RESERVE THE RE	· Andersor	n lames
		o=ExchangeLab					zu Budboiseij	, , , , , , , , , , , , , , , , , , , ,	1, 7411165
	- 10 17 17 17 THE	PDLT)/cn=Recipi	13.			727	o23-andersoni	iml: Hawk	. Harrison
	80	abs/ou=Exchang	20				1.7	1 (72)	
	Mason, Stephe		0) (6)				[/o=Exchange		
	[10] [10] [10] [10] [10] [10] [10] [10]	Group (FYDIBO	/ \ /		하나 하는 하나 아이를 살았다. 유민이는	하나 하는 것이 없는 것이 없다.	1		
		(b) (6)		Diamond, Mi		(b) (6)		zalez, Nin	
	[/o=Exchangel	abs/ou=Exchang	ge Adminis	strative Group	(FYDIBOH			cn=user3	3c2f486d]
Subject:	Re: ACTIV Pred	clinical full worki	ng group						

All –

(b) (4) Thanks -Clint From: (b)(6)When: 10:00 AM - 11:00 AM September 30, 2020 Subject: ACTIV Preclinical full working group Location: https://fnih.zoom.us (b)(6)Changing time for preclinical WG Joseph Menetski is inviting you to a scheduled Zoom meeting. Join Zoom Meeting https://fnih.zoom.us/ (b) (6) Meeting ID: (b) (6) Passcode: (b) (6) One tap mobile (b) (6) US (Germantown) JS (Chicago) Dial by vour location (b) (6) US (Germantown) US (Chicago) US (New York) JS (San Jose) US (San Jose) US (Tacoma) US (Houston) Meeting ID: (b) (6) Passcode: (b) (6) Find your local number: https://fnih.zoom. (b) (6)

Tountas, Karen (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=40C04FEF6F1E46F5B750753CD5A14F93-TOUNTASKH] 7/23/2020 3:56:22 PM Adam, Stacey (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dcd875f0679648859e1cf101c0943414-adamsj4]; Alison C. Roxby Punturieri, Antonello (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ca7f3106e5f24b5cb5e933c6ee7a6bc7-punturieria]; Bascles, Lionel Baseler, Beth (NIH) [C] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2363525c118a468b9e8f5f61707c63f5-bbaseler]; Culp, Michelle (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4e38fa37e0424217aa0a283cba9e5098-mculp]; Judy Currier [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=890082c7c1e34902b0f535320cd16650-jscurrier.m]; Victoria Davey [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2c8291f38ec342f895243c0617e115ec-victoria.da]; Desrosiers, Elizabeth A. Dickens, Jim (NIH/NCATS) [C] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=12591c90404e46caba73079cf4a5e2ea-dickensj]; Draghia-Akli, Ruxandra | Eaton, Niles [Erbelding, Emily (NIH/NIAID) [E] (b) (6) (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e976ebf7b14142fbb3c5c294efb334fe-erbeldingej]; Gadbois, Ellen (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0243d1d6e6f248268d2edec566c26c2a-gadboisel]; Garner, Carlos Goff, David (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=036113c7be0f42f897d1294cfbb99c10-goffdc]; Grace, Beth (NIH/NIAID) [C] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c75f1e9e678842258cf6472505f68cd8-bgrace]; Higgs, Elizabeth (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0601ca55a82841aba16353b96cff8ca9-ehiggs]; Hudson, Fleur Doroshow, James (NIH/NCI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a1d0fb9f055940c39b387cae2485faa6-doroshoj]; James, Stephanie (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f0032ef62ca343dfb4bf79577e2aa8d1-jamesst]; Beigel, John (NIH) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=492ae062f7d74e3cbd894e30160869f0-jbeigel]; Kan, Virginia Karg, Carissa B [Barrett, Kevin (NIH/NIAID) [E] (b) (6) (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0490b8cf48984327b737d027f4fddd81-barrettk2]; Krapp, Katharina Kublin, James Krauss, Randy D. [(b)(6)(b) (6) Kurilla, Michael (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dc4e85061e3943b9b8ad3f426727861f-mkurilla]; Payton, Manizhe (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=81d1c1824bfa438a94da81520a8bca90-paytonma]; Lee, Marina (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=98ee193dbea74e9bb92f2ef0f1753543-leemarina]; Miller, Marissa A (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=afea8bcd1c054bcd9250da63e1dbe947-millerma2]; Martinez, Mary Lin McNay, Laura (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d089e838a3824b60b91b6c394fedd335-lmcnay]; Menetski, Joseph (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5001af52dc4a427ea3d34f1e072f8cb7-menetskijp]; Mensah, George (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=284d85649e634a0a91bb0b9aac84846c-mensahga]; Nayak, Seema (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=51d5ee6848004578b5bf9c808eca8f6f-nayaksu]; Aggarwal, Neil (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d4c9de6615504ff9889f3b0c44a63526-aggarwalnr]; Kim, Peter (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group

From:

Sent:

To:

(FYDIBOHF23SPDLT)/cn=Recipients/cn=c48148e476824ce893260acf33b0f774-kimp2]; Peter Dull Qashu, Felicia (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=366447a553f44696b2c79484d90e41e5-qashufm]; Reineck, Lora (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a62d88ba0c3b44e3bb922236c61304b3-reineckla]; Mason, Robin (OS/ASPR/BARDA) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=77156b112de94c439dbccb6894954618-Robin.Mason]; Sanchez, Adriana Santos, Michael (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ab38cb6836de44e18ef4cc6952f65f80-santosmr]; Simpson, Shelly (NIH) [C] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=371206262b394fecaab6f43a3a6f9de6-shsimpson]; Sizemore, Christine (NIH/FIC) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=05494833e0fc47a9acac194cd338b201-csizemore]; Vogel, Susan (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a18354e56c6c45d5b4a9701770890c81-svogel]; Engel, Theresa (NIH) [C] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e86305ea82754e65b67a63591ed867ba-engelt]; Thompson, Taylor, M.D. Weinmann, Gail (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f38a543b4021483ba67e42af1165dcad-weinmang]; Wholley, David (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group

(NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]; Rosenberg, Yves

(FYDIBOHF23SPDLT)/cn=Recipients/cn=a5cb3e9a3a2747c38c42f68f5c8e40cf-rosenbey]

CC: Wachtel, Jonathan

(b)(6)

ACTIV CTC Dashboard Quick Reference Guide Subject: Attachments: CTC Dashboard Quick Reference Guide.pdf

Dear ACTIV Capacity Dashboard/GeoTracker Tool Users,

Attached is a hot-off-the-presses high-level guide to using the ACTIV Clinical Trial GeoTracking Tool. Hope you find this helpful, but feel free to reach out if you have any questions.

If you haven't used the dashboard lately, you may notice changes to the look and improvements to a variety of features enjoy! Login links may be found at the bottom of the guide.

Best regards, Karen

Karen H. Tountas, PhD

Scientific Program Manager

Foundation for the National Institutes of Health

fnih.org

11400 Rockville Pike, Suite 600, North Bethesda, MD 20852



Donate to the FNIH's Pandemic Response Fund to combat COVID-19: fnih.org/pandemic



Confidentiality Notice: Information contained in this e-mail and attachments may be legally privileged and confidential. If you are not an intended recipient, you are hereby notified that dissemination, distribution or copying this e-mail and attachments is strictly prohibited; please delete the e-mail and attachments increadiately

From: George, Jill (NIH/OD) [E] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=F90BFFB4B3A2464382ADC29B127AED4E-GEORGEJIL] Sent: 9/9/2020 6:29:00 PM To: Parker, Ashley (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras]; Brodd, Lauren (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ba665dea08e54171b3d6890c2518ddb9-leponelm] Subject: RE: ACTIV Therapeutics-Clinical Working Group Meeting Right. Not in PDF. ----Original Message---From: Parker, Ashley (NIH/OD) [E] <ashley.parke (b) (6) Sent: Wednesday, September 9, 2020 2:00 PM To: George, Jill (NIH/OD) [E] < (b) ((b)(6)Brodd, Lauren (NIH/OD) [E] < (b) (6) Subject: RE: ACTIV Therapeutics-Clinical Working Group Meeting No -- I thought we had a PDF version that worked fine before but maybe not. Does the hover over not work in PDF? If so, I will let the group know. Thanks, Ashley ----Original Message----From: George, Jill (NIH/OD) [E] < (b)(6)Sent: Wednesday, September 9, 2020 1:49
To: Parker. Ashlev (NIH/OD) [E] < Brodd, Lauren (NIH/OD) [E] (b) (6) (b)(6)Subject: RE: ACTIV Therapeutics-Clinical Working Group Meeting Did you figure out how to make hover over work in a PDF? The PPTX file is working fine. ----Original Message----From: Parker, Ashley (NIH/OD) [E] < (b)(6)Sent: Wednesday, September 9, 2020 1:45 PM To: George, Jill (NIH/OD) [E] (b)((b)(6)Brodd, Lauren (NIH/OD) [E] (b) (6) Subject: RE: ACTIV Therapeutics-Clinical Working Group Meeting Hi Jill and Lauren, The clinical trial matrix is out for review by the ACTIV Tx working group. Jill -- Helen shared the attached PDF and I noticed the hover over does not work. I am not concerned about this issue given it's the WG reviewing but wanted to flag in case something needs to be tweaked in the PP file attached for future sharing using PDF. Thanks. Ashley ----Original Message---From: Chen, Helen Q. < (b) (6) Sent: Wednesday, September 9, 2020 1:27 PM To: Adam, Stacey (FNIH) [T] < (b) (6) (b)(6)Bozzette, Sam (NIH/NCATS) [E] Butterton, Joan (b)(6)De Claro, R. Angelo (FDA/CDER) (b)(6)Eisner. Mark < (b) (6) (b) (6) Gottesdiener, Keith Draghia-Akli, Ruxandra < (b) (6) (b) (6) Eric Hughes >; Judy Currier Kım, Elizabeth LaVange, Lisa < (b) (6) (b)(6)(b)(6)Levy, Elliot < Mellors, John W < Menon, Sandeep (b) (6) (b)(6)(b)(6)Parker, Ashley (NIH/OD) [E] < (b) (6) Patel, Naimish <naimish.patel@sanoti.com>; Peppercorn, Amanda <amanda.f. (b)(6)Poole, Mike (b) (6) : Proschan, Michael (NIH/NIAID) (b)(6)Read, Sarah (NIH/NIAID) |E| < (b)(6)Santos, Michael (FNIH) [T] < (b) (6) Yuan Li Shen. (b)(6)Stein, Peter (FDA/CDER) < (b)(6)Wholley, David (FDA/CDER) : Buchman, Tim (OS/ASPR/BARDA) (CTR) <Tim.Buchman@hhs.gov>; Collins, Sylva (FNIH) [T] (b)(6)Garner, Ćarĺ Koroshetz, Walter Amanda Peppercorn <amanda. (FDA/CDER) < (b) (6) (b) (6) (b)(6)<ga Higgs. Elizabeth (NIH/NIAID) [E] (b)(6)(NIH/NINDS) LEJ ; Timothy Burgess u>: Reineck, Lora (b) (6) (b) (6) Aggarwal, Neil (NIH/NHLBI) [E] < (NIH/NHLBI) [E] < (b) (6) (b)(6)Goff. David (NIH/NHLBI) [E]

(b)(6)

Gadbois, Ellen (NIH/OD) [E] Rosenbera, Yves (NIH/NHLBI) [E] < (b) (6) (b) (6) Brown, Jeremy (NIH/NINDS) [E] <

```
le (NIH/OD) [E] < (b) (6) Jacquelin Beigel, John (NIH) [E] < (b) (6) (b) (6) Petrovick, Martha - 0449 - MITLL
                                  Culp, Michelle (NIH/OD) [E] <
                                                                                                                         Jacqueline Kirchner
                              (b) (6)
                                                                                                                                               Phillips, L
Revell CIV DTRA RD (ÚSA) <
                                                                         Sizemore, Christine (NIH/FIC) [E]
                                                  (b)(6)
<
               (b) (6)
                   (b)(6)
Cc: Colvis. Christine (NIH/NCATS) [E] <</pre>
                                                                                                        Desrosiers. Betsy
                                                                                                                            Kurilla, Michael
                                                                                                 (b) (6)
                       (b) (6)
                                                     Jansen. Kathrin <
                                            (NIH/NCATS) IEI <
                                           (b) (6)
                                                                                                                              Youna. John
                                                                                                            (b) (6)
                  (b)(6)
                                                                                                   Butcher, Tina <
                                                                                                                                          (b)(6)
                                                                                                          Melencio, Cheryl (FNIH) [T]
Tountas, Karen (FNIH) [T]
                                                       Macone, Erin <
                                                                                      (b)(6)
                               (b) (6)
Demarcus <
                                 Salathin, Carla <
Menetski, Joseph (FNIH) |T| <
                                                                                (b) (6)
             (b)(6)
<
            (b) (6)
                                                                                          (b)(6)
                                                                                                               James. Stephanie (FNIH) [T]
<
                                                                         (b) (6)
                                                                                                  btolman <
           (b) (6)
                              Wachtel. Jonathan <
                                                                                                                             (b) (6)
                                                                                                                                                    Alvarez,
                                                            Gonzalez, Nina < (
Rose Li Central Account <
                                                                                                                                Dana Carluccio
Rosa Maria <
                                  (b) (6)
                                                                                                     (b) (6)
                           (b)(6)
                                                                                                                      (b)(6)
<1
                                                                                                                                                 Margaret
                                                                                                              (b) (6)
Anderson ≺
                                (b)(6)
                                                            Lucas Smalldon <
                                                                                                                                                 Stratton,
                              (b) (6)
                                                                                                       Mollicá. Linda /US
                                                                          (b)(6)
Benjamin <
                                            Oashu. Felicia (NIH/OD) [E] < (b) (6)
(b) (6) Rubin. Daniel B. (FDA/CDER) <
(b) (6) Wung, Peter /US <
                  (b)(6)
                                                                                                        (b) (6)
                                                                                                                                Patterson, Amy
(NIH/NHLBI) [E] < Hilary (NIH/NIAID) [E] <
                                         (b) (6)
                                                                                                                               (b) (6)
                                                                                                                                                         Marston,
                                                                                                                     (b)(6)
                                                                                                                                            ; Hoots, W. Keith
                                                                 Groesch, Mary (NIH/NHLBI) [E] < | Kindzelski, Andrei (NIH/NHLBI) | E|
                                                                                                                                                  Shipp,
(NIH/NHLBI) [E] <
                                         (b) (6)
                                                                                                                               (b)(6)
Allan (NIH/NHLBI) |E| <
                                                (b) (6)
                                                Hone, David M (Dave) CIV DTRA J9 (USA) <
                    (b) (6)
                                                                                                                                 (b)(6)
Reisler, Ronald B CTR USARMY DOD JPEO CBRND (USA) <
                                                                                                     (b) (6)
                                                                                                                                   Freire, Maria (FNIH)
                 (b) (6)
                                                                          (b) (6)
                                   Elsaid, Olivia <
[T] <
                                                                                                   Appell, Evan <
                                                                                                                                      (b) (6)
Subject: RE: ACTIV Therapeutics-Clinical Working Group Meeting
Dear ACTIV TX-Clinical Working Group Members,
As we have discussed previously, NIH has developed a table to summarize ACTIV and other NIH-supported
COVID-19 trials. The goal of the table is to be informative to ACTIV and NIH leadership and to be shared more broadly once the information within it is public.
We would appreciate your review of this draft version of the table, which we are sharing ahead of
tomorrow's Working Group meeting. Please do not share the table or the information in it further.
are looking forward to your input.
Warm regards,
Stacey, Mike, and Helen
----Original Appointment----
From: Adam, Stacey (FNIH) [T] < (b)(6)
Sent: Wednesday, June 17, 2020 8:48 AM
To: Adam, Stacey (FNIH) [T]; Bozzette, Sam (NIH/NCATS) [E]; Butterton, Joan; De Claro, R. Angelo
To: Adam, Stacey (FNIH) [T]; Bozzette, Sam (NIH/NCATS) [E]; Butterton, Joan; De Claro, R. Angelo (FDA/CDER); Draghia-Akli, Ruxandra; Eisner, Mark; Gottesdiener, Keith; Hughes, Eric; Judy Currier; Kim, Elizabeth; LaVange, Lisa; Levy, Elliot; Mellors, John W; Menon, Sandeep; Parker, Ashley (NIH/OD) [E]; Patel, Naimish; Peppercorn, Amanda; Poole, Mike; Proschan, Michael (NIH/NIAID) [E]; Read, Sarah (NIH/NIAID) [E]; Santos, Michael (FNIH) [T]; Shen, Yuan Li (FDA/CDER); Stein, Peter (FDA/CDER); Wholley, David (FNIH) [T]; Buchman, Tim (OS/ASPR/BARDA) (CTR); Collins, Sylva (FDA/CDER); Amanda Peppercorn; Garner, Carl; Higgs, Elizabeth (NIH/NIAID) [E]; Koroshetz, Walter (NIH/NINDS) [E]; Timothy Burgess; Reineck, Lora (NIH/NHLBI) [E]; Aggarwal, Neil (NIH/NHLBI) [E]; Rosenberg, Yves (NIH/NHLBI) [E]; Goff, David (NIH/NHLBI) [E]; Brown, Jeremy (NIH/NINDS) [E]; Gadbois, Ellen (NIH/OD) [E]; Culp, Michelle (NIH/OD) [E]; Jacqueline Kirchner; Beigel. John (NIH) [E]; Phillips, L Revell CIV DTRA RD (USA); Petrovick, Martha - O449 - MITLL; (b) (6) Sizemore, Christine (NIH/FIC) [E] Cc: Colvis. Christine (NIH/NCATS) [E]: Desrosiers. Betsy: Jansen. Kathrin; Kurilla, Michael (NIH/NCATS)
Petrovick, Martha - 0449 - MITLL; (b)(6) Sizemore, Christine (NIH/FIC) [E]
Cc: Colvis, Christine (NIH/NCATS) [E]; Desrosiers, Betsy; Jansen, Kathrin; Kurilla, Michael (NIH/NCATS)
Subject: ACTIV Therapeutics-Clinical Working Group Meeting
When: Thursday, September 10. 2020 1:00 PM-2:00 PM (UTC-05:00) Eastern Time (US & Canada). Where: https://fnih.zoom.us/ (b)(6)
Stacey Adam is inviting you to a scheduled Zoom meeting.
Join Zoom Meeting
https://fnih.zoom.us
                                                                    (b)(6)
Meeting ID:
                         (b) (6)
Password: (b) (6)
One tap mobile
                                                                   US (Germantown)
                             (b) (6)
                                                                   US (Chicago)
```

Dial by vour location
(b)(6)

US (Germantown)
US (Chicago)
US (New York)
US (Tacoma)
US (Houston)
US (San Jose)
US (San Jose)

Meeting ID: (b) (6)
Password: (b) (6)
Find your local number: https://fnih.zoom.u (b) (6)
This message (including any attachments)
contains confidential information intended for a specific individual and purpose, and is protected by
law. If you are not the intended recipient, you should delete this message and any disclosure, copying,
or distribution of this message, or the taking of any action based on it, by you is strictly prohibited.

Deloitte refers to a Deloitte member firm, one of its related entities, or Deloitte Touche Tohmatsu Limited ("DTTL"). Each Deloitte member firm is a separate legal entity and a member of DTTL. DTTL does not provide services to clients. Please see www.deloitte.com/about to learn more.

v.E.1

Sent:

6/18/2020 12:07:43 PM

To:

Brodd, Lauren (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=ba665dea08e54171b3d6890c2518ddb9-leponelm]

Subject:

RE: ACTIV rosters for website

Hi Lauren,

Thank you for doing this – I will follow up with Cheryl to see if we can get more information on the discrepancies you've identified.

Please see additional responses in red below.

From: Brodd, Lauren (NIH/OD) [E] <

(b) (6)

Sent: Wednesday, June 17, 2020 6:42 PM

To: Parker, Ashley (NIH/OD) [E] <

(b) (6)

Subject: ACTIV rosters for website

Hi Ashley,

I compared the WG rosters (using file "ACTIV Working Group Rosters- MASTER" from Cheryl's email yesterday, below and attached) to the website. Few things:

- Preclinical Working Group: Damon Deming is listed on the Master excel file, but not on the website.
- Therapeutics Clinical Working Group: David Goff and Yves Rosenberg are both listed on the website, but not in the Master excel file.
 - Note: on the website, David Goff is listed for both the Therapeutics Clinical and the Clinical Trial Capacity WGs (not on both in the excel sheet).
- Vaccines Working Group: Gregory Glenn is listed on the Master excel file, but not on the website.
- The only addition for WG members that I have seen through email is Therese Takas. She is both listed in the excel file and on the website.
- I compared the names listed in the ACTIV WG Rosters- MASTER file with the website. Is there anything else I should be looking for/comparing aside from the names of WG members (such as members of the leadership/executive committees, or participating companies)? Yes, please compare the EC members listed and company names with those listed on the website ACTIVleadership is not listed on the website. And do I need to do anything with the "Master and WG Email list for ACTIV" file? I think it would be useful to update the current master email spreadsheet or create a new one to include 1. EC tab (name, position, company, and email), 2. leadership tab (name, position, company, and email), and 3. company only tab with list of alphabetized company names this will make it easier to compare moving forward. It may also be a good idea to make sure the names/emails in the master match those listed for the working group rosters (they are prepared by different staff at FNIH and we've had issues with those not matching previously).

Thanks,

Lauren

From: Melencio, Cheryl (FNIH) [T] (b)

(b)(6)

Sent: Tuesday, June 16, 2020 8:59 AM

To: Parker, Ashley (NIH/OD) [E]

(b) (6)

Cc: Brodd, Lauren (NIH/OD) [E]
Subject: RE: Intro to Lauren Brodd

Nice to meet you Lauren. Enclosed are the spreadsheets and I will send them each Friday.

Cheryl

Cheryl Melencio

Administrative Manager, Research Partnerships

Foundation for the National Institutes of Health

(b) (6)

fnih.org

11400 Rockville Pike Suite 600 North Bethesda, MD 20852

Donate to the FNIH's Pandemic Response Fund to combat COVID-19: fnih.org/pandemic



From: Parker, Ashley (NIH/OD) [E] <

(b)(6)

Sent: Tuesday, June 16, 2020 8:56 AM

(b) (6)

To: Melencio, Cheryl (FNIH) [T] **Cc**: Brodd, Lauren (NIH/OD) [E]

Subject Intro to Louren Broad

Subject: Intro to Lauren Brodd

Good morning Cheryl,

I hope you are off to a great start this week! I want to virtually introduce you to Lauren Brodd, cc'd here — Lauren will be working with Renate and myself on the ACTIV communications for the NIH website. I would like to ensure that she also receives the updates for members who are added to the working groups and companies who may continue to join — this will help us with keeping our website up to date.

I informed Lauren of our weekly receipt of the two spreadsheets, one with emails that you've managed and the other with the list of working groups managed by the FNIH COMMs. If you could share any updates to these spreadsheets that would be great (these were last received on June 3rd) and we will look forward to our regular updates on Fridays.

Thank you, Ashley

Ashley Parker, Ph.D.

Special Assistant to the NIH Director for Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)

Office of the Director | National Institutes of Health

Tel: (b) (6)

NIH National Institutes of Health

Santos, Michael (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=AB38CB6836DE44E18EF4CC6952F65F80-SANTOSMR] 7/3/2020 7:23:09 PM Lowy, Douglas (NIH/NCI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (b) (6) (FYDIBOHF23SPDLT)/cn=Recipients/cn=f1b7b8fe4739478bb17840c56902718a-lowyd]; Arvin, Ann [/o=ExchangeLabs/ou=Exchange Administrative Group (b) (6) (FYDIBOHF23SPDLT)/cn=Recipients/cn=3bbf6108d53148f684dad333fce983de-aarvin.stan]; Beth Bell Cavaleri Marco (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b)(6)Greg Glenn [(b)(6)(b)(6)(b) (6) Haynes, Barton [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5d4a05845b5b4069ad0447fb60ebfa79-hayne002.mc]; hotez@bcm.edu; Marks, Peter (FDA/CBER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b2e527dbda2b4a86b8d72f06b813d471-MarksP.fda]; Mascola, John (NIH/VRC) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=7f78b40a596b4ca4a2850a429d1ae3f2-imascola]; Messonnier, Nancy (CDC/DDID/NCIRD/OD) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=441f65db836c4a89a42aecb9a0d9b96c-NAR5]; Nelson Michael [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=7c3323ab6a02468689fa2c51a87c43cc-NelsonMicha]; Offit, Paul [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cbd9cc56fdbe4598a57b423d484dcf9f-offit.email]; Seals, Jonathan (OS/ASPR/BARDA) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d7a87d49ccba4e3caaf5eb5d3586b1cc-Jonathan.Se]; (b) (6) (b) (6) Tal Zaks [(b) (6) (b) (6) Cohen, Myron [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2141b9e28c1a421fb3c1c4f75dd4c457-myron_cohen]; Erbelding, Emily (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange (b) (6) Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e976ebf7b14142fbb3c5c294efb334fe-erbeldingej]; Gruber, Marion (FDA/CBER) (b) (6) (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ebf7a8eb8dd541b2883a966ea5afd809-GRUBER.fda]; Hamilton, Holli (OS/ASPR/BARDA) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a28fc2f8eb134b00b5eaa4222d0576cc-Holli.Hamil]; Ledgerwood, Julie (NIH/NIAID) [E] (b) (6) (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5dc9f31ded594eff8ac506d2c4103c15-ledgerwood]; Lowy, Douglas (NIH/NCI) [E] (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f1b7b8fe4739478bb17840c56902718a-lowyd]; Marks, Peter (FDA/CBER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b2e527dbda2b4a86b8d72f06b813d471-MarksP.fda]; Marovich, Mary (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=bfd0192d165d4643accf6347728dbaeb-marovichma]; Mascola, John (NIH/VRC) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=7f78b40a596b4ca4a2850a429d1ae3f2-jmascola]; Nelson Michael [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=7c3323ab6a02468689fa2c51a87c43cc-NelsonMicha]; kayvon.modjarrad.civ@mail.mil; Kathleen Neuzil [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=33958e1252cf4266bffc8d94988f5715-kneuzil.som]; Offit, Paul [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cbd9cc56fdbe4598a57b423d484dcf9f-offit.email]; Merlin Robb [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=6442891c7f7b404486500d6ed251a686-MerlinRobb]; Wholley, David (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]; Melencio, Cheryl (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group

From:

Sent:

To:

```
(FYDIBOHF23SPDLT)/cn=Recipients/cn=279e14fa7428415bb86087d08b628e6f-melencioc]; Laurent Humeau
                                     Schrag, Stephanie (CDC/DDID/NCIRD/DBD) [/o=ExchangeLabs/ou=Exchange Administrative
              Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9be29b344ba14363bdecaa43582ca226-ZHA6]; Verani, Jennifer R.
              (CDC/DDID/NCIRD/DBD) [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=7c249692151d46d6ac80cb28ada3d3a0-qzr7]; Parker, Ashley (NIH/OD) [E]
              [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras]; Wachtel, Jonathan
                                       Hotez, Peter Jay [
                                                                                                       Tal Zaks
                       (b) (6)
                                                             (b) (6)
                                                                                    (b) (6)
                                                                       Greg Glenn [
                                                                                          (b) (6)
                        (b) (6)
                                         Gebo, Kelly (NIH/OD) [G] [/o=ExchangeLabs/ou=Exchange Administrative Group
                        (b) (6)
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=009cf99ae63f4f71b5b1204a73ded609-geboka]; Jacqueline Miller
CC:
              Tolman, Brett [
                                    (b)(6)
                                                            (b) (6)
                                                                            Hopps, Markay [
                                                                                                     (b) (6)
              Kozlowski, Mary (NIH/NCI) [C] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=15373a5a1d8a4fa89d49ba9c8561cc94-kozlowskimt]; Johnson, Maureen
              (NIH/NCI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=0cb4ad1bebe64791b0415a7eb4bf71db-johnsonr];
                                        Jeneffer Haynes [
                       (b) (6)
                                                               (b) (6)
                                                                Austin, Sarah (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange
                       (b) (6)
                                                 (b) (6)
              Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=292fcb760f9f4f199ebe343e08ef1781-austinsj];
                          (b) (6)
                                             Isabel Ramsey [
                                                                       (b) (6)
                                                                                          Parker, Ashley (NIH/OD) [E]
              [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras]; Marston, Hilary
              (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=ab30660917b942ffba9ae95d631116f3-marstonhd]; Qashu, Felicia (NIH/OD)
              [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=366447a553f44696b2c79484d90e41e5-gashufm]; Culp, Michelle (NIH/OD)
              [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=4e38fa37e0424217aa0a283cba9e5098-mculp]; Gadbois, Ellen (NIH/OD) [E]
              [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=0243d1d6e6f248268d2edec566c26c2a-gadboisel]; Wholley, David (FNIH) [T]
              [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]; Melencio, Cheryl (FNIH)
              [T] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=279e14fa7428415bb86087d08b628e6f-melencioc]; Menetski, Joseph (FNIH)
              [T] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=5001af52dc4a427ea3d34f1e072f8cb7-menetskijp]; Adam, Stacey (FNIH) [T]
              [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=dcd875f0679648859e1cf101c0943414-adamsj4]; Tountas, Karen (FNIH) [T]
              [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=40c04fef6f1e46f5b750753cd5a14f93-tountaskh]; James, Stephanie (FNIH) [T]
              [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=f0032ef62ca343dfb4bf79577e2aa8d1-jamesst]; Colvis, Christine (NIH/NCATS)
              [E] [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=4b7e84cce098457896b2df19fa172c87-ccolvis]; Desrosiers, Betsy
                                               Hughes, Eric [
                                                                                      Kurilla, Michael (NIH/NCATS) [E]
                                                                      (b) (6)
              [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=dc4e85061e3943b9b8ad3f426727861f-mkurilla]; Read, Sarah (NIH/NIAID) [E]
              [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=527b160038004a199ae6e0bac2226099-readsa]; Young, John
                                                                           Hamilton, Holli (OS/ASPR/BARDA)
                                         Paul Gillard [
                                                             (b) (6)
              [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=a28fc2f8eb134b00b5eaa4222d0576cc-Holli.Hamil]; Modjarrad, Kayvon CIV
              USARMY MEDCOM WRAIR (USA)
                                                                            Kathleen Neuzil [/o=ExchangeLabs/ou=Exchange
                                                         (b) (6)
              Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=33958e1252cf4266bffc8d94988f5715-kneuzil.som];
              Schrag, Stephanie (CDC/DDID/NCIRD/DBD) [/o=ExchangeLabs/ou=Exchange Administrative Group
              (FYDIBOHF23SPDLT)/cn=Recipients/cn=9be29b344ba14363bdecaa43582ca226-ZHA6]; Verani, Jennifer R.
```

(CDC/DDID/NCIRD/DBD) [/o=ExchangeLabs/ou=Exchange Administrative Group

	(FYDIBOHF23SPDLT)/cn=R	ecipients/cn=7c249	692151d46d6ac	80cb28ada3d3a0-qzr	7]; Thornburg, Natalie						
	(CDC/DDID/NCIRD/DVD) [/	o=ExchangeLabs/o	u=Exchange Adn	ninistrative Group							
	(FYDIBOHF23SPDLT)/cn=R	(FYDIBOHF23SPDLT)/cn=Recipients/cn=c8d079e00a5649639c6f1425f3bb075f-nax3]; Gonzalez, Nina									
	[/o=ExchangeLabs/ou=Exc	hange Administrati	ve Group (FYDIB	OHF23SPDLT)/cn=Rec	ipients/cn=user3c2f486	d];					
	'Wachtel, Jonathan' [(b) (6)	Stratton, Ben	amin [(b) (6) Anderson,	Margare					
	(b) (6)	(b) (6)	(b) (6) Betha	ny Stokes					
	(b) (6)	Kath	leen Callahan [(b) (6)	(b) (6)						
	(b) (6)	(b) (6	5)	(b) (6)	(b) (6)						
	Johnson, Maureen (NIH/N	CI) [E] [/o=Exchange	eLabs/ou=Exchai	nge Administrative Gr							
	(FYDIBOHF23SPDLT)/cn=R	ecipients/cn=0cb4a	d1bebe64791b0	415a7eb4bf71db-joh	nsonr]; Kozlowski, Mary						
	(NIH/NCI) [C] [/o=ExchangeLabs/ou=Exchange Administrative Group										
	(FYDIBOHF23SPDLT)/cn=Recipients/cn=15373a5a1d8a4fa89d49ba9c8561cc94-kozlowskimt]; Austin, Sarah										
	(NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group										
	(FYDIBOHF23SPDLT)/cn=R	ecipients/cn=292fc	b760f9f4f199ebe	e343e08ef1781-austir	nsj]; Soriano Osejo, Dou	glas					
	(b) (6)	Stratton, I	Benjamin [(b) (6)	Sitar, Sandra (NIH/VRC)	[C]					
	[/o=ExchangeLabs/ou=Exchange Administrative Group										
	(FYDIBOHF23SPDLT)/cn=Recipients/cn=79e781b1f84a4f878583062a6ae87017-sitars]; Tong, Tina (NIH/NIAID) [E]										
	[/o=ExchangeLabs/ou=Exchange Administrative Group										
	(FYDIBOHF23SPDLT)/cn=R	ecipients/cn=79a14	013c720446080	9b8c4213282808-ton	gtl]; Kurilla, Michael (NI	H/NCATS					
	[E] [/o=ExchangeLabs/ou=	[E] [/o=ExchangeLabs/ou=Exchange Administrative Group									
	(FYDIBOHF23SPDLT)/cn=Recipients/cn=dc4e85061e3943b9b8ad3f426727861f-mkurilla]; Tountas, Karen (FNIH) [T]										
	[/o=ExchangeLabs/ou=Exchange Administrative Group										
	(FYDIBOHF23SPDLT)/cn=R	ecipients/cn=40c04	fef6f1e46f5b750)753cd5a14f93-tount	askh]; Desrosiers, Elizab	eth A.					
	(b) (6)	Isabel Ra	msey [(b) (6)	Sridhar, Saranya /US						
	(b) (6)	Brian Rosen [(b) (6)	Cheryl Keech	(b) (6)	Sadoff,					
	Jerald [JRDUS] [(b)	(6) Michael	, Nelson [/o=Exc	hangeLabs/ou=Exchar	nge Administrative Grou	р					
	(FYDIBOHF23SPDLT)/cn=R	ecipients/cn=05b9c	a6b24634974b7	aeb3fcaead1623-nmi	chael.hi]; Kayvon Modja	irrad					
	(b) (6)										
Subject:	Notes and materials from	the Vaccines Worki	ng Group meetir	g							
Attachments:	2020-07-01 Vaccines Work	ing Group meeting	Summary Notes	.docx; 20200701 Vac	ines Working Group						
	Meeting.pptx: SARS-CoV-2 Vaccine Development - Role of CHIMs - NEJM - 2020.pdf										

Dear Vaccines Working Group and Vaccines Clinical Trials Sub-Group members,

Thank you for your participation in the Vaccines Working Group meeting, and particular thanks to Doug and Larry for leading the conversation and fostering extensive input from the group.

Attached are the meeting notes, materials, and the NEJM Perspective published on behalf of the Working Group on Wednesday.

As always, please reach out with any updates, questions or suggestions.

Best regards, Brett and Mike

Michael Santos, PhD

Associate Vice President, Science | Foundation for the National Institutes of Health

From: Santos, Michael (FNIH) [T] Sent: Tuesday, June 30, 2020 1:02 PM

Subject: Agenda for the Vaccines Working Group meeting tomorrow

Dear Vaccines Working Group and Vaccines Clinical Trials Sub-Group members,

The agenda topic for tomorrow's meeting of the Vaccines Working Group (Wednesday, 10:30am ET / 7:30am PT / 4:30pm CEST) will be the disparities in the burden of COVID-19 on sub-populations and the implications for representation of sub-populations in efficacy trials.

Given the topic, we are adding the members of the Vaccines Clinical Trials Sub-Group to the invite: you are welcome to join the meeting. We will still have Thursday's meeting of the Vaccines Clinical Trials Sub-Group as planned, on the topic of testing COVID vaccines in pregnant women in bridging studies.

We are looking forward to your participation. Please don't hesitate to reach out with any questions or suggestions.

Best regards, Brett and Mike

Michael Santos, PhD Associate Vice President, Science

Foundation for the National Institutes of Health

(b) (6) <u>fnih.org</u>

11400 Rockville Pike, Suite 600, North Bethesda, MD 20852



Stay at the forefront of FNIH news: fnih.org/newsletter

LaVange, Lisa M [(b) (6) 1/23/2021 6:32:31 PM Adam, Stacey (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dcd875f0679648859e1cf101c0943414-adamsj4]; Bozzette, Sam (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=85f05a3619cf47c7ae39d7bcf0aac88d-bozzettesaa]; Butterton, Joan [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=219ecac4faae4ebab8a45ce8ee2490c3-joan butter]; De Claro, R. Angelo (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c495c3ee25ca461ba6a829b124062448-DECLAROR.fd]; Draghia-Akli, Ruxandra [Gottesdiener, Keith [(b) (6) Eric Hughes (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f97951a53cd54153b5daa9d99ad4ec90-EricHughes]; Judy Currier [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=890082c7c1e34902b0f535320cd16650-jscurrier.m]; Kim, Elizabeth Levy, Elliot [(b) (6) Mellors, John W [/o=ExchangeLabs/ou=Exchange (b) (6) Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user257cb364]; Menon, Sandeep Parker, Ashley (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras]; Patel, Naimish Peppercorn, Amanda [(b) (6) (b) (6) Poole, Mike (b) (6) Proschan, Michael (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=7b45059209b4468bb4ba02b0dfbbb3e4-proscham]; Read, Sarah (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=527b160038004a199ae6e0bac2226099-readsa]; Santos, Michael (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ab38cb6836de44e18ef4cc6952f65f80-santosmr]; Shen, Yuan Li (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ae30a02e983e4e8a979dfec7257a1802-shenyu.fda]; Stein, Peter (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b4a14118481b4b39ba7e62a8d6425f79-Peter.Stein]; Wholley, David (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]; Buchman, Tim (OS/ASPR/BARDA) (CTR) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=00f8a853d8d740f8a8cdd55cbf8eb9da-Tim.Buchman]; Collins, Sylva (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f6b8f588067140fe988f0832c2387725-Sylva.Colli]; Amanda Peppercorn (b) (6) Garner, Carl (b) (6) : Higgs, Elizabeth (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0601ca55a82841aba16353b96cff8ca9-ehiggs]; Koroshetz, Walter (NIH/NINDS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e8338dd7cdcd432e986961f1548c5ec6-koroshetzw]; Timothy Burgess [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=52e5e03dcbc847709eaab64457efa57e-TimothyBurg]; Reineck, Lora (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a62d88ba0c3b44e3bb922236c61304b3-reineckla]; Aggarwal, Neil (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d4c9de6615504ff9889f3b0c44a63526-aggarwalnr]; Rosenberg, Yves (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a5cb3e9a3a2747c38c42f68f5c8e40cf-rosenbey]; Goff, David (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=036113c7be0f42f897d1294cfbb99c10-goffdc]; Brown, Jeremy (NIH/NINDS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ce971eefec944a68a94addd3b24835f5-brownj7]; Gadbois, Ellen (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0243d1d6e6f248268d2edec566c26c2a-gadboisel]; Culp, Michelle (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=4e38fa37e0424217aa0a283cba9e5098-mculp]; Jacqueline Kirchner

From:

Sent:

To:

	[(b) (6)	В	Beigel, John	(NIH) [E] [/o=ExchangeLa	abs/ou=Ex	change Administrativ	ve	
	Group (FYDIBOHF23S		Recipients/cn	=492ae062f	7d74e3cb	d894e3016086	9f0-jbeige	el]; Phillips, L Revell C	VIC	
	DTRA RD (USA) [(b) (6)) Petr	ovick, Martl	na - 0449	- MITLL [(b) (6)			
	(b) (6)							e Administrative Gro	up	
	(FYDIBOHF23SPDLT)/	cn=Recipie	ents/cn=05494	833e0fc47a	9acac194	cd338b201-csi	zemore]; l	Larry Tsai		
	(b) (6)									
CC:	Colvis, Christine (NIH,									
	(FYDIBOHF23SPDLT)/									
	[(b) (6) Lowy, Douglas (NCI) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=54fa75fe6e304e34ba567c66b832baa0-drl.helix.n]; Young, John									
							-			
	(b) (6)		Biggs, Mary [(b) (6		Butcher, Tina		(b) (6)		
	DeMarcus, Forrest [,	b) (6) o Administratio	Macone,	Erin [(b) (6)	ivielend	cio, Cheryl (FNIH) [T]		
	[/o=ExchangeLabs/ou (FYDIBOHF23SPDLT)/				hh06007	dooheagaef m	olonciacl:	Salathin Carla		
	(b) (6)							Administrative Grou	ın	
	(FYDIBOHF23SPDLT)/								λþ	
	(b) (c			Li Central Ad		(b) (6		Lucas Smalldon		
	(b) ((b) (6)	Mollica, Li		Eucus Sinandon		
	(b) (6)							dministrative Group		
	(FYDIBOHF23SPDLT)/									
	(NIH/NHLBI) [E] [/o=E							,		
	(FYDIBOHF23SPDLT)/						tersal; Ru	ubin, Daniel B.		
	(FDA/CDER) [/o=Exch						.,			
	(FYDIBOHF23SPDLT)/cn=Recipients/cn=35c2891059134111a3ed28f929042aad-RUBIND.fda]; Marston, Hilary									
	(NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group									
	(FYDIBOHF23SPDLT)/	(FYDIBOHF23SPDLT)/cn=Recipients/cn=ab30660917b942ffba9ae95d631116f3-marstonhd]; Chen, Helen								
	[/o=ExchangeLabs/ou	=Exchang	e Administrativ	ve Group						
	(FYDIBOHF23SPDLT)/					12 (A) (A)				
	(b) (6)					_	_	ge Administrative Gro		
	(FYDIBOHF23SPDLT)/					:2eca59d4c-ho	otswk]; Gi	roesch, Mary (NIH/N	HLBI)	
			hange Administrative Group							
	(FYDIBOHF23SPDLT)/cn=Recipients/cn=69ab77a4c9bf499383186b9d9870344e-groeschm]; Shipp, Allan (NIH/NHLBI)									
	[E] [/o=ExchangeLabs/ou=Exchange Administrative Group									
	(FYDIBOHF23SPDLT)/cn=Recipients/cn=16001e8ab49c4489aef107bd0ce27715-shippa]; Kindzelski, Andrei									
	^^ 7 [[[[[[[[[[[[[[[[[[(NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=8bda5194bdca4d2594626f6313d2db5c-kindzelskia]; Hone, David M (Dave)								
									/e)	
	CIV DTRA J9 (USA) [(b) (6) Walker Paula			CTR USARMY I			roun	
	(b) (6)							nge Administrative G	Toup	
	T) T	(FYDIBOHF23SPDLT)/cn=Recipients/cn=fbe81b9b832e40acbf5fd03bcfd32930-walkerp1]; Sorosa, Alex [/o=ExchangeLabs/ou=Exchange Administrative Group								
	(FYDIBOHF23SPDLT)/	_		50	5793cff91	45h09d91h-Co	ntact_f12	1. Lumsden Joanne		
	(NIH/NCATS) [C] [/o=l						maci_iiz	.j, carrisacii, soanne		
	(FYDIBOHF23SPDLT)/						sdeniml:	Lerner, Andrea		
	(NIH/NIAID) [E] [/o=E		This could provide the said fractions				isaciijiiij,	zerner, / marea		
	(FYDIBOHF23SPDLT)/						nnellvaml	: Embry, Alan (NIH/N	IIAID)	
	[E] [/o=ExchangeLabs							, = , , ,		
	(FYDIBOHF23SPDLT)/	•	-			:b83fd599d-em	brval			
Subject:	RE: Summary of the A									
	,									
Very nice ar	nouncement and imn	ressive d	ata analysis u	tilizing nati	ents from	n three differ	ent nlatfe	orm trials Congrate	s to	

Very nice announcement and impressive data analysis utilizing patients from three different platform trials. Congrats to the ACTIV-4 team!

Lisa

From: Adam, Stacey (FNIH) [T] < (b) (6)

Sent: Friday, January 22, 2021 3:50 PM

To: Boz	zette, Sam (NI	H/NCATS) [E] <	(b) (6)	В	Butterton	, Joan <		(b) (6)	De Claro,
R. Ange	elo (FDA/CDER) < (b) (6)		Draghia-	-Akli, Rux	andra <	(b)	(6)	Gottesdiener,
Keith <	(ric Hughes		(b) (6)		Judy Cui	rrier	
<	(b) (6)	Kim, Elizab					_isa M <lisa< td=""><td></td><td>Levy,</td></lisa<>		Levy,
Elliot <	(b) (6)	Mellors, Joh							
		(b)		Patel, N	aimish <		(b) (6)		ercorn,
		(b) (6)	Poole, N	1ike <				Proschan,	
	IAID) [E] <		Read, Sa						, Michael (FNIH)
		Shen, Yuan Li (FI						er (FDA/CDE	
<peter.< td=""><td></td><td>s.gov>; Wholley, Dav</td><td></td><td></td><td></td><td>Bu</td><td>chman, Tim</td><td>(OS/ASPR/B</td><td>ARDA) (CTR)</td></peter.<>		s.gov>; Wholley, Dav				Bu	chman, Tim	(OS/ASPR/B	ARDA) (CTR)
<		Collins, Sylva (FDA/CDER)	<	(b) (6)		Amanda	Peppercorn	
<	(b) (6)							oeth (NIH/NIA	
<	(b) (6)	Koroshetz, Walte							
<t< td=""><td>(b) (6)</td><td>Reineck, I</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>	(b) (6)	Reineck, I							
<	(b) (6)	Rosenberg, Yve	s (NIH/NHL	BI) [E] <	((b) (6)	Gof	f, David (NIH)	
<		Brown, Jeremy (NI							D) [E]
<	(b) (6)	Culp, Michelle (
<		b) (6)						Phillips, L Re	evell CIV DTRA
RD (US	- 000	b) (6) Petro					(b) (6)		
		Sizemore, Chri	stine (NIH/I	FIC) [E] <		(b) (6)		Larry Tsai	
<	(-) (-)								
		NIH/NCATS) [E] <						(b) (6)	2.70
		(b) (6) Young, Jo					gs, Mary <		
Butche	r, Tina <		DeMarcu					Macone, Eri	n
<		Melencio, Cheryl (
<		Menetski					Dana C		to the section of the section of
<	(b)	• •	lose Li Cent		nt <	(b) (6)	Lucas Sr	
<	(b)			(b) (6)		Mollica	, Linda /US		b) (6)
Qashu,	Felicia (NIH/O	D) [E] <felicia. (<="" td=""><td>b) (6)</td><td>Patterson</td><td>i, Amy (N</td><td>IH/NHLB</td><td>(I) [E] <</td><td>(b) (6)</td><td>Rubin,</td></felicia.>	b) (6)	Patterson	i, Amy (N	IH/NHLB	(I) [E] <	(b) (6)	Rubin,
		<daniel.rubin@fda.h< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td></daniel.rubin@fda.h<>							
	(b) (• •							
<	(b) (6)	Groesch, Mary	(NIH/NHLE	31) [E] <	(b)) (6)			
<		Kindzelski, Andrei							Dave) CIV DTRA
1000 1000	1) <						O CBRND (20-110-110-110-110-110-110-110-110-110-1	
<	(b) (6)	Walker, P						Sorosa, Alex	//
<		Lumsden, Joann					L	erner, Andre	a (NIH/NIAID)
[E] <	(b) (6)	Embry, Alar				(6)			
Subject: Summary of the ACTIV Therapeutics-Clinical Working Group									

Dear ACTIV TX-Clinical WG Members,

Thank you all for a good meeting yesterday and a good discussion on the upcoming variant work. Your feedback was helpful. Please find attached the summary of the meeting. If you have any additions or amendments, please let me know.

In addition, we wanted to share with you breaking news today. The ACTIV-4a trial has it first results for moderately ill patients.

https://www.nih.gov/news-events/news-releases/full-dose-blood-thinners-decreased-need-life-support-improved-outcome-hospitalized-covid-19-patients

We will be inviting in Judith Hochman, the PI of ACTIV-4a, to present on these results at a future TX-Clinical WG.

I hope you all have a great weekend!

Kind regards, Stacey

Stacey J. Adam, PhD

Director, Cancer

Research Partnerships

Foundation for the National Institutes of Health

Direct: (b) (6) | Mobile: (b) (6)

fnih.org

11400 Rockville Pike, Suite 600, North Bethesda, MD 20852

f in 9 0



From: Adam, Stacey (FNIH) [T] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=DCD875F0679648859E1CF101C0943414-ADAMSJ4] Sent: 5/6/2020 2:35:42 AM To: Bozzette, Sam (NIH/NCATS) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=85f05a3619cf47c7ae39d7bcf0aac88d-bozzettesaa]; Butterton, Joan [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=219ecac4faae4ebab8a45ce8ee2490c3-joan butter]; Collins, Sylva (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f6b8f588067140fe988f0832c2387725-Sylva.Colli]; Judy Currier [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=890082c7c1e34902b0f535320cd16650-jscurrier.m]; De Claro, R. Angelo (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c495c3ee25ca461ba6a829b124062448-DECLAROR.fd]; Mark Eisner Keith Gottesdiener [Eric Hughes (b) (6) (b) (6) (b)(6)LaVange, Lisa M [I (b)(6)Elliott Levy [(b) (6) Sandeep Menon [(b) (6) Amanda Peppercorn [amanda.f. Proschan, Michael (b)(6)(NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=7b45059209b4468bb4ba02b0dfbbb3e4-proscham]; Read, Sarah (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=527b160038004a199ae6e0bac2226099-readsa]; Amanda Peppercorn (b)(6)Price, Dionne (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a583eced842c44b18bb6fcd3820bee21-priced.fda]; Rubin, Daniel B. (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=35c2891059134111a3ed28f929042aad-RUBIND.fda]; Shen, Yuan Li (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ae30a02e983e4e8a979dfec7257a1802-shenyu.fda]; Farley, John (FDA/CDER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=40b4c4456b14464788f31fe7bcaa09bc-FARLEYJ.fda]; Goff, David (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=036113c7be0f42f897d1294cfbb99c10-goffdc]; Vincent, Michael Wung, Peter /US [Karen Lynn Price (b) (6) (b) (6) Pamela Tenaerts, M.D. [Koroshetz, Walter (NIH/NINDS) (b) (6) (b)(6)[E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e8338dd7cdcd432e986961f1548c5ec6-koroshetzw]; Patterson, Amy (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=afad1ca74b3e449d8b4f3191d65bb70f-pattersa] CC: Macone, Erin [Mary Biggs [(b) (6) Demarcus [(b)(6)(b) (6) Tountas, Karen (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=40c04fef6f1e46f5b750753cd5a14f93-tountaskh]; Wachtel, Jonathan Elizabeth Kim [Parker, Ashley (NIH/OD) [E] (b) (6) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=306b2244466140faa95aaaafe06ebd70-parkeras]; Butcher, Tina Wholley, David (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cd9e702fcf28414883d0b6996d677257-wholleyd]; Melencio, Cheryl (FNIH) [T] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=279e14fa7428415bb86087d08b628e6f-melencioc]; Hoots, W. Keith (NIH/NHLBI) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=328221d5416d4fc59262c6c2eca59d4c-hootswk] Subject: Follow-up from ACTIV TX-Clinical Master Protocol Ad Hoc Meeting Attachments: ACTIV_Therapeutics-Clinical_MP Sub-Group Meeting_Key Takeaways_05052020.pdf

Dear TX-Clinical Master Protocols Subgroup,

Please find attached the quick capture summary and action items from our meeting today. If you have any additions or amendments, don't hesitate to let us know.